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Statement of originality  
 
 
 
This thesis and the work to which it refers are the results of my own efforts. Any ideas, data, 
images or text resulting from the work of others (whether published or unpublished) are fully 
identified as such within the work and attributed to their originator in the text, 
reference/bibliography or in footnotes. This thesis has not been submitted in whole or in part 
for any other academic degree or professional qualification. I agree that the University has 
the right to submit my work to the plagiarism detection service TurnitinUK for originality 
checks. Whether or not drafts have been so assessed, the University reserves the right to 
require an electronic version of the final document (as submitted) for assessment as above.  
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Section A Research project 
 
 
 
Abstract 
 
 
 
Background information 
 
 
The premise of this study was that hearing deterioration, associated with treatment for head 
and neck cancer, has a negative impact on patients’ quality of life. However, there have 
been no studies to assess this phenomenon in people receiving current UK treatment, and 
there is little information on the impact of subsequent hearing deterioration.  
 
Objective 
 
This study, conducted in one UK hospital, aimed to investigate the incidence and severity of 
hearing deterioration, and patient experience of it, following treatment for head and neck 
cancer. 
 
 
Design 
 
 
A sequential mixed methods explanatory design was chosen as it was the most appropriate 
for addressing the research aims. A critical realist framework underpinned the study. A 
prospective observational repeated measures design was employed to obtain quantitative 
data in Phase 1 of the study to assess changes in hearing at the end of treatment, and at 3-
month follow-up post-treatment, using pre-treatment test level comparison. The Common 
Terminology Criteria for Adverse Events (version 4.03) were used to determine the 
incidence and severity of hearing deterioration. Results from Phase 1 were used to inform 
selection of participants for Phase 2 of the study. An approach informed by phenomenology 
	 5 
using interview methodology, was used to explore patient experience of hearing 
deterioration.  
 
Study sample 
 
Fifty adults who had been diagnosed with head and neck cancer were recruited to Phase 1 
of the study using a consecutive sampling approach. These participants were due to receive 
standard UK curative radiotherapy (intensity modulated radiotherapy) or chemoradiotherapy 
(including the use of cisplatin or carboplatin). From the 50 participants recruited, 13 who had 
hearing deterioration were selected using purposive sampling for one-to-one interviews to 
obtain in-depth information on their experience of hearing loss.  
 
Results 
 
The incidence of hearing deterioration was 57% in the 42 participants who completed testing 
at the end of treatment, and 50% percent in those who completed 3-month follow-up testing. 
At 3-month follow-up, 26% of participants had major (Grade 3) hearing deterioration in at 
least one ear. Patients who had chemoradiotherapy were more likely to experience hearing 
deterioration compared with those who had had radiotherapy only (p=0.01). Older patients 
were more at risk of hearing deterioration than younger participants (p=0.03), but if hearing 
deterioration occurred it appeared that younger patients suffered more severe deterioration 
than older patients (p=0.02).  
 
Aural change (including hyperacusis) experienced by some participants during treatment 
required a change in treatment regimen for them. Participants reporting either minor (Grade 
1) or major hearing deterioration were adversely affected by their aural symptoms that 
manifested with treatment, and the impact of tinnitus (the incidence of which is not covered 
by existing studies), was extensive in head and neck cancer survivors. Another emerging 
finding in this study was that middle ear dysfunction, in the early post treatment phase, had a 
	 6 
negative impact on patient experience. A further novel finding was that participants with 
bilateral mild-moderate or moderate severity, mid-high frequency sudden-onset hearing loss 
required lip-reading to assist their communication.  
 
There was evidence that some participants played down their aural symptoms, yet hearing 
deterioration had a negative impact on their overall quality of life, including generating a 
sense of loss (principally in older patients) and isolation (associated with younger patients). 
Finally, there was varied experience among participants receiving information on their 
hearing test results and on the process of receiving support for their hearing and tinnitus 
concerns. 
 
Conclusions and recommendations 
 
 
This current study provides evidence that could be used to increase awareness of the 
potential scale and impact of hearing deterioration following head and neck cancer 
treatment, in the early post treatment period. A larger multi-centre UK study would test the 
issues identified in the study to inform national policy, clinical practice and education. 
 
The study suggests a number of changes for consideration in improving current clinical 
practice when designing care provision of patients preparing for and recovering from 
radiotherapy or chemoradiotherapy for head and neck cancer. One key recommendation is 
for the adoption of a multidisciplinary approach in developing appropriate protocols to inform 
and support patients about hearing and tinnitus concerns that may occur with their 
treatment. (Word count 678).
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ACS     American Cancer Society 
ANOVA    Analysis of variance  
ASHA     American Speech Language Hearing Association  
 
B 
BS EN ISO    British, European and International Standard  
BSA     British Society of Audiology 
 
C 
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PROM    Patient reported outcome measure 
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Q 
QLQ     Quality of Life Questionnaire 
 
R 
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SCN    Supportive care needs  
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TNM (see also glossary) Tumour, Nodes and Metastasis  
	 11 
Glossary of terms 
 
 
A 
Acquired hearing loss  Hearing loss developed after birth 
Analysis of variance  A statistical method used to compare the means of 
two groups that have even distribution of data   
Auditory brainstem  A hearing test that tells how the auditory nerve and                                
  response test    the brain pathways for hearing are working 
Auditory cortex   Part of the brain that perceives sound 
Auditory nerve   The nerve that transmits sound from the ear  
towards the brain 
Aural fullness   Feeling of pressure within the ear 
 
B 
Bonferroni correction  A test used to determine confirm statistical  
significance in multiple group analysis 
 
C 
Carcinoma A type of cancer  
Categorical data Data arranged into groups for statistical analysis 
Central auditory system Part of the hearing (auditory) system that includes 
the auditory cortex  
CINAHL  A health sciences database of nursing and allied 
health journals (see abbreviations) 
Clarivate Analytics   A company that owns a collection of services,  
including those for scientific and academic  
research 
Cochlea    The sense organ that translates sound into  
nerve impulses to be sent to the brain  
COCHRANE    A non-profit, non-governmental organisation that  
organises medical research to provide evidence-
based information  
Conductive hearing loss  Hearing loss affecting the middle (and/or outer)  
ear component(s) of the peripheral auditory  
system 
Consecutive convenience   A type of sampling that includes all accessible  
sampling    subjects 
Constructivism   A research paradigm which states that learning is  
an active, contextualised process of constructing 
knowledge rather than acquiring it 
Critical realism A paradigm which states that phenomena exist 
and are understood uniquely within the 
environment in which they are explored 
 
D 
Department of Health   A department within UK Government 
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Dialectical pluralism   A research paradigm: a process theory for  
discussing and maintaining differences to enable 
integration of divergent views and methods to 
produce a more complex and meaningful whole 
Distortion product OAE   A type of otoacoustic emission (see abbreviations) 
  
E  
Ear drum (tympanic membrane) The structure that separates the outer ear and 
middle ear 
EBSCO host    A repository of research databases (see  
abbreviations) 
EMBASE    A healthcare science database (see abbreviations) 
 
F 
Fisher’s exact test   A statistical test used to assess categorical data
     of two small sized groups 
 
H 
Hearing deterioration  A reduction in the ability to hear 
Hearing loss    The inability to perceive and discriminate  
everyday sounds  
Hearing (auditory) system  Part of the body used for sensing and processing  
sound, consisting of the peripheral and central 
auditory systems 
Hyperacusis    Loudness discomfort to every day sounds 
Hypopharyngeal    Pertaining to the hypopharynx  
Hypopharynx    The lowest part of the pharynx which leads to the  
     larynx  
I 
Inner ear    Part of the peripheral auditory system that contains  
the hearing sense organ (cochlea) 
K 
kHz     A unit for measuring the frequency of sound (see  
abbreviations) 
 
L 
Laryngeal    Pertaining to the larynx 
Larynx     Cavity in the throat containing vocal cords 
 
M  
Mann Witney U test A statistical test to compare the means of two 
groups that have uneven distribution of data   
Maximum purposive sampling A type of sampling in which subjects, who have 
diverse characteristics, are selected to obtain the 
widest understanding of a phenomenon  
MEDLINE  An international literature database of life sciences 
and biomedical information (See abbreviations) 
Metaparadigm   A framework in which more restricted  
structures of conceptual modules develop 
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Middle ear    Part of the peripheral auditory system, usually air- 
filled, which contains the ossicles 
Mixed hearing loss   Hearing loss affecting the middle (and/or outer)  
component(s) of the ear, together with damage to 
the inner ear (and/or the auditory nerve) of the 
peripheral auditory system 
Mixed methods   A methodology for conducting research that  
involves collecting, analysis and integrating 
quantitative and qualitative data 
Nasopharyngeal    Pertaining to the nasopharynx  
Nasopharynx    The upper part of the pharynx that lies behind the  
nose 
 
O  
Otoacoustic emission(s)  Sounds generated from within the cochlea (see  
abbreviations) 
OME     Fluid in the middle ear cavity (see abbreviations) 
Oral cavity    The cavity of the mouth 
Oropharyngeal    Relating to the oropharynx  
Oropharynx    The part of the throat at the back of the mouth  
behind the oral cavity 
Ossicles    Bones in the middle ear used to transmit sound 
Otology    The study of the anatomy and diseases of the ear 
Ototoxicity    Damage to the hearing function of the ear by  
drugs, chemicals or treatment   
Outer ear    Part of the peripheral auditory system comprising  
the pinna and ear canal 
 
P 
Paranasal sinuses Small hollow spaces in the bones around the nose 
Peripheral auditory system Part of the hearing system that consists of the ear 
and auditory (cochlear) nerve 
Pharyngeal     Relating to the region of the pharynx  
Pharynx    The passage that lead from the cavities of the  
nose and mouth to the larynx (throat) 
Phenomenology The philosophical study of the structures of 
experience and consciousness 
PICO An acronym for diagnostic questions based on 
these four areas of knowledge and action: 
Population, Patient or Problem; Intervention (or 
prognostic factor or exposure); Comparison (or 
intervention); and Outcome  
Pinna     External part of the ear 
Positivism A philosophical system recognising only that which 
can be scientifically verified 
Pragmatism    A research approach that evaluates theories or  
beliefs in terms of the success of their practical 
application 
PRISMA    A method for searching databases reporting items  
for systematic review (see abbreviations) 
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ProQUEST A repository of databases that includes scholarly 
journals, newspaper articles and reports  
Prospective observational  A study design in which multiple recordings 
repeated measures    of a phenomenon are made over a period of time  
PsycARTICLES   A healthcare science database of full-text articles  
from journals in behavioural sciences published by 
the American Psychological Association 
PsychINFO    A healthcare science database devoted to peer- 
reviewed literature in behavioural science and  
mental health 
Psychology and behavioural        A database that includes journals which covers 
sciences collection    topics such as emotional and behavioural  
characteristics 
PubMed    A full-text archive of biomedical and life sciences  
journal literature  
Pure tone audiometry A key hearing test used to identify an individual’s 
hearing threshold levels 
 
Q 
Qualitative research   Research exploring human experience to convey  
why people have thoughts and feelings that might 
affect the way they behave 
Quantitative research  A research method dealing with numbers and  
anything that is measurable in a systematic way of 
investigating phenomena and their relationships 
R 
Regression (analysis/test)  A statistical test that assesses the strength of  
association between two or more groups 
 
S 
Salivary gland   The tissue in the mouth that secretes saliva 
Shapiro-Wilk test   A statistical test to verify how even is the  
distribution of data within a group 
Sensorineural   Pertaining to the inner ear and/or the auditory  
nerve of the peripheral auditory system 
SNHL     Hearing loss due to damage of the inner ear  
and/or the auditory nerve (see abbreviations) 
Speech discrimination test  A type of hearing test to estimate ability to  
understand and repeat single-syllable words  
Speech reception test  A type of hearing test to identify the lowest  
threshold level at which at least half the words 
spoken can be heard 
SPSS     A statistics package of computer software (see  
abbreviations) 
Squamous cell carcinoma Most common cell type of cancer in 
the head and neck region  
Standard deviation  A statistical term to quantify the amount of 
variation or dispersion of a set of values (see 
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Stapedial reflex test   A type of hearing test to monitor the 
muscle contraction that occurs in the middle ear in 
response to loud sounds 
Survivorship    Quality of life after treatment 
 
T 
TNM      A system for classifying cancers (Tumour, Nodes  
and Metastasis)  
Transient evoked OAE  A type of otoacoustic emission 
Tympanic membrane  The structure that separates the outer and middle    
  (ear drum)    ear components    
Tympanometry   A type of hearing test that measures middle ear  
function 
Type of hearing loss  The identification of the location of damage within  
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multidisciplinary academic literature, 
including journals, books and conference 
proceedings 
Wiley     A company that specialises in academic publishing  
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Chapter 1 Introduction 
 
 
 
1.0 Background 
 
This thesis: “A study of hearing deterioration following treatment for head and neck cancer in 
a UK hospital”, arose from the researcher’s involvement in the assessment and 
management of adults with hearing loss at the audiological clinic of a major London hospital.  
Hearing is the perception of sound, and hearing loss is defined as the ‘inability to perceive 
and discriminate everyday sounds including warning signals, speech, and music’ (Luxon, 
2014, p.533). In recent years, the clinic has received an increasing number of patients 
requesting support and advice on referral to audiology because of hearing loss following 
treatment for head and neck cancer (HNC). Sometimes these patients were referred up to 
two years after treatment, rather than at an earlier stage following it. Therefore, the 
researcher wanted to find out if patients have hearing difficulties soon after treatment, so 
that they might access support if required at an earlier time following treatment completion. 
He also wanted to determine the scale of the problem at his current hospital. 
 
In a previous post at a children’s hospital, the researcher was involved in the systematic 
assessment and monitoring of children’s hearing following cancer treatment. Some children 
who developed hearing deterioration were offered alternative treatment that reduced 
damage to hearing. However, in the researcher’s current place of work in a general hospital, 
the systematic assessment and monitoring of hearing in adult patients receiving treatment 
for HNC has not been standard procedure in service provision. Thus, it was not clear if, and 
to what extent, hearing deterioration followed treatment of the cancer for this patient group. 
 
To address this situation, the researcher, in consultation with oncologists specialising in the 
treatment of patients suffering from HNC, conducted a pilot study to measure patients’ 
hearing before and after treatment. This protocol involved testing hearing using pure tone 
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audiometry (PTA), the standard hearing test, at two time points: after a diagnosis of cancer 
but prior to treatment, and at a time point following the completion of treatment. The pilot 
study undertaken in 2013 at the researcher’s hospital compared the average threshold of 
hearing of two groups of patients: one prior to treatment (n=24), and the other at various 
time points after treatment (n=43). The average hearing threshold at different frequencies 
within the speech hearing range was poorer for each of the frequencies after treatment 
compared to pre-treatment equivalents.  
 
This pilot study indicated that hearing deterioration occurred after treatment, but the 
conclusion was of limited value as different HNC patients were compared in each group. 
This finding further fuelled the desire to assess hearing deterioration following treatment of 
HNC in more depth. Therefore, the premise of this study was that hearing deterioration is 
both associated with treatment of patients with HNC, and that such a deterioration has a 
negative impact on these patients. 
 
This introductory chapter provides a description of hearing, the impact of hearing loss, and 
an overview of HNC. Chapter 2 (Literature review) will present the findings of a review of 
current literature on ear-related side effects following treatment for HNC. Discussion of these 
findings indicate how the study aims were established to determine the incidence, severity 
and patient experience of hearing deterioration. Chapter 3 (Methodology) outlines the 
methodological approach adopted in the current study, and Chapter 4 (Methods) discusses 
the overall schema of the methods used in the study. Chapter 5 (Results – Quantitative 
data) presents statistics on the incidence and severity of hearing deterioration derived from 
testing the hearing of participants, and Chapter 6 (Results – Qualitative data) presents 
findings from interviews with patients on their experience of hearing change following their 
cancer treatment. The quantitative data and the findings on patient experience are 
considered and discussed collectively in Chapter 7 (Discussion), in the context of current 
knowledge and practice. Chapter 8 (Conclusion) offers conclusions from the study and 
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makes recommendations for clinical practice, and suggestions for education and future 
research.   
 
1.1 Hearing   
 
Hearing is the perception of sound, which begins with the collecting and processing of 
sounds by the ear (Pickles, 2012). The ear is structurally divided into three parts. The outer 
ear consists of the pinna, which is the visible and most external part of the ear, and the ear 
canal, which channels sound from the pinna inwards. The ear canal is separated from the 
middle ear by the ear drum – the tympanic membrane. The middle ear houses the three 
bones, or ossicles, that transmit sounds from the outer to the inner ear. The inner ear 
contains the cochlea, the hearing sense organ, which converts sound energy into an 
electrical form, for transmission along the auditory (cochlear) nerve. The ear and the 
auditory nerve consist of the peripheral auditory system. Electrical information emitted 
through the auditory nerve is delivered to the brain and is perceived as sound within the 
auditory cortex of the central auditory system (Luxon, 2014).  
 
1.1.1 Types of hearing loss 
 
Damage to any part of the hearing system from the ear to the auditory cortex within the brain 
may cause hearing loss (Luxon, 2014). Damage to different parts of the ear causes different 
types of hearing loss: conductive hearing loss when damage occurs to either outer or middle 
ear components; sensorineural hearing loss (SNHL) ensues following impairment to the 
inner ear and/or cochlear nerve; mixed hearing loss results from a combination of conductive 
or SNHL (Luxon, 2014). Different types of loss are detected using transducers that produce 
air conduction or bone conduction stimuli (Wood, 1995). 
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1.1.2 Ototoxicity and grades of hearing deterioration 
 
Ototoxicity is damage to the ear (Collins English Dictionary, 2018) which is treatment 
induced, and usually associated with impairment of the inner ear (Chang, 2013), although 
other parts of the hearing system can be affected (Jereczek-Fossa et al., 2003; Landier, 
2016). Ototoxicity can lead to hearing deterioration – a reduction in the ability to hear – by 
either developing an existing hearing loss, or creating a new loss. Changes in hearing are 
sometimes graded to indicate the quantity of change. There are different systems available 
to grade hearing deterioration that include clinician-rated assessments, such as the Late 
Radiation Morbidity Scoring Criteria, from the Radiation Therapy Oncology Group (Cox and 
Stetz, 1995), and psycho-acoustical measures, for example within the Common Terminology 
Criteria for Adverse Events (CTCAE) version 4.03 produced by the National Cancer Institute 
(NCI), (NCI, 2010). In these systems, Grade 0 usually indicates no change in hearing and 
Grade 1 reflects a slightly noticeable or minimally measured hearing change; the higher the 
grade number, the greater the increase in a change of hearing. 
 
 
1.1.3 Descriptors of hearing level 
 
 
Frequencies of sound important to human speech are most commonly measured in adults 
using the psycho-acoustic test of PTA (Wood, 1995). Decibels (dB) are units of sound 
pressure, and normal hearing is accepted as thresholds of hearing ≤20dB hearing level 
(dBHL) between 0.25 kilo Hertz (kHz - a unit to measure the frequency of sound) and 8kHz 
(Luxon, 2014). Severity of hearing loss ranges from mild to profound, depending on the 
average threshold over the speech frequencies. There are different classification systems for 
describing hearing levels including that from the World Health Organisation (World Health 
Organisation, 2018), although the system recommended for use in the UK derives from The 
British Society of Audiology (BSA), (BSA, 2011). 
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1.1.4 Impact of hearing loss 
 
 
In an evaluation of the social and economic implications of hearing loss in Europe and the 
UK, Shield (2006) reported on the significance of acquired hearing loss in adults, and 
determined that it can lead to communication and other social difficulties. Other studies have 
described how hearing loss affects the well-being and quality of life of patients with age-
related hearing impairment (Monzani et al., 2008; Wallhagen, 2010; Stark and Hickson, 
2004; Preminger and Meeks, 2010; Preminger and Meeks, 2012) and those affected by 
sudden-onset hearing loss of unknown cause (Härkönen et al., 2017).  
 
Experience of hearing loss is usually associated with negative connotations. Deaf people 
who use signing communication and have profound hearing loss (at birth, or before the 
acquisition of language) are prone to isolation and depression, as shown in an interview 
study by Sheppard and Badger (2010). A phenomenological investigation by Aquino-Russell 
(2006) conducted by email correspondence, showed that patients with acquired hearing loss 
(cause not provided) might also experience isolation and other problems with their hearing 
change. The study showed a developing awareness of mis-hearing, with feelings of 
frustration and inadequacy. Another interview study with participants who had acquired mild-
moderate hearing loss also revealed that participants felt others perceived them as being 
ignorant, unfriendly and unapproachable (Heffernan et al., 2016). These negative 
experiences indicate that hearing loss can lead to feelings of frustration, inadequacy and 
isolation, negative self-image and negative perceptions that others may have of the person 
with hearing impairment – in short, a diminished quality of life. However, no studies have 
acknowledged the impact a deterioration in hearing of sudden-onset following HNC 
treatment has on a patient’s quality of life, and no study, until now, had undertaken to 
evaluate the impact of HNC treatment on patients’ hearing.  
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1.2 Overview of head and neck cancer  
 
Cancers of the head and neck affect structures in the upper aero-digestive tract (Donovan 
and Glackin, 2012), and are classified by anatomical position. The major subtypes of the 
head and neck are: the oral cavity, nasal cavity and the paranasal sinuses, larynx, salivary 
glands and pharynx. The latter is further subdivided into the oropharynx, nasopharynx and 
hypopharynx areas (Palaniappan, Owadally and Evans, 2015). It can be seen in Table 1.1 
below that cancers of the oral cavity, and those of the oropharynx, are the most frequently 
diagnosed in the UK, from information obtained by the Healthcare Quality Improvement 
Partnership (HQIP), from the 2014 National Head and Neck Cancer Audit (HQIP, 2014). 
 
Head and neck cancer subtype Number Percentage (%) 
Oral cavity 2684 32.3 
Oropharynx 2439 29.4 
Larynx 1763 21.2 
Salivary Glands 504 6.1 
Hypopharynx 423 5.1 
Nasal cavity and paranasal sinuses 335 4.1 
Nasopharynx 151 1.8 
Table 1.1 Subtypes of head and neck cancer (England and Wales) (Health Quality 
Improvement Partnership, 2014) 
 
 
In addition to the 8299 patients, shown in Table 1.1, who were diagnosed with one of the 
seven subtypes of HNC in England and Wales, there were 130 with cancer of the mandible 
or maxilla (HQIP, 2014). These cancers were not included in the previous National Audit in 
2012 (HQIP, 2012), and this demonstrates that definitions of HNCs differ. Consequently, it is 
difficult to obtain comparative information of the proportion of subtypes in other countries 
that have different definitions of HNC. For example, current information available from the 
US provides information on the number of new cases of laryngeal and pharyngeal cancer, 
but does not provide the numbers in each subtype of pharyngeal cancer, or give data on the 
number of either salivary gland or nasal cavity cancer (Siegel, Miller and Jemal, 2017). It is 
therefore difficult to obtain a consistent reporting of HNC statistics.  
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Head and neck cancers account for 5% of all cancers (Goon et al., 2009) and are the 
seventh most common cancer worldwide, with men typically affected more than women by a 
2:1 ratio (Cancer Research UK, 2016). Ferlay et al. (2015) reported that there were 
approximately 529,000 new cases of HNC identified worldwide in 2012, when reporting on 
oral cavity, laryngeal and pharyngeal cancers. The HQIP reported in the 2012 National Head 
and Neck Cancer Audit that there were approximately 8,100 new cases of this disease in the 
UK in 2011 (HQIP, 2012).  
 
Although cancer of the oral cavity provides the greatest number of all the HNCs (Ferlay et 
al., 2015), there is wide global variation regarding the proportion of HNCs that contribute to 
overall cancer diagnoses. Men in developed countries have a higher proportion of oral 
cancer (7%) than those in less developed countries (5%), whereas men in less developed 
countries have a higher incidence of nasopharyngeal cancer (NPC) (2%) than those in 
developed countries (0.6%; Ferlay et al., 2015).  
 
In 2014, 3% of all new cancer cases in the UK (Cancer Research UK, 2016) originated in the 
head and neck region. Although information on the number of HNCs as a proportion of all 
cancers within many countries is not readily available, Table 1.2 provides information for 
comparing UK rates to those of The Netherlands and the United States: 
 
Country Proportion (%) 
The Netherlands 4.9 
US 3.7 
UK 3.0 
Table 1.2 Proportion of head and neck cancer of overall new cancer cases (Siegel, Miller 
and Jemal, 2017) 
 
 
The percentage of HNC diagnosed in the UK is lower than that of all new cancer cases 
(4.9%) in the Netherlands (Ledeboer et al., 2005), and different to that in the US (Siegel, 
Miller and Jemal, 2017). Variation in these proportions is due to the underlying aetiology, 
including different smoking and alcohol consumption rates, which will be discussed in the 
next section. 
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1.2.1 Aetiology of head and neck cancer 
 
Worldwide, tobacco smoking and alcohol consumption are the main causes of HNC 
(Donovan and Glackin, 2012). An article published by the American Cancer Society (ACS) 
for guidelines on Head and Neck Cancer Survivorship states that tobacco smoking and 
alcohol consumption account for 75% of cases of HNC (Cohen et al., 2016). Combined use 
of tobacco and alcohol increases the risk of developing HNC (Hashibe et al., 2009). In the 
UK, smoking and alcohol consumption (respectively) contribute up to 79% and 30% of HNC 
(Cancer Research UK, 2018a).  
 
Another cause for HNC is the chewing of recreational substances (betel leaf and areca nut) 
native to South Asian countries. This is specifically associated with increased risk of oral 
cavity cancer (Ho et al., 2002). Ingestion of mate, a tea drink common in South America, 
affects the oral cavity and also causes cancer in the pharynx and larynx (Goldenberg, Golz 
and Joachims, 2003).   
 
Occupational exposure to fine particles such as wood dust (Yu and Yuan, 2002) or 
chemicals including formaldehyde (Luce et al., 1993) can also cause HNC. Infection by the 
Epstein Barr virus causes nasopharyngeal (Chien et al., 2001) or salivary gland cancer 
(Chan et al., 1994), whereas the human papillomavirus (HPV) is another risk factor for 
oropharyngeal cancer (Adelstein et al., 2009; Cancer Research UK, 2017). Although alcohol 
consumption and smoking are still the main causes of HNC, trends in causation are 
changing due to efforts made to address substance use, and the rise in different sources of 
the disease. 
 
1.2.2 Incidence trends 
 
Health education programmes on smoking prevention in the US have been influential in 
decreasing US incidence of HNC due to tobacco use from 1985 to 2005 (Sturgis and 
Cinciripini, 2007). However, general lowering in incidence of HNC in the US due to tobacco 
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use has been countered by a rise in incidence due to HPV infection (Chaturvedi et al., 
2011). This change in epidemiology of HNC in the US has been reflected in England. The 
2010 document ‘Profile of Head and Neck Cancers in England’, produced by the Oxford 
Cancer Intelligence Unit (OCIU) provides trends for different types of HNC in England 
between 1990 and 2006, and noted that incidence of laryngeal cancer had fallen due to 
reduction in smoking. However, there had been an increase in oral cavity cancer incidence 
by 30% during that period, linked to an increase in migrants to the UK from South Asia who 
engage in betel leaf chewing. A doubling in the incidence of oropharyngeal cancer affecting 
younger people was detected, attributed to the rise in HPV infection (OCIU, 2010).  
 
Overall, between the decade spanning 2003-2005 and 2013-2015, there has been an 
increase in incidence of HNC in the UK by 24% (Cancer research UK, 2018b), with the 
highest number of new cases diagnosed (between 2013-2015) in people aged between 65 
and 69 years of age (Cancer research UK, 2018c). In addition to the rising incidence of HNC 
in the UK, there is an increase in survival rates from being diagnosed with HNC which is 
discussed below. 
 
1.2.3 Survival rates 
 
Survival rates for different types of HNC in England for men are given in Table 1.3 below 
alongside comparison with other European populations (Cancer research UK, 2017b). 
 
Location England (%) Europe (%) 
Lip 88 88 
Tongue 47 39 
Nasopharynx 47 47 
Oropharynx 44 36 
Hypopharynx 25 24 
Larynx  63 59 
Table 1.3 Five-year survival rates for men in England compared to Europe (Cancer 
research UK, 2017b) 
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Although there is some similarity between survival rates in England and Europe, there are 
notable differences with tongue and oropharyngeal cancer. Explanations for international 
differences include differences in the stage at which a diagnosis is made and access to high-
quality care (De Angelis et al., 2013). 
 
Cancer UK has compared overall 1-year and 5-year survival rates for each subtype of HNC, 
for patients diagnosed between 2009 and 2013 in England, summarised in Table 1.4:  
 
Head and neck cancer subtype 1 year (%) 5 years (%) 
Hypopharynx 60.5 27.8 
Nasopharynx 80 50 
Nasal cavity and paranasal sinuses 74.8 51.4 
Oral cavity 78.4 56.1 
Oropharynx 83.7 65.6 
Larynx  85.3 65.4 
Salivary gland 85.8 67.0 
Table 1.4 Survival rates for head and neck cancer (England) (Cancer Research UK, 2017c) 
 
In England, survival rates varied considerably, based on the location of the cancer within the 
head and neck region. It is interesting to note that patients who have cancers in the adjacent 
regions of the hypopharynx and larynx had widely different survivorship rates, due to the 
stage at which a diagnosis is made. Although laryngeal and hypopharyngeal cancers have 
similar aetiology (mainly tobacco use and alcohol consumption), laryngeal cancers are often 
diagnosed at an early stage (due to symptoms such as acquiring a hoarse voice), whereas 
the symptoms of difficulty in swallowing, that characterise hypopharyngeal cancers, are 
often detected at an advanced stage of disease (Palaniappan, Owadally and Evans, 2015). 
Cancer Research UK provides data to show that differences in survivorship may also occur 
within subtypes of HNC depending on the stage of disease at diagnosis. For example, 
survival rates for laryngeal cancer in England, at five years following diagnosis range from 
approximately 90% to 40% for early and advanced stage disease respectively (Cancer 
Research UK, 2018d).   
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Although there is an increasing number of HNC patients being diagnosed each year, the 
OCIU (2010) provides information showing that there has also been increased survivorship 
in England from the early 1990s to the 2000s, which is summarised in Table 1.5: 
 
Head and neck  
cancer subtype 
 1-year survival rate (%) 5-year survival rate (%) 
1990-2 2004-6 1990-2 2000-2 
Hypopharynx 49.0 58.9 22.3 26.1 
Nasopharynx 65.9 78.5 39.8 49.4 
Oral cavity 72.5 78.7 49.6 55.6 
Oropharynx 65.6 79.2 38.0 52.1 
Larynx 82.8 85.1 64.2 65.3 
Salivary gland 76.2 83.7 58.5 69.3 
Table 1.5 Improved survival rates over time (England) (Oxford Cancer Intelligence Unit, 2010) 
 
 
An increase in survival rates for all subtypes of HNC, at both one year and five years after 
diagnosis (Table 1.5), has been attributed to an improvement in diagnostic techniques and 
the development of new regimens incorporating a combination of treatments. The use of 
radiotherapy (RT) in addition to surgery has led to increased survivorship for salivary gland 
cancer, and the use of chemoradiotherapy (CRT) rather than RT alone has improved 
nasopharyngeal survival rates (OCIU, 2010). Increases in survival for people with HNC 
mean that more people are living with these cancers for longer and the quality of their 
survivorship needs to be addressed. Survivorship will be discussed after a more detailed 
update on current UK treatments.  
 
1.2.4 Treatment of head and neck cancer  
 
Cancer treatment is either curative or palliative in intent. Curative, or radical, treatment of 
HNC was the focus of the current study, as the purpose of this treatment regimen is to 
maximise cure and local control of the cancer. In addition, curative treatment aims to 
minimise functional damage to the region affected by the cancer, and reduce collateral 
damage to other organs, although current management guidelines do not refer to ear related 
side-effects from treatment (Palaniappan, Owadally and Evans, 2015). Palliative treatment, 
on the other hand, differs in intent, with the aim to control the disease rather than to provide 
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a cure (Palaniappan, Owadally and Evans, 2015). The principal curative treatments for HNC 
in the UK are surgery, RT and chemotherapy. Treatment regimens can involve the use of 
one (primary) treatment or a combination of modes of treatment – surgery is advocated for 
the removal of disease or to limit its spread.  
 
Radiotherapy is used to target and kill local cancer cells using high-energy electromagnetic 
rays and is used in the treatment of 60-70% of patients with HNC (Palaniappan, Owadally 
and Evans, 2015). Radiotherapy can be used alone or following surgery. Another form of 
therapy is targeted molecular therapy that uses biological agents to block specific cellular 
pathways to hinder cancer growth (Rao, Fury and Pfister, 2012). Targeted molecular therapy 
can be administered in conjunction with chemotherapy (Russell and Colevas, 2012) or with 
RT (Palaniappan, Owadally and Evans, 2015). In the UK, standard RT treatment for HNC is 
typically a dose of 65 Gy delivered in 30 fractions over a six-week period, while the principal 
chemotherapy drugs used are the platinum-based compounds cisplatin and carboplatin. 
Typical chemotherapy regimens include administration of cisplatin 100 mg/m2 twice (within a 
month) or weekly cisplatin at 40 mg/m2 for six weeks (Palaniappan, Owadally and Evans, 
2015). Cancers in the head and neck can be described by histology. The majority (90%) of 
cancers in this region arise from the squamous cell layer and are named head and neck 
squamous cell carcinoma (Bose, Brockton and Dort, 2013). Targeted molecular therapy 
includes the use of cetuximab, an inhibitor that specifically targets the epidermal growth 
factor receptor which commonly is over-expressed in squamous cell carcinoma (Bonner et 
al., 2006).  
 
Planning treatment for patients with HNC requires careful consideration of the tumour 
characteristics, the cancer’s location, the patient’s overall health, and the morbidity 
associated with treatment (Palaniappan, Owadally and Evans, 2015). Cancers are classified 
as early (0-II) or late (III-IV) stage, based on the ‘TNM’ system of measuring: the size of the 
tumour (tumour – T); assessing whether the cancer has spread to local lymph nodes (N); 
and gauging if there has been metastasis of the cancer (M). Early stage cancers have not 
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spread to the lymph nodes, whereas late stage cancers may have done so. Appendix 1.1 
shows detailed staging of HNCs (Cancer Treatment Centres of America, 2016).  
 
Location Total 
cases 
Curative 
treatment 
Surgical  Non-
surgical  
 
% of curative 
treatment that is 
non-surgical  
Tongue 880 593 515 78 13.2 
Oropharynx 2035 1476 433 878 59.5 
Larynx (early) 756 501 136 365 72.9 
Larynx (late) 579 380 193 187 49.2 
Table 1.6 First treatment received for head and neck cancer (Healthcare Quality Improvement 
Partnership, 2014) 
 
 
Eighty-six percent of patients diagnosed with HNC in the UK (England and Wales) receive 
treatment (HQIP, 2014), although it is not clear what percentage receive curative or palliative 
treatment. Table 1.6 shows the first treatment received in curative treatment for some of the 
subtypes of HNC (HQIP, 2014). It can be seen that surgery is the main treatment used for 
cancer of the tongue, while the proportion of non-surgical treatment is greater in treating 
other cancers, such as oropharyngeal or laryngeal cancer. Palaniappan, Owadally and 
Evans (2015) note that the treatment type that is provided depends on the stage of cancer, 
with a greater proportion of early stage laryngeal cancers being treated using RT, compared 
with later stage cancers. Surgery is not advised for curative nasopharyngeal treatment, due 
to the location of the nasopharynx close to critical structures in the skull base; instead RT is 
used for early stage, and CRT for later stage treatment of NPC respectively.   
 
The treatment regimen selected involves multidisciplinary team (MDT) discussion on the 
prospect of physical and functional organ preservation, and possible side effects of 
treatment (Simcock and Simo, 2016). While it is not clear what proportion of treatment 
regimens use singular or multimodal therapy, treatment for early stage HNC tends to be 
single modality, whereas advanced cancers of stage III and IV in any location within the 
head and neck are treated using a multimodal regimen (Palaniappan, Owadally and Evans, 
2015). A patient’s age and overall health will affect the treatment selected for HNC. The 
Karnofsky performance scale is used as a measure of patient health and functional status 
 41 
prior to treatment and is used in HNC treatment services; higher scale scores indicate 
suitability of using radical, curative treatment (Bonner et al., 2006). Among older patients, 
the effects of alcohol and smoking related co-morbidities including cardiac and respiratory 
problems may lower performance scale scores and thereby reduce treatment options 
(Lalami et al., 2009). 
 
1.2.5 Survivorship 
 
Follow-up of patients with HNC has primarily focussed on ensuring that there is no 
recurrence of disease (Simo et al., 2014). More recently, concern has shifted to the overall 
well-being of cancer survivors post treatment, and an increasing emphasis has been placed 
on the need to cope with side effects of treatment (Simcock and Simo, 2016). Table 1.7 
summarises some side effects resulting from treatment for HNC, following surgery, RT, 
chemotherapy, and combined CRT. It shows that hearing deterioration is clearly identified as 
a side effect for most treatments: 
 
Treatment Side effect 
Surgery 1 Alteration of cosmetic appearance  
Facial nerve paralysis 
Radiotherapy 2 Mucositis 
Hearing deterioration 
Chemotherapy 3 Renal dysfunction 
Hearing deterioration 
Combined chemoradiotherapy 4 Swallowing dysfunction 
Hearing deterioration 
Table 1.7 Side effects of treatment  
Key: 1 – Simcock and Simo, 2016; 2 – Jereczek-Fossa et al., 2003; Bentzen and Trotti, 2007; 3 – Lalami et al., 
2009; 4 – Frowen and Perry, 2006; Theunissen et al., 2015 
 
 
Each of the side effects recorded in Table 1.7 may affect patient well-being. Patients are 
presently encouraged to provide feedback on any symptoms they experience following 
treatment. The London Cancer Alliance’s Holistic Needs Assessment (London Cancer 
Alliance, 2013) does not have hearing loss as a side effect of treatment, however, Aintree 
University Hospital has included hearing problems in their patients concerns inventories 
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used for assessing well-being after diagnosis and following treatment (Aintree University 
Hospital, 2017 and 2018). While hearing-related problems are beginning to be recognised by 
some service providers, hearing problems following treatment have not been recognised at a 
national policy level. 
 
The HQIP 2014 HNC audit recognises that patients require intensive multimodality 
treatments and prolonged rehabilitation/long-term support to achieve an adequate recovery. 
However, hearing loss is not included among the long list of side-effects suffered by HNC 
patients following treatment. Likewise, the Department of Health (DH) document on 
survivorship ‘Improving Outcomes: A strategy for Cancer’ (DH, 2011) recognises the need to 
reduce ill health associated with cancer treatment including unmet physical or psychological 
support needs, but does not mention the need to offer support to adult patients in the UK 
who have hearing loss as a result of their treatment, which is surprising as the use of RT, 
with or without chemotherapy, is associated with hearing deterioration following cancer 
treatment. It is important therefore to understand the extent and impact of hearing loss on 
HNC patients, which is what this study was designed to address.   
 
1.3 Summary 
 
Since the beginning of the early 2000s, there has been an increase in the incidence of HNC 
cases in the UK year on year. This increase is linked to changing aetiological factors, with 
the decrease in alcohol consumption and tobacco use (the principal causes of HNC), being 
countered by the increase of other factors that include HPV associated infection. In addition, 
there is evidence of enhanced survivorship attributed to improved diagnosis and treatment of 
the disease. Many more people are living five or more years following diagnosis when 
compared to the early 1990s. Consequently, there has been a shift in focus with cancer 
treatment, from solely reducing the risk of disease recurrence, to providing an effective cure 
with minimal side effects. However, a deterioration in hearing following treatment is not 
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thought to be a significant occurrence as it does not feature in current National Health 
Service (NHS) policy on cancer survivorship (DH, 2011), even though acquired hearing loss 
has considerable implications for patient quality of life because of its wide-ranging effects on 
communication and social effectiveness. The next chapter reviews the literature on ear-
related side effects following HNC treatment.  
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Chapter 2 Literature review 
 
 
 
2.1 Introduction  
 
There already are reviews on hearing deterioration following HNC treatment (for example 
Mujica-Mota, Waissbluth and Daniel, 2013; and Theunissen et al., 2015), but these reviews 
are limited by including papers that: assessed hearing change using outdated treatment 
methods; focussed on one particular type of hearing loss – SNHL; included papers on 
children and adolescents; considered only the number of people affected rather than 
explored experience of hearing deterioration. These limitations helped to formulate the 
questions for the literature review presented in this chapter: how many adult patients who, 
following treatment for their HNC using current techniques, have hearing loss? What is their 
experience, and are there any factors that influence a change in hearing? 
 
This chapter begins with an outline of the search strategy used to identify relevant literature, 
and then appraises the quality of the papers selected. It then continues with a narrative 
reporting on themes based on the review questions, and then continues with a synthesis of 
the findings to formulate the research aims. The outline for the chapter is provided by Figure 
2.1 below: 
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Figure 2.1 Outline of Chapter 2 
 
 
2.2 Search strategy 
 
A search undertaken systematically was adopted to identify literature and to answer the 
questions: how many adult patients who, following treatment for their HNC using current 
techniques, have hearing loss? What is their experience, and are there any factors that 
influence a change in hearing? 
 
2.2.1 PICO 
 
The PICO model was used for clarifying terms to be used in a literature search strategy 
(University of Illinois, 2017). For this search, the ‘P’ (Population) were patients who had 
HNC; the ‘I’ (Intervention, exposure, cause or prognosis) was treatment of HNC; ‘O’ 
(Outcome measured) was hearing deterioration following treatment. There was no ‘C’ 
PICO terms used 
Database search and selection of 
articles using the PRISMA flow chart 
Data extraction   
to formulate 
summary tables 
 
Quality assessment of selected articles 
Critical appraisal of generated themes 
 
Synthesis of results and 
formulation of 
the research aims  
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(Comparison) in the search question. The search terms used for each of these three key 
phrases (head and neck cancer/ treatment/ hearing deterioration) were confirmed as 
appropriate by two academic librarians, with experience in searching literature from medical 
journals in general, and with one possessing particular experience in searching ear, nose 
and throat (ENT) journals.  
 
The three key phrases were searched within the PubMed database using relevant terms or 
subject headings (in brackets) for each phrase: 
1. Population – Head and neck cancer: {MH “Head and Neck Neoplasms”} OR 
{[cancer* OR carcinom* OR neoplasm* OR tumor* OR tumour*]} AND [head* OR 
neck* OR (MH “Head+”) OR (MH “Neck+”) OR ear* OR throat* OR laryng* OR (MH 
“Salivary Glands+”) OR salivary gland*]}; 
2. Intervention – Treatment: [(MH “Drug Therapy+”) OR (MH “Radiotherapy+”) OR (MH 
“Otolaryngology+”) OR (MH “Surgical Oncology”) OR (MH “Medical Oncology+”) OR 
chemotherapy* OR radiotherapy* OR “surg* N3 cancer*” OR “surg* N3 carcinoma*” 
OR “surg* N3 neoplasm*” OR “surg* N3 tumor*” OR “surg* N3 tumour*” OR “treat* 
N2 cancer*” OR “therap* N2 cancer*” OR (MH “Molecular Targeted Therapy”) OR 
(MH “Antibodies, Monoclonal+”); 
3. Outcome – Hearing deterioration: [(MH “Hearing Disorders+”) OR “hearing N3 
disorder*” OR “hearing N3 loss” OR “hearing N3 problem” OR “hearing N3 difficult+” 
OR deaf* OR hypoacus* OR otot*]. 
 
The searches for key phrases 1, 2 and 3 were then combined using the AND command to 
identify relevant literature on: how many adult patients who, following treatment for their 
head and neck cancer using current techniques, have hearing loss? What is their 
experience, and are there any factors that influence a change in hearing? This search 
strategy was then translated for use across other databases that contained literature which 
used quantitative or qualitative methods to address research in the health sciences. 
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2.2.2 Databases and PRISMA 
 
Searches of eight electronic databases were performed between 19 December 2017 and 17 
January 2018; the following databases were used:  
• MEDLINE, CINAHL, PsycARTICLES, PsychINFO, Psychology and behavioural 
sciences collection (assessed via the EBSCO host);  
• EMBASE (via ProQUEST);  
• COCHRANE (via Wiley) and  
• Web of science (via Clarivate Analytics) 
 
Although the researcher was aware that a systematic review would provide the most robust 
appraisal of the literature and synthesis of results (Mallett et al., 2012), it was decided to 
undertake a review conducted systematically from a pragmatic and time consideration 
perspective. 
 
Articles were then selected using the PRISMA method (Figure 2.2) for identifying relevant 
literature (Moher et al., 2009). The PRISMA flow-chart has a clear format that was adapted 
in this study for selecting articles for a narrative review.  
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Figure 2.2 Search strategy to identify articles on incidence and experience of hearing  
                     loss in people having had treatment for their head and neck cancer  
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2.2.3 Inclusion and exclusion criteria 
 
The researcher selected or excluded articles based on information contained in their title, 
abstract or full text, using the following inclusion and exclusion criteria:  
 
Inclusion criteria – studies that were: 
 
• Research using qualitative, quantitative or mixed-methods approaches to assess 
incidence of hearing loss, or patient experience of hearing loss, following treatment 
with curative intent for HNC at any point in time; 
• Original articles in peer-reviewed journals; 
• Conducted with human subjects; 
• Conducted with adults – aged 18 years plus; 
• Written in the English language. 
 
Exclusion criteria –  studies that were: 
 
• Investigating benign tumours, skull-based cancer or cancer arising from outside the 
head, childhood cancer (including adolescents) or cancers of the auditory system; 
• Assessing tinnitus [the perception of sound that is not generated from an external 
source (Baguley, Cope and McFerran, 2016)] only; 
• Assessing balance problems only; 
• Assessing the mechanics of hearing loss but not assessing perceptual change from 
baseline by psychoacoustic testing; 
• Using novel or obsolete treatment methods; 
• Case reports, review articles in peer-reviewed journals, presentations at conferences 
or editorials; 
• Assessing recurrent or metastatic disease, solely measuring hearing loss caused by 
disease, multiple cancer studies (unless HNC was assessed independently), or 
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studies using palliative treatment. This approach resulted in 15 articles for in-depth 
review, with 16 articles excluded following review of the full paper (Table 2.1): 
 
1st Author (year) Focus Why excluded 
Chen (2006) Sensorineural hearing loss following 
treatment of NPC 
Included children 
Hitchcock (2009) Sensorineural hearing loss following 
treatment of HNC 
Did not provide incidence rates of hearing loss or 
experience of it 
Huang (2015) Toxicity and quality of life in NPC 
following treatment 
Included children 
Hwang (2015) Hearing assessment after treatment 
of NPC  
Results from current treatment were not 
separated from obsolete treatment  
Jereczek-Fossa 
(2011) 
Hearing assessment after treatment 
of parotid cancer 
Results from patients who had recurrent or 
metastatic disease were not separated from 
those who were newly diagnosed 
Low (1996)
  
Hearing before and after radiotherapy 
of NPC 
Did not measure a change in hearing  
Low (2006) Sensorineural hearing loss following 
treatment of NPC 
Included children 
Theunissen 
(2014a) 
Cochlea function after treatment of 
HNC 
Results from patients who had ear related 
disease, or from an unknown primary were not 
separated from those who had HNC 
Tsang (2012) Otologic function after treatment of 
NPC 
Did not provide incidence rates of hearing loss or 
experience of it 
Wang (2003) Hearing assessment after treatment 
of NPC 
Included children 
Wang (2004)
  
Hearing assessment after treatment 
of NPC 
Included children 
Wang (2009) Middle ear function following 
treatment of NPC 
Results from patients who had recurrent disease 
were not separated from those who were newly 
diagnosed 
Wolden (2006) Hearing assessment after treatment 
of NPC 
Included children 
Zuur (2007) Ototoxicity after treatment of HNC Results were duplicated within an included article 
Zuur (2008) Hearing assessment after treatment 
of HNC 
Results from patients who had lung or 
oesophageal disease were not separated from 
those who had HNC 
Zuur (2009) Risk factors for hearing loss after 
treatment of HNC 
Results from patients who had recurrent or 
metastatic disease were not separated from 
those who were newly diagnosed 
Table 2.1 Papers excluded following full review 
Key: HNC – head and neck cancer; NPC – nasopharyngeal cancer     
  
 
2.2.4 Data extraction  
 
The researcher extracted data systematically from the 15 selected articles using forms 
based on the COCHRANE data collection form (COCHRANE, 2017) for quantitative data. 
The forms were amended to include the COREQ checklist (Tong, Sainsbury and Craig, 
2007), and Maxwell checklist (Maxwell, 1992), to obtain data from qualitative studies. Data 
that were extracted are shown in Table 2.2.
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General information  
Date the form  
 was completed 
Name of person  
 extracting data 
Title of the      
 article 
Authors Journal of  
 publication 
Date of publication 
 
Country in which the  
 study took place 
Population and setting 
Definition of head     
 and neck cancer 
Subtypes of cancer  
 investigated 
Stage of  
 cancer 
Histology 
Aetiology 
Inclusion criteria 
Exclusion criteria 
Method of  
 recruitment 
 
Was recruitment  
 done in an  
 acceptable way? 
Methods   
Aims of Study 
 
Are aims clear? Design 
 
Methodology Start date 
 
End date Duration of  
 participation 
Participants 
Total number  
People per cluster  
Subgroups reported Age 
 
Sex  
 
Co-morbidities Were there baseline   
 imbalances between  
 groups? 
Withdrawals and  
 exclusions 
Quantitative method checklist   
What Test was  
 performed 
Definition of hearing  
 change 
Is testing technique  
 validated? 
Is equipment  
 validated/calibrated? 
Time points for testing 
Is a reason given for time points of testing? 
 
Imputation of missing  
 data: if yes – what  
 method used? 
Is statistical   
 analysis used  
 appropriately?  
 
Have confounding  
 factors been  
 identified? 
Have confounding  
 factors been  
 accounted for? 
Risk of bias and validity 
Was patient  
 assignment  
 randomised?  
Was blinding of  
 participants     
 and personnel done?  
Blinding of  
 outcome  
 assessment 
Incomplete  
 outcome data 
Other bias 
Selective  
 outcome  
 reporting? 
Treatment group information 
Type of treatment 
 
Number randomised to  
 group 
Description of  
 intervention 
Duration of treatment  
 period 
Timing of  
 treatment 
Results: hearing deterioration incidence 
Time point after treatment and hearing  
 frequency (range) assessed 
Risk factors for hearing deterioration 
Quality assessment of results for randomised controlled trials and cohort studies  
How precise are the  
 results? 
Do you believe  
 the results?   
Can the results be applied to the 
local population? 
Do the results of this study fit with other    
 evidence? 
What are the implications of this study for  
 practice? 
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Qualitative method checklist  
Which author/s  
 conducted the    
 interview or focus  
 group?  
What were the researcher’s  
 credentials?  
What was the 
researcher’s  
 occupation at the time of  
 the study?  
Was the researcher male/  
 female?  
What experience or training 
had the researcher? 
Was a relationship  
 established prior to  
 starting the study? 
 
What did the  
 participants know  
 about the researcher?  
What characteristics were  
 reported about the  
 interviewer/facilitator?  
What methodological  
 orientation was stated to  
 underpin the study?  
How were participants  
 selected?  
 
Method of approach: How  
 were participants  
 approached?  
Sample size: How  
 many participants  
 were in the study?  
How many people     
 refused to participate  
 or dropped out?  
 
Setting of data  
 collection: Where was the  
 data collected? 
Was anyone else present  
 besides the participants  
 and researchers?  
What are the important  
 characteristics of the   
 sample?  
 
Were questions, prompts,  
 guides provided by the  
 authors? Was it pilot  
 tested?  
Were repeat interviews  
 carried out? If yes,  
 how many?  
 
Did the research use  
 audio or visual  
 recording to collect the  
 data? 
Were field notes made  
 during and/or after the   
 interview or focus group?  
What was the duration of  
 the interviews or focus  
 group? 
Was data saturation   
 discussed? 
Were transcripts returned to  
 participants for comment    
 and/or correction?  
How many data coders  
 coded the data?  
 
Did authors provide a  
 description of the  
 coding tree?  
Were themes identified in  
 advance or derived from the  
 data?  
What software, if  
 applicable, was used to  
 manage the data? 
Did participants provide  
 feedback on the findings 
 
Were participant quotations  
 presented to illustrate the  
 themes / findings? Was   
 each quotation identified? 
Was there consistency  
 between the data   
 presented and the      
 findings? 
Were major themes  
 clearly presented in  
 the findings 
Is there a description of 
 diverse cases or discussion  
 of minor themes?  
    
Results: Hearing deterioration – patient experience 
Themes 
Quality assessment of results for qualitative studies 
How factually accurate  
 is the account?   
How well do findings    
 represent meanings from  
 the participants’ perspective? 
How do the findings of  
 the study support  
 underlying theory? 
How generalisable are the  
 results 
 
How reproducible are the  
 results?    
 
Has the researcher  
 minimised their bias? 
 
Have ethical issues been taken into consideration? 
Other information  
Have important populations been excluded from the  
 study?  
 
Does the study directly address the review question?  
 
Key conclusions of study authors 
 
Table 2.2 Data extracted from included articles
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An example of a completed data extraction form that was used for obtaining data from a 
paper that used quantitative methods is in Appendix 2.1, and an example used for obtaining 
data from a paper that employed qualitative methods is in Appendix 2.2. Data from the 
extraction assessment forms included quality assessment derived from the Critical Appraisal 
Skills Programme (CASP) checklists for cohort and qualitative studies (CASP 2017a; CASP 
2017b). 
 
2.3 Quality assessment 
 
The CASP checklists have a ‘yes’, ‘no’ or ‘cannot tell’ scoring system for nine (qualitative 
study) or 11 (quantitative study) aspects of quality assessed. However, CASP checklists do 
not provide an overall score of quality. Other research appraisal systems do provide an 
overall score, but these are focussed solely on randomised controlled studies, e.g. the 
Jadad score (Moher et al., 1998) or systematic reviews, e.g. the Qualsyst evaluation tool 
(Kmet, Lee and Cook, 2004). The Mixed Methods Assessment Tool (Pluye et al., 2011) has 
the benefit of comparing studies of different methodologies within the same checklist. 
However, it too does not have an overall score for quality, and is limited to the quality of 
study methods without an assessment of results obtained. Therefore, to gain an overall 
assessment of quality, the researcher created a rating scale based on the number of ‘yes’ 
responses obtained using the CASP criteria. The CASP criteria and derived rating schemes 
are shown for quantitative studies (Appendix 2.3) and for qualitative studies (Appendix 2.4). 
The grading of low, medium or high quality for each study was entered into the final column 
of summary Table 2.3 (below), with low being poor quality, medium being moderate quality, 
and high being good quality. 
 
The researcher made an assessment of quality for each of the 15 included articles. Nine of 
the papers were deemed to be of high quality, with four of moderate quality and two of low 
quality. One quantitative paper was chosen at random, and this, together with the qualitative 
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paper were independently assessed for quality by one of the student’s supervisors and a 
further independent researcher, using the developed criteria. There was complete 
agreement between all three researchers, implying that the results obtained by the 
researcher for all 15 papers would be representative of all three researchers. The different 
quality ratings that were obtained for the studies that employed quantitative methods will be 
discussed first, and will then be followed by a discussion on the quality of the one paper that 
utilised qualitative methodology. 
 
2.3.1 Quantitative paper quality 
 
For the 14 papers that used quantitative methodology, the CASP questions deemed most 
important on quality were: 
• Question 2 – Was the cohort recruited in an acceptable way – was everybody 
included who should have been included? This question assessed selection bias; 
• Question 4 – Was the outcome accurately measured to minimise bias – do the 
measures truly reflect what you want them to (have they been validated)? This 
question addressed measurement bias; 
• Question 9 – Do you believe the results – can they be due to bias, chance or 
confounding? Are the design and methods of this study sufficiently flawed to make 
the results unreliable? Question 9 inquired about reporting bias. 
 
Of these three questions, question 9 was scored ‘yes’ most often (eight out of 14 papers), 
with question 2 scored most poorly (only two out 14 papers marked ‘yes’). The main 
limitation of the quantitative papers therefore was in the selection of participants, and how 
many were included in analysis. None of the papers were scored ‘yes’ for each of these 
three questions, but those papers that were classified overall as being of high quality papers 
were characterised by being clear in how participants were recruited and in how audiological 
testing was performed, exemplified by Chan et al. (2009). Those that were of low quality 
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were characterised by not being clear how results were obtained for hearing deterioration, 
exemplified by Cho et al. (2016). 
 
2.3.1.1 Selection bias 
 
The third column of Table 2.3 shows a question mark before the sampling technique used 
for twelve of the papers that used a retrospective or prospective cohort study design. 
Although it was implicit that all suitable patients were available for recruitment, these papers 
were not explicit in the method in which subjects were selected, and it could not be assumed 
that all those diagnosed within the timeframes stated were indeed invited to participate. Only 
two papers (Chan et al., 2009 & Hsin et al., 2010) stated that the method of recruitment was 
consecutive sampling. However, this method of sampling has its limitations, as the sample 
may not be fully representative of the population (Bowers, House and Owens, 2011). 
 
Attrition bias is a form of selection bias that is evident from the drop-out rate of participation. 
The drop-out rate varied between papers even when they were assessed at the same time 
period after treatment. Whereas some papers had participation rates within the 60-90% 
range a year after treatment (for example 86% in Li et al., 2010, and 76% in Loimu et al., 
2015), one paper, Pan et al. (2005), had a much-reduced rate of 40%, but provided no detail 
as to why this rate was so low. It is possible that those participants who had not continued in 
the study by Pan et al. (2005) possessed different characteristics to those who remained in 
the study (for example they may have been exposed to a higher radiation dose), that may 
have influenced hearing deterioration rates. Therefore, the results from Pan et al. (2005) 
need to be treated with caution due to possible attrition bias. 
 
2.3.1.2 Measurement bias 
 
Measurement bias was potentially evident in all the 12 papers that measured hearing 
deterioration. Although PTA – used to determine the incidence in hearing deterioration – is 
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the basic and routine test conducted in audiology, it cannot be assumed that it is performed 
using standard techniques such as those recommended by the BSA (2011). It is important to 
specify what frequencies are tested in order to replicate findings. However, five articles (Cho 
et al., 2016; Cheraghi et al., 2015; Niemensivu et al. 2015, Pan et al., 2005; and Petsuksiri 
et al., 2011) were not clear in specifying what frequencies were tested for air and bone 
conduction levels, and consequently, it would not be easy to replicate the method used for 
PTA testing from each of these papers. In addition, none of the selected papers stated the 
technique used for performing PTA, and this could in part be explained by the majority of 
papers (62%) not being in audiology or otology journals, but being within oncology or 
radiology journals with less focus on testing technique compared to treatment regimes.  
 
However, Chan et al. (2009) in their publication within the International Journal of Radiation 
Oncology, Biology, and Physics, stated that equipment was calibrated every six months, 
therefore ensuring that sound stimuli for testing were within prescribed limits. Papers written 
in otology journals would be expected to provide more detail on testing method. Niemensivu 
et al., 2015 mentioned that licenced audiologists performed the testing in their paper 
published in the European Archives of Otorhinolaryngology, whereas Li et al. (2010) in the 
Journal of Laryngology and Otology, made no mention of calibration details nor personnel 
involved in testing.  
 
Although it was probable that testing was performed in routine and standard ways, there was 
greater potential for bias in how deterioration was classified because authors used different 
criteria for classifying hearing change (Table 2.3). Although there currently is no agreed level 
of clinical significance for hearing deterioration after treatment, the majority of papers in this 
review (seven out of 12) used a hearing deterioration of ≥15dB as significant. 
 
Standard PTA records hearing thresholds, between 0.25 to 8kHz, in 5dB levels, and the 
accepted test-retest variability within a clinical test session (lasting between 15-30 minutes) 
is 5dB (BSA, 2011). Therefore, it would seem reasonable to assume that a change in 10dB 
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would be a clinically significant deterioration following treatment, and this was used by 
Niemensivu et al. (2015), Pan et al. (2005), Petsuksiri et al. (2011) and Shorter et al. (2017). 
However, there is minimal evidence to support the use of a 10dB change in standard 
practice. Konrad-Martin et al. (2010), referred to by Niemensivu et al. (2015), determined 
that ≥10dB threshold hearing change, at two adjacent frequencies, was reliable in detecting 
ototoxicity, and this provides a useful bench mark. However, Konrad-Martin et al. (2010) 
based their findings on patients tested up to 20kHz of hearing, whereas standard practice is 
to test up to 8kHz. Simpson, Schwan and Rintelmann (1992), referred to by Petsuksiri et al. 
(2011), did not recommend a threshold dB change but rather recommended that an 
assessment of multiple frequencies was more accurate for detecting the ototoxic effects of 
cisplatin. Simpson, Schwan and Rintelmann compared change in hearing tests from 
baseline to tests performed up to 6 months after treatment, of 31 subjects who received 
cisplatin treatment (for what disease was not provided) compared with 21 controls who 
received no medication. Therefore, there is limited evidence to support a change in ≥10dB 
threshold as clinically significant.  
 
Most of the articles in this review (seven out of 12) used a ≥15dB change in threshold for 
determining a clinically significant change in hearing. In view of the difficulty in substantiating 
a clinically significant change, it is sensible to use a system employed by the majority of 
articles; five deemed to be of high quality. Two articles (Cheraghi et al., 2015, and 
Theunissen et al., 2014b) referred to guidelines produced by NCI. These guidelines are the 
CTCAE that are commonly used by oncologists to determine changes in function to different 
body systems following treatment. The CTCAE version used by Theunissen et al. (2014b) 
was v 3 (NCI, 2006), and that by Cheraghi et al. (2015) was v 4.03 (NCI, 2010). Each of the 
CTCAE versions 3 and 4.03 have the same criteria for changes in hearing, with the least 
change (Grade 1) being used by Theunissen et al. (2014b) and Cheraghi et al. (2015) to 
determine incidence in hearing deterioration. A Grade 1 change for hearing is an increase in 
hearing threshold of at least ≥15dB averaged at two contiguous test frequencies (1-8kHz) in 
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at least one ear (NCI, 2006 and NCI, 2010). Although the NCI do not provide references to 
support this criterion, Konrad-Martin et al. (2010) stated that the most reliable method for 
detecting hearing deterioration following ½-octave step frequency sizes was achieved for 
shifts ≥15dB at one or more adjacent frequencies. It has already been mentioned that 
Simpson, Schwan and Rintelmann (1992) recommended for an assessment across multiple 
frequencies in determining hearing deterioration. Therefore, combining the findings from 
Konrad-Martin et al. (2010) and Simpson, Schwan and Rintelmann (1992), it appears that a 
≥15dB shift in threshold, across two or more adjacent frequencies is the most appropriate to 
use in determining a clinically significant change in hearing; this is used in the CTCAE 
criteria. 
 
Measurement bias was also evident in one of the two papers that reported on quality of life 
rather than on incidence in hearing deterioration. The paper by Loimu et al. (2015) used the 
15D questionnaire that had been validated and widely used in patients with cancers other 
than head and neck. In contrast, Lastrucci et al. (2017) used five questionnaires in their 
study but the authors did not state the reliability and validity of some of these instruments, 
and therefore caution is required regarding the generalisability of results obtained in their 
study. 
 
2.3.1.3 Reporting bias 
 
In contrast to the concerns raised above regarding participant sampling and measurement of 
outcomes, the majority of the quantitative papers in this review were good at reporting 
results and the rationale behind statistical analysis used. Two exceptions though were Cho 
et al. (2016) and Niemensivu et al. (2015).  
 
Cho et al. (2016) were not clear in their methods how they arrived at a figure of <0.1% 
incidence in hearing deterioration in their study. In addition, Cho et al. (2016) investigated 
sudden deafness, which is defined as a rapid decline (less than three days) of more than (or 
		 59 
equal to) 30dB SNHL in at least three contiguous frequencies without an identifiable cause. 
However, Cho et al. (2016) only performed monthly audiological assessment, and so it is not 
clear whether the hearing loss they reported was strictly defined as sudden deafness. 
Reporting bias was also evident in the paper by Niemensivu et al. (2015). These authors 
addressed both hearing and tinnitus concerns in their paper. One table showed that two 
patients with a 0-score had slight tinnitus, yet others with a 0-score experienced no tinnitus – 
it was not made clear what was the distinction between ‘no tinnitus’ or ‘slight tinnitus’.  
 
 
2.3.2 Qualitative paper quality 
 
 
The one paper on patient experience, Nund et al. (2015), was of high quality. These authors 
described the use of maximum variation sampling to obtain a diverse sample to report on 
communication problems following HNC treatment. The authors also used open-ended 
interviews that were appropriate for the phenomenological stance adopted. The method for 
generation of themes was clearly stated using thematic analysis as outlined by  
Braun and Clarke (2006). Themes were explicated by incorporation of supportive participant 
quotes. However, there were some concerns with this paper regarding data density, as it 
was not clear how many interviewees were represented in each theme. There may also 
have been researcher bias, as the assumptions, reasons and interests in the research 
topic by the authors were not made clear. 
 
 
2.3.3 Summary of quality assessment 
 
 
There were some concerns regarding selection bias in the papers in this review that used 
quantitative methods, with the majority not being clear on how participants were recruited. It 
was noted that measurement bias was potentially evident in all of the quantitative papers 
reviewed, as none made clear the method for hearing testing. Only two papers referred to 
recommended guidelines that used evidence-based criteria for hearing change of ≥15dB 
averaged across several frequencies, although it was noted that there is no current standard 
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definition for clinically significant hearing deterioration. In contrast, the reporting of results 
overall in the quantitative papers was of good quality, and the one paper that used 
qualitative methods was also of good quality. Therefore, the overall method used for data 
collection and reporting in the 15 papers selected for this review was of good quality to draw 
valid conclusions from the following themes to be discussed. 
 
2.4 Summary of findings 
 
Data from the data extraction forms were used to create the literature review summary table, 
Table 2.3, depicting: the 1st author; the site of the cancer; the number of participants; what 
treatment was used; the classification used to identify a change in hearing; the study 
findings or results, and risk factors for hearing deterioration. The final column in Table 2.3 
has a rating of study quality, which was derived from the CASP checklists. 
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1st Author 
(year) 
country 
Site of Cancer  
No. of 
participants  
 
Study 
Design 
Sampling 
Method 
Treatment  
 
Classification of  
psychoacoustic 
hearing change 
(Frequencies) 
Study findings/ results Risk factors 
discussed 
*significant (p£0.05) 
Quality 
 
Chan  
(2009)  
Hong Kong 
Nasopharynx 
N=87 
Nasopharynx 
Quantitative 
RC 
? consecutive 
Pre-Post 
RT or 
CRT 
Increase in  
bone conduction  
thresholds 
³10dB (0.5-4kHz) 
Incidence of hearing loss 
range: 9-55% (see sections on 
incidence based on range of 
hearing, and time after treatment) 
Gender, *age, baseline 
hearing, *treatment dose and 
treatment regime, time of 
testing after treatment 
High 
Cheraghi  
(2015) 
Iran 
General  
Head and Neck 
N=29 
 
Quantitative 
PC 
? consecutive 
Pre-Post 
RT or 
CRT 
Increase in hearing 
thresholds 
³15dB (0.25-
12kHz) 
Incidence of hearing loss = 51% Age, treatment dose and 
treatment regime 
(no significance testing done) 
Medium 
Cho 
(2016) 
Taiwan 
Nasopharynx 
N=1636 
 
Quantitative 
RC 
Consecutive  
Pre-Post 
RT or 
CRT 
Increase in hearing 
thresholds 
³30dB (0.5-4kHz) 
Incidence of hearing loss <1% *Treatment type, *treatment 
dosage, age, gender, time of 
test,  
Low 
Hsin 
(2010) 
Taiwan 
Nasopharynx 
N=26 
 
Quantitative 
RC 
Consecutive 
Pre-Post 
RT or 
CRT 
Increase in  
bone conduction  
thresholds 
³20dB (0.5-4kHz) 
Incidence of hearing loss = 46% *Tumour size 
*Treatment type 
High 
Lastrucci 
(2017) 
Italy 
Nasopharynx  
N= 56  
 
Quantitative 
RC   
? consecutive 
Questionnaire 
RT or 
CRT 
Not measured 
 
Clinician rated hearing loss not 
related to questionnaire scores on 
quality of life 
Gender, age, tumour stage, 
time of assessment after 
treatment, * treatment type  
High 
Li 
(2010) 
China 
Nasopharynx 
N=42 
 
Quantitative 
PC 
? consecutive 
Pre-Post 
RT Increase in  
bone conduction  
thresholds 
³15dB (0.5-4kHz) 
Incidence of hearing loss  
range: 10-98% (see sections on 
incidence based on range of 
hearing, and time after treatment) 
 
*Time of test after treatment Medium 
Loimu  
(2015) 
Finland 
General  
Head and Neck 
N=64 
 
Quantitative 
PC 
? consecutive 
Questionnaire 
RT or 
CRT 
Not measured Questionnaire hearing scores at  
1-year post treatment did not differ 
from those at baseline 
Time of test after treatment 
Type of cancer 
Medium 
Niemensivu 
(2015) 
Finland 
General  
Head and Neck 
N=28 
 
Quantitative 
RC+PC 
? consecutive 
Pre-Post 
CRT  
 
Increase in  
bone conduction  
thresholds 
³10dB (0.5-8kHz) 
Incidence of hearing loss  
range: 0-32% 
(see section on incidence in hearing 
deterioration based on range of 
hearing) 
Treatment dose 
(no significance testing done 
for hearing) 
Low 
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1st Author 
(year) 
country 
Site of Cancer  
No. of 
participants  
Study 
Design 
Sampling 
Method 
Treatment  
 
Classification of  
psychoacoustic 
hearing change 
(Frequencies) 
Study findings/ results Risk factors 
discussed 
*significant (p£0.05) 
Quality 
 
Nund  
(2015) 
Australia 
General  
Head and Neck 
Survivors: 
N=14;  
Carers: N=9 
Qualitative 
Phenomenology 
Purposive 
Interview 
Non-
surgical 
therapy 
N/A Theme 1: Impairments in 
communication; 2: Challenges in 
everyday communicating; 3: Broad 
ranging effects of communication 
changes; 4: Adaptations made 
Not discussed High 
Oh 
(2004) 
South 
Korea 
Nasopharynx 
N=25 
 
Quantitative 
PC 
? consecutive 
Pre-Post 
CRT Increase in  
bone conduction  
thresholds 
³15dB (0.5-4kHz) 
 
Incidence of hearing loss range: 4-
27% (see sections on incidence 
based on range of hearing, and time 
after treatment) 
Gender, age, * middle ear 
status, *treatment type, 
*treatment dose 
High 
Pan 
(2005) 
US 
 
General  
Head and Neck 
N=35 
 
Quantitative 
PC 
? consecutive 
Pre-Post 
RT or 
CRT 
Increase in  
bone conduction  
thresholds 
³10dB (0.4-
0.8kHz) 
Incidence of hearing loss range: 22-
100% (see sections on incidence 
based on range of hearing, and time 
after treatment) 
Gender, *age, *Treatment dose Medium 
Petsuksiri 
(2011) 
Thailand 
Nasopharynx 
N=27 
 
Quantitative 
RC 
? consecutive 
Pre-Post 
CRT Increase in  
bone conduction  
thresholds 
³15dB (0.5-4kHz) 
Incidence of hearing loss range: 7-
37% 
(see section on incidence in hearing 
deterioration based on range of 
hearing) 
Age, co-morbidity, time after 
treatment, middle ear status, 
treatment type, *treatment 
dose 
High 
Shorter 
(2017) 
Australia 
General  
Head and Neck 
N=38 
 
Quantitative 
RC 
? consecutive 
Pre-Post 
CRT Increase in  
bone conduction  
thresholds 
BC ³10 or ³15dB  
(0.5-8kHz) 
Incidence of hearing loss range: 4-
93% 
(see section on incidence in hearing 
deterioration based on range of 
hearing) 
HPV status, *alcohol 
consumption and tobacco use, 
tumour stage/location, baseline 
hearing, treatment type, 
*treatment dose 
High 
Theunissen 
(2014b) 
The 
Netherlands 
General  
Head and Neck 
N=36 
 
Quantitative 
RC 
? consecutive 
Pre-Post 
CRT Increase in 
hearing 
thresholds 
³15 (0.25-12kHz) 
Incidence of hearing loss range: 78-
81% (see section on time after 
treatment) 
 
*Time of test after treatment High 
Wang 
(2015) 
China 
Nasopharynx 
N=51 
 
Quantitative 
RC 
? consecutive 
Pre-Post 
CRT Increase in 
hearing 
thresholds 
³15dB (0.5-4kHz) 
Incidence of hearing loss range: 16-
61% (see section on incidence in 
hearing deterioration based on 
range of hearing) 
Gender, *age, *tumour stage, 
*middle ear status, *treatment 
type, *treatment dose 
High 
Table 2.3 Summary table of data from articles for review 
Key: RC – retrospective cohort; PC – prospective cohort; RT – Radiotherapy; CRT – Chemoradiotherapy 
 
		 63 
2.4.1 Overview of selected articles 
 
 
Across 15 papers, 2184 patients were assessed who received HNC treatment, and nine 
carers were assessed in the work of Nund et al. (2015) (Table 2.3). The range of patients 
assessed in each paper ranged from 14 (Nund et al., 2015) to 1636 (Cho et al., 2016). All 15 
papers provided demographic information on the age of participants, with ages ranging from 
18 years (Petsuksiri et al., 2011) to 83 years (Lastrucci et al., 2017). The median age range 
across the papers was 42 years (Cheraghi et al., 2015) to 60 years (Theunissen et al., 
2014b). Thirteen papers provided the gender of participants; Petsuksiri et al. (2011) did not 
provide information on gender, whereas the gender of the participants in Chan et al. (2009) 
was not clearly provided. All thirteen articles that did provide the gender of HNC patients 
recruited a greater proportion of male participants, with almost equal numbers in Pan et al. 
(2005) (male to female ratio of 18:17) to the most extreme difference in numbers in Shorter 
et al. (2017) (male to female ratio of 33:5). As men are typically more affected with HNC 
than women by a 2:1 ratio (Cancer Research UK, 2016), it is not surprising that there were 
more males who received treatment in these studies compared with females. However, the 
ratio provided by Shorter et al. (2017) suggests that there was an over-representation of 
men in their study. This may have affected the results of incidence in hearing deterioration in 
the study by Shorter et al. (2017), if being male or female is considered a greater risk in 
developing hearing loss following treatment (see section 2.6.2 on risk factors associated with 
hearing deterioration).  
 
Eight papers focussed on NPC, whereas seven were on cancers within the HNC region in 
general (Table 2.3). Seven of the articles selected for review originated from South East 
Asia, and all of these focussed on cancers of the nasopharynx. Nasopharyngeal cancer is 
the most common cause of HNC in Southern China, and the 5th most common of all cancers 
in Hong Kong (Tsang et al., 2012), whereas NPC accounts for only 2% of HNC in the UK 
(HQIP, 2012). Although the initial search identified some papers that were conducted in the 
UK, these were excluded for various reasons (Appendix 2.5), including hearing loss as a 
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presenting feature of NPC (Glynn et al., 2006), rather than following treatment for this 
disease. 
 
Fourteen articles used quantitative methodology, whereas one used qualitative 
methodology; there were no mixed methods articles (Table 2.3). Twelve articles assessed 
incidence of hearing deterioration following treatment, whereas two measured quality of life. 
Only one of the papers used qualitative methodology to gain patient experience of hearing 
change (Nund et al., 2015). This was not unexpected given the relatively few articles using 
qualitative research in Audiology compared with quantitative studies (Vestergaard Knudsen 
et al., 2012), and within medicine in general (Gagliardi and Dobrow, 2011). 
 
Seven papers assessed the use of RT or CRT; six papers assessed only CRT treatment, 
and one paper assessed the use of RT alone (Li et al., 2010). Nund et al. (2015) did not 
make it clear what treatment was used, apart from that it involved non-surgical techniques. 
There was no initial restriction imposed for date of publication when performing the literature 
search, but only papers from 2004 onwards were selected. This reflected change in 
treatment regimens for HNC that arose around this time: radiotherapy advanced from earlier 
conventional 2-dimensional (2D) delivery to 3-dimensional (3D) and intensity modulated 
radiotherapy (IMRT), and bleomycin ceased to be used with these patient groups. However, 
although RT or concurrent CRT were used within the 15 selected papers, there was much 
variation in the combination and dosages of RT and chemotherapy used. It is noted that 
none of the papers assessed the effect of surgical intervention alone on hearing. 
 
A range of classification criteria was used for determining hearing deterioration, based on 
how much change in hearing was deemed to be clinically significant, and the hearing 
frequency range that was assessed (Table 2.3). The different criteria used contributed to the 
wide variation in reported incidence of hearing deterioration – from none (Niemensivu et al., 
2015) to 100% (Pan et al., 2005). This wide variation has been identified and reported in 
similar reviews (Theunissen et al., 2015; Mujica-Mota, Waissbluth and Daniel, 2013). There 
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was also large variation reported in the incidence of hearing deterioration within individual 
articles (including: Chan et al., 2009; Li et al., 2010; Shorter et al., 2017). These papers 
assessed hearing change across a different range of time-points after treatment: between 
one and three months after treatment (n=4 papers); at six months after treatment (n=5); one 
year after treatment, (n=5); two years after treatment (n=4); more than two but less than five 
years after treatment (n=4); and more than five years after treatment (n=3). 
 
Different factors were discussed that could contribute to hearing deterioration after 
treatment, with the treatment regimen itself being the factor most assessed in eleven papers 
Table 2.3). Other factors assessed were: age (seven papers); gender (five); tumour stage 
(four); time after treatment (seven), and middle ear status (three) for the development of 
SNHL. In view of the heterogeneity of factors that could contribute to the incidence of 
hearing deterioration, including different treatment regimens and the variety of hearing 
deterioration classification systems, the results of this literature review are presented as a 
narrative synthesis of themes derived from Table 2.3. 
 
2.5 Themes – Findings 
 
Information from Table 2.3 will be discussed in more depth within the following themes that 
address different aspect of the review questions: 
Theme 1 – Incidence of hearing deterioration -  
Incidence of sensorineural hearing loss in general head and neck cancer; 
Incidence of sensorineural hearing loss in nasopharyngeal cancer; 
Incidence of conductive hearing loss;  
Incidence in hearing deterioration based on range of hearing;  
Tests used -  
Tympanometry; 
Other. 
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      Theme 2 – Risk factors associated with hearing deterioration -  
Profile of patients; 
Age; 
Gender; 
Co-morbid disease; 
Recreational activity; 
Tumour size; 
Pre-treatment hearing level; 
Middle ear status; 
      Type of treatment -  
Radiotherapy technique; 
Radiotherapy dosage; 
Chemotherapy; 
Time after treatment. 
 
      Theme 3 – Patient experience -   
Quality of life; 
Lived experience. 
 
2.5.1 Theme 1 – Incidence of hearing deterioration 
 
The first question of this review was: how many adult patients who, following treatment for 
their HNC using current techniques, have hearing loss? Within the 12 articles that measured 
hearing deterioration following HNC, there was the widest possible range of 0-100% 
incidence. Five of these articles reported on treatment of general HNC (Cheraghi et al., 
2015; Niemensivu et al., 2015; Pan et al., 2005; Shorter et al., 2017; Theunissen et al., 
2014b), whereas the remaining seven focussed only on cancer of the nasopharynx (Chan et 
al., 2009; Cho et al., 2016; Hsin et al., 2010; Li et al., 2010; Oh et al., 2004; Petsuksiri et al., 
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2011; Wang et al., 2015). All 12 papers measured the incidence of SNHL, however, only five 
(Hsin et al., 2010; Oh et al., 2004; Petsuksiri et al., 2011; Theunissen et al., 2014b; Wang et 
al., 2015) also measured mixed or conductive loss. 
 
This theme will report first on the findings of SNHL in people following treatment of general 
HNC, secondly on papers reporting SNHL in people following treatment of NPC only, and 
thirdly on conductive hearing loss following treatment. It will then conclude with the variation 
in incidence based on which frequency range was assessed, and the tests used in 
assessment.  
 
2.5.1.1 Incidence of sensorineural hearing loss in general head and neck cancer 
 
There were five papers that reported on sensorineural hearing deterioration following 
treatment for general HNC, ranging from 0-100% incidence (Cheraghi et al., 2015; 
Niemensivu et al., 2015; Pan et al., 2005; Shorter et al., 2017; Theunissen et al., 2014b).  
 
There was only one paper reporting 0% incidence (Niemensivu et al., 2015), and also only 
one that reported 100% incidence (Pan et al., 2005). Both Niemensivu et al. (2015) and Pan 
et al. (2005) reported their findings on a small sample of general HNC patients. Although 
Niemensivu et al. (2015) assessed 28 patients in their study, only 22 underwent hearing 
testing before and after treatment. Pan et al. (2005) conducted serial hearing tests and 
reported 100% incidence of hearing loss in two patients tested at 2½ years after treatment. 
However, it is difficult to draw conclusions from Pan et al. (2005) and from Niemensivu et al. 
(2015) given the small sample sizes. 
 
Three studies on general HNC reported incidence of sensorineural hearing deterioration 
between 4-93% (Cheraghi et al., 2015; Shorter et al., 2017; Theunissen et al., 2014b). 
These three papers were assessed as being of moderate to high quality (Table 2.3), and 
reported their incidence rates of hearing deterioration on larger, albeit still small, sample 
sizes of: n=29 (Cheraghi et al., 2015); n=38 (Shorter et al., 2017); n=36 (Theunissen et al., 
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2014b). Therefore, there is a little more confidence in the validity of results from these three 
studies compared with the studies by Niemensivu et al. (2015) and Pan et al. (2005) 
regarding the range in incidence of hearing deterioration. However, there were limitations in 
each of these three studies in the range of subjects who were assessed.  
 
The paper by Theunissen et al. (2014b) only assessed patients with oropharyngeal, oral 
cancer or hypopharyngeal cancer. In contrast, Cheraghi et al. (2015) included patients with a 
greater range of HNCs, including those who had NPC, parotid cancer, or cancer of the 
sinuses. These three subtypes of HNC accounted for 72% of the patients in the study by 
Cheraghi et al. (2015), but account for only 12% of patients who have HNC in the UK (HQIP, 
2012). The study by Shorter et al. (2017) included patients with cancer of the oropharynx 
who received treatment, and these patients accounted for 70% of their study sample. 
However, only 28% of HNC patients have oropharyngeal cancer in the UK (HQIP, 2012). 
Therefore, although there is evidence to suggest that sensorineural hearing deterioration 
following treatment of general HNC has ranged between 4-93%, it is not clear if this range 
applies to a general cohort of UK HNC patients eligible for treatment.  
 
 
2.5.1.2 Incidence of sensorineural hearing loss in nasopharyngeal cancer 
 
The incidence of sensorineural hearing deterioration reported in the seven articles on 
treatment of NPC range from <1% (Cho et al., 2016), to 98% (Li et al., 2010). However, the 
paper by Cho et al. (2016) was deemed to be of overall low quality (Table 2.3), and 
incidence in hearing deterioration was based on a higher change (30dB) compared with the 
other papers that assessed changes in hearing following treatment of NPC. Therefore, the 
results from Cho et al. (2016) have limited generalisability, and a more accurate 
representation of incidence of hearing change in treating NPC was arguably derived from 
the other papers (Chan et al., 2009; Hsin et al., 2010; Li et al., 2010; Oh et al., 2004; 
Petsuksiri et al., 2011; Wang et al., 2015). 
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After Cho et al. (2016), the next lowest incidences in hearing deterioration following 
treatment of NPC were 4% (Oh et al., 2004) and 7% (Petsuksiri et al., 2011). The authors of 
both these papers used the definition of hearing deterioration as an increase in bone 
conduction thresholds by ³15dB. This definition is argued as being the most appropriate to 
use for determining a change in hearing (section 2.4.1.2 – measurement bias). These 
authors conducted their studies in other similar ways. They recorded a change of hearing in 
the same low frequency range (average of 0.5, 1 and 2kHz), and at the same time after 
treatment (one year). In addition, both Oh et al. (2004) and Petsuksiri et al. (2011) assessed 
larger numbers of participants from which to draw valid conclusion (27 and 48 respectively) 
and both papers were judged to be of high quality (Table 2.3). Consequently, there is much 
to commend the validity in the lower end of incidence in hearing deterioration as being 4% 
following NPC treatment. 
 
At the other end of incidence in hearing deterioration were the studies by Li et al. (2010) and 
Wang et al. (2015), who provided the two highest rates of incidence in hearing deterioration 
following treatment of NPC (98% and 61% respectively). Li et al. (2010) assessed hearing 
deterioration in 48 ears from 29 patients, and Wang et al. (2015) assessed a similar number 
of cases (51 patients). Both authors assessed hearing change at the same time after 
treatment (5 years), employed the same classification (³15dB change), and were judged to 
be of medium or high quality. However, there was a difference in the treatment used in the 
studies by Li et al. (2010) and by Wang et al. (2015). Li et al. (2010) reported on change 
following 3D-conformal RT, whereas Wang et al. (2015) reported on change following more 
recent RT in the form of IMRT. Consequently, although there is evidence to support the 
assertion of the upper end of sensorineural hearing deterioration as being 98% following 
treatment of NPC, consideration must be taken of the type of treatment used (please refer to 
section 2.5.2.2 – treatment).  
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2.5.1.3 Incidence of conductive hearing loss 
 
The incidence of conductive loss in the papers reviewed ranged from 3-44% (Hsin et al., 
2010; Oh et al., 2004; Petsuksiri et al., 2011; Theunissen et al., 2014b; Wang et al., 2015). 
All five of these papers were assessed as being of high quality (Table 2.3), therefore the 
findings from them are viewed as being of high validity. Four of these papers assessed 
treatment for NPC (Hsin et al., 2010; Oh et al., 2004; Petsuksiri et al., 2011; Wang et al., 
2015), whereas only one was on treatment for general HNC (Theunissen et al., 2014b). It is 
noted that the radiation exposure to the cochlea differed greatly between these two patient 
groups, and that different incidence rates were recorded. 
 
The incidence of conductive loss following NPC treatment ranged between 19-44%, with 
radiation exposure to the cochleae ranging between 34-66 Gy (Hsin et al., 2010; Oh et al., 
2004; Petsuksiri et al., 2011; Wang et al., 2015). In contrast, there was only 3-7% incidence 
in conductive loss in patients treated for cancers of the oropharynx, oral cavity or 
hypopharynx, with radiation dosage to the cochleae at 13 Gy (Theunissen et al., 2014b).  
 
Although there is less evidence on findings of conductive loss compared with SNHL 
following treatment of HNC, that which is available has high validity and suggests a range of 
between 3-44%. It is noted that this range may be influenced by radiation dosage to the 
cochlea (please refer to section 2.5.2.2 – treatment). 
 
2.5.1.4 Incidence in hearing deterioration based on range of hearing 
 
Incidence in hearing deterioration varied greatly depending on which frequency range was 
assessed. Table 2.4 below expands on Table 2.3 to provide the speech frequencies that 
were assessed in each article, and incidence of hearing loss at each of these frequency 
ranges. 
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 Frequency range of hearing 
and 
% incidence of hearing deterioration 
1st Author (year) 
 
Low (0.5-2kHz 
average) 
 
Middle (1-2-4KHz average) 
or High (4kHz) 
Extended High 
 >4kHz to 8kHz 
Chan (2009) 9-22 43-55  
Cheraghi (2015)   51 
Cho (2016) <1   
Hsin (2010)  46  
Li (2010) 10-60 15-98 40-96 
Niemensivu (2015) 0 14 32 
Oh (2004) 4-10 25-27  
Pan (2005)  22-33 38-100 
Petsuksiri (2011) 7 37  
Shorter (2017) 4 21 93 
Theunissen (2014b)   79-81 
Wang (2015) 16 61  
Table 2.4 Frequency range assessed  
 
Table 2.4 shows that different frequency ranges were assessed to determine incidence of 
hearing deterioration following treatment for HNC. The incidence of hearing deterioration for 
low frequency speech hearing ranged from 0-60%, that for mid frequency speech from 14-
98%, and that for high frequency speech from 32-100%.  
 
The marked difference in incidence between the different hearing ranges is made clear in 
those eight articles that assessed more than one frequency range (Chan et al., 2009; Li et 
al., 2010; Niemensivu et al., 2015; Oh et al., 2004; Pan et al., 2005; Petsuksiri et al., 2011; 
Shorter et al., 2017; Wang et al., 2015). In each of these articles, there was higher incidence 
of hearing deterioration in the higher frequencies. As five of these articles were of high 
quality (Table 2.3), there is much evidence to support the finding that incidence in hearing 
deterioration depends on the range of frequencies assessed, with higher speech frequencies 
being more affected. There is therefore evidence to support the testing of higher frequencies 
as these are more sensitive to changes in hearing during treatment, however, there is also 
the need to detect lower frequency changes, as low and mid-frequency hearing (≤4kHz) 
contribute to 95% of speech intelligibility, whereas >4kHz frequencies contribute to only 5% 
of speech understanding (Pavlovic, 1987).  
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2.5.1.5 Tests used for assessing a change in hearing 
 
All 12 articles included in this review that measured incidence in hearing deterioration 
assessed a perceptual change in hearing using PTA. Although the majority of articles used 
PTA only (Chan et al., 2009; Cho et al., 2016; Cheraghi et al., 2015; Oh et al., 2004; 
Petsuksiri et al., 2011; Shorter et al., 2017; Theunissen et al., 2014b; Wang et al., 2015), 
four studies employed other tests in their assessment of hearing change (Table 2.5): 
 
1st Author (year) Other hearing tests 
Hsin (2010) Tympanometry 
Li (2010) Tympanometry; stapedial reflexes; auditory brainstem responses 
Niemensivu (2015) Otoacoustic emissions 
Pan (2005) Tympanometry, stapedial reflexes; speech reception; speech discrimination 
Table 2.5 Tests used in addition to pure tone audiometry 
 
 
 
Tympanometry 
 
Tympanometry is an objective test used to measure middle ear function (BSA, 2013) and is 
often performed to confirm the nature of middle ear dysfunction with conductive hearing loss 
found on PTA. Three papers in this review all used tympanometry in addition to PTA (Hsin et 
al, 2010; Li et al., 2010; Pan et al., 2005). However, neither Hsin et al. (2010) nor Pan et al. 
(2005) referred to the tympanometry results obtained in their studies. Li et al. (2010) 
mentioned that only 12 ears of 42 patients either produced a type B tympanogram (a lack in 
a change of compliance function of the middle ear to a pressure change), or a type C 
tympanogram (negative pressure within the middle ear cavity). Therefore, tympanometry 
was used minimally within the articles included in this review.  
 
 
Other 
 
The stapedial reflex test assesses the function of different structures, including the auditory 
nerve and muscles within the middle ear, in response to loud sounds. Stapedial reflex 
testing is sometimes used in addition to tympanometry, and the reflex test was used to 
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confirm middle ear dysfunction in one patient in the study by Li et al. (2010). Only Pan et al. 
(2005) also mentioned stapedial reflex testing as part of their testing battery. These authors 
also included speech reception and speech discrimination tests as part of the test battery in 
their article, yet only mentioned PTA results.  It is most likely that speech tests were 
performed as usual practice but were not relevant to the study by Pan et al. (2005). 
Stapedial reflex testing and speech testing were used minimally within the articles of this 
review.  
 
Li et al. (2010) used auditory brainstem response (ABR) testing to assess the nerve pathway 
from the auditory nerve to the brain, following RT for NPC, and determined that ABR were 
significantly delayed at one-year post treatment compared to pre-treatment hearing levels. 
ABR deterioration included an increase in wave I to wave V inter-peak latency, indicating 
that central processing of auditory stimuli may be adversely affected by 3D RT. As ABR 
testing was only reported in one article, it is apparent that most authors in this review 
focussed on changes in peripheral hearing ability, as measured by PTA.  
 
It is of interest that only one of the 12 articles (Niemensivu et al., 2015) that measured 
incidence of hearing deterioration used otoacoustic emission (OAE) testing in addition to 
PTA. Otoacoustic emission testing objectively assesses inner ear function, and it is 
advocated by the American Speech-Language-Hearing Association (ASHA) (Konrad-Martin 
et al., 2005) as a sensitive measure of ototoxic damage. This is because changes of OAEs 
precede changes of PTA thresholds in patients receiving ototoxic drugs (Lonsbury-Martin 
and Martin, 2001). Niemensivu et al. (2015) reported that there was no change in OAEs for 
patients in their study, but mentioned using transient evoked OAE. This type of OAE detects 
frequencies up to 4kHz, whereas the use of distortion product OAE detects higher frequency 
change, and Niemensivu et al. (2015) mentioned that distortion product OAE may have been 
more suitable to use.  
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2.5.2. Theme 2 – Risk factors associated with hearing deterioration 
 
The second question of this literature review was: ‘are there any factors that influence a 
change in hearing?’. Table 2.3 shows the summary of risk factors, which are expanded upon 
in Table 2.6 below. Incidence of hearing deterioration in each of the 12 papers of this 
literature review was determined using descriptive statistics. However, risk factors 
associated with hearing deterioration were assessed in the majority of the papers by using 
inferential statistics; only Cheraghi et al. (2015) did not use inferential statistics. Other 
papers used inferential statistics that were not directly related to the purposes of this review: 
Pan et al. (2005) confined their statistical assessment to comparison in hearing change 
between the irradiated and non-irradiated ears of patients, and therefore their results are not 
considered in this assessment of change of hearing from baseline assessment of the same 
ear; Cho et al. (2016) made comparison only of IMRT to the older obsolete use of 2D RT; 
Niemensivu et al. (2015) assessed difference in the experience of tinnitus. Therefore, Table 
2.6 does not include the statistics from Cheraghi et al. (2015), Cho et al. (2016), Niemensivu 
et al. (2015), or from Pan et al. (2005). In addition to risk factors that may be associated with 
treatment, Table 2.6 also includes ‘time after treatment’ as some papers also assessed if 
hearing deterioration progressed with time.  
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1st Author 
(year) 
Age Gender Comorbidity Recreational 
activity 
Tumour 
size 
Baseline 
hearing 
Middle 
ear status 
Treatment 
 
Time after 
treatment 
Chan (2009) S  
p=0.026 
NS X X X X X  S 
p=0.013 – Radiotherapy 
p=0.020 – Chemotherapy 
 NS 
Hsin (2010) X X X X S 
p=0.007 
X X X X 
Li (2010) X X X X X X X X NS 
Oh (2004) NS  NS X X X X S  
p<0.050 
S 
p<0.050 – Radiotherapy 
NS – Chemotherapy 
NS 
Petsuksiri 
(2011) 
NS X NS X X X  NS S 
 p=0.047 – Radiotherapy 
NS – Chemotherapy 
 NS 
Shorter (2017) NS  NS X S 
p=0.006 – smoking 
p=0.008 – alcohol 
NS NS X S  
NS – Radiotherapy 
p<0.006 – Chemotherapy 
X 
Theunissen 
(2014b) 
X X X X X X X X S  
p=0.045 – low 
frequency 
p=0.014 – mid 
frequency 
Wang (2015) S  
p=0.034 
NS X X S  
p=0.011 
X S 
 p=0.012 
S 
p=0.022 – Radiotherapy 
p=0.035 – Chemotherapy 
X 
Table 2.6 Risk factors associated with hearing deterioration 
Key: S – statistically significant; NS – not statistically significant; X – not tested (no results)
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2.5.2.1 Patient characteristics 
 
Table 2.6 shows that age, gender, co-morbid disease, recreational activity, tumour size, 
baseline hearing level, and middle ear status were assessed as potential factors for 
influencing the developing of, or being associated with, hearing loss.  
 
 
Age 
 
Five papers in this review considered a patient’s age as a potential risk factor in hearing 
deterioration (Chan et al., 2009; Oh et al., 2004; Petsuksiri et al., 2011; Shorter et al., 2017; 
Wang et al., 2015). Two papers reviewed found a statistically significant association of an 
increase in age with an increased incidence in hearing deterioration (Chan et al., 2009: 
p=0.026; Wang et al., 2015: p=0.034). Chan et al. (2009) used regression analysis, whereas 
Wang et al. (2015) used Fisher’s exact test, and used 40 years of age as the cut-off in their 
categorical analysis. However, no explanation was given as to why Wang et al. (2015) used 
40 as the cut-off age; the median age of participants in their study was 42 years. 
 
In contrast, the three other authors (Oh et al., 2004; Petsuksiri et al., 2011; and Shorter et 
al., 2017) all determined that there was no association in hearing loss with age, even though 
they also used Fisher’s test or regression statistics for their analysis. As similar statistics 
were employed across these five papers, there was no agreement in the effect of age on 
hearing deterioration.  
 
Gender  
 
Only four papers assessed gender and hearing deterioration after treatment (Chan et al., 
2009; Oh et al., 2004; Shorter et al., 2017; Wang et al., 2015). The statistical assessments 
from all of these high-quality papers were in agreement that gender did not influence hearing 
deterioration; Chan et al. (2009) determined p=0.61, and Wang et al. (2015) reported 
p=0.33, whereas Oh et al. (2004) and Shorter et al. (2017) reported p>0.05. 
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Co-morbid disease 
 
The co-morbid diseases assessed were diabetes mellitus and hypertension. The two articles 
in this literature review that assessed diabetes and hypertension as risk factors for 
developing hearing change, Pan et al. (2005) and Petsuksiri et al. (2011), determined that 
there was no association between these conditions and hearing deterioration. 
 
 
Recreational activity 
 
Only one paper (Shorter et al., 2017) assessed the effect of smoking and drinking as 
potential risk factors in the development of hearing loss after treatment for HNC. Shorter et 
al. (2017) used regression analysis and determined statistical significance in the 
development of high frequency (8kHz) hearing deterioration with increased smoking and 
alcohol consumption. The mean tobacco use was described as 28.7 ‘pack years’, and 
alcohol consumption was 18.6 ‘standard drinks’ per week for patients acquiring high 
frequency hearing deterioration. Although interesting findings, it is difficult to utilise these 
results as they derive from one paper only. 
 
 
Tumour size 
 
Three papers investigated tumour size and risk of hearing deterioration, with conflicting 
findings (Hsin et al., 2010; Shorter et al., 2017; Wang et al. 2015). Shorter et al. (2017) 
found no significant difference in hearing deterioration between different tumour sizes 
(p>0.05), whereas Hsin et al. (2010) and Wang et al. (2015) found a statistically significant 
association of tumour size with the amount of hearing deterioration (p=0.007 and p=0.012 
respectively). However, information provided by each author on tumour staging was different 
that made it difficult to make meaningful comparison. Shorter et al. (2017) grouped together 
stage 1 and 2 tumours in their calculations on statistical significance, whereas Wang et al. 
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(2015) grouped together stages 1-3 tumours in their calculations. Hsin et al. (2010) provided 
the number of cases for each tumour size from 1 to 4 in their analysis.  
 
Hsin et al. (2010) investigated different tumour sizes, on the premise that the larger the 
primary tumour, the greater the radiation treatment volume over the skull base and temporal 
bone (which houses the ear). Hsin et al. (2010) found that the development of middle ear 
effusion (which causes a conductive hearing loss) was associated significantly with greater 
tumour size (p=0.007). In contrast, Wang et al. (2015) found significance in the development 
of SNHL with tumour size; the larger the tumour size, the higher the incidence of hearing 
loss (p=0.012). As both Hsin et al. (2010) and Wang et al. (2015) reported on treatment for 
NPC using IMRT, it is not clear why they found significance in deterioration to different parts 
of the ear.  
 
 
Pre-treatment hearing level 
 
As hearing deteriorates with age (Davis, Ostri and Parving, 1990; Shield, 2006), it was 
reasonable to expect that the pattern of hearing deterioration associated with pre-treatment 
hearing would be similar to that of age, discussed above. However, only Shorter et al. (2017) 
assessed the statistical significance of pre-treatment hearing level in determining hearing 
deterioration in their study, and determined that there was no significance. Chan et al. 
(2009) did not assess the effect of pre-treatment hearing, as they performed univariate 
analysis and found that pre-treatment hearing level was closely associated with age. They 
therefore used age instead of pre-treatment hearing level in their multivariate analysis on 
risk factors.  
 
 
Middle ear status 
 
Table 2.6 shows that only three papers studied the effect of middle ear dysfunction on 
further development of a hearing change, and all three assessed patients being treated for 
		 79 	
NPC (Oh et al., 2004; Petsuksiri et al., 2011; Wang et al., 2015). These three papers 
assessed the development of SNHL in relation to middle ear dysfunction either before 
treatment or following treatment of NPC. Two of these papers (Oh et al., 2004, and 
Petsuksiri et al., 2011) determined that pre-existing otitis media with effusion (OME – fluid in 
the middle ear cavity) was not significant in the development of SNHL. The presence of 
OME after treatment was a significant factor in determining SNHL after treatment by Oh et 
al. (2004) and Wang et al. (2015), but these findings contrasted those of Petsuksiri et al. 
(2011) who also assessed OME after treatment and development of SNHL. As all three 
papers were deemed to be of high quality (Table 2.3) it is not clear whether or not post-
treatment OME is significantly associated with the development of SNHL. 
  
2.5.2.2 Treatment 
 
The main factor that influenced deterioration in hearing was the treatment regime used. 
Table 2.6 shows that five papers in this review that used inferential statistics to determine 
changes from baseline hearing in the same ear found statistically significant differences 
depending on the type of treatment used, and the dosages administered.   
 
 
Radiotherapy technique 
 
Articles included in this review reported on incidence of hearing deterioration following the 
more modern techniques of RT, such as 3D conformal or IMRT. Consequently, comparison 
of these techniques with the older technique of 2D RT is not assessed in detail. However, it 
is important to note that statistical difference was reported in five papers of this review (Cho 
et al., 2016; Hsin et al., 2010; Oh et al., 2004; Petsuksiri et al., 2011 and Theunissen et al., 
2014b), with less hearing deterioration obtained with the newer techniques. This is because 
IMRT and 3D-conformal RT allow radiation to conform precisely to the 3D shape of the 
primary tumour, thereby reducing radiation of adjacent structures (Teo, Ma and Chan, 2004; 
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Lee, 2002). It is therefore important to review incidence rates using the most current 
treatment modalities, and the dosages used. 
 
Radiotherapy dosage 
 
Five papers specifically assessed the effect of radiation dosage on hearing deterioration 
using IMRT or 3D-conformal RT (Chan et al., 2009; Oh et al., 2004; Petsuksiri et al., 2011; 
Shorter et al., 2017; Wang et al., 2015), although others mentioned the radiation dosages 
used in their studies. Radiotherapy that is effective in treating primary cancer in the head 
and neck ranges from 50-70 Gy, regardless of whether this is for general HNC (Cheraghi et 
al., 2015; Shorter et al., 2017; Theunissen et al., 2014b) or for specifically NPC (Cho et al., 
2016; Hsin et al., 2010; Li et al., 2010). With 3D and IMRT imaging techniques, it is possible 
to calculate radiation dosages to structures adjacent to the primary HNC. Radiation dosage 
to the cochlea varied depending on the type of primary cancer being treated. 
 
The range of the median dose to the cochlea was between 45-49 Gy when treating NPC 
only (Chan et al., 2009; Petsuksiri et al., 2011; Wang et al., 2015). However, there was a 
wide difference in the median dose delivered to the cochlea when treating general HNC, with 
11, 18 and 47 Gy reported by Shorter et al. (2017), Theunissen et al. (2014b), and Pan et al. 
(2005) respectively. This difference was due to each of these three papers containing 
different proportions of HNC subtypes, including that of NPC. The proportion of patients with 
NPC was: 3% in Shorter et al. (2017), 0% in Theunissen et al. (2014b), and 11% in Pan et 
al. (2005), reflecting the differences in the median radiation dose exposure to the cochlea. 
All three of these papers also showed a large variation in the incidence rate of hearing 
deterioration (Table 2.3). The variability in incidence rate with radiation dose was shown to 
be statistically significant in most of the papers that assessed radiation dose and hearing 
deterioration. 
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Four out of five papers reported that an increase in radiation dosage to the cochlea was 
associated with a statistically significant increase in hearing deterioration (Chan et al., 2009; 
Oh et al., 2004; Petsuksiri et al., 2011; Wang et al., 2015). Some papers reported a cut-off 
dosage at which hearing deterioration was either reduced or avoided if cochlea exposure 
was less than this amount. Wang et al. (2015) determined the lowest cut-off at 39Gy. Other 
authors determined similar cut-off dosages: 47Gy (Chan et al., 2009) and 50Gy (Petsuksiri 
et al., 2011). However, Oh et al. (2004) found that the much higher cut-off dosage of 64Gy 
was important in determining treatment induced hearing loss when using 3D-conformal RT. 
Other studies either used mean IMRT dosage treatment (Petsuksiri et al., 2011) or used a 
dose response relationship to determine their lower cut-off dosage (Chan et al., 2009). The 
only paper not to have found a relationship between radiation dosage and hearing 
deterioration was Shorter et al. (2017), but this was probably due to the median radiation 
dosage to the cochlea of patients in their study being low at 11Gy.  
 
 
Chemotherapy 
 
Five papers assessed the effect of cisplatin chemotherapy on hearing deterioration following 
HNC treatment (Wang et al., 2015; Chan et al., 2009; Oh et al., 2004; Petsuksiri et al., 2011; 
Shorter et al., 2017). Three of these papers reported that an increase in chemotherapy 
dosage was associated with an increase in hearing deterioration (Wang et al., 2015; Chan et 
al., 2009; Shorter et al., 2017) although there was a wide variation in what was deemed to 
be a significant cut-off dosage. Wang et al., 2015 found a cut-off of 200mg/m2 of cisplatin 
dosage to be important in determining hearing deterioration, whereas Shorter et al. (2017) 
found a greater value of 588mg/m2 as their cut-off. Both Wang et al. (2015) and Shorter et 
al. (2017) used Fisher’s test and categorical values to determine significance.  
 
However, there were also two papers that did not find chemotherapy as a risk factor to 
hearing change. Oh et al. (2004) did not find any effect of cisplatin dose on hearing loss in 
their study; this may be due to the large RT dosages used (65 Gy exposure to the cochlea) 
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over-riding the effect of cisplatin. Petsuksiri et al., 2011 also reported that cisplatin dosage 
(cut-off 600mg/m2) was not a factor in determining hearing deterioration, and this contrasted 
the finding by Shorter et al. (2017) who also assessed hearing change with high dosage 
chemotherapy. It was not clear why Petsuksiri et al. (2011) and Shorter et al. (2017) gave 
contrasting findings, but it is noted that whereas all the patients in the study by Petsuksiri et 
al. (2011) received IMRT, a third of patients in the study by Shorter et al. (2017) were treated 
by 3D RT.  
 
Interestingly, Wang et al. (2015) reported that carboplatin, when used instead of cisplatin, 
due to cisplatin intolerance or renal problems, did not increase the risk of hearing loss in the 
11 patients in their study.  
 
2.5.2.3 Time after treatment 
 
Although there is much evidence to show that hearing deteriorates with HNC treatment 
(section 2.5.1 – incidence in hearing deterioration), it is not clear whether hearing further 
deteriorates over time following treatment. Table 2.6 shows that five papers assessed the 
incidence of hearing deterioration over time (Chan et al., 2009; Li et al., 2010; Oh et al., 
2004; Petsuksiri et al., 2011; Theunissen et al., 2014b). Table 2.7 below shows more clearly 
the effect of time after treatment on hearing deterioration across different frequency ranges. 
 
1st 
Author 
Incidence of  
HL % 
1-3 months 
PT 
Incidence of  
HL % 
6 months 
PT 
Incidence of  
HL % 
1 year  
PT 
Incidence of  
HL % 
2 years 
PT 
Incidence of  
HL % 
>2 and <5 
years PT 
Incidence of  
HL % 
³5 years 
PT 
L M/
H 
E L M/
H 
E L M/
H 
E L M/
H 
E L M/
H 
E L M/
H 
E 
Chan     9 49  14 
 
55  12 
 
43 
 
 22 
 
50 
 
    
Li 10 15 40    32 26 71 42 73 75    60 98 96 
Oh 
 
   6 27  4 27     10 25     
Pan 
 
 22 47  25 38  50 46  50 40  33 100    
Theuni
-ssen 
  78 
 
           81 
 
   
Table 2.7 Incidence of hearing deterioration over time 
Key: L –low frequency average (0.5, 1 and 2kHz threshold); M-mid frequency average (1-2-4kHz): H-high 
frequency threshold at 4kHz; E-extended high frequency (>4kHz) 
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There was no agreement on the effect of treatment on the incidence of hearing deterioration 
over time (Table 2.7), with three papers showing an overall increase (Chan et al., 2009, Li et 
al., 2010, and Pan et al., 2005), and two papers showing no change (Oh et al., 2004, and 
Theunissen et al., 2014b).  
 
However, only Theunissen et al. (2014b) accounted for the effects of ageing on hearing over 
time, and found no change in the incidence of hearing deterioration at 4½ years after 
treatment, compared with three months after treatment. However, when assessing changes 
in average threshold changes (rather than incidence of hearing change), Theunissen et al. 
(2014b) did find statistically different thresholds in hearing, of p=0.045 in low frequency bone 
conduction thresholds (0.5-2kHz), and of p=0.014 in mid frequency air conduction thresholds 
(1-4kHz) when comparing hearing 4½ years after treatment with hearing three months after 
treatment. Although these results were statistically significant, they were clinically limited to 
<5dB deterioration in thresholds from three months after treatment to 4½ years after 
treatment.  
 
Although the focus of this current study is on hearing deterioration, changes in hearing within 
the early post treatment phase (up to one year) may also be of improvement, which was 
reported by Oh et al. (2004) due to resolution of middle ear dysfunction. Cheraghi et al. 
(2015) also reported transient deterioration in hearing following RT, but the authors were not 
clear whether the inner ear or middle ear was initially affected. It is therefore unclear whether 
hearing always deteriorates with time following HNC treatment, or if there may be some 
improvement during the early post treatment phase.  
 
2.5.3 Theme 3 – Patient experience of hearing deterioration 
 
 
The third question assessed in this literature review was to discover patient experience of 
hearing loss following treatment of HNC. Three papers were identified: Lastrucci et al. 
(2017) and Loimu et al. (2015) both used quantitative methodology with questionnaires and 
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focussed on quality of life, whereas Nund et al. (2015) used interviews and qualitative 
methodology to explore lived experience.  
 
2.5.3.1 Quality of life 
 
Lastrucci et al. (2017) and Loimu et al. (2015) assessed quality of life in general following 
treatment of HNC, rather than specifically focussing on hearing related change. Whereas 
Loimu et al. (2015) assessed quality of life in patients with different types of HNC, Lastrucci 
et al. (2017) examined quality of life only of patients with NPC. 
 
Lastrucci et al. (2017) had two aspects to their study. The first aimed to identify any risk 
factors related to side effects after treatment, and the second aimed to assess if toxicity was 
related to questionnaire scores about quality of life and functional status. Fifty-six patients 
completed the toxicity assessment, whereas 25 of these went on to complete the 
questionnaires. 
 
The first aspect, on risk factors related to side effects and toxicity, was assessed in Lastrucci 
et al. (2017) using the CTCAE v 4.03 (NCI, 2010), at a median time of seven years after 
treatment. The CTCAE has a hearing related scale that can be monitored using hearing 
tests (as discussed in section 2.5.1 of this study) or by a clinician rated score. The three 
grades that are rated by clinicians are: Grade 1 – A subjective change in hearing; Grade 2 – 
Hearing loss but hearing aid intervention not indicated; Grade 3 – Hearing loss with hearing 
aid or intervention indicated; (NCI, 2010). Hearing loss of Grade 1 and 2 was reported in 20 
patients (32%), second only to xerostomia (lack of ability to produce saliva) as a side-effect 
following treatment; no Grade 3 hearing loss was reported. Lastrucci et al. (2017) 
determined that there were no risk factors (age, gender, stage of cancer, time elapsed from 
the end of treatment, RT technique, chemotherapy) identified with this subjective clinician-
rated assessment of hearing loss. 
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The second aspect, on quality of life, was conducted at a median of four years after 
treatment, using five questionnaires, of which three were self-rated patients and related to 
general well-being in NPC patients. One of these questionnaires specifically assessed 
quality of life following treatment of NPC: The Functional Assessment of Cancer Therapy 
Nasopharyngeal Cancer Questionnaire (FACT-NP). This questionnaire includes a question 
on hearing: ‘I have trouble hearing’. Another questionnaire, Functional Assessment of 
Cancer Therapy (FACT-G) was used to rate quality of life following treatment for any type of 
cancer, and it has four subscales that are used to assess physical, social/family, emotional, 
and functional well-being. A third questionnaire used by Lastrucci et al. (2017), the EQ-5D-
3L, is a generic instrument used to measure quality of life across the five domains of: 
mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Toxicity scores 
(obtained from the first aspect of this study, including those for hearing loss) were analysed 
together with questionnaire scores using the chi-squared test, and there was no statistically 
significant association between any of these questionnaires and with hearing loss, indicating 
that hearing concerns did not appear to have an impact on quality of life.  
 
In contrast to Lastrucci et al. (2017), Loimu et al. (2015) assessed quality of life with patients 
with a range of head and cancers, including those who had cancer in the oropharynx, larynx, 
hypopharynx, nasal cavity, as well as the nasopharynx. Also, Loimu et al. (2015) assessed 
quality of life in the early post-treatment phase, using questionnaire scores from baseline as 
a comparison with those obtained up to one year post-treatment. Loimu et al. (2015) used 
the validated quality of life 15D patient self-report that has a question on hearing. This 
question has a 1-5 Likert scale for answering:  
• 1 – I can hear normally, i.e. normal speech (with or without a hearing aid);   
• 2 – I hear normal speech with a little difficulty;  
• 3 – I hear normal speech with considerable difficulty; in conversation, I need voices 
to be louder than normal;   
• 4 – I hear even loud voices poorly; I am almost deaf; 
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• 5 – I am completely deaf.  
 
The questionnaire scores obtained were compared with those in the general population and 
were weighted to reflect the age distribution of the patients. Mann-Whitney U testing was 
used to determine significant differences between the patients’ own scores, as well as those 
with the general population. Loimu et al. (2015) also used CTCAE for assessing treatment 
related toxicity (NCI, 2006). 
 
Loimu et al. (2015) determined that the dimension of hearing within the 15D questionnaire 
did not differ significantly throughout the 12 months period, nor did it differ from the general 
population. Hearing did not differ between the subtypes of laryngeal and pharyngeal cancer, 
whereas there were differences in other dimensions between these subtypes including the 
dimensions of speech, breathing, sleeping and mental function. Clinician rated hearing loss 
was determined in only one patient (2%) with Grade 3 change. 
 
2.5.3.2 Lived experience of hearing deterioration 
 
Nund et al. (2015) conducted interviews to investigate the experience of communication 
changes following non-glottic HNC treatment, using a phenomenological approach. They 
interviewed 14 patients and nine carers to assess the impact of changes to voice, speech 
and hearing, and they used variation sampling to explore common and shared experiences 
(Patton, 2002) across different ages (greater or less than 65 years) and gender (male or 
female). 
 
The four themes that emerged from the study by Nund et al. (2015) – listed in Table 2.3 – 
related to communication difficulties for both patients and carers following cancer treatment.  
This exploration of hearing related difficulties experienced by survivors and carers was a 
strength of the study by Nund et al., (2015), and contrasted to quality of life studies by 
providing real life examples of how daily living was affected. The phenomenological 
approach adopted by Nund et al. (2015) therefore appeared to be successful in obtaining an 
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understanding of how communication difficulties produced a negative impact on patient 
experience. However, a weakness was that it excluded survivors who suffered from pre-
existing hearing loss and it was not clear how many of those interviewed developed a 
deterioration in their hearing, nor the extent of deterioration if this occurred. Another 
observation was that maximum variation sampling was used for selecting patients, but no 
comment was made on differences in experience regarding age, gender, nor with difference 
in the severity of hearing loss.  
 
2.6 Discussion on findings from the literature review 
This section discusses the findings of this literature review within the wider context of other 
articles and policy in the field of HNC. 
 
2.6.1 Incidence of hearing deterioration 
 
From the literature examined in this chapter, the majority (12 out of 15) reported the 
incidence of hearing loss following HNC treatment, and specifically following sensorineural 
damage. It is noted that half of these papers were on cancers of the nasopharynx. This is 
not surprising as structures in the nasopharynx lie in close proximity to the ear, and RT for 
structures in the nasopharynx directly irradiates one or both ears such that the inner ear may 
receive 80-100% of the prescribed radiation dose (Raaijmakers and Engelen, 2002). 
 
There was a wide variation in the incidence of hearing loss reported, from 4-93% in general 
HNC, and from 4-98% in treatment of NPC, even after disregarding incidence rates from 
papers with questionable results (Cho et al., 2016; Niemensivu et al., 2015; Pan et al., 
2005). Therefore, further work is needed to establish incidence rates in the UK to gain an 
understanding of the problem of hearing deterioration in a UK population, using UK current 
treatment.  
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2.6.1.1 Incidence in sensorineural hearing loss 
 
All the selected articles reviewed assessed sensorineural type of hearing loss following HNC 
treatment. The large variation in SNHL obtained in this study was similar to other studies 
that conducted systematic reviews on HNC treatment. Mujica-Mota, Waissbluth and Daniel 
(2013) assessed the impact of RT and determined a range in hearing deterioration from 0-
85% in the speech frequencies. However, Mujica-Mota, Waissbluth and Daniel (2013) 
included the results of studies using the now obsolete 2D RT in their findings, as well as 
those that used non-irradiated ears as the comparator for assessing hearing change. 
Theunissen et al. (2015) included the assessment of chemotherapy in their review, and 
reported the range of hearing deterioration of 0-58% in the speech frequencies after RT, and 
of 5-79% in these frequencies after chemoradiation. As with Mujica-Mota, Waissbluth and 
Daniel (2013), Theunissen et al. (2015) included results from 2D RT. Therefore, even with 
the most current therapies used, as examined in the current review, there is a wide range 
reported in incidence of sensorineural hearing deterioration following HNC treatment. 
 
What is apparent, though, is that it is not possible to apply the results examined in this 
review of incidence in hearing loss to a general cohort of patients undergoing treatment for 
HNC in the UK. Papers were restricted in the range of general HNC patients that were 
assessed (Theunissen et al., 2014b); were not clear if all eligible patients for treatment were 
recruited (Shorter et al., 2017); or had a different proportion of patients to that diagnosed 
with HNC in the UK (Cheraghi et al., 2015). There also were no articles pertaining to studies 
in the UK found in the literature reviewed, and it was difficult to apply those results that were 
obtained to a UK population because of variation in HNC subtypes that were studied, and 
variation in treatment used. Such findings highlight the need for an investigation of hearing 
deterioration following standard UK treatment on a UK cohort of patients with general HNC, 
to help with forming policy in support of cancer patients. This is important as the UK 
documentation on improving care in cancer survivorship (DH, 2011) does not include 
treatment related hearing loss. 
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2.6.1.2 Incidence in conductive hearing loss 
 
Fewer papers reviewed assessed a conductive (or mixed) type of hearing loss following 
treatment, compared with those that investigated SNHL, therefore, a study on hearing 
deterioration in the UK needs also to capture middle ear dysfunction. None of the papers 
selected for this review focussed on conductive hearing loss, although five of them recorded 
the incidence of conductive loss change, ranging from 3-44%. The findings also showed that 
patients who received treatment for NPC were more prone to develop middle ear 
dysfunction, presumably due to higher radiation dose exposure compared to other subtypes 
of HNC. However, a reason for a lack of focus in conductive loss is that this type of loss is 
more associated with transient changes of hearing compared to SNHL (Jereczek-Fossa et 
al., 2003). When conductive hearing loss does occur, it can be as disabling and 
handicapping as SNHL (Lutman, Brown and Coles, 2009), and therefore should not be 
discounted. 
 
In this review, it was seen that incidence of hearing deterioration was less in the low speech 
frequency range compared with the high frequency range (Chan et al., 2009; Li et al., 2010; 
Oh et al., 2004; Shorter et al., 2017). These findings are consistent with those reported in 
animal studies (Konishi, Gupta and Prazma, 1983; Schweitzer et al.,1984; Talmi, Finkelstein 
and Zohar, 1989). There is merit in assessing low and mid-frequency hearing, as these 
frequencies contribute to 95% of speech intelligibility, whereas >4kHz frequencies contribute 
to only 5% of speech understanding (Pavlovic, 1987). However, as shown above, higher 
frequencies are more susceptible to treatment-induced changes, and are also important in 
the perception of music and in sounds of nature (Theunissen et al., 2014b). Therefore, 
incidence of hearing deterioration depends on which frequency range is assessed: whether 
the focus of enquiry is mainly on speech perception, or on damage to cochlea function. As 
there is a lack of information in how much hearing deterioration occurs following treatment of 
a UK population, a study conducted in the UK should first assess SNHL damage of the 
speech frequencies, essential for communication, rather than the higher frequencies. In 
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addition, there is need to determine the incidence of conductive hearing loss following 
treatment of HNC in the UK. 
 
2.6.1.3 Classifying hearing deterioration 
 
There were also different classification systems employed for denoting significant hearing 
deterioration. The use of single frequency changes, and use of less than a 15dB change 
may be due to normal variation when performing serial audiometry for the detection of 
treatment related hearing deterioration (Simpson, Schwan and Rintelmann, 1992). In their 
study on ototoxicity, Waissbluth, Peleva and Daniel (2017) compared different classification 
systems currently in use, and reported that the same patient group had incidence in hearing 
deterioration of 29%, 38%, 54% or 61% depending on which system was used. It is 
therefore argued that ≥15dB change in hearing, averaged over several frequencies, is most 
appropriate to use (Konrad-Martin et al., 2010), which is used within the CTCAE 
classification schemes versions 3 and 4 (NCI 2006; NCI 2009). The CTCAE schema was 
used in three papers of this review (Cheraghi et al., 2015; Shorter et al., 2017; Theunissen 
et al., 2014b). This scale assesses changes in the 1-8kHz speech hearing range, so it not 
only assesses the mid-frequencies that are important for understanding speech, but also the 
higher frequencies that are more sensitive for detecting ototoxicity (Simpson, Schwan and 
Rintelmann, 1992).  
 
As it is not clear what is the incidence of hearing deterioration in a cohort of general HNC 
patients, any future studies on incidence should use standard PTA, and assess standard 
speech frequencies up to 8kHz. However, such studies must state the conditions and 
method in which audiometry is performed, as it cannot be assumed that the test is 
conducted in a standard way. This lack of transparency was a common failing in the 
literature reviewed in this study. Although other tests, such as OAE tests, have merit in 
detecting pre-clinical changes in auditory function, in this review there was no evident 
change in cochlea function in the one paper that assessed these emissions (Niemensivu et 
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al., 2015). Therefore, it is best first of all to ascertain the scale of perceptual hearing loss 
using PTA and also use tympanometry as this is important in confirming dysfunction of the 
middle ear system.   
 
Although it is advocated to establish incidence in hearing deterioration within the peripheral 
hearing system using PTA and tympanometry, dysfunction of higher auditory pathways 
needs to be considered. The findings by Li et al. (2010) in the delay of auditory brainstem 
responses one year following RT, support those of Lau et al. (1992) but contrast those of 
Low et al. (2005) who found no change in these responses in the longer term. Earlier in this 
chapter it was mentioned that Li et al. (2010) reported 98% incidence in hearing 
deterioration with 3D RT, whereas Wang et al. (2015) reported 61% incidence following 
IMRT. Therefore, it may be that newer radiation techniques reduce radiation exposure to the 
cochlea, but retrocochlear loss still needs to be considered as possible with newer treatment 
for HNC. 
 
2.6.2 Risk factors associated with hearing deterioration 
 
There were various risk factors assessed in this review, including age, gender, co-morbid 
disease, recreational activity, tumour size, baseline hearing level, and middle ear status, but 
there was little agreement in which of these were associated with hearing deterioration.  
 
2.6.2.1 Patient characteristics 
 
Age 
 
Hearing deterioration is known to develop with increasing age (Shields, 2006; Davis, Ostri 
and Parving, 1990), and it has been postulated that the ears in older patients might have 
pre-existing degenerative changes that make them more vulnerable to irradiation toxicity 
with HNC treatment (Ho et al., 1999). However, in the current review there were contrasting 
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findings: two out of five papers that assessed age with hearing deterioration showed a 
significant change in hearing with increasing age. Other studies on HNC also report 
contrasting findings on whether age affects hearing deterioration: Honore et al. (2002) found 
a significant association, whereas (Wang et al., 2015) found no association. 
 
Gender 
 
There is evidence to suggest that difference in gender is associated with difference in 
hearing in general, with men voicing more complaints with hearing compared to women 
(Shields, 2006; Davis et al., 2007). This may be due to differences in high frequency hearing 
ability. Men have poorer higher frequency thresholds than women (Gates et al., 1990), due 
in part to greater exposure to industrial noise (Shields, 2006). Also, higher frequency hearing 
may be afforded protection by ovarian hormones in women (Murphy and Gates, 1997). 
Conversely, men have better hearing at low to mid-speech frequencies (Pearson et al., 
1995), for reasons not known. However, regarding hearing deterioration in this review, there 
was agreement in that there was no significant association in the four papers that assessed 
gender (Chan et al., 2009; Oh et al., 2004, Shorter et al., 2017; Wang et al., 2015). This is in 
agreement with other studies on HNC (Bhandare et al., 2007; Herrmann et al., 2006), 
although men have been shown to have significant deterioration in one study assessing long 
term changes in hearing after NPC treatment (Kwong et al., 1996).  
 
Co-morbidity 
 
There is little agreement in general as to whether being diagnosed with diabetes mellitus or 
hypertension (causing microvascular insufficiency or oxidative stress) makes an individual 
more susceptible to developing hearing loss (Agrawal, Platz and Niparko, 2009; Aladag et 
al., 2009; Aimoni et al., 2010; Harner, 1981; Parving et al., 1990). However, in this review, 
both Pan et al. (2005) and Petsuksiri et al. (2011) failed to find an association with these 
diseases and hearing deterioration.  
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Recreational activity 
 
Cigarette smoking is thought to contribute to hearing deterioration by adversely affecting 
antioxidative mechanisms or the blood supply to the ear (Cruickshanks et al., 1998), and 
high alcohol consumption also is associated with hearing deterioration (Dawes et al., 2014). 
Both smoking and alcohol consumption are associated with the majority of HNC cases 
(Donovan and Glackin, 2012; Cohen et al., 2016), however only one paper in this review 
(Shorter et al., 2017) assessed the association of these substances with hearing 
deterioration after HNC. Shorter et al. (2017) found a significant association in both high 
alcohol consumption and high smoking use with an increased incidence in hearing 
deterioration, although it was not clear what was meant by ‘standard drink’ in their study. In 
contrast, in one other paper that assessed the effects of alcohol, there was less hearing 
deterioration in those who consumed alcohol than in those who did not, with the authors 
speculating that this finding may be due to alcohol improving perfusion of the inner ear 
(Herrmann et al., 2006), so it is difficult to draw definitive conclusions.  
 
Tumour size 
 
There was a lack of agreement as to whether tumour size affected hearing deterioration in 
this literature review, with two (Hsin et al., 2010; Wang et al., 2015) out of three papers 
determining a significant association. It may be that with these two papers that assessed 
treatment of NPC, there was more radiation dosage affecting the cochlea with an increase in 
the nasopharynx tumour size. However, in the paper by Shorter et al. (2017) on general 
HNC, tumour size was not found to be significantly associated with hearing deterioration, 
probably as cancers in their study were more distal to the cochlea than those of the 
nasopharynx. 
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Pre-treatment hearing level 
 
Only Shorter et al. (2017) in this this review assessed baseline hearing level, and these 
authors found no significant association between this and hearing deterioration. This finding 
agreed with Grau et al. (1991). However, these findings contrasted with Zuur et al. (2007) 
who found that patients with better pre-treatment hearing levels suffered more severe 
hearing loss than those who possessed poorer hearing to start with.  
 
Middle ear status 
 
It has been suggested that middle-ear effusion after RT is evidence of radiation complication 
and a potential cause for damage in the inner ear and development of persistent SNHL 
(Wang et al., 2004). However, there was no agreement in three papers within this review as 
to whether middle ear dysfunction was a factor in determining further hearing loss: Oh et al. 
(2004) and Wang et al. (2015) found a significant association with development of SNHL 
with post treatment OME, whereas Petsuksiri et al. (2011) failed to do so.  
 
2.6.2.2 Treatment 
 
There was evidence to suggest that an increase in radiation dose was associated with 
hearing deterioration. Four out of five papers in this review reported that an increase in 
radiation dosage to the cochlea was associated with a statistically significant increase in 
hearing deterioration (Chan et al., 2009; Oh et al., 2004; Petsuksiri et al., 2011; Wang et al., 
2015). This finding is consistent to that reported in other literature (Schot et al., 1992; 
Bhandare et al., 2007). Only Shorter et al. (2017) in the current review did not find a 
significant association with dose and hearing deterioration, but this was probably because of 
the low radiation dosages with IMRT used in their study. 
 
However, there was less agreement in the effect of chemotherapy on hearing deterioration,   
with only three out of five studies finding a significant association between increased 
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cisplatin levels and increased hearing deterioration (Wang et al., 2015; Chan et al., 2009; 
Shorter et al., 2017). Those that did not find an association between chemotherapy and 
hearing deterioration either investigated patients exposed to large radiation dosages (Oh et 
al., 2004), or to 3D RT (Petsuksiri et al., 2011) that may have masked the effect of the 
chemotherapy. Other papers suggest that increased hearing loss does occur with increase 
in cisplatin dosages (Chen et al., 2006; Zuur et al., 2007). Interestingly, Wang et al. (2015) 
reported that carboplatin, when used instead of cisplatin, due to cisplatin intolerance or renal 
problems, did not increase the risk of hearing loss in the 11 patients in their study. This 
merits consideration of carboplatin as an alternative to cisplatin treatment for aural protection 
in treatment of HNC.  
 
Although none of the 15 papers included in this literature review assessed hearing 
deterioration following surgery alone, Cancer Research UK report that conductive hearing 
loss can occur with surgery to treat paranasal cancer (Cancer Research UK, 2018e). Hyde 
and Bailey in 2000 reported conductive hearing loss amongst patients who received surgery 
for maxillary sinus cancer. However, UK guidelines now advocate that RT or CRT is always 
used following surgery for all stages of paranasal cancer (Palaniappan, Owadally and 
Evans, 2015), and a study by Won et al. (2009) reported no incidence of hearing loss in 44 
patients treated for paranasal cancer by a combination of surgery with RT or CRT, which 
may indicate improvement in surgical techniques to minimise damage to the ear. 
 
2.6.2.3 Time after treatment 
 
Chan et al. (2009) and Li et al. (2010) reporting on NPC, and Pan et al. (2005) reporting on 
general HNC, recorded an increase in the incidence of hearing deterioration with time. 
However, hearing deterioration is known to increase with increasing age (Shields, 2006; 
Davis, Ostri and Parving, 1990). It is therefore important to correct for the effect of ageing 
with hearing change, which was not performed in any of these three studies. Only 
Theunissen et al. (2014b) accounted for the effect of ageing on hearing in their study, and 
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although they noted statistically significant deterioration in hearing at 4½ years after 
treatment, the change was less that 5dB which is of minor clinical significance. Of interest 
was the finding that hearing within the first year after treatment may not only deteriorate, but 
may also show improvement, and this is important to consider when informing patients of the 
possible outcomes of their hearing after treatment. 
 
Therefore, there was no conclusive evidence from the studies reviewed regarding the 
influence that the following factors have with hearing deterioration after HNC treatment: a 
patient’s age or gender, their pre-existing hearing status, their tumour size or location, or 
when after treatment the assessment is made. However, there is strong evidence to suggest 
that more modern techniques of radiation treatment (e.g. IMRT) decrease incidence of 
hearing deterioration, and that an increase in RT dosage or in chemotherapy (cisplatin) 
dosage increases the rate in incidence of hearing change. Therefore, to help inform UK 
policy, it is important to study hearing deterioration on a general cohort of HNC patients 
using current UK treatment regimen.   
 
2.6.3 Patient experience of hearing deterioration 
 
 
2.6.3.1 Quality of life         
 
The two questionnaire studies included in this literature review appeared to indicate that 
hearing changes following HNC treatment do not have an impact on quality of life (Lastrucci 
et al., 2017; Loimu et al., 2015). However, part of these studies involved the use of clinician 
rated scoring. Clinician rated scoring is known to underestimate the effect of speech and 
voice problems encountered by patients (Lazarus et al., 2014; van der Molen et al., 2012). 
Therefore, it is not clear whether the toxicity assessment made by the clinicians regarding 
hearing change, according to CTCAE, could also be an underestimate. Also, a sizeable 
number of patients who had toxicity assessment did not complete the questionnaires. Five 
refused to take part and it is assumed that the remaining 18 had died. It is not certain how 
		 97 	
many of these 23 patients were affected by hearing difficulties, and how they would have 
answered the questionnaires; their responses could have been significantly different 
regarding quality of life. However, the study by Loimu et al. (2015) did use a patient rating 
self-assessment questionnaire that also indicated that hearing change following HNC 
treatment did not have an impact on patients. However, in comparison to other dimensions 
assessed in the 15D questionnaire, hearing change may not be a priority to patients, so that 
when answering questions together, hearing may not be scored that highly. It might be 
better to have a study that only assesses hearing on its own, or in the context of 
communication, to tease out difficulties that are encountered, as in an interview study. 
 
 
2.6.3.2 Lived experience of hearing deterioration 
 
The one interview study in this current review on lived experience (Nund et al., 2015) clearly 
suggested, in contrast to Loimu et al. (2015) and Lastrucci et al. (2017), that communication 
change arising from hearing deterioration does adversely impact patient experience. Another 
article on the lived experience of patients with HNC found that patients felt isolation due to 
their difficulties with speech articulation in communication (Swore Fletcher et al., 2012). 
Patient experience of hearing loss is generally negative, with associated feelings of loss and 
isolation, and of stigma associated with the loss (Aquino-Russell, 2006). One strength of the 
study by Nund et al. (2015) was its exploration of hearing-related difficulties experienced by 
survivors and carers, but a weakness was that it excluded survivors with pre-existing hearing 
loss and it was not clear how many of those interviewed suffered from a hearing 
deterioration, nor the extent of deterioration if this occurred. In order to obtain an 
understanding of the contribution that hearing has on patient experience, it will be necessary 
to conduct a separate study that focusses on hearing alone, and includes those who may 
have pre-existing hearing loss. In view of the lack in sensitivity of quantitative methods in 
drawing out this experience, a qualitative study appears to be most suited to do this.  
As this literature review has indicated, there is limited awareness of the impact of hearing 
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deterioration following HNC treatment. The NHS (2016) has focussed on the need to have 
patient-centred care, and has developed a holistic needs assessment of patients who have 
had cancer. Although some local centres have created patient concerns inventories that 
include patient rating of hearing concerns after treatment (Aintree University Hospital, 2017), 
others have inventories that do not yet include hearing (London Cancer Alliance, 2013). 
There is therefore a need to identify patient experience in hearing deterioration more widely 
to update policy as required to improve living well in cancer survivors.  
 
2.7 Summary of literature review 
 
This literature review has shown that hearing deterioration is an important side-effect to 
consider following HNC treatment. However, there is a wide variation in the rates in 
incidence of hearing loss following HNC treatment, mainly due to different classification 
systems used to define clinically significant hearing deterioration, and also due to different 
subtypes of HNC that were treated. In addition, there were no papers found on hearing 
deterioration following current treatment of a UK population. Also, there is little 
understanding of the impact that hearing loss has on patient experience for those who have 
hearing-related change with HNC treatment. Although there is a rising incidence of HNC 
cases in the UK, current UK policy and associated research indicates that there is a lack of 
awareness of hearing related problems resulting from cancer treatment (DH, 2011). 
 
In view of these findings, this current study aimed first to assess the incidence of hearing 
deterioration in patients following current treatment of HNC in order to gauge the extent of 
this problem in a UK centre, and to explore patient experience following this deterioration. It 
is proposed that this study would create a clearer picture of the risk and incidence of hearing 
loss in UK HNC patients, and therefore this study could be of use to raise awareness of the 
issue with practitioners about the needs of patients, with updating policy as required, and 
improving quality of life for cancer survivors by better monitoring and early intervention.  
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Chapter 3 Methodology 
 
 
 
3.1 Introduction  
 
Chapter 2 reviewed literature on hearing deterioration in HNC patients following treatment, 
and it became apparent that there were no UK publications describing the incidence of 
hearing deterioration in this population. In addition, the review revealed that there was 
limited exploration on the impact of this deterioration on the patient experience of HNC in the 
UK or elsewhere. To address this lack of information, the aims of the current study were 
delineated as follows:  
The primary research aims were, for patients who were due to receive current treatment in a 
UK hospital -  
1. to assess the incidence and severity of hearing deterioration after treatment for 
head and neck cancer; 
2. to explore the lived experience of participants with hearing deterioration after 
treatment for head and neck cancer. 
The secondary aims were - 
 a.  to describe overall hearing levels; 
 b.  to determine types of hearing loss; and 
c.  to explore the incidence and severity of hearing deterioration in relation to patient 
demographics and types of treatment.  
 
This chapter discusses the chosen methodology, and gives an overview of the methods, 
appropriate to investigate the research aims as set out above. It will provide the rationale 
behind the design used. The chapter begins with the context of the study and the theoretical 
perspective underpinning the research, as these elements were integral in formulating the 
research aims. 
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3.2 Context and theoretical framework  
 
The premise of this study was that hearing deterioration, associated with treatment for HNC, 
has a negative impact on patients. At the study centre, some adult patients had completed 
treatment more than two years before seeking help with their hearing. It was not clear as to 
why patients were being seen two years after treatment: was hearing loss progressive and 
only caused a problem many years after treatment? Did patients suffer hearing loss soon 
after treatment but were not aware of support they could receive? Did patients experience 
hearing loss soon after treatment, but were not concerned as they had survived their 
cancer? These questions formed the basis of the primary research aims - 
• First, to determine the extent of the phenomenon of hearing deterioration following 
head and neck cancer treatment by measuring hearing change. The focus here was 
to assess the incidence and severity of hearing deterioration, particularly in the early 
post treatment stage, for patients undergoing current UK treatment;  
• Secondly, to explore patient experience of hearing deterioration for this patient 
group. 
 
The literature review in Chapter 2 revealed that there have been many articles (all 
conducted outside the UK) that investigated measurable hearing deterioration following CRT 
or RT alone (Theunissen et al., 2015). This was the first UK study to explore incidence and 
severity of hearing deterioration in patients with general HNC undergoing current UK 
treatment, including single or multimodal treatment. Following this quantitative enquiry, 
participants with varying levels of hearing deterioration were selected for assessment of their 
experience of hearing change in the context of cancer treatment. Therefore, both 
quantitative and qualitative methods were required to investigate hearing deterioration after 
HNC treatment for this study. 
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3.2.1 Critical realism 
 
All aspects of this study were consistent with the theoretical framework (paradigm) of critical 
realism; critical realists believe that phenomena exist, but that all aspects of phenomena 
cannot be fully known (Illing, 2010). The phenomenon of hearing deterioration was the focus 
of enquiry for this study, and deterioration can be identified and measured using different 
criteria (Theunissen et al., 2015). Arguably, experience of hearing deterioration will vary 
depending on the context in which the deterioration occurs, and this variation accords with 
the critical realist understanding of phenomena. Further, critical realists believe that 
phenomena are understood by employing both quantitative methods and qualitative 
methods (Bazeley and Kemp, 2012). The majority of research enquiries discussed in 
Chapter 2 focussed on measuring hearing deterioration following treatment of HNC. The 
hypothesis for those studies (Chan et al., 2009; Cheraghi et al., 2015; Cho et al., 2016; Hsin 
et al., 2010; Li et at., 2010; Niemensivu et al., 2015; Pan et al., 2005; Petsuksiri et al., 2011; 
Shorter et al., 2017; Theunissen et al., 2014b) was that there was an association between 
hearing deterioration and treatment. For example, Chan et al. (2009) stated that 
‘sensorineural hearing loss is a common and important complication after RT in patients with 
nasopharyngeal carcinoma’; and Theunissen et al. (2014b) mentioned that ‘both RT and 
cisplatin are known for their ototoxic effects, leading to hearing loss’. These studies used 
deductive (quantitative) methods for determining incidence of hearing deterioration. 
However, the researcher was aware that individuals experience similar hearing impairment 
levels differently (Meddis et al., 2010; Harrison, 2016). Consequently, it can be difficult to 
predict how an individual will be affected in every-day life following a deterioration in their 
hearing, as there will be variation in people’s attitude to hearing impairments, and also 
variation in people’s communication and other hearing difficulties (Thomas, 1988). 
 
In addition to assessing the extent of hearing deterioration, the researcher wanted to explore 
patient experience of hearing deterioration, and thereby gain an understanding of the range 
of problems specific to this group of patients. Two papers that were reviewed in Chapter 2 
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used quantitative questionnaire studies which indicated that hearing deterioration following 
HNC treatment does not have an impact on quality of life (Lastrucci et al., 2017; Loimu et al., 
2015). However, it is known that clinician rated measures (as used in these studies), may 
under-estimate problems encountered by patients (Lazarus et al., 2014; van der Molen et 
al., 2012). Subsequently, the findings from Lastrucci et al. (2017) and Loimu et al. (2015) 
contrasted those of Nund et al. (2015) who reported that hearing deterioration did impact on 
patient experience in their study on broad communication difficulties following HNC 
treatment. Nund et al. (2015) used the process of induction to gain knowledge of patient 
experience using qualitative methods; induction is the process of piecing together 
information from participants to see if there are common themes (Carlsson, Nilbert and 
Nilsson, 2006). 
 
In addition to the belief that an understanding of phenomena can only be approximate, 
critical realists also believe that interpretation of this information is influenced by the 
experience and background of the researcher (Phillips and Burbules, 2002). Through his 
clinical work, the researcher came to this project with an awareness of the impact that 
hearing deterioration has on patients. He also brought to the project knowledge and 
expertise in interpreting the severity of hearing deterioration, and an awareness that patients 
are affected by their hearing deterioration in different ways. Consequently, his experience 
contributed to his interpretation of the results obtained in this study. The critical realist 
paradigm was deemed to be the most appropriate theoretical framework to use for 
underpinning this research.  
 
3.3 Methodology  
 
As stated above, most studies on hearing deterioration have focussed on measuring the 
incidence of hearing change (Theunissen et al., 2015; Mujica-Mota, Waissbluth and Daniel, 
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2013) using quantitative methods. To explore both incidence and patient experience of 
hearing deterioration, the methodology of mixed methods was used for this study.  
Mixed methods research draws on the results from quantitative and qualitative methods by 
incorporating both the importance of the physical world as well as that of human experience 
(Johnson and Onwuegbuzie, 2004). The mixed methods approach was required to explore 
both measurable psychoacoustic change (a change in the perception of sound) and the lived 
experience in suffering from hearing deterioration following HNC treatment. Mixed methods 
methodology has two distinct phases for each of the quantitative and qualitative methods 
used, and also requires a level of integration between the phases (Leech and Onwuegbuzie, 
2009). There are various designs for these different phases (Terrell, 2012) that may require 
weighting of the relative importance of each (Creswell, 2003). The research design for this 
study will be discussed in the next section. 
 
3.4 Research design 
 
Figure 3.1 Study design (mixed methods sequential explanatory design, with Phase 1 data used to inform 
selection of Phase 2 participants)  
 
 
The current study employed a sequential model design (Terrell, 2012; Ivankova, Creswell 
and Stick, 2006) with the quantitative phase followed by the qualitative phase (Figure 3.1 
above). It was necessary for the phases to be arranged this way because the quantitative 
phase data was used for selecting participants for the qualitative phase, as it was important 
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to recruit people with hearing deterioration for the qualitative interviews. There were two 
levels of integration between the phases: first, the selection of participants for the qualitative 
phase, using the data from the quantitative phase, and secondly in the interpretation of the 
results from each phase. The study design was constructed to address the four areas 
outlined by Creswell (2003): 
 
Implementation: what sequence of (qualitative and quantitative) methods is         
      used in the overall research design?  
Priority: which methods are most important in data analysis, particularly in  
      influencing decisions when findings from different methods do not agree? 
Integration: at what stage of the research design are the data from the different  
      methods put into relation with each other?  
Theoretical perspective: is the theory informing the analysis explicit from the  
      beginning or emergent during the research process?  
Table 3.1 Characteristics of mixed methods studies (from Creswell, 2003) 
 
3.4.1 Implementation – Determining sequencing of methods 
 
The first aspect to consider when conducting mixed methods study is how the two phases 
are undertaken time wise in relation to each other (Table 3.1). Selection of participants for 
an exploration of their experience of hearing deterioration required first the identification of 
participants with a measured deterioration in their hearing. The study needed to start 
therefore, with the quantitative phase. The sequential design, with completion of the 
quantitative phase prior to starting the qualitative phase, was therefore chosen in preference 
to a concurrent or nested design, where there is overlap in the phases (Terrell, 2012).  
 
Another mixed methods approach that could have been used was for the qualitative phase 
of the study to be conducted concurrently with the quantitative phase, so that the 
examination of the lived experience of each participant was conducted at the same interval 
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in the early post treatment stage. This design would have provided a full exploration of the 
experience of hearing deterioration, as all participants identified with hearing change would 
have been selected for the qualitative phase. However, this design was not adopted for 
theoretical and practical reasons. It was not known how many participants would have 
hearing deterioration, and there was the possibility of repetition and duplication of responses 
in conducting an exploration of experience on all the participants. Corbin and Strauss (2014) 
discussed this idea of theoretical saturation when a researcher has explored in-depth 
categories or themes identified in qualitative research. On the practical front, there were time 
constraints in conducting the study, as it was necessary to plan the quantitative and 
qualitative phases separately, to accommodate the researcher’s limited time available in 
maintaining both study and work requirements.  
 
An alternative method would have been to perform a quantitative assessment on one group 
of participants and a qualitative study performed on another group, resulting in two separate 
studies. Even if the same criteria of hearing deterioration were used for selection of 
participants for the qualitative assessment, because the two groups would have different 
demographic characteristics, the phenomenon of hearing deterioration would be assessed in 
different contexts, making it difficult to integrate data from each group. If different criteria of 
hearing deterioration were used in selection of participants for the qualitative phase, different 
patient experience would be obtained, and again it would be difficult to integrate the data to 
obtain the benefits of mixed methods study. Consequently, it was necessary to conduct the 
two phases of study on the same patient group.  
 
3.4.2  Priority – Determining which phase was ascribed priority 
 
The second aspect to consider when conducting mixed methods study is which, if either, of 
the two phases that are conducted, is given priority (Table 3.1). The data from the two 
phases provided information on different aspects of hearing deterioration; Phase 1 provided 
data on a measured amount of hearing change, whereas Phase 2 provided patients 
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experience of this change. Therefore, an assessment of convergence, divergence or 
correlation of the results from each phase was not applicable, and both the quantitative and 
qualitative phases were given equal importance. However, the phases were ascribed 
different priority based on novelty and policy perspectives: 
o Novelty - In this study, the qualitative phase was given more priority and 
weight of significance than the quantitative phase from a novelty aspect, because up until 
the present study there was limited information on patient experience of hearing 
deterioration. There is only one other study (Nund et al., 2015) that includes some aspect of 
qualitative methodology to explore experience of hearing deterioration following HNC 
treatment. Consequently, it was anticipated that the current study would provide novel 
findings on the experience of hearing deterioration, as the qualitative phase focussed on the 
impact of the experience of hearing change, rather than on more broad communication 
change as in Nund et al. (2015). Conversely, although there have been no recent studies 
that have assessed the extent of hearing deterioration following HNC treatment in a UK 
hospital, there are already many other studies from other countries that have measured the 
extent of hearing deterioration (for example Chan et al., 2009; Cho et al., 2016; Pan et al., 
2005). So, although the quantitative phase was expected to provide new data from a UK 
population to add to existing knowledge on incidence of hearing deterioration, the qualitative 
phase was expected to produce more novel findings.   
o Policy - The quantitative phase of this study had more priority than the 
qualitative phase for informing policy, as arguably, health policy in both audiology and HNC 
is currently dominated by quantitative evidence. The quantitative phase of the study 
provided data on incidence of hearing deterioration, types of hearing loss, and risk of 
hearing deterioration following HNC treatment which would be used for planning services 
effectively. However, it was the contention of this study that findings from the qualitative 
phase of the study should have considerably more importance than has been the case in the 
shaping of policy, as patient experience of cancer survivorship is now being recognised 
(NHS, 2016). 
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3.4.3 Integration – Determining links between the phases 
 
The third aspect to consider when conducting mixed methods study is how data from each 
of the phases mix, or integrate with each other (Table 3.1). There were two areas of 
integration in this study and these are shown in Figure 3.1. The first stage of integration was 
in the sampling for the qualitative phase of the study. Results of the quantitative phase were 
used to inform the sampling for qualitative data collection; participants identified with hearing 
deterioration were eligible for selection for the qualitative phase of study. The second stage, 
at which the data from each of the different phases were mixed was in interpretation (which 
took place in both Chapters 6 and 7), where the results were explored to understand 
experiences of patients who had different levels of hearing deterioration, and to establish if 
there were any patterns or risk factors that were related to patient experience.  
 
It has been argued that a truly mixed methods study is one that integrates results from 
quantitative and qualitative data (Kroll and Neri, 2009), with the conversion of data into either 
quantitative or qualitative forms for comparison (Onwuegbuzie and Teddlie, 2003). A study 
that does not integrate results could possibly be regarded as two distinct studies viewing the 
same phenomenon from different angles, and studies that utilise mixed methods in this way 
often publish results in separate papers (O’Cathain et al., 2007). Although, data were not 
integrated by conversion, the results of the quantitative and qualitative phases were brought 
together to provide a more complete understanding of hearing deterioration, including 
whether this phenomenon was homogeneous or heterogeneous for study participants. 
 
3.4.4 Theoretical perspective 
 
The premise of this study was that hearing deterioration, associated with treatment of 
patients with HNC, has a negative impact on these patients. To help inform policy for cancer 
survivorship in the UK, it was necessary to quantify the incidence and severity of 
deterioration for a population receiving treatment of hearing deterioration using UK treatment 
		 108 	
protocols, prior to exploring the lived experience through qualitative enquiry. The critical 
realist approach underpinning this study has been discussed as being appropriate to use 
earlier in this chapter. However, alternative frameworks could have been used. 
 
3.4.5 Alternative theoretical frameworks 
 
The use of both quantitative methods and qualitative methods (in mixed methods 
methodology), was required to address the research for this study. Research paradigms that 
focus only on the use of either quantitative methodology alone (positivism – Guba and 
Lincoln, 1994) or qualitative methodology alone [for example constructivism – Guba and 
Lincoln, 1994; or phenomenology – (Lopez and Willis, 2004)] were not appropriate for 
underpinning this research.  
 
However, there are other paradigms that facilitate the use of both quantitative and qualitative 
methods that may have been suitable for underpinning this research. The pragmatist uses 
whatever methods are most suitable to answer the research question, rather than focussing 
on what the nature of reality is (Morgan, 2007; Creswell and Plano Clark, 2007; Feilzer, 
2010). Dialectical pluralism is a metaparadigm that allows researchers and stakeholders 
from different paradigmatic positions to embrace these differences and create a holistic 
understanding of phenomena (Burke Johnson, 2015). However, it appears to the researcher 
that the dialectical pluralistic approach may be another form of pragmatism to answer 
research questions. As the researcher believes that different aspects of reality are 
discovered through different types of research, the critical realist stance appeared most 
suitable for formulating ideas of how to study the phenomenon of hearing deterioration. In 
this research project, hearing deterioration was the reality being investigated, with insight 
obtained specifically on incidence, severity and patient experience in the context of HNC 
treatment. A detailed description of which type of quantitative and qualitative methods that 
was used in this study will now be discussed.   
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3.5 Quantitative methods  
 
To assess incidence and severity of hearing deterioration after HNC treatment (the first of 
the primary aims of this study) it was necessary to assess changes in psycho-acoustic 
hearing levels before and after treatment, using a non-experimental, observational 
prospective repeated measures method.  The repeated measures method enables the 
measurement of hearing at different time points for a cohort (Mark and Reichardt, 2009). 
This method, used in other studies discussed in the literature review (Li et al., 2010; Oh et 
al., 2004), was the most appropriate to use for this study, as it did it not seek to establish 
causality (required for experimental methods) – nor did it seek to establish the effectiveness 
of an intervention (used in quasi-experiment methods – Walliman, 2006). The repeated 
measures method, using psycho-acoustic hearing tests, was also used for addressing the 
secondary research aims of this study that were: (a) to describe overall hearing levels; (b) to 
assess types of hearing loss; and (c) to explore the incidence and severity of hearing 
deterioration in relation to patient demographics and types of treatment. 
 
3.6 Qualitative methods 
 
For this study, the second primary research aim was to assess the lived experience of 
participants with hearing deterioration after treatment for HNC. The significance that patients 
gave to their lived experience was of interest, rather than a description of the reality of their 
experience, so an approach informed by interpretive phenomenology (Lopez and Willis, 
2004), appeared most appropriate to use. 
  
The approach informed by interpretive phenomenology fits within the critical realist stance 
underpinning this study and provided the qualitative approach to the mixed methods design. 
The qualitative inquiry provided an understanding of how patients experienced, and were 
affected by, hearing deterioration in the context of HNC treatment. The specific context from 
which experiences are being drawn is considered important within interpretive 
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phenomenology, as is the specialist knowledge of the researcher. Both these aspects were 
relevant for this study. Because of his awareness of the impact of hearing deterioration, and 
desire to provide knowledge and inform policy, the researcher determined to explore the 
phenomenon of deterioration in the context of cancer treatment. 
 
3.7 Summary  
 
This chapter has demonstrated how the critical-realist paradigm adopted by the researcher 
underpinned both the research aims and the mixed methods approach used for investigation 
in this study. The critical-realist approach provided the philosophical framework for 
determining both the incidence and severity of hearing deterioration, and the assessment of 
patient experience of this deterioration, following HNC treatment. This study employed a 
sequential design, with the quantitative data collection phase followed by a qualitative data 
phase, in a mixed methods design. This design included integration between the two phases 
of study at two stages: first, with quantitative data used to inform appropriate sampling for 
the qualitative phase; and secondly, with integration of results by interpretation of data in 
Chapters 6 and 7 (Results – Qualitative data, and Discussion, respectively) of the study. A 
non-experimental, observational prospective repeated measures method was used for 
obtaining quantitative data, and a method informed by interpretive phenomenology was used 
to provide qualitative data to explore and assess the lived experience of hearing 
deterioration following HNC treatment.  
 
The next chapter provides an account of the methods used for conducting the research 
study, and the instruments that were selected as most appropriate for data collection in both 
the quantitative and qualitative phases of this study, based on the methods of repeated 
measures, and an approach informed by interpretative phenomenology, respectively.   
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Chapter 4 Methods 
 
4.1 Introduction 
 
This chapter presents the chosen methods for determining hearing deterioration, and the 
chosen research instrument to explore patient experience. It first shows the timeline for the 
study, and then presents the overall schema of the quantitative and qualitative methods 
used. The chapter continues to discuss the methods used for conducting the study and 
presents each phase of the study in turn, starting with the quantitative phase. For each 
phase, criteria used for determining the study sample for data collection will be discussed, 
followed by an outline of the process for recruiting participants, and then an in-depth 
discussion of the instruments used for data collection. The method employed for data 
collection and analysis is then described. The chapter concludes with ethical and 
governance considerations for conducting the study.  
 
To re-iterate, the primary research aims were, for patients who were due to receive current 
treatment in a UK hospital: 
1. to assess the incidence and severity of hearing deterioration after treatment for head 
and neck cancer; and  
2. to explore the lived experience of participants with hearing deterioration after 
treatment for head and neck cancer. 
   The secondary aims of this study were: 
      a.   to describe overall hearing levels; 
      b.   to determine types of hearing loss; and 
      c.   to explore the incidence and severity of hearing deterioration in relation to  
            patient demographics and types of treatment.  
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4.1.1 Study timeline 
 
The timeline for conducting the study is shown in Figure 4.1: 
 
Figure 4.1 Study timeline 
 
 
4.2 Quantitative phase 
 
This first phase of the study, outlined in Figure 4.1, comprised a series of hearing tests: 
within two weeks of cancer diagnosis (Test 1), at the end of treatment (Test 2), and three 
months after completion of treatment (Test 3). Data obtained within this phase were used to 
address the first of the primary aims of the research project, and all three of the secondary 
aims.  
 
4.2.1 Sample size 
 
The quantitative phase of the study was conducted to collect data to determine the incidence 
(by proportion) of patients who had hearing deterioration following treatment and to 
differentiate levels of severity. Participants for the project were invited from among patients 
who were consecutively diagnosed with HNC by oncologists at the researcher’s hospital. 
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This method of selection is called ‘convenience consecutive sampling’, where study 
participants are drawn from a population receiving treatment in one institution (Teddlie and 
Yu, 2007). Consecutive sampling is convenient for recruitment in studies, particularly if there 
is limited time for conducting the research, but the sample may not be fully representative of 
the population (Bowers, House and Owens, 2011). For this study, participants were recruited 
over a 6-month period. The one-year survival rate of HNC patients varies considerably, 
between 60-90%, depending on location and stage of the cancer with an aggregate of 80% 
survivorship (OCIU, 2010). Consequently, an attrition rate of approximately 20% was 
assumed in this study. 
 
It was necessary to estimate how many participants should be recruited to increase the 
validity of the results obtained. The estimate was determined using data obtained from the 
pilot study performed prior to the current project (Appendix 4.1). The pilot compared 
the hearing of a group of patients (from a range of HNCs) prior to treatment, with those 
tested after treatment, and assessed the average difference in 6 or 8kHz (high speech 
frequencies), as RT and CRT affect mainly high frequencies of hearing (Zuur et al., 2007). A 
hearing difference of approximately 15dB was determined across these frequencies, and 
this criterion was deemed to be most appropriate for detecting hearing deterioration (see 
discussion in Chapter 2).  
 
The focus of the current study was to identify the quantity of patients who had an average of 
15dB deterioration in hearing following treatment, rather than to determine the average 
threshold shift. However, it was necessary to estimate how many patients would have at 
least a 15dB deterioration for recruitment. Siobhan Crichton, statistician from King’s College 
London, used raw data from the pilot data, and stated: ‘With 38 patients, there will be 80% 
power to detect a change of 15dB between pre and post treatment (averaged across 
frequencies of 6 or 8kHz) between time 1 and 2, or time 1 and 3 (of the three time points 
used in the study), using a paired T-test and assuming a standard deviation of 8.9 (taken 
from the pre-treatment hearing pilot data) and an overall 5% level of significance. Allowing 
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for 15% drop-out rate 44 patients will be recruited’. Adapting the attrition rate from 15% to 
20% meant that 48 participants needed to be recruited for 38 to complete the study and 
enable 80% power for the study. The throughput of newly diagnosed HNC patients at the 
study centre is 200 per year, of which 60-70% would require RT or CRT (Palaniappan, 
Owadally and Evans, 2015); therefore, approximately 60 patients would be eligible within the 
6-month recruitment period allowed for this study. Although it was not known how many of 
these patients would be eligible to participate, or who would decline participation, it was 
suggested that approximately 20% may not be recruited, as van den Berg et al. (1997) 
determined a refusal rate of 17% in their clinical trial. Therefore, it was anticipated that 48 
patients would be recruited to the study over a period up to six months, to allow for those 
who would not consent or would not be eligible for involvement. Of these, 38 would complete 
the study (due to 20% attrition rate, OCIU, 2010), which would be sufficient to enable 80% 
power. 
 
Although 50 participants would be sufficient to draw statistical significance from this study, 
more would need to be recruited for identifying the incidence of hearing deterioration in the 
UK. However, due to timeframe constraints for completing the study, it was not possible to 
increase the time for recruiting at the study centre. In addition, it would be necessary to 
conduct studies across different UK centres to allow for regional differences in diagnosis of 
HNC subtypes. Therefore, the results from this study would only reflect incidence of hearing 
deterioration at this local tertiary UK centre.  
 
4.2.2 Recruitment 
 
Patients were recruited from the study centre on a consecutive convenience sampling basis 
following a diagnosis of HNC from February 2015 to August 2015, over a period of six 
months. It is recognised that consecutive sampling has limitations as it may not account for 
seasonal variation and the sample population may not be fully representative of the 
population being assessed, however consecutive sampling is convenient particularly if there 
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is limited time for conducting research (Bowers, House and Owens, 2011). An oncologist 
who diagnosed the HNC of potential participants gave them an information sheet to explain 
the purpose and nature of the study. On the same day, the potential participant met the 
researcher to discuss any questions that the patient had regarding involvement in the study. 
Following a period of at least 24 hours, the researcher again met the potential participant to 
obtain written, informed consent to participate in the study. Patient demographics including 
age, date of birth, gender, type of cancer and the treatment method to be used, were 
recorded. Additional information on aetiology of HNC, and type and dosage of treatment was 
obtained from medical notes. Participant information was stored on an excel spreadsheet 
that was password secured (see section 4.5.1 on ethical considerations). Participants were 
recruited using the following inclusion and exclusion criteria: 
 
4.2.2.1 Inclusion criteria 
 
• newly diagnosed with HNC;  
• aged 18 years and over; 
• due to receive standard curative treatment using calibrated equipment and 
administered by trained clinicians [RT, administered as IMRT using calibrated 
equipment, and if administered chemotherapy (adjuvant to RT or concurrent with 
RT), using cisplatin, carboplatin or cetuximab]; 
• able to provide written informed consent. 
 
4.2.2.2 Exclusion criteria 
 
• patients requiring interpreter services (there was no funding arrangement to obtain 
interpreters for this study); 
• patients with a pre-existing audiological condition e.g. Meniere’s disease; 
• patients with ear wax not removed prior to testing. 
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4.2.3 Instruments used to measure hearing deterioration 
 
Pure tone audiometry is the standard technique used to measure psycho-acoustic hearing 
thresholds (BSA, 2011). The PTA technique requires participants to respond each time they 
hear a sound. Sound stimuli are presented at different intensity levels within the speech 
frequency range, and the threshold of hearing for each frequency of sound is recorded. Test 
stimuli can be produced from either air or bone conduction transducers. Responses made 
from air conduction stimuli represent a subject’s ability to hear sounds throughout the whole 
hearing pathway; those made from bone conduction stimuli assess hearing from the cochlea 
to the auditory cortex. Difference in air and bone conduction thresholds may demonstrate a 
block in sound transmission, such as temporary build-up of fluid within the middle part of the 
ear (Hsin et al., 2013).  
 
Pure tone audiometry hearing testing was performed by different audiologists within the study 
centre using a standard technique (BSA, 2011). Each audiologist has been trained and 
assessed as competent in performing PTA. Testing was performed in a standardised, 
soundproofed room, using audiometers calibrated to deliver standard audiometric sound 
pressures for speech frequencies at 0.25, 0.5, 1, 2, 3, 4, 6 and 8kHz 
for air conduction stimuli, and at 0.5, 1, 2, 3 and 4kHz for bone conduction stimuli. Air 
conduction and bone conduction thresholds at each of these frequencies were measured for 
each ear at the three hearing testing time points for this study. Testing used a standard, reliable 
and reproducible approach, and generated valid measurements. The use of audiologists in 
addition to the researcher minimised researcher bias for this study, and each audiologist used 
the same standard technique. 
 
Tympanometry is an audiology test that assesses the function of the middle ear component of 
the peripheral auditory system. Tympanometry was performed in addition to PTA to identify if 
hearing loss comprised a component of middle ear dysfunction, and so assisted with 
determining type of hearing (being normal hearing or hearing loss of sensorineural, conductive 
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or mixed type). Tympanometry was performed using standard impedance meters within a 
standardised environment and using a recognised technique (BSA, 2013). Middle ear 
measurement parameters of peak pressure, maximum compliance, and ear canal volume were 
recorded for each ear at the three hearing testing time points, and the numerical values were 
recorded and stored on an excel spreadsheet.  
 
Audiometers for performing PTA, and middle ear analysers for performing tympanometry, in this 
study were calibrated to deliver test stimuli and record responses in accordance with relevant 
BS EN ISO standards (BSA 2011; BSA 2013). The use of standard equipment and techniques 
for performing and interpreting hearing test results were required for obtaining valid and 
repeatable results. Ethical approval for the study is found in section 4.5 of this chapter. 
 
4.2.4 Data collection 
 
All of the participants who enrolled in the study were due to have hearing testing (PTA and 
tympanometry) at Test 1, Test 2 and Test 3: 
• Test 1 – within two weeks of diagnosis and prior to their treatment, all participants 
had a baseline hearing test by a trained audiologist at the hospital where the study 
was conducted and where this procedure is standard practice. It was anticipated that 
this would be the participant’s scheduled routine hearing test prior to the 
commencement of their cancer treatment. The majority of participants had their pre-
treatment hearing test immediately after consenting to take part in the study. Testing 
was on a day that participants also had a pre-treatment dental appointment to 
minimise inconvenience and maximise attendance compliance. Some participants 
required dewaxing of their ears and this was arranged with the specialist nurse 
service at the study hospital before undertaking hearing tests. Participants undertook 
cancer treatment lasting between six to 15 weeks; 
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• Test 2 – the second test assessment was set to coincide with the completion of 
oncology treatment, and this assessment was co-ordinated with the radiotherapy 
department at the study centre; 
• Test 3 – the third test assessment was set to coincide with the date of the 
participants’ routine 13-week post treatment follow-up oncology appointment. 
 
The hearing assessments took place in the audiology department of the study hospital and 
each assessment took up to 30 minutes to complete. 
 
Hearing thresholds for each required frequency were recorded as numerical figures that were 
stored in an audiology patient management system and then transferred to an excel datasheet 
for data analysis. Standard tympanometry parameters of middle ear pressure, peak compliance 
and ear canal volumes were also recorded as numerical figures on an excel datasheet for data 
analysis. 
 
4.2.5 Data coding 
 
Results obtained from conducting hearing tests and tympanometry were brought together 
and coded in different ways (described below) to provide information on the incidence and 
severity of hearing deterioration, the overall description of hearing loss severity, and the type 
of hearing loss.  
 
4.2.5.1 Defining and grading hearing deterioration 
 
In Chapter 2 it was discussed that there are different methods for determining hearing 
deterioration, and that, combining findings from Konrad-Martin et al. (2010) and Simpson, 
Schwan and Rintelmann (1992), it appeared that ≥15dB shift in threshold, across two or 
more adjacent frequencies was the most appropriate for determining a clinically significant 
deterioration in hearing. This definition is used within the CTCAE criteria produced by NCI, 
with the latest version being version 4.03 (NCI, 2010) prior to starting the project. The 
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CTCAE criteria for hearing were used in some of the studies discussed in the literature 
review (Cheraghi et al., 2015; Theunissen et al., 2014b). The CTCAE criteria are familiar to 
the oncologists at the study centre, as the scale is used for assessing whole body systems 
and the impact of cancer treatment. Therefore, the CTCAE scale was used in this study to 
enable results to be readily understood by both oncology and audiology disciplines. 
 
The CTCAE scale (in Appendix 4.2) has a grading system on hearing deterioration that may 
follow cancer treatment, with Grade 1 being the most minor deterioration, and Grade 4 the 
most major. A Grade 1 deterioration in hearing for adults enrolled in a hearing-monitoring 
programme (for a 1, 2, 3, 4, 6 and 8kHz audiogram of air conduction thresholds) is one 
where there is an average threshold shift of between 15 and 25dB across two contiguous 
frequencies in at least one ear. For this study, a clinically significant loss was defined as any 
grade of deterioration, when comparing pre-treatment hearing thresholds with those 
obtained at the end of treatment or at 3-month follow-up post treatment. Air conduction 
threshold values were used, rather than bone conduction, to demonstrate a change in 
functional hearing, although both air and bone conduction results were recorded. Air 
conduction thresholds provided the overall level of hearing, regardless of whether the 
hearing change was permanent or temporary, whereas bone conduction thresholds provided 
levels of more permanent loss. For this study, it was important to determine overall hearing 
and the impact of hearing loss, whether temporary or permanent, on patients. Any graded 
change in hearing was included in the statistic for determining the incidence of hearing 
deterioration, as any grade may be detrimental to patients, particularly if participants already 
possessed hearing loss prior to treatment. In addition, hearing loss had the potential to 
deteriorate further with time (Bentzen and Trotti, 2006).  
 
Hearing deterioration was graded according to the four numerical grades for hearing in the 
CTCAE criteria (see Appendix 4.2). The criteria used a comparison of air conduction hearing 
thresholds measured at 1, 2, 3, 4, 6 and 8kHz obtained pre-treatment with those obtained at 
either the end of treatment or at 3-month follow-up post treatment. Graded data were 
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entered and analysed as categorical data in an excel spreadsheet. Using comparison of 3- 
month follow-up hearing levels with those obtained pre-treatment, participants who had any 
grade of hearing deterioration were eligible for recruitment for the second phase of the 
study. A full sampling framework for the qualitative phase is provided in section 4.3.1 of this 
chapter. 
 
4.2.5.2 Defining descriptors of hearing level and types of hearing loss 
 
There are different ways to describe levels of hearing, mainly based on which country data 
are derived from. This study used the UK system, summarised in Table 4.1:  
 
Descriptor Average hearing threshold levels (dBHL) 
No loss (normal hearing) <20 
Mild hearing loss  20-40 
Moderate hearing loss  
 
41-70 
Severe hearing loss  
 
71-95 
Profound hearing loss  In excess of 95 
Table 4.1 Descriptors of hearing level (British Society of Audiology, 2011) 
 
The BSA describes hearing levels based on the average of air conduction pure tone 
frequencies at 0.25, 0.5, 1, 2 and 4kHz. Using these criteria, the researcher was able to 
establish the proportion of participants in the study project within each severity level of 
hearing loss. However, there are no statistics using these BSA criteria for comparing the 
proportion of people in the UK who have hearing loss with those who have normal hearing. 
 
In addition to air conduction thresholds, bone conduction thresholds were measured to 
determine hearing through direct stimulation of the cochlea, and both these thresholds were 
used to determine types of hearing loss. The type of hearing loss for each ear was 
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determined to assess potential temporary or permanent hearing change using BSA 
guidelines for tympanometry (BSA 2013), and PTA as follows:  
• Normal hearing: air conduction hearing thresholds between 0.25 and 8kHz ≤ 
20dBHL 
• Conductive hearing loss: bone conduction thresholds between 0.5-4kHz ≤ 20dBHL, 
and air-bone gap in at least one of the frequencies between 0.5-2kHz ≥ 15dB. 
• Sensorineural hearing loss: air conduction hearing thresholds between 0.25 and 
8kHz > 20dBHL, and air-bone gap between 0.5-2kHz < 15dB. 
• Mixed loss: bone conduction thresholds between 0.5-4kHz > 20dBHL, and air-bone 
gap in at least one of the frequencies between 0.5-2kHz ≥ 15dB.  
 
Tympanometry was performed to confirm normal hearing or to assist with the classification 
of hearing loss type as being conductive, mixed, or sensorineural. Therefore, for this study, 
the BSA guidelines on PTA and tympanometry were used to describe hearing level, and 
classify type of hearing loss before treatment, at the end of treatment and at 3-month follow-
up.  
 
4.2.6 Statistical analysis 
 
Data obtained following coding were analysed using either descriptive or inferential statistics 
(Table 4.2) depending upon different characteristics that were measured:   
 
Descriptive 
statistics 
Patient demographics 
Incidence and severity of hearing deterioration  
Descriptor of hearing loss severity 
Type of hearing loss 
Inferential statistics Severity of hearing deterioration with participant demographics 
Missing data 
Table 4.2 Statistical analysis used 
 
		 122 	
4.2.6.1 Descriptive statistics 
 
In order to assess incidence and severity of hearing deterioration in context, it was 
necessary to obtain data on the characteristics of the participant population. Demographic 
data on age, gender, location of cancer, stage of cancer, aetiology, treatment regime and 
pre-treatment hearing loss status were kept on an excel spread sheet. Text data were 
transformed as numerical category data, and then transferred to the Statistics Package for 
Social Sciences (SPSS) software v22 for analysis. Descriptive statistics were obtained for: 
the age and gender of participants; the location, stage and aetiology of the cancer; the 
treatment regimen used; and the descriptor of hearing loss severity prior to treatment. 
 
Descriptive statistics were used to determine the incidence and severity of hearing 
deterioration (the first of the primary research aims) by comparing hearing levels at the end 
of treatment and at 3-month follow-up with pre-treatment levels. Incidence of hearing 
deterioration was based on the proportion of participants with any grade of deterioration (in 
one or both ears) according to the CTCAE for hearing (NCI, 2010). Severity of hearing 
deterioration was based on the proportion of participants with each grade of deterioration (in 
one or both ears) according to the same CTCAE scale, with the greater severity taking 
precedence.  
 
The proportion of participants who had hearing described as normal, or as a mild/ moderate/ 
severe/ or profound loss, according to BSA criteria, was calculated for each hearing level 
status. The proportion of ears amongst the participants that had normal hearing, conductive 
loss/ mixed loss/ or SNHL was also calculated to identify each different type of hearing loss.  
 
4.2.6.2 Inferential statistics 
 
In Chapter 2, it was noted that pre-treatment hearing levels, a patient’s age, the type of 
treatment, and time of follow-up may be covariables to treatment in influencing the degree of 
hearing deterioration following treatment, and that multivariate analysis is required to assess 
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the impact of covariables. In this study, however, hearing deterioration was not measured as 
a continuous variable but as a categorical variable. Consequently, as hearing deterioration 
was the dependent variable, it was not applicable to use multivariate analysis of continuous 
data on hearing.  
 
However, it was possible to use the effect of age on hearing deterioration, by making age 
the dependent continuous variable. The analysis of variance (ANOVA) test was used to 
assess for statistical significance in the mean values of the age of participants with different 
degrees of hearing deterioration. The ANOVA test is used in the analysis of continuous 
variables and suitable for within-participant repeated measures design, when more than two 
measurements over time are made on an individual participant. There are three assumptions 
required for performing ANOVA tests: first, that the distribution of data is normal (assessed 
using the Shapiro-Wilk test); secondly that scores from participants are independent of each 
other; thirdly, that group variance and covariance are homogenous (Martin and Bridgmon, 
2012). If ANOVA was found to be significant, it was necessary to employ the Bonferroni test 
to assess for a true difference in multiple analysis. The Bonferroni test reduces type 1 error 
(identifying a significant result when, in fact the result could be because of chance) in 
multiple analyses on the same data (Statistics solutions, 2017).  
 
The association of factors, other than age, with hearing deterioration were assessed using 
analysis of categorical data. The Fisher’s exact test of categorical variables was the 
inferential statistical analysis used to assess the relation between the potential covariables 
of pre-treatment hearing level, gender and treatment type, with different levels in severity of 
hearing deterioration. Stage of cancer was also tested as a covariable. Fisher’s test is used 
for comparisons of independent categorical data arranged within a two cell times two cell 
table, to assess significant differences within the table, either when the total data is less than 
20, or when the total sample is less than 20, and one cell value is less than five (Zibran, 
2017). The assumption for using the Fisher’s test is that the row and column values of the 
table are treated as fixed quantities, so that variation within these rows and tables is allowed, 
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if there is no variation in the totals for the rows or columns respectively (Mould, 1998). If 
Fisher’s test was found to be significant, the Bonferroni test was again employed to confirm 
any significance found in multiple analyses. 
 
4.2.6.3 Missing data 
 
Raw numerical data on hearing threshold levels were kept on an excel spreadsheet and 
transferred to a SPSS version 22 database. The one-year survival rate of HNC patients 
varies considerably, between 60-90%, depending on the location and stage of cancer, with 
an aggregate of 80% survivorship (HQIP, 2012). Consequently, attrition was expected in this 
longitudinal study, and the Fisher’s exact test was used to determine patterns of missing 
data to assess whether there was any difference in patient demographics between those 
who partially completed testing scheduling and those who completed all the tests. However, 
as no statistical comparison of absolute hearing level was made either for individual 
participants or for groups of participants, computation of missing values was not required. 
 
4.2.7 Validity and reliability of quantitative findings 
 
The CASP checklist for cohort studies (Appendix 2.3) was adapted to use as a quality 
assessment for the quantitative phase of data collection for this study -  
• Does the study address a clearly focused issue? Yes – The aims of the study are 
given – Section 4.1; 
• Was the cohort recruited in an acceptable way?  Yes – A consecutive convenience 
sample of participants with general head and neck cancer was recruited – Section 
4.2.2; 
• Was the exposure accurately measured to minimise bias?  Yes – An outline of what 
treatment patients received is provided – Section 4.2.2.1; 
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• Was the outcome accurately measured to minimise bias? Yes – The hearing test 
method is provided in detail – Section 4.2.3; 
• Have the authors identified all-important confounding factors? Yes – Age, pre-
treatment hearing level, type of treatment and time after treatment – Section 4.2.6.2; 
• Have they taken account of the confounding factors in the design and/or analysis? 
Yes – Using modified methods – Section 4.2.6.2; 
• Was the follow-up of participants long enough? Yes – To identify hearing change in 
the early post treatment phase – Section 4.2.4.   
 
4.3 Qualitative phase 
 
The second phase of the study, outlined in Figure 4.1, entailed conduct of 13 interviews with 
participants to generate qualitative data, and so to address the second main aim of the 
research project, namely: ‘to explore the lived experience of participants with hearing 
deterioration after treatment for HNC’. The reason for choosing interviews will be discussed 
in section 4.3.3 below. 
 
4.3.1 Sample size   
 
It was anticipated that from the sample of 50 participants from the quantitative phase (data 
collected from hearing tests) there would be 20% attrition, leaving 40 participants available 
for the qualitative phase. It was predicted that 38 participants would be required to complete 
testing for 80% power to obtain a 15dB difference in hearing following treatment using pilot 
data prior to this study.  
 
Guest, Bunce and Johnson (2006) suggested that between six to 12 interviews are sufficient 
to obtain breadth of information on a phenomenon, particularly if an in-depth assessment is 
required as in interpretive phenomenological studies (Smith and Osborn, 2008). Such  
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studies are conducted on small sample sizes, to gain a detailed analysis of the perceptions 
of a group of individuals (Smith and Osborn, 2008).  
 
Therefore, it was determined that a purposive sampling technique be employed, and in order 
to obtain as much breadth of information and maximum variation as possible, at least 12 
interviews be conducted. More than 12 participants were invited to interview, to allow for any 
who were not able to attend at short notice and the difficulty in re-arranging appointments 
within the timeframe of conducting the study. Consequently, more than 12 participants were 
interviewed.  
 
Grade of 
deterioration 
a 
Gender Age (years) 
b 
Pre-treatment 
hearing status  
c  
1-2  3-4 Male Female Young Old Normal Hearing 
loss 
Table 4.3 Sampling framework for interview selection    
Key: a- based on CTCAE (v4.03) for hearing deterioration; b- based on mean age of participants who had 
hearing deterioration at 3 months following treatment (mean age determined in Chapter 5); c- based on BSA 
criteria. 
 
Purposive sampling techniques are used in qualitative studies that deliberately select 
individuals for the important information they can provide for answering a research study’s 
questions (Teddlie and Yu, 2007). It is noted that maximum purposive sampling has its 
limitations. Although participants are selected to provide a broad understanding of the 
phenomenon of hearing deterioration, it cannot be guaranteed that the full range of 
experiences of hearing deterioration are obtained, as some participants not selected for 
interview may have different experiences (Cook, 2015). However, to maximise the greatest 
range in information obtained (Scott et al., 2007), Table 4.3 above shows the sampling 
framework used for this study. Each of the eight characteristics in the sampling framework 
was used to guide sampling to provide maximum divergence in participant demographics, 
for a broad understanding on patient experience of hearing deterioration. The categories 
were chosen to represent different degrees of deterioration (minor, Grades 1-2; or major, 
Grades 3-4) to explore the impact on patient experience of participants who had a minor or 
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major hearing deterioration. As the researcher wanted to obtain maximum diversity in this 
study, different characteristics of gender, age and pre-treatment hearing status were 
selected, as each of these characteristics has been linked with different amounts of hearing 
deterioration (Theunissen et al., 2015). Multiple variation sampling enabled the researcher to 
assess if the phenomenon of hearing deterioration was homogenous or heterogeneous 
across different patient characteristics.  
 
4.3.2 Recruitment 
  
All participants identified with any Grade (1-4) of hearing deterioration, as specified in the 
CTCAE criteria version 4.03 (NCI, 2010), were eligible for interviewing. Purposive maximum 
variation sampling, based on the sampling framework shown in Table 4.3, was used to 
select participants for exploring patient experience of hearing deterioration as widely as 
possible.    
 
The researcher approached participants by telephone after they had their 3-month follow-up 
hearing assessment (and within a year of this assessment) to inform them of Phase 2 of the 
study. Those participants who verbally agreed to participate in Phase 2, or those who were 
not contactable by telephone, were sent an information sheet by first class post, giving 
details of the purpose and nature of the second phase of the study. Following a period of at 
least 24 hours from posting the participant information sheet, the researcher phoned 
potential participants and arranged an interview for those wishing to continue with their 
participation in the study. Written, informed consent was obtained prior to their interview. 
Interviews were held after the 3-month follow-up hearing tests were completed and not 
before, as it was considered appropriate to allow participants time to recover from their 
treatment.  
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4.3.3 Qualitative method 
 
The qualitative method of interviewing was chosen for Phase 2 data collection, as this is 
often used for exploring patient experience in many studies, and has been used successfully 
in the one study identified in the literature review (Chapter 2) on hearing problems in HNC 
patients using a phenomenological approach (Nund et al., 2015). 
 
Of the different types of interview available, semi-structured interviewing was chosen to 
provide rich data on opinions, feelings and experiences, with pre-set questions and flexibility 
to enable the participants to develop ideas and speak more widely on issues (Denscombe, 
2010). Semi-structured interviews were of benefit for this research because they enabled 
participants to give in-depth information of their experience of hearing deterioration, and 
allowed greater flexibility for the researcher to probe more deeply, when appropriate. This 
approach was also appropriate for use within a critical-realist framework. The interviews 
were held in the hospital premises in a private and quiet room used for clinical investigation 
in the Audiology department, and were conducted by the researcher. The interviews lasted 
up to one hour. The semi-structured format enabled the researcher to ask pre-determined 
questions, to have flexibility in the order of asking these questions, or to modify them 
according to what was most appropriate for the interviewee (Robson, 2002). The interviews 
had a few specific questions that were open-ended to allow patients to elaborate (Barbour, 
2008) on their experience of hearing deterioration.  
 
The main areas addressed at interview were:  
1. The experience of hearing deterioration: hearing loss prior to treatment, and     
    deterioration during and following treatment were explored, with the particular 
    focus on the impact on daily living; 
2. Information and support: questions were asked to determine what information 
    and support the interviewees were aware of – and what they felt was available –          
    that would help them understand and manage their condition; 
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 3. Further support: interviewees were asked what further support would help them  
     manage or cope with their hearing deterioration following cancer treatment. 
 
The main questions that were asked in the interview schedule are provided in Appendix 4.3. 
By referring to the interview schedule, it was possible for the interviewer to maintain the 
focus of the interview on the main subject areas, however participants were allowed to 
digress if this enabled them to discuss other areas of concern, and allow the interview to be 
free flowing. 
 
4.3.4 Data collection 
 
The responses from interviews were recorded using a dictaphone and transcribed verbatim 
by an external agency used by the researcher’s hospital for transcribing medical notes. A 
copy of the transcript was available on request to give participants an opportunity for review 
and comment. No comments were received, so there was no need to make any corrections 
to transcripts. The raw data from the dictaphone was erased at the end of the study. The 
transcribed accounts were then stored on encrypted computers at the study centre for data 
analysis. A study supervisor reviewed the transcript from the first interview and gave advice 
on enhancing the interview technique and stressed the need to avoid asking leading 
questions. The validity and reliability of the qualitative data from this study are discussed 
later in this chapter.  
 
4.3.5 Data analysis 
 
The researcher listened to the transcribed data to enhance his memory of the context in 
which the data was obtained, and to ensure accuracy and immersion in the data.  
The framework analysis method (Ritchie and Lewis, 2003) was systematically used to obtain 
themes from the transcribed interview data, as shown in Figure 4.2:  
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Figure 4.2 Formation of themes 
 
Each transcript was printed out into a hard copy. Each quote that was obtained from the 
interview transcripts was identified and marked using a highlighter pen. Each quote was an 
‘in vivo code’ (Ritchie and Lewis, 2003). A preliminary thought or meaning was ascribed to 
each code. Each of these thoughts or meanings was then used to form ‘initial categories’. 
All the transcripts were read to form a coding matrix (part of which is shown in Table 4.4) of 
initial categories: 
 
 
 
 Initial categories from Transcript 1 that were on similar topics were 
identified and grouped together to form initial themes  
The initial themes were integrated to 
create the  
final themes 
All interviews were read through to gain an overview of their 
content 
All quotes from each transcript were marked and identified as ‘in 
vivo’ codes. Each code was described to give an initial meaning 
 
The meaning of each code was made to create  
 initial categories 
 
Initial categories from the other transcripts were grouped into the 
initial themes from Transcript 1 if possible, or used to create 
additional initial themes 
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Interview 
transcript 1 
Description 
(In-vivo codes) 
Preliminary 
thoughts or 
meanings 
Initial categories 
‘before the 
treatment that he 
[husband] never 
had to repeat 
himself and that 
but he is realising 
that’s how it is or 
just does not talk to 
me’ 
 
‘It is like a very 
high-pitched 
whistle in my head 
constantly but it 
does not affect my 
sleeping and I have 
sort of learnt to sort 
of ignore it during 
the day’ 
‘before the 
treatment that he 
never had to repeat 
himself’ 
 
 
 
 
 
 
‘high-pitched 
whistle in my head 
constantly’ 
 
 
‘I have sort of 
learnt to sort of 
ignore it’ 
To make the 
patient understand, 
the husband 
needed to repeat 
what he said 
 
Husband ceased 
communication 
 
 
 
Perception of 
tinnitus is constant  
 
 
 
Cope with tinnitus 
by ignoring it 
Others needed to 
repeat themselves 
 
 
 
 
Withdrawal by 
partner from 
communication 
 
 
 
Continuous tinnitus 
 
 
 
 
Ignore tinnitus 
Table 4.4 Coding matrix of initial categories 
 
The initial categories from Transcript 1 were then grouped to create initial themes, 
using a coding index. Table 4.5 shows part of the coding index. These initial themes were 
used to group initial categories in other transcripts, with the coding index extended with the 
formation of additional initial themes.  
 
Initial categories Initial Theme 
White noise 
Whistle sound 
Buzzing sound 
Tinnitus sensation 
Asks speaker to repeat  
Asks speaker to speak louder 
Tells others there is a hearing problem 
Communication adaptation 
Not bothered by hearing change 
Not bothered with hearing aids 
Hearing in context of cancer treatment 
Attitude to hearing deterioration 
Table 4.5 Coding index (example) 
 
Final themes were generated from related initial themes ensuring that each final theme had 
responses from at least 50% of the participants so that the data represented a level of 
patterned response (Braun and Clarke, 2006). The final themes had categories that covered 
all aspects of data on patient experience of hearing deterioration following treatment for 
		 132 	
HNC. These themes also contained similar responses made by patients to identify patterns 
of responses. Framework analysis provides a process where it is possible to link original 
source data to the generated themes, thereby increasing the validity of findings (Smith and 
Firth, 2011).  
 
4.3.6 Validity and reliability of qualitative findings 
 
The validity and reliability of the results obtained in the qualitative phase of study was 
assessed based on a checklist provided by Maxwell (1992) on threats to validity of 
qualitative research, and how these threats can be addressed:   
• Descriptive validity: How factually accurate is the account? To ensure all aspects of 
each interview were captured, the interviews in this study were recorded and then 
transcribed verbatim; 
• Interpretive validity: How well do the findings presented by the researcher represent 
meanings from the participants’ perspectives? The researcher employed an 
approach informed by phenomenology in this study, to draw out understanding of 
how research participants experienced their hearing deterioration following HNC 
treatment. The use of open-ended questions made it easier for participants to share 
their experiences, and where necessary enabled the researcher to probe more 
deeply. Interpretations by the researcher on what was said could be traced back to 
participants’ own quotes (using framework analysis) to determine conscious beliefs 
and feelings. Unstated or subconscious intentions were given greater validity by 
grouping similar quotes from different participants and from relevant sources in the 
wider literature. The researcher was mindful of this approach to minimise his 
interpretations on what was said by participants. The researcher was also aware that 
the participants might have responded differently if someone else had conducted the 
interview, as the participants were known to the researcher from the quantitative 
phase of the study.  
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• Theoretical validity: How do the findings of the study support underlying theory? 
Hearing deterioration in general is associated with poorer quality of life, and it was 
expected to be associated with negative patient experience following treatment of 
HNC. However, some participants acknowledged their hearing loss, and this 
appeared to minimise the impact on quality of life. 
• Generalisability: How generalisable are the results to the patient group, or to other 
groups? Purposive sampling was used to enable participants to give as wide a 
variation as possible on patient experience. The findings are generalisable to other 
patients who have had similar treatment and have had hearing deterioration based 
on the CTCAE criteria (v4.03), and who have been interviewed around a year 
following the completion of their treatment. 
• Evaluative validity: How reproducible are the results obtained? Using framework 
analysis, each theme that was generated included responses from at least 50% of 
interviewees, showing that they were representative of the experiences of the 
participants as a whole. It is possible to link the original data to the generated 
themes, thereby increasing the validity of the findings. 
• Researcher bias: How has the researcher minimised his bias on the research? It was 
noted that participants might have responded differently to the researcher than to 
another interviewer, as the researcher knew the participants. However, as the 
interviewer had to be flexible and ask appropriate probing questions on the key 
subject area of hearing deterioration, it was necessary for the study researcher to 
perform the interviews. In interpretive phenomenology, the experience and expertise 
of the interviewer is a significant feature. If the interviewer has an understanding of 
the subject area, they are better able to clarify responses and ask relevant additional 
questions. The researcher asked questions that were not leading but open-ended to 
enable participants to express their views, and all responses were recorded and 
included in interpretation. 
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4.4 Integration of quantitative and qualitative data 
 
In this mixed methods study, data from the quantitative phase (from testing) was used to 
inform selection of participants for interview in the qualitative phase. Data was not converted 
into either a textual or numerical format for comparison, but the results from each of the 
quantitative and qualitative phases were integrated in a narrative form to provide a broader 
understanding of the phenomenon of hearing deterioration after HNC treatment. Patterns of 
responses in Phase 2 were drawn from patients’ characteristics and severity of deterioration 
data, obtained from Phase 1 data, and these patterns were reported in Chapter 6 of this 
thesis. Further, data from the quantitative and qualitative phases were discussed together in 
Chapter 7, to assess if there were patterns in patient experience, based on data obtained 
from the quantitative phase, that were separate to patient characteristics and severity of 
deterioration data. The bringing together of data in this way provided a more complete 
understanding of the phenomenon of hearing deterioration, including whether it was 
homogeneous or heterogeneous for participants.  
 
4.5 Ethical considerations 
 
The ethical threats in conducting the study were mainly generic to research. The information 
sheet, on the nature and reason for the project, was given to patients eligible for inclusion, 
and signed consent was obtained. Participants were informed that the study would follow 
standard research ethical and legal practices, were free to withdraw at any point, and were 
informed that data collected would be kept strictly confidential. Participants were identified 
by a unique study number rather than by their name or address, so that they could not be 
recognized from any information obtained. The NHS code for confidentiality was adhered to 
with this anonymisation of data. Interview transcripts were also made anonymous. 
 
With the introduction of additional hearing testing that was not part of usual procedure (at the 
end of treatment and at 3-month follow-up), specific ethical approval for this study was 
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required. Similar approval was required for the interviews, recognising that the time involved 
in attending these assessments could cause inconvenience for participants with the 
disruption of their daily routine. Furthermore, participants’ permission was required before 
any information that was of a sensitive nature could be shared with a clinical nurse specialist 
in head and neck oncology. An inventory of all the necessary requirements to proceed with 
this project is provided in Appendix 4.4 including: 
• details of the organisations that provided approval for the study;  
• the standard statement for compliance and non-compliance of research studies;  
• the standard monitoring and audit framework for this study. 
 
Initial acceptance from Ethics, and Research and Development Departments was sought 
and granted in January 2015, further approval granted in May 2016, and an amendment was 
required to address in full the stated aims of the study. Ethics approval was granted as the 
study showed the necessary beneficence, non-maleficence, respect for autonomy and 
justice required for a UK research study. In particular for this study, the participant 
information sheet provided details for patients on support they could receive if they became 
unduly upset in their interview. The information sheet also told patients of any inconvenience 
they may have due to the requirement to attend additional appointments for the study.  
 
4.5.1 Data handling 
 
The researcher had access to the participants’ identifiable personal data, but the study 
supervisors had access only to anonymised personal data. National Health Service 
computers used for the study were password secured for the safe keeping of electronic files, 
and participant information sheets, consent forms and transcriptions of interviews were kept 
in secure storage in a locked filing cabinet located on the study premises to which only the 
researcher had access. After the study ended, research data was kept for 12 months by the 
researcher and then given to the University of Surrey for archiving in accordance with their 
data storage policy for ten years.  
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4.5.2 Finance and indemnity  
 
The study was insured by the NHS Indemnity scheme for providing cover for non-negligent 
and negligent harm. The University of Surrey provided indemnity for the overall study 
methodology and framework.    
 
4.6 Summary 
 
This chapter has provided the rationale for the instruments used to address the research 
aims of this study. The chapter has also shown the process by which participants were 
selected for the study, and the method for obtaining and analysing data that were reliable 
and valid. The chapter has concluded with the framework for conducting the study to ensure 
it adhered to standard research governance policy.  
 
The following chapters, 5 and 6, present the results of the data collection for each of the two 
phases of the study: Chapter 5 with the results of Phase 1 data obtained using quantitative 
methods, and Chapter 6 with the results of Phase 2 data acquired using qualitative methods.  
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Chapter 5 Results – Quantitative data 
 
 
5.1 Introduction 
 
This chapter presents the results of the quantitative (first) phase of the research, addressing 
the first primary research aim: to assess the incidence and severity of hearing deterioration; 
and the secondary aims: (a) to describe overall hearing levels; (b) to assess types of hearing 
loss; and (c) to explore differences in severity of hearing deterioration in relation to patient 
demographics and types of treatment. Patients included those who were due to receive 
treatment for HNC at a UK hospital.  
 
Data was collected from hearing tests on 50 patients over a period of one year (February 
2015 to February 2016). The chapter provides a description of the demographics of 
participants, both those who completed the hearing tests and those who did not. The chapter 
then presents statistics addressing this primary research aim, and the three secondary aims 
[the other primary research aim (to explore the lived experience of participants involved in 
this study) will be covered in Chapter 6, which presents the results of qualitative data 
gathered from patient interviews]. 
 
5.2 Recruitment 
  
Of the 62 patients invited to participate in the study, one declined participation, and 11 were 
excluded, so that 50 were recruited (80.6%). The reasons for exclusion from the study, and 
the number of participants at each stage of testing are shown in Figure 5.1 below: 
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Figure 5.1 Recruitment and participation 
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It can be seen in Figure 5.1 that of 12 patients who were not included in the study, two had a 
pre-existing audiological condition: one had Meniere’s disease (a balance condition that is 
characterised by fluctuating hearing loss) and the other had profound hearing loss in one ear 
such that deterioration in hearing could not be measured.  
 
5.3 Test completion and attrition 
  
All 50 participants who consented to the study had pre-treatment hearing tests (Test 1) with 
the expectation that they would have treatment. However, one participant did not start 
treatment as a watchful-wait policy was subsequently adopted for their care. For the 
remaining 49 participants, the mean time between completion of Test 1 and the start of 
treatment was 2.3 weeks. 
 
Of the 49 participants who started treatment, there were 42 who completed Test 2, and 42 
who completed Test 3 (Figure 5.1). However, only 40 completed all three hearing tests for 
this study. The largest drop-out rate that was expected, based on a one-year survival rate for 
HNC patients, was 20% (HQIP, 2012). One participant died during Phase 1 data collection 
of the study; this participant did not have either Test 2 (end of treatment) or Test 3 (3-month 
follow-up). Other reasons for nine participants not completing either Test 2 or 3 were: a 
change in treatment to palliative care; a change to non-UK standard treatment (proton 
therapy); incomplete treatment by voluntary withdrawal; one participant was too ill to attend 
a test appointment; difficulty in scheduling the hearing test. The attrition rate for not 
attending the post-treatment test was 16%, and at 3-month follow-up was also 16%. These 
rates were less than the 20% anticipated based on survival rates (HQIP, 2012), but testing 
for this study for each participant was less than a year. The mean time between the end of 
treatment and Test 2 was 0.8 weeks, and that for the end of treatment and Test 3 was 14.0 
weeks.  
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There were ten participants who did not complete either the end of the treatment test (Test 
2) or the 3-month follow-up test (Test 3), and their characteristics are shown in Table 5.1 
below:  
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3 2 + 3 70 M Oropharynx IV CRT Mild HL V  
4 2 81 F Salivary 
gland 
II RT Mild HL S 
13 2 72 M Oral cavity IV RT Moderate HL A + S 
24 2 + 3 62 M Oropharynx IV CRT Mild HL S 
26 2 + 3 69 M Oropharynx IV CRT Normal A + S 
31 3 54 M Larynx I RT Normal S 
32 2 + 3 62 M Oropharynx IV CRT Mild HL A + S 
33 2 + 3 67 M Larynx I RT Mild HL None 
38 3 72 M Oropharynx III RT Mild HL A + S 
39 2 + 3 37 F Nasopharynx III CRT Mild HL None 
Table 5.1 Characteristics of participants who missed testing 
Key: Gender (M-Male; F-Female); Treatment plan (CRT-Chemoradiotherapy; RT-Radiotherapy only); HL – 
hearing loss; * descriptor of the worse ear; Aetiology (V-Virally confirmed; A-Alcohol use (>14 units/week); S-
Having smoked) 
 
Eight of the ten participants who did not complete either Test 2 or 3 were male, with equal 
numbers (n=5) receiving RT or CRT (Table 5.1). The difference in characteristics of the ten 
participants who missed either Test 2 or 3 was not significant statistically (p≥0.05, using 
Fisher’s exact test) compared with the 40 who completed both Test 2 and 3, with: 
• the male to female ratio (p=0.09)  
• the older patient to younger patient ratio (using the median age of 61 years to define 
the age split; p=0.47), and  
• the ratio of participants receiving RT only to those who were treated with CRT 
(p=0.47).  
As there appeared to be no pattern to, or prediction of, the participants who missed either 
Test 2 or 3, data that was missing were therefore viewed as ‘missing at random’. 
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Consequently, statistical selection bias was minimised when interpreting results from either 
the full (Test 1) or partially completed (Test 2 or Test 3) data sets.  
  
 
5.4 Participant demographics 
 
The demographics of the participants recruited to the study are shown in Table 5.2. The 
mean age of the 50 participants recruited was 60.7 years [standard deviation (SD) 10.6 
years]. The male to female ratio in the study population was two to one, which reflects the 
proportion of patients diagnosed with HNC in a UK population. The largest proportion of 
patients in this study had oropharyngeal cancer (52%); this cancer accounts for 28% of all 
patients diagnosed with HNC in the UK.  
 
The majority of participants had hearing loss (n=43) that was mainly sensorineural in type 
(n= 74 ears). Among eight participants, eight ears manifested mixed hearing loss on PTA 
before treatment, six with abnormal tympanometry results: three with type B (flat – indicating 
middle ear effusion or a tympanic membrane perforation), two with type C (negative middle 
ear pressure) tympanograms, and one with a Type AD (high compliance) tympanogram, 
which indicated healing of the tympanic membrane following perforation. The proportion of 
participants with bilateral hearing loss, using BSA criteria, was 36%. 
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Characteristic Number Study % UK population % 
Gender    
Male 34 68 67 k 
Female 16 32 33 
    
Location    
Oral cavity 6 12 31 
Nasopharynx 3 6 2 
Oropharynx 26 52 28 
Hypopharynx 3 6 6 
Nasal cavity 1 2 5 
Salivary 3 6 5 
Larynx 8 16 23 
    
Histology    
Squamous cell carcinoma 45 90 85 l 
Non-squamous cell carcinoma 5 10 15 
    
Stage of cancer    
I 4 8  
II 5 10  
III  12 24  
IV 29 58  
    
Aetiology    
   Subgroup    
   Alcohol use a 18 36  75 m 
   Smoking history b 33 66   
   Viral infection c 12 24  20 
    
Treatment    
Radiotherapy only d 22 44  
Chemoradiotherapy 28 56  
    
Hearing type (patients)     
Normal e 7 14  
Hearing loss f 43 86  
    
Hearing type (ears)    
Normal g 18 18  
Mixed loss h 8 8  
SNHL i 74 74  
    
Hearing level descriptor 
(patients) j 
   
Normal bilaterally 22 44  
Unilateral loss 10 20  
Bi mild loss 15 30  
Bi mild/moderate loss 1 2  
Bi moderate loss 2 4  
Table 5.2 Patient, cancer and treatment characteristics 
Key: a- Heavy alcohol use >14 units per week; b- current or ex-smokers; c- Epstein-Barr or human 
papillomavirus confirmed infection; d- including cetuximab; e- Normal: Pure tone audiometry: - air conduction 
hearing thresholds between 0.25 and 8kHz ≤ 20dBHL, bilaterally; f- Hearing loss: Pure tone audiometry: - air 
conduction hearing thresholds between 0.25 and 8kHz >20dBHL, in at least 1 ear; g- Normal: Pure tone 
audiometry: - air conduction hearing thresholds between 0.25 and 8kHz ≤ 20dBHL; h- Mixed loss: bone 
conduction thresholds between 0.5-4kHz > 20dBHL, and air-bone gap in at least 1 of the frequencies between 
0.5-2kHz ≥ 15dB; i- Sensorineural hearing loss (SNHL): air conduction hearing thresholds between 0.25 and 
8kHz > 20dBHL, and air-bone gap between 0.5-2kHz < 10dB; j- BSA (2011) descriptors. k- Cancer research UK 
(2016); l- HQIP (2012); m- Hobbs (2010)  
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Twenty-eight of the participants received IMRT with chemotherapy. Twenty-one of these 
received the administration of cisplatin only (200-500mg/m2). Five participants started with 
cisplatin, but then were changed onto carboplatin treatment due to adverse events during 
treatment (on review of their medical notes); three of these participants had developed 
tinnitus (the perception of sound when there is no external source). Two participants 
received carboplatin treatment only, as they had pre-treatment hearing loss. Three 
participants received cetuximab administration along with their IMRT. The remaining 19 
participants had IMRT only treatment.  
 
5.5 Incidence of hearing deterioration 
 
One of the main aims of the study was to determine the incidence of hearing deterioration 
following treatment of HNC. The findings presented in Table 5.3 show results of hearing 
deterioration following end of treatment and at 3-month follow-up. Participants were 
classified as experiencing: ‘no hearing deterioration’ if neither ear had hearing deterioration; 
a ‘minor hearing deterioration’ if hearing deteriorated by only Grade 1 or 2 criteria in one or 
both of their ears; or a ‘major hearing deterioration’ if at least one ear had Grade 3 change: 
 
 
Frequency 
Proportions 
% 
Incidence of 
hearing 
deterioration % 
(a) End of treatment    
    
No hearing deterioration 18 43  
Minor hearing deterioration 13 31 57 
Major hearing deterioration 11 26  
Missing at random 8   
    
(b) 3-month follow-up    
    
No hearing deterioration 21 50  
Minor hearing deterioration 10 24 50 
Major hearing deterioration 11 26  
Missing at random  8   
Table 5.3 Incidence of hearing deterioration (n=42) 
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Part (a) of Table 5.3 shows that 57% of the participants who completed testing at the end of 
treatment had hearing deterioration, with 26% experiencing a major deterioration. Part (b) of 
Table 5.3 shows that 50% of participants who completed testing at 3-month follow-up had 
hearing deterioration compared to pre-treatment hearing levels, with 26% developing major 
change.  
 
There were 40 participants who completed all three hearing tests for this study. Although the 
majority of these participants had no change in hearing when comparing end of treatment to 
3-month follow-up testing, Table 5.4 below shows that some participants had an 
improvement in hearing, whereas others had a deterioration:  
 
 Test 3 to Test 2 
Improved 6 (15%) 
No change 30 (75%)  
Deterioration 4 (10%)  
Table 5.4 Inter-test hearing change 
 
It can be seen that 15% of participants had improved hearing between the end of treatment 
and 3-month follow-up tests (Tests 2 and 3). An improvement in hearing may be due to 
resolution of OME that restores normal middle ear function. This finding supported the more 
detailed assessment of hearing deterioration at 3-month follow-up rather than at the end of 
treatment, to determine severity of persistent (or developed) hearing deterioration instead of 
a more transient state of hearing deterioration. The characteristics of the participants who 
completed Test 3 (n=42) of this study are shown in Appendix 5.1.  
 
5.6 Severity of hearing deterioration 
 
Determination of the severity of hearing deterioration was part of one of the main aims of this 
study. As none of the 42 participants who were tested at 3-month follow-up had Grade 2 or 
Grade 4 deterioration, results of minor deterioration and major deterioration corresponded to 
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Grade 1 and Grade 3 deterioration respectively. Of the 21 participants who had hearing 
deterioration, ten (24%) had minor deterioration, and 11 (26%) had major deterioration 
(Table 5.3). 
 
5.7 Descriptors of hearing level 
 
One of the secondary aims of the study was to describe the overall hearing levels of patients 
before and after treatment. The descriptors of hearing level for participants before treatment, 
and at 3-month follow-up is shown in table 5.5 below:  
 
 
Pre-treatment 
hearing (%) 
Post-treatment 
hearing (%) 
 Normal bilaterally 
Unilateral mild hearing loss 
 Unilateral moderate hearing loss 
Bilateral mild hearing loss 
Bilateral mild/moderate hearing loss 
Bilateral moderate hearing loss * 
Total 
19 (45.2) 12 (28.6) 
6 (14.3) 4 (9.5) 
1 (2.4) 2 (4.8) 
13 (31.0) 18 (42.9) 
1 (2.4) 2 (4.8) 
2 (4.8) 4 (9.5) 
42 42 
Table 5.5 Descriptors of hearing level (n=42 at pre-treatment and at 3-month follow-up) 
Key: *includes one participant with bilateral moderate/severe hearing loss) 
 
Hearing levels shown in Table 5.5 are those described according to BSA guidelines (BSA, 
2011) using the 5-frequency octave average of 0.25, 0.5, 1, 2 and 4kHz. The proportion of 
participants with bilateral hearing loss increased from 38.1% before treatment to 57.1% at 3-
month follow-up, with a doubling in the proportion of those who had moderate severity 
hearing loss. 
 
5.8 Types of hearing loss  
 
Another of the secondary aims of this study was to determine types of hearing loss, and to 
assess if hearing loss prior to and after treatment was due to damage to the middle ear, 
inducing a conductive hearing loss, the inner ear and/or the auditory nerve, inducing a 
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SNHL, or a combination of these anatomical areas, causing a mixed hearing loss. Prior to 
treatment, the majority of the 42 participants (72%), who completed Tests 1 and 3 had SNHL 
(in at least one ear) due to high frequency loss between 6 and 8kHz, which is common in 
age-related hearing loss (Davis et al., 2007). The proportion of patients with each type of 
hearing loss found by PTA and tympanometry prior to treatment and at 3-month follow-up is 
shown in Figure 5.2. Participants who had at least one ear with a mixed loss was assigned 
to the ‘mixed hearing loss’ group; none of the participants had conductive hearing loss at 
baseline or at 3-month follow-up testing. Those participants who had at least one ear with 
SNHL and the other not with a mixed hearing loss were placed in the SNHL group.  
 
 
Figure 5.2 Change in type of hearing loss 
 
 
The majority of patients (approximately two-thirds) developed SNHL hearing loss, with 
approximately one-third developing mixed loss in at least one ear (Figure 5.2), and as a 
mixed loss is a combination of sensorineural and middle ear dysfunction, all 21 participants 
who suffered a hearing deterioration developed a sensorineural loss in at least one ear. One 
patient, who had borderline SNHL prior to treatment had improvement in their hearing to 
normal levels following treatment, and this improvement was within the usual test-retest 
variation for PTA. The eight ears from seven participants who had mixed hearing loss at 3-
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month follow-up had abnormal tympanometry: six with type B (flat tympanograms), one with 
type C tympanograms (negative middle ear pressure), and one with a Type AD tympanogram 
(high compliance tympanogram). The tympanometric tests therefore confirmed middle ear 
dysfunction within these nine ears. 
 
5.9 Hearing deterioration and patient characteristics 
 
Another secondary aim of this study was to explore the incidence and severity of hearing 
deterioration in relation to patient demographics and types of treatment. Because there were 
no significant associations between the presence and severity of hearing deterioration with 
gender, type of cancer or stage at diagnosis, this section concentrates on the severity of 
hearing deterioration by age. The mean age of the 42 participants completing the testing at 
3-month follow up was 60.5 years (SD 10.5). Table 5.7 (below) provides the mean values of 
participants with no hearing deterioration, and with those who had either a minor or a major 
deterioration at 3-month follow-up. This information is provided graphically in Figure 5.3; 
 
 
Figure 5.3 Comparison of age with hearing deterioration at 3-month follow-up 
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The age of participants in each of the three groups shown in Figure 5.3 was normally 
distributed (using Shapiro-Wilk test) such that a comparison of the means was possible 
using ANOVA. The Bonferroni test, that reduces type 1 error in multiple analyses, showed a 
statistically significant difference between the mean age of those participants who had a 
minor hearing deterioration when compared with those participants who had no deterioration 
(p=0.03). There too was a statistical difference between the mean age of those participants 
who had a minor deterioration when compared with those who had a major hearing 
deterioration (p=0.02), implying that if deterioration took place, younger patients suffered a 
major deterioration in their hearing. Comparison of all participant characteristics with hearing 
deterioration is shown in Table 5.7 below: 
 
 No 
deterioration 
(%) 
Minor 
deterioration 
(%) 
Major 
deterioration 
(%) 
Total p value 
 
Risk factor 21 (50) 10 (24) 11 (26) 42  
      
b. Gender      
Male 14 (52) 7 (26) 6 (22) 27 *1.00 
Female 7 (46) 3 (20) 5 (33) 15  
      
c. Stage of tumour      
Early 6 (75) 2 (25) 0 8 *0.23 
Late 15 (44) 8 (24) 11 (32) 34  
      
d. Hearing 21 (50) 10 (11) 11 (26)   
Normal a 4 (57) 0 3 (43) 7 *1.00 
Hearing loss b 17 (49) 10 (29) 8 (23) 25  
      
e. Treatment 21 (50) 10 (24) 11 (26)   
Radiotherapy 14 (74) 4 (21) 1 (5) 19 *=0.01 
Chemoradiotherapy 7 (30) 6 (26) 10 (44) 23  
Odds ratio = 6.4, relative risk = 2.4, of developing hearing deterioration with chemoradiotherapy 
verses radiotherapy 
      
Age - Mean (years)  
All 42 participants  
60.4 years 
(CI 57.4 – 63.7) 
58.8 68.7 56.3  **0.03 
***0.02 
Table 5.7 Hearing deterioration at 3-month follow-up after treatment 
Key: () percentage per category.  *Fisher’s exact test (p <0.05 significant – comparison of no deterioration with 
hearing deterioration). **Bonferroni test (p <0.05 significant – minor deterioration to no deterioration). ***Bonferroni 
test (p <0.05 significant – minor deterioration to major deterioration; a: Normal: Pure tone audiometry: - air 
conduction hearing thresholds between 0.25 and 8kHz ≤ 20dBHL, bilaterally; b: Hearing loss: Pure tone 
audiometry: - air conduction hearing thresholds between 0.25 and 8kHz >20dBHL, in at least one ear 
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There was an odds ratio of 6.4 and a relative risk of 2.4 of participants developing hearing 
deterioration with CRT when compared with RT (Fisher’s exact test; p=0.01). There were 21 
participants with hearing deterioration. All of the 16 participants with chemotherapy-induced 
hearing loss had cisplatin as part of their treatment regime; neither of the participants who 
had carboplatin only treatment developed further hearing loss. Of the five participants who 
had radiotherapy-induced hearing loss, three had cetuximab administration along with their 
IMRT; the remaining two had IMRT only treatment.  
 
Figure 5.4 Hearing deterioration across subtypes of head and neck cancer 
 
The bar graph above (Figure 5.4) shows that hearing deterioration occurred across all seven 
subtypes of HNC; there appeared to be no pattern to the hearing deterioration in each 
subtype.   
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5.10 Summary 
 
Fifty participants were recruited for hearing testing in Phase 1 of this study, and all 
completed pre-treatment tests. Forty-two participants completed end of treatment testing 
and 3-month follow-up testing. 
 
The incidence of hearing deterioration found in this study of patients receiving standard 
curative UK treatment for HNC was 57% for those completing testing at the end of 
treatment, and 50% at 3-month follow-up. These percentages were obtained using CTCAE v 
4.03 criteria for hearing deterioration. Major hearing deterioration was evident in 26% of 
participants at the end of treatment and at 3-month follow-up; however minor hearing 
deterioration was evident in 31% of participants at the end of the treatment, and this reduced 
to 24% at 3-month follow-up. Hearing deterioration was found in all seven subtypes of HNC.   
 
The majority of participants at 3-month follow-up had sustained hearing deterioration, 
although some (15%) had improvement compared to end of treatment tests. All participants 
developed SNHL at 3-month follow-up, however mixed hearing loss was evident for a third 
of these. The proportion of patients with bilateral hearing loss rose from 38.1% before 
treatment to 57.1% after treatment (using BSA, 2011) criteria. 
 
In relation to types of treatment, participants had a statistically significant (p=0.01) greater 
risk (2.4) of developing hearing deterioration if they had CRT rather than if they had RT 
alone. Although older participants (mean age 68.7 years) had a greater risk of developing 
hearing deterioration compared with participants who suffered no deterioration (mean age 
58.8 years; p=0.02), if deterioration occurred, major hearing deterioration was more evident 
in younger participants (mean age 56.3 years; p=0.03).  
 
The next chapter presents the results of interviews with a sample of participants who were 
 
selected to provide a qualitative perspective on the experience of hearing deterioration after 
 
treatment on quality of life.                                       
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Chapter 6 Results – Qualitative data   
 
6.1 Introduction 
 
This chapter presents findings from patient interviews undertaken to address the second of 
the two primary research aims: to explore the lived experience of participants with hearing 
deterioration after treatment for head and neck cancer. The key objective of this qualitative 
element of the investigation was to explore patients’ experience of hearing loss within a year 
of treatment completion, by ascribing meaning to statements made by participants at 
interview.  
 
The demographics of participants interviewed are presented first and are followed by a 
summary table of the themes that emerged from analysis of the interview data. Each theme, 
representing different aspects of patient experience, will then be presented with reference to 
characteristics that were identified for selecting participants for interview to assess patterns 
in responses that were provided (see Chapter 4, section 4.3.1). The findings on the 
perception of tinnitus are also included, as this symptom accompanied that of hearing 
deterioration for the majority of participants. The chapter concludes with a summary of the 
qualitative findings.  
 
6.2 Demographic information 
 
Thirteen participants out of 21 with measured hearing deterioration (determined from the 
quantitative data – Chapter 5) were interviewed. The demographic details of these 
participants are shown in Table 6.1 below. Participants were interviewed on average (mean) 
11½ months post treatment (range eight to 13½ months).  
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2 3 F 52 Hypopharynx IVA None CRT Normal 
5 1 M 59 Tongue III S A RT Normal 
6 3 F 56 Nasopharynx III V CRT Hearing Loss (Mild) 
7 3 M 46 Tongue IVA None CRT Hearing Loss (Mild) 
9 1 M 61 Tongue IVA S A CRT Normal 
11 3 M 51 Tonsil IVA None CRT Normal 
12 1 M 72 Tongue IVA S A CRT Hearing Loss (Mild) 
17 3 M 59 Tongue IV S A CRT Normal 
29 3 F 67 Gingiva III None RT Normal 
30 1 M 64 Tongue IVA A CRT Hearing Loss (Mild) 
42 1 F 75 Nasal cavity II S RT Hearing Loss (Mild) 
51 3 F 44 Oropharynx IVB S  CRT Normal 
53 3 M 65 Glottis III S  CRT Hearing Loss (Mild) 
Table 6.1 Characteristics of participants taking part in interview 
Key:  *Greatest grade for a participant; Aetiology (S: smoker or ex-smoker; A: alcohol intake > 14 units per week; 
V: viral infection either Epstein-Barr or human Papilloma virus positive). Treatment type (CRT: 
chemoradiotherapy; RT: radiotherapy); Pre-treatment hearing level descriptor (BSA, 2011) ** of ear with poorer 
hearing 
 
The demographic information contained in Table 6.1 shows that the mean age of 
participants was 60 years (range 44 to 75), and that the majority of those who were 
interviewed were male (62%). Over half the participants had smoking-related cancer, and 
high alcohol consumption was associated with 38% of participants. One participant had 
virally confirmed cancer, but four participants had no known aetiological factor. Participants 
with cancer in each of the head and neck subtypes (apart from the salivary glands) were 
interviewed, with the majority of participants presenting with late (III or IV) stage cancer 
(92%); most participants had CRT (77%) to treat it. 
 
Approximately equal numbers of participants had either normal hearing or mild hearing loss 
prior to treatment. The proportion of participants who developed bilateral hearing 
deterioration was 69%, with 62% acquiring Grade 3 (major) deterioration in at least one ear 
at 3-month follow-up. To obtain as wide a range of experiences as possible (and to 
determine if hearing deterioration was experienced differently) participants included men and 
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women, those who were younger or older (and equal) than the mean age (60 years) of those 
who were interviewed, those who had normal hearing or mild hearing loss pre-treatment, 
and those who had either mild or major hearing deterioration at 3-month follow-up.  
 
6.3 Themes 
 
The coding framework that was used for generating categories in the first interview is shown 
in Appendix 6.1, and the categories that were assigned to create themes according to 
framework analysis (described in Chapter 4, section 4.3.5), is shown in Appendix 6.2. Five 
themes with subthemes were identified from the interview data (Table 6.2 below):  
 
Themes Subthemes 
1 Sensation of impairment 
Hearing change 
Tinnitus 
Progression of aural change 
2 Functional changes 
Communication difficulties 
Problems with entertainment 
Problems with environmental sounds 
3 Coping mechanisms General coping strategies Use of assistive devices 
4 Emotional responses to aural change 
Attitude to hearing deterioration 
Downplaying of symptoms  
Sense of loss  
Social isolation  
5 Information and support 
Pre-treatment information 
Discussion of aural changes 
Further support 
Table 6.2 Main themes and subthemes arising from the interview data 
 
Each theme is discussed below, with reference made to participant quotes (presented in 
italics). Demographic information regarding the following characteristics are presented 
alongside the quotes to assist with identifying patterns in responses made by participants: 
their study number, gender (male=M or female=F), age in relation to the mean age (60 
years) of participants interviewed [younger than mean age=Y; older (or equal) than mean 
age=O], the severity of their hearing deterioration (Grade 1=G1 or Grade 3=G3), and pre-
treatment hearing status (N=normal or HL= hearing loss). As the majority of participants who 
had hearing deterioration had combined chemotherapy rather than RT alone, it was difficult 
to compare directly the impact these therapies had on patient experience. 
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6.3.1 Theme one – Sensation of impairment 
 
This section begins with a general consideration of participants’ experience of hearing 
change, and then gives specific attention to the sensation of tinnitus among those who had 
this additional symptom.  
  
6.3.1.1 Hearing change 
 
The majority of participants who had a measurable deterioration in hearing noticed a 
difference in their hearing after treatment, whether it was a sudden change: “It was 
immediately…after I had day 1 and 29 of Cisplatin” (P51, F, Y, G3, N), or a less dramatic 
change: “Just a decline in the hearing; just that I couldn’t hear” (P17, M, Y, G3, N). Whereas 
some participants felt a non-specific decline in hearing, others were more specific: “I lost all 
the high-pitched hearing” (P11, M, Y, G3, N), indicating that these participants were acutely 
aware of which part of their hearing range had been affected by treatment. However, there 
appeared to be no difference in the perception of hearing change between men and women, 
those who were young or old, or those who had a hearing loss or had normal hearing before 
treatment. Whereas all participants who had Grade 3 hearing deterioration were aware of a 
change in their hearing, not all those with Grade 1 change felt much difference: “Bearing in 
mind I’m old, I’m 76, I don’t feel it is much worse than it was before” (P42, F, O, G1, HL), or 
had a change that suggested a minor difference: “I did feel that there were things that I was 
able to hear before, that I do not hear now. I cannot be specific about what that is” (P12, M, 
O, G1, HL). Therefore, it seemed that participants who had a major measured deterioration 
in hearing following treatment either had a sudden or less dramatic change in hearing, 
whereas those who had a minor measured deterioration either had a vague perception of 
hearing change, or noticed no change at all.  
 
		 155 
Sudden changes in hearing appeared to occur during treatment, whereas more gradual 
change was experienced after the completion of treatment: “I think it was when the 
radiotherapy had finished, probably a few days after” (P11, M, Y, G3, N). These findings 
showed that hearing change manifested at different times for participants in relation to when 
they received their treatment. Thus, it was not possible to predict when hearing deterioration 
was to be experienced; also, there was no pattern in relation to different participant 
characteristics. However, those who were aware of a hearing change or tinnitus during 
treatment may have been offered an alternative treatment to complete their therapy. 
 
In addition to experiencing general deafness and/ or reduced pitched hearing, some 
participants felt a sensation in the ear such as fluid, pressure, a popping or a blocked 
sensation: “My left ear filled with fluid or it felt like that, and it felt pressurized...” [my ear] just 
blocked itself… it is almost like something is stuck, there is something in my ear to stop 
hearing at all, so the high pitch goes at the same time as the pressure is there as well” (P11, 
M, Y, G3, N), or “I noticed my ear was like being on a plane, so I could feel it popping” (P7, 
M, Y, G3, N). This sensation of pressure change, or of fluid, is most probably due to middle 
ear effusion that sometimes follows RT treatment for HNC. It was interesting to note that 
participants felt that this pressure made them ‘stop hearing at all’, which suggests that this 
experience had a significant negative impact. Participants with only Grade 3 deterioration in 
hearing mentioned fluid sensation, possibly indicating that those who had minor deterioration 
may have had a resolution of fluid by the time of their interview.  
 
6.3.1.2 Tinnitus  
 
Although this study was primarily focused on hearing change, the majority of participants 
who experienced hearing deterioration had also acquired tinnitus. Some participants 
experienced tinnitus at the same time as their hearing deterioration yet, as will be reported 
below, in this study tinnitus was often the more distressing symptom.  
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A common finding was that participants experienced tinnitus in different ways, and one 
participant at the beginning of his treatment experienced hyperacusis (the intolerance to 
every day sounds) with his tinnitus. Each participant experienced a different type of sound, 
for example: “It is literally just like a mmmmmm, but very very faint and very high pitched” 
(P11, M, Y, G3, N). They also experienced tinnitus in different locations: in the head, in the 
ear or over the ears, for example “It sort of hovers [participant gesticulating with his hand 
moving over his head]” (P12, M, O, G1, HL). These findings suggested that the sensation of 
tinnitus following hearing deterioration manifested itself in various different ways. Also, there 
appeared to be no pattern as to whether participants experienced hearing deterioration and 
tinnitus concurrently, or at different times. However, the distress with tinnitus was evident in 
some participants: “In the left ear I’ve got terrible ringing for quite some time” (P53, M, O, 
G3, HL), and was particularly evident in the one participant who had hyperacusis: “The 
noise…combined with external stimulus, I guess that caused the ears to hurt” (P7, M, Y, G3, 
N). This distress led to a change in treatment for this participant. It was noted that more 
severe tinnitus was experienced by those participants with Grade 3 deterioration in hearing. 
 
6.3.1.3 Progression of aural change 
 
Participants experienced different progression in their symptoms of hearing deterioration 
during and after treatment. Some participants experienced temporary hearing loss during 
their treatment that indicated first, the presence, and then secondly, the resolution, of middle 
ear effusion: “When I had the first [dose of cisplatin], day two I woke up and it was like I was 
under water. My hearing was very like I had got water in my ears, and I sort of was not 
shouting at people, but could not hear myself talk. Well after about a week that improved, it 
went, and my hearing went back to normal” (P51, F, Y, G3, N). After the completion of 
treatment up to the time of interview, some participants felt that their hearing deterioration 
fluctuated in intensity: “[my] hearing could be a bit all over the place at times” (P7, M, Y, G3, 
N). Others mentioned that their hearing difficulty was maintained in severity: ‘It feels like I am 
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underwater with my left ear so everything is really muffled and then it just stayed like that” 
(P11, M, Y, G3, N), whereas others, following the initial deterioration, subsequently 
perceived an improvement: “I mean [the hearing] is improving slowly” (P53, M, O, G3, HL). 
An improvement in hearing indicated that participants could have had confirmed psycho-
acoustical (measurable) change if hearing testing was performed at the time of interview. 
Although maintained severity, or decreased severity, in hearing loss following treatment was 
apparent, further deterioration in hearing was not clearly stated by participants. However, 
some participants were uncertain when asked if there had been a change in their hearing: “I 
really could not say. I mean after a while you just get on with things so you do not really pay 
too much attention [to your hearing]” (P12, M, O, G1, HL). These findings indicated that the 
sensation of hearing deterioration was most prominent during or within a few months 
following treatment, as it was in this period that the majority of participants experienced their 
hearing problems most acutely, although others had maintained difficulty with hearing by the 
time of their interview one year after receiving either RT or CRT for their cancer. 
 
There was also variation in the progression of tinnitus. Some participants experienced 
continuous tinnitus: “It is like a very high-pitched whistle in my head, constantly [present]” 
(P51, Y, F, G3, N), fluctuating tinnitus: “[The tinnitus] seems to come and go I think, because 
sometimes I’m not aware of it, and then I think oh I’ve got that noise in my ear” (P29, F, O, 
G3, N), or a lessening in the severity in tinnitus from when first experienced with treatment 
“With the treatment there was the tinnitus…it is very mild now” (P12, M, O, G1, HL). Some 
participants experienced a change in how they perceived their tinnitus: “The high-pitched 
whistling that I had went… and was replaced by... a white noise… it is just kind of a shhhhh 
noise these days” (P7, M, Y, G3, HL). It was clear that participants not only experienced 
hearing deterioration and tinnitus at different times and in different ways during or after 
treatment, but also experienced the progression of their symptoms differently. Arguably, this 
may make it difficult to advise patients when or how they would experience these symptoms 
after treatment, and how their symptoms would progress.  
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Therefore, all partipants with a major measured hearing deterioration were aware of a 
change in hearing, whereas only some of those with a minor deterioration experienced a 
loss. Some participants noticed their hearing change first during treatment, whereas others 
perceived their change following the completion of their RT or CRT, with some participants 
with Grade 3 deterioration experiencing the sensation of fluid build-up, as well as hearing 
loss, with their treatment. In addition, most participants who suffered a loss in hearing also 
experienced tinnitus, and that those with major deterioration expressed more distress with 
their tinnitus than those with Grade 1 change. There was no pattern to the progression of 
either hearing loss or tinnitus, so that it was not possible to predict symptom progression. 
Apart from the observations made above on the different sensations perceived by 
participants who had Grade 1 or Grade 3 deterioration, there were no patterns apparent 
based on other patient characteristics. This first theme described how participants perceived 
their aural symptoms. The next theme presents how these symptoms affected daily living of 
participants interviewed.  
 
6.3.2 Theme two – Functional changes  
 
For the eight participants with Grade 3 hearing deterioration there were more circumstances 
where they encountered hearing difficulty compared with the two who perceived a change in 
hearing with their Grade 1 deterioration. This difference may be due in part to the different 
lifestyles of participants as well as different severity in their hearing deterioration levels; 
however the majority of the quotations included in this section are from partcipants with 
Grade 3 deterioration. 
 
6.3.2.1 Communication difficulties 
 
All but one of the participants who perceived a change in hearing experienced difficulty in 
communication; participant 30 (M, O, G3, HL) may not have noticed this difficulty as he 
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mentioned leading a mainly solitary life. The other participants were either specific in the 
type of speech they had difficulty with: “If they had a voice which was sort of a pitched voice 
or a high-pitched voice, like a lady’s type of voice, I could hear them, but I couldn’t tell you 
what they were saying” (P53, M, O, G3, HL)”, or were less clear: “[I have] general deafness” 
(P17, M, Y, G3, N). Hearing in background noise was a particular concern: “But it’s really if 
there’s noise, background noise, that’s when I have a problem” (P29, F, O, G3, N). Some 
participants spoke of the difference they had noticed with listening in certain situations 
following treatment: “I find it very difficult, and you know, I have my phone turned up loud, 
“say that again, can you say that again?”…the telephone’s been more difficult” (P17, M, Y, 
G3, N), or “I was pretty good at distinguishing [and understanding speech in] noise. I could 
focus on what was being said and I could hear what people were saying” (P12, M, O, G1, 
HL). Therefore, hearing deterioration had an impact on everyday communication, particularly 
for participants used to socialising when there was background conversational noise, when 
before treatment there was less or no difficulty.  
 
All participants with minor hearing deterioration, or unilateral (affecting one side only) major 
hearing deterioration (P29, F, O, G3, N; and P11, M, Y, G3, N), said they had no difficulty 
when hearing in quiet situations. This was not unexpected, as people with mild hearing loss 
usually do not have difficulty in these situations as normal conversational speech levels are 
loud enough for them to understand speech, and those with unilateral loss are able to hear 
well via their unaffected ear. However, responses provided by some of those participants 
with major bilateral (affecting both sides) hearing deterioration revealed that some were 
required to lip-read, even in quiet, due to their sudden-onset hearing deterioration. Some 
participants were aware that they needed others to face them: “I force [my daughter] to look 
at me…so I can focus on what she is saying…I find that if people are talking to me I am 
very, very good at picking up the visual cues” (P7, M, Y, G3, N), whereas others made 
comments that indicated they were not aware that they were lip-reading: “Sometimes my 
husband has a habit of sitting with his laptop on his lap and obviously the screen is rig
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front of him so sometimes I cannot hear him. I know it sounds silly, it is as though it has 
been blocked by the screen” (P51, F, Y, G3, N). Participant 51 did not recognise that the 
difficulty with communication stemmed from her hearing deterioration, and that the computer 
screen blocked her from seeing her husband’s face and from lip-reading, although she felt 
that sounds were being physically blocked by the screen. Therefore, when some patients 
experienced sudden hearing deterioration following treatment, and discovered that they 
were required to lip-read, this change came as a surprise as they were not aware of this 
possible requirement prior to treatment. The fact that some participants did not recognise the 
value of lip-reading revealed a lack in service provision in preparing patients adequately to 
cope with possible hearing deterioration with treatment.  
 
The effect of tiredness and hearing deterioration that followed cancer treatment combined to 
increase the negative impact of these symptoms: “A big contributory factor [to having 
hearing problems] is when I’m tired. A year on, I spoke to the oncologist today, and there are 
still some evenings when I get absolutely shattered…I notice things far more when I’m tired. 
So, I think that’s a contributory factor” (P7, M, Y, G3, N). Participant 7 also had difficulty in 
processing speech: “My … daughter is 13 and like all children, now she thinks she should 
talk at the speed of light... I was having difficulty un-jumbling the constant stream of 
information coming at me” (P7, M, Y, G3, N). In addition, tiredness exacerbated his tinnitus: 
‘’I find when I’m quite tired the white noise is more prevalent” (P7, M, Y, G3, N). Other 
participants did not clarify if they experienced tiredness, but the responses made by 
Participant 7 suggest that if patients suffer fatigue following their cancer treatment, they may 
have greater difficulty in understanding speech and an increased perception of tinnitus.  
 
6.3.2.2 Problems with entertainment  
 
All ten of the participants who perceived a change in their hearing were affected in their 
leisure activity and socialising. Difficulty with television listening was encountered by most 
participants: “if I am watching telly for example I used to be able to hear it at a very low 
		 161 
volume” (P12, M, O, G1, HL), although some did not experience this problem (for example, 
participant 29 who had a unilateral hearing deterioration). Understanding speech was 
particularly difficult when there was background noise in the programmes: “[With] a lot of 
programmes I’ve found these days, the background noise is so loud compared to the 
dialogue noise” (P7, M, Y, G3, N). For some participants with major hearing deterioration, 
their appreciation of music was also affected: “I like dance music, and I was not listening to 
dance music because they use high frequencies… and that was a definite no, no, [but] it’s 
reignited my love of guitar-based music, because obviously, a lot [of] lower tones and drum 
sounds [are] going on” (P7, M, Y, G3, N). A struggle to hear music was most problematic for 
participant 11 (M, Y, G3, N) who acquired a unilateral deterioration in hearing: “I am a 
musician…so that I have found really difficult obviously because I cannot hear in stereo 
anymore”. Other participants did not mention how their hearing loss affected their listening to 
music. However, not all participants experienced difficulty when participating in other forms 
of entertainment: “I go to the cinema a lot and when I’m at the cinema it causes no 
problems. There are no subtitles at the cinema obviously, but I don’t find I’m missing 
dialogue or I don’t get the film out after I’ve seen it at the cinema and go “I didn’t understand 
what they were talking about”“ (P7, M, Y, G3, N). Cinema going as a hobby, though, was 
spolied for another participant: “You cannot hear some things that happen at the cinema” 
(P51, F, Y, G3, N).  
 
In summary, all participants experienced some difficulty when engaging in entertainment on 
their own, although it was noted that participants were affected in different ways depending 
on their type of hearing deterioration, and the form of entertainment. Comments made by 
some participants, with Grade 3 hearing change, indicated that their deterioration also had 
an impact on the quality of their social life in gatherings with background music: “If we have 
people round and we have a bit of music on and we’re talking, I have to say “do you mind, 
we’ve got to turn the music down if we’re going to have a conversation”, because I can’t 
really listen to both, you know, listen to the music and talk to you at the same time”. It’s all a 
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bit much” (P17, M, Y, G3, N), or “it is loud noisy social events… You know, what is the lesser 
of two evils? You are either really loud with the music and that, or you cannot hear people. 
They are the big ones, big social gathering events” (P51, F, Y, G3, N). Other participants did 
not comment on how they were affected in similar situations, either because they 
encountered these less frequently, or such situations were not problematic. It appeared, 
therefore, that for those participants who mentioned lifestyles that involved gatherings with 
background music, there was the dilemma of which activity to be involved in: listening to the 
music or engaging in conversation, whereas before their treatment they were able to enjoy 
both activities at the same time.  
 
6.3.2.3 Problems with environmental sounds 
 
Changes in hearing following HNC treatment also affected the hearing of non-speech 
sounds (other than music) that were mentioned by a few of the participants at interview. 
Computer use is part of everyday modern life, and sounds from the keyboard and mouse 
had now become silent “I do not hear anything now when I do the computer. I may have 
before, I do not know, I cannot really remember” (P12, M, O, G1, HL). It is noted that this 
participant experienced only minor unilateral deterioration, yet this small change in hearing, 
was sufficient to create this functional difficulty. Potentially, this patient’s baseline hearing 
level (of mild hearing loss) was a factor, however, there were no patients with Grade 1 
deterioration and normal pre-treatment hearing to compare with. Another more concerning 
aspect of high-frequency hearing loss is the inability to hear doorbells (of high pitch): “the 
doorbell sometimes has been a problem yes. At times I may not have noticed it, but since I 
did not notice it I am not aware that I have not noticed it!” (P12, M, O, G1, HL). The lack of 
awareness of hearing the doorbell was discussed with this participant at interview, and it 
was suggested that a bell with a lower frequency pitch be obtained. Difficulty with hearing 
the doorbell was also mentioned by participant 7: “since the treatment finished, I have 
realised that some of the high tones…now [I] have difficulty hearing, …[including from] the 
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doorbell” (P7, M, Y, G3, N), although others stated they were able to hear the doorbell, for 
example, participants 17 (M, Y, G3, N) and 30 (M, O, G1, HL). Reassuringly, when the 
majority of participants were asked, none had difficulty in hearing (high-pitched) fire or 
smoke alarms, as these alarms are usually much louder than doorbells.  
 
In this theme it is reported that participants had functional changes in hearing that affected 
communication, entertainment and socialising, as well as hearing environmental sounds. 
There were more widely reported changes for participants with Grade 3 deterioration 
compared with Grade 1 deterioration, particularly in quiet situations where the requirement 
to lip-read following (sudden-onset) treatment associated hearing loss was evident for those 
who had Grade 3 change only. There were no differences in functional change based on 
other patient characteristics of age or gender, although it is noted that a subtle change in 
hearing was enough for a participant with pre-treatment loss to notice he could not hear 
sounds from the computer, and participants with unilateral hearing deterioration (both minor 
or major) were also adversely affected by their change in hearing. 
 
6.3.3 Theme three – Coping mechanisms 
 
This theme is closely related to the next theme on emotional response to hearing 
deterioration, as the attitude of participants towards the impact of their hearing deterioration 
had a bearing on what strategies they used to overcome their hearing difficulties. All ten of 
the participants who perceived a change in hearing found strategies to cope with their 
change. Those who had severe hearing deterioration (Grade 3) gave more examples of how 
they coped compared with those who had less severe (Grade 1) deterioration, but it was 
evident that younger participants discovered more strategies than older ones amongst those 
with Grade 3 deterioration. There are two parts to this theme: general strategies used to deal 
with difficulties in communication and entertainment, and the use of assistive devices to help 
deal with aural changes that occur with treatment for HNC.  
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6.3.3.1 General coping strategies 
 
All the younger participants who perceived a change in hearing found ways, with their 
friends and family, to enhance communication. The most common was for the participant to 
ask for words to be repeated or made louder: “I’m really sorry I can’t hear you… can you 
speak up” (P6, F, Y, G3, HL) or “people had to keep repeating what they were saying or 
speak up louder” (P2, F, Y, G3, N). Other common tactics adopted were: to reduce 
background noise or move to a quieter place: “if there is a cacophony of sound and 
somebody is trying to talk to me you almost have to … go to somewhere quieter to hear” 
(P11, Y, M, G3, N); to lip-read: “I had to be more alert of what people were saying to me, you 
know, and watch their mouth to see if they was talking to me” (P17, M, Y, G3, N); to gain 
attention: “If I ignore them they do not take offence by it; they just nudge me and go “I was 
talking to you”” (P51, F, Y, G3, N – when talking with friends), to ask others to speak more 
slowly: “I have to say, look, slow down” (P7, M, Y, G3, N – when talking to his daughter). For 
one older participant, his wife made the adaption to the change in her husband’s hearing: 
“[There is] more communication from [my wife], having to repeat things” (P12, M, O, G1, 
HL); two older participants acquired hearing aids as part of this study (P53, M, O, G3, HL; 
P29, F, O, G3, N). Older participants generally gave no examples of initiating by themselves 
means to improve their communication. 
 
A reason for the difference in the efforts made between older and younger participants to 
improve their communication could be that older participants were not aware of the need to 
do so, as those they spoke with may have had hearing problems themselves. When asked if 
others had commented on his hearing deterioration, one participant said “They wouldn’t 
notice” (P30, M, O, G1, HL). This participant mentioned that he led a fairly solitary life; 
however, other older participants who led more active lives chose not to clarify in their 
conversations what was being said: “Certainly in crowded rooms, I mean if there are several 
people around and there is a lot of chat going on it is difficult to distinguish what is being 
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said, so sometimes you just nod your head in anticipation that you have got the right notion!” 
(P12, M, O, G1, HL), or “I just make out I‘m thick’” (P53, M, O, G3, HL). Therefore, 
participants who perceived a deterioration in their hearing coped with changes in 
communication in different ways. It appeared that younger participants made efforts to 
enhance communication, whereas older participants tended to be less inclined to deal with 
the effects of their hearing loss. The differences found could be linked to different lifestyles 
of each individual, or to different attitudes towards hearing loss by different age groups, and 
this aspect will be developed further in the next theme.  
 
Most participants found that they were able to listen to the television by simply increasing the 
volume: “The television, I normally have it on setting 1; I have had to put it up to 14 or 15” 
(P30, M, O, G1, HL). Another tactic was to use subtitles: “I put subtitles on the TV these 
days” (P7, M, Y, G3, N), or to concentrate more with television viewing: “I might have to 
strain a little bit harder” (P6, F, Y, G3, HL)“, or to use earphones: “I need a bit more volume 
and I use earphones. I find it easier to hear with earphones than with just the open speaker” 
(P12, M, O. G1, HL). Increasing the volume was also used for radio listening: “I have the 
radio up a little bit louder “ (P6, F, Y, G3, HL), and the musician with unilateral hearing loss 
found the means for adapting to his loss when listening to music: “If I am working on a track I 
have to put my headphones on and listen to one side for the stereo and turn the 
headphones around and listen” (P11, M, Y, G3, N).  
 
Most of the seven participants who had tinnitus dealt with it by ignoring it: “I try my hardest 
to ignore it, because otherwise I would just go mad. I mean, to have a continuous noise 
in your head all the time, you’d just go mad” (P6, F, Y, G3, HL). For some others who had 
persistent tinnitus following treatment, or had intermittent tinnitus, it was not clear how they 
managed their tinnitus, although hearing aids were of use for one participant (see the 
section on assistive devices, below). Therefore, it appeared that participants at interview had 
fewer strategies in coping with their tinnitus problems than they did with their hearing 
deterioration, yet tinnitus appeared to have a greater negative impact. 
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6.3.3.2 Use of assistive devices 
 
Three of the 13 participants had acquired hearing aids by the time of their interview. These 
three had worn their aids for two months, and provided feedback on how hearing aids had 
made a difference. Two participants had noted benefit in some situations more than others. 
Hearing the television, or conversation in quiet was improved with hearing aiding: “I can hear 
the telly and if we’re there on our own, I can hear my husband talking to me, you know, I can 
hear all that” (P29, F, O, G3, N), or in company: “Once I have got my hearing aids in, in 
general conversation I am fine in a room of people, absolutely fine…If there’s company and 
there’s sounds [the hearing aids] make it easier for me to listen to somebody. I can hear 
somebody’s voice, you know. Otherwise if there’s sounds there and I haven’t got it in, I don’t 
hear the voice very well” (P51, F, Y, G3, N). However, hearing speech in background noise 
was still problematic: “I struggle in a crowded bar or a pub or anything like that, that has also 
got music…because then I cannot wear my hearing aids because everything is just way too 
loud” (P51, F, Y, G3, N). Participant 51 also found the hearing aids helped her deal with 
tinnitus: “If I put my hearing aids in, [the tinnitus] goes. So it is nice to have some peace and 
quiet”. However, the third participant, although stating that hearing aids were of general help, 
still struggled to obtain clarity in hearing speech: “I’ve got some hearing aids which did help, 
but as I always said, it’s not the volume which I think hearing aids are more designed for, it’s 
discerning the level of the person’s talking” (P53, M, O, G3, HL). Although there was only a 
limited time following fitting to gauge the benefit of hearing aids, these devices did improve 
listening for some participants, particularly where there was a reduced level of background 
noise; hearing aids also provided some relief from tinnitus.  
 
Participant 7 (M, Y, G3, N) suffered from hyperacusis in a short period during treatment and 
resorted to his own method to cope: ”I changed my doorbell at home, because it was such a 
high-pitched noise it annoyed me so much when it came on that I had to change it for a 
lower tone noise”, and “I would just clap my hands over my ears. I bought some noise 
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cancelling headphones, anything to just try to shut everything out in the hope that [the 
tinnitus] would internally subside. In addition [I started] having the TV turned down”. The 
hyperacusis for participant 7 subsided so that he is now able to continue with everyday 
living, including watching the television without encountering pain. However, when 
experiencing hyperacusis, it appears that this participant found relief from his hyperacusis by 
the use of noise cancelling headphones, or changing the pitch of a doorbell to a lower tone  
following damage to high frequency hearing with his treatment. This younger participant 
sourced information himself, rather than obtaining advice from a health professional, 
possibly highlighting a gap in service provision for delivering necessary advice.  
 
Although two participants mentioned being aware of fluid, or pressure in their ears following 
treatment for HNC, only one described management of his OME. Participant 7 (P7, M, Y, 
G3, N) referred to advice given by a clinical nurse specialist on how to alleviate his middle 
ear dysfunction: “…[obtain] a little blue tube, put a balloon on it, pinch nose, blow down it 
and it does the same thing as trying to pop your ears on a plane, but equalizes the pressure 
between the balloon and your ears, therefore not damaging it. I was also prescribed 
medication to try and get rid of the fluid in the ears as well, and that worked marvellously 
well over a period of about eight weeks. The popped feeling in my ear went away”. The other 
participant with OME (P11, M, Y, G3, N) still struggled with his middle ear dysfunction at the 
time of his interview, and, although he was offered a hearing aid for his affected ear, he 
declined its use: "I was offered a hearing aid if I wanted one, but I find I can cope without 
one and I am still hoping for the day that the hearing comes back better than it is now, so I 
can cope with that, but I was offered a hearing aid if I wanted one”. However, he was still 
affected by the pressure in his ear: “you just think I wish it would clear, but I know it has not 
and I cannot do anything about it to make it clear so you just kind of put up with it”. It was not 
clarified with this participant if he was offered the same advice given to participant 7; it is 
possible that he was not, and this would indicate variation in service provision.   
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All the participants found different ways to adapt to their hearing deterioration and deal with 
changes in communication and non-speech sounds. Those participants who had Grade 3 
deterioration used more widespread solutions compared with those who had Grade 1 
change. Lifestyle had a bearing on intiatives made to enhance the understanding of speech, 
although it was evident that younger participants made more effort than older participants for 
improving speech communication; it appears that older participants were less inclined to 
deal with their hearing problems. Assistive devices were generally of use for dealing with 
aural concerns, however, there were fewer tactics used, and devices available, for dealing 
with tinnitus compared with hearing deterioration. It appeared that information and 
management advice supplied by health care professionals to deal with aural concerns was 
in some instances variable or inadequate, given that patients searched for their own 
solutions.  
 
6.3.4 Theme four – Emotional responses to aural change 
 
This theme has four aspects to it: attitude to hearing deterioration; the downplaying of 
hearing deterioration or tinnitus; the sense of loss; and the experience of isolation through 
the tendency for patients and those they associated with to withdraw from interaction. 
 
6.3.4.1 Attitude to hearing deterioration 
 
In dealing with younger and older participants, there appeared to be a difference in their  
reactions to their hearing deterioratation. Some younger participants were not afraid to let 
others know of their difficulty: “I'm not shy about saying “I can't hear properly with that 
[noise], can we turn it down?” So it hasn't bothered me, you know” (P17, M, Y, G3, N). Many 
did not feel that hearing deterioration had affected their lifestyle: “[the hearing loss] is not 
causing a problem” (P2, F, Y, G2, N); or feel that the hearing loss affected how she felt: “[my 
hearing loss] has not made me self-conscious or I am not embarrassed by it or anything like 
that. You know how many people have hearing problems in this day and age?  You know it 
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does not upset me, it does not embarrass me, it does not worry me, no, I am fine with it” 
(P51, F, Y, G3, N). Some also had an attitude of wanting to overcome the difficulties they 
encountered, be it their hearing problem: “I might have to strain a little bit harder [to listen 
following treatment], rather than just completely relaxing… but I try and fight it; I'm a fighter” 
(P6, F, Y, G3, HL), or hyperacusis: “I'm kind of a very very stubborn person who refuses to 
let things kind of get in the way” (P7, M, Y, G3, N). One participant showed indifference to 
both his blocked ear sensation: “you just kind of put up with it”, and his tinnitus: "[the tinnitus] 
…is one of those things I can put up with and it does not keep me awake, it does not affect 
me during the day or anything. You know you notice it more in quiet times, but you can tune 
out of it quite easily" (P11, M, Y, G3, N). The younger participant fitted with hearing aids 
even accepted the use of these devices: “I do not mind the fact that I have to wear hearing 
aids. I am fine with it…it has not made me self-conscious or anything like that, and I mean I 
have got long hair but I wear my hair up and when I have got my hearing aids in and I really 
do not mind if people see them or not” (P51, F, Y, G3, N). Participant 17 accommodated his 
hearing loss, experienced in the context of surviving cancer and treatment for it: “When 
you're having your treatment and then the long recovery period, your hearing is sort of one 
of the lesser points you're worried about. You're more worried about your general health. 
Your biggest issue is your eating and everything like that, so your hearing comes sort of way 
down the line a little bit, you know, but it is important, but it's not important at the time, you 
know, not quite as important, you know” (M, Y, G3, N). Each of the six younger participants 
who were interviewed mentioned that they were not bothered by their aural change or their 
use of hearing aids, and felt that their hearing deterioration had not made a negative impact 
on their day-to-day life.   
 
Although some older participants also suggested that the hearing deterioration was not a 
problem to them: “I've got used to it now, don't bother really” (P53, M, O, G3, HL), others 
were not sure, when asked how the change had affected them: "I do not know” (P12, M, O, 
G1, HL). There were comments made that indicated older participants seemed less ready to 
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come to terms with their hearing loss: “[My wife] has commented on [my hearing loss], only 
because there are things that I need to hear and I am constantly saying "what", but she does 
tend to talk to me when she is miles away as far as I am concerned!” (P12; M, O, G1, HL), or 
the need for a hearing aid: “Well I had a hearing test. I didn't really take much notice of it 
because my right ear was still perfect…it was recommended that I have a hearing aid” (P29, 
F, O, G3, N). Therefore, unlike younger participants, older patients appeared less ready to 
acknowledge their hearing deterioration, and seemed to put the onus on others to make up 
for and adapt to their (the patients’) hearing difficulties.    
 
6.3.4.2 Downplaying of symptoms 
 
Although most participants said that their hearing change did not bother them, some 
revealed emotions and attitudes which suggested that aural change had a negative effect on 
their well-being. Downplaying of symptoms was conveyed when participants stated that they 
were not adversely affected by their hearing loss or tinnitus, but they disclosed negative 
feelings of anxiety, disappointment, frustration, annoyance or guilt that showed the impact of 
hearing deterioration and tinnitus on their quality of life.  
 
During treatment, some participants had an awareness of their hearing deterioration or 
tinnitus and voiced disappointment in their symptoms returning during treatment, or anxiety 
in the severity of their symptoms being maintained. For example, participant 51, who 
experienced hearing deterioration suddenly during treatment indicated disappointment when 
she said, “I thought it was going to get better like it did on day one when I had the first lot of 
chemotherapy” (F, Y, G3, N). Participant 7 shared his anxiety that the severity of his tinnitus 
that was experienced with treatment would not improve “the worry [was] whether or not it 
was going to subside with time as well, or if it was going to be a permanent fixture” (P7, M, 
Y, G3, N). These participants showed disappointment or anxiety at the prospect of their 
symptoms being maintained, or in the return of symptoms if there was temporary respite, 
perhaps because there was now another problem to deal with as a result of their cancer 
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treatment. Both participants 7 and 51 were younger participants, had Grade 3 deterioration, 
and had normal pre-treatment hearing. However, other participants with some similar 
characteristics who also first experienced their aural change during treatment (including P6, 
F, Y, G3, HL; P29, F, O, G3, N), as well as participant 30 (M, O, G1, HL) did not express 
similar feelings. It is possible that participants 7 and 51 experienced more severe symptoms 
during treatment than other participants because they hinted at feelings of anxiety or 
disappointment, and that these feelings were more related to this severity, rather than due to 
their younger age or normal hearing before treatment. 
 
After treatment, some participants felt frustrated, annoyed or guilty because of their aural 
change. Frustration occurred when not being able to perform an everyday task of listening 
and understanding conversation, which was possible to do prior to hearing deterioration 
following treatment: “I mean it gets a bit frustrating, and I’d say it gets frustrating if I’m having 
a conversation or I can’t hear…” (P6, F, Y, G3, HL). Irritation in others was sensed by 
participants: “Things like the television, I might have it up higher than say normal, which 
annoys my mum” (P6, F, Y, G3, HL). The irritation of experiencing tinnitus was keenly felt at 
some times more than others and expressed as annoyance: "It is never overwhelming but 
sometimes it is really annoying” (P11, M, Y, G3, N), or as a nuisance: “Annoying, sometimes 
more annoying than others … Every once in a while, it comes to the fore of the brain and it is 
just a nuisance” (P12, M, O, G1, HL). The feeling of irritation or annoyance stemmed from 
the intermittency of tinnitus, and possibly a lack in control to overcome this symptom. It was 
not made clear in what circumstances the feeling of annoyance with tinnitus was 
exacerbated. The feeling of guilt was apparent on changes made to accommodate hearing 
deterioration: “It's not fair on, you know I live with my mum, and it's not fair on her if the 
television is up really loud, so I try and manage with it not quite so loud”; ”It’s just 
embarrassing to say, ’look I'm really sorry’; if I'm on the telephone and having a conversation 
with someone, other than a friend, it's a bit embarrassing, having to keep saying “I'm really 
sorry, but I can't hear you, can you speak up?”; it must be annoying for them and it's 
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embarrassing for me” (P6, F, Y, G3, HL). However, such feelings were not communicated by 
other participants (for example P2, F, Y, G3, N). Feelings of annoyance and guilt with 
tinnitus or hearing deterioration, therefore, impacted some participants and those whom they 
were with, although other participants were not affected in this way, indicating that hearing 
deterioration and tinnitus affected individuals differently.  
 
6.3.4.3 Sense of loss  
 
The sense of loss in experiencing a deterioration in hearing was sometimes revealed by 
some of the older participants. One shared her feelings of disappointment because of a 
change in her hearing: “I felt disappointed… because my hearing was perfect before the 
radiotherapy” (P29, F, O, G3, N). However, disappointment appeared to go deeper than 
being associated with a change in physical functioning; it, together with embarrassment, was 
also associated other types of loss: that of self-worth, identity, and self-confidence. Loss in 
each of these three attributes is commonly associated with hearing loss. There was stigma 
in being identified with a hearing problem after treatment that indicated deafness was 
associated with reduced self-worth: “I haven't allowed [my partner] to tell anybody” (P53, M, 
O, G3, HL). This finding would suggest that participant 53 was reluctant to use hearing aids 
that were provided. The wearing of a hearing aid affected the self-confidence of another 
participant: “I felt disappointed that I needed a hearing aid … It is vanity. I didn't want to wear 
a hearing aid. It just takes the confidence away” (P29, F, O, G3, N). The stigma of deafness 
also affected the self-identify of participant 29, by the feeling of suddenly ageing: ‘[I feel]…as 
if I'm about 90”  (F, O, G3, N – aged 67), however, participant 12 (M, O, G1, HL) appeared 
not to be adversely affected by his hearing change. These findings indicate that hearing 
deterioration following treatment had a significant impact for some of the older participants in 
this study on their self-image, self confidence and identity with the stigma of hearing loss, or 
in receiving a hearing aid, whereas younger participants provided no evidence of being 
affected by the association of acquiring hearing loss, or by wearing hearing aids.  
		 173 
6.3.4.4 Social isolation 
 
Some younger participants conveyed feelings of isolation by withdrawing from usual social 
activity. Isolation was indicated by reduced telephone use: “So I generally don't speak that 
much on the phone [to my children]… because I find it difficult to hear a lot of the 
conversation” (P17, M, Y, G3), withdrawal from social activity: “It is silly things, like I used to 
go to the pictures, I do not go to the pictures anymore because… [of] the noise” (P51, F, Y, 
G3, N), or reduced interaction with their partner: “I think … because my hearing was so good 
before the treatment that [my husband] never had to repeat himself and that, but he is 
realising that’s how it is; or [he] just does not talk to me” (P51, F, Y, G3, N). Although 
participants declared some readiness to come to terms with their hearing deterioration, there 
was evidence to suggest that this symptom affected quality of life through reduced social 
activity and conversation with family. Withdrawal from social activity was not evident in the 
other participants. Although both participants 17 and 51 experienced Grade 3 deterioration, 
having had normal hearing prior to treatment, they appeared to have lifestyles that revolved 
around social activity. Therefore, the isolation sensed by these younger participants may be 
linked more to their lifestyle rather than because of their age. 
 
There were patterns identified with emotional responses to hearing deterioration following 
HNC treatment. Whereas younger participants generally were ready to admit to their hearing 
deterioration, older participants tended to be more reluctant to acknowledge their loss.  
Younger participants experienced withdrawal from social interaction with friends and family, 
although isolation may be more related to patient lifestyle rather than age. The sense of loss 
was associated with older participants. Downplaying of symptoms was evident with some 
participants who expressed feelings including those of annoyance and guilt. There appeared 
to be no patterrn to the responses made based on pre-treatment hearing level, or on patient 
gender. 
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6.3.5 Theme five – Information and support 
 
Information participants received on hearing deterioration and on further support appeared in 
some instances to be insufficient and inadequate. 
 
6.3.5.1 Pre-treatment information 
 
Prior to treatment, participants were provided with information that hearing deterioration may 
take place with treatment: “I knew it was a possible side-effect of the treatment so I was half 
prepared for it” (P7, M, Y, G3, N), but the provision of so much other information at the same 
time reduced awareness of this possibility for other participants. The diagnosis of cancer 
became so significant that it caused a distraction from other issues such as hearing loss: “It 
is a lot to take on board, when you are first told that you have got cancer, and this is what is 
going to happen. They do briefly explain that this is possible what could happen from having 
chemoradiotherapy, so they talk about your loss of taste buds, saliva, the mouth ulcers, loss 
of hearing. They talk about it, but to be perfectly honest with you, you do not take it in. All 
you hear is the word cancer and then that is it. You really did not get much to start with, 
because they were more concerned with giving you how you were physically going to feel 
and cope with it for six weeks” (P51, F, Y, G3, N). Therefore, although information that 
hearing deterioration may occur with treatment was given to study participants prior to 
starting RT or CRT, the shock of being diagnosed with cancer may have reduced the 
realisation that hearing deterioration may follow treatment. Also, the focus of information 
prior to treatment may be prioritised to getting patients through treatment and the restoration 
of vital body functions, rather than alerting patients to the possibility of suffering a hearing 
change and details of what that change may involve. 
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6.3.5.2 Discussion of aural changes 
 
During treatment, participants had regular meetings with staff (oncologists or radiographers) 
involved in monitoring the side-effects of treatment, although it was left to participants to 
report any aural concerns: “At no point throughout [the treatment] do they ask you how your 
hearing is. They just say to you “Any other things?” and I just happened to mention about the 
hearing. But they never actually say “Have you noticed any hearing problems, difficulty, 
noises, tinnitus?” anything like that. Never do they mention that” (P51, F, Y, G3, N). Some 
participants were prepared to share changes that they experienced with treatment, as they 
were aware before treatment that hearing deterioration may occur: “We were able to, 
normally every week, get a comprehensive list of things we would talk to the doctor about, 
and normally the most pressing things, and at that time the hearing had suddenly gone… 
from everything was alright, to something's a bit different now, so we immediately brought 
that up. Because I was kind of expecting it, they were on [my] list” (P7, M, Y, G3, N). 
Therefore, although participants had regular meetings with clinicians (radiographers and 
oncologists) during treatment to discuss side-effects, the clinicians’ checklist did not contain 
hearing problems. Consequently, patients needed to mention aural changes (hearing 
deterioration or tinnitus), and these changes may not be apparent if patients are focused on 
other side-effects of treatment. 
 
However, mentioning aural changes during treatment led to a change in treatment for some 
participants who were interviewed. This change occurred for a participant who had aural 
pain: “Initially the first two rounds were cisplatin with also 5FU, which I kept with me at home. 
Following some whistling in my ears, after the first two rounds of that… I went back for the 
consultation and said, “Look it's quite painful” … They made a decision that they would 
try me on the carboplatin to see if that alleviated some of the symptoms” (P7, M, Y, G3, N).  
It was found that other participants (P53, M, O, G3, HL; P51, F, Y, G3, N), following a review 
of their treatment plan, also had a change in treatment from cisplatin to carboplatin. 
Therefore, in some cases, a change in treatment took place following side-effects that 
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included aural change. This highlighted the need to have aural change as part of a checklist 
of side-effects used by clinicians during treatment. 
 
The confusion and inadequacy within service provision was highlighted by the lack of clarity 
in who would discuss and manage hearing difficulties once they occurred. One participant 
gave a clear indication that the oncologists were expecting audiologists to do this: “When I 
actually spoke to the oncology team and explained that I had the hearing problem, they were 
very much, “Oh that is standard, that is going to happen, but do not worry, you are under 
audiology”. So, they did not go into it at all then” (P51, F, Y, G3, N). There appeared to be an 
assumption made by oncologists that the audiology team would provide information and 
support on hearing deterioration. However, this assumption did not seem to be 
communicated adequately between audiology and oncology, as there were varying levels of 
information shared by audiologists about participants’ hearing. Some participants felt the 
information provided by the audiologist was appropriate: “Everything was explained along 
the way and I understood it all so that was all fine" (P11, M, Y, G3, N). However, others had 
less comprehensive support: “I must admit some of the people I've had the hearing tests 
with haven't really said too much about the results, and if there's any real outcome of it, you 
know” (P17, M, Y, G3, N). This lack in consistency was apparent at interview, as although 
some participants had discussions about their aural concerns with audiologists or oncology 
staff soon after they experienced their hearing deterioration or tinnitus, others only got to 
discuss these concerns when they came to interview one year after treatment. One 
participant was not sure if what he was hearing was in fact tinnitus: “I am assuming it is 
tinnitus only because people have described sort of a high-pitched ringing, not quite like a 
mosquito, but it is sort of a similar thing. Maybe that isn't tinnitus, maybe it is something else, 
I do not know" (P12, M, O, G1, HL). Another stated at their interview: “I’ve had no real 
conversation…if there’s anything that could be done with my hearing” (P17, M, G3, Y, N). 
These findings suggest that there was inconsistency in how information on hearing and 
tinnitus problems with study participants was provided, as some patients did not have the 
		 177 
opportunity to discuss their aural concerns until interview a year after treatment, even though 
they experienced these concerns during or soon after receiving CRT or RT. From these 
comments it was not clear which service, audiology or oncology, was to provide information 
and support to patients when they experienced hearing loss or tinnitus, and when such 
information was to be given.   
 
6.3.5.3 Further support 
 
Participants suggested that further support could be given in three areas: more indication 
pre-treatment of possible severity and progression of aural change with treatment; the 
implementation of more hearing tests with monitoring; and a fuller explanation of hearing 
loss and tinnitus management. 
 
One participant expressed his surprise at the severity of their hearing deterioration: “Well, I 
mean [I was told] a lot of things like you would lose your taste and you would lose weight, 
but you know, nobody said your hearing’s [going to be so bad]” (P53, M, O, G3, HL). Others 
were uncertain about progression of their aural symptoms, and one suggested the use of a 
colour coded chart to help provide suitable information on aural changes: “Maybe having a 
graded list of potential side-effects and symptoms, and say these are really, really common, 
and… breaking it down into, you know, [a] green, yellow and red kind of scenario, saying 
“The green stuff -  you're going to get that, it's going to die down, don't worry about it, and we 
normally expect these things to start here and finished around here If it's outside that, come 
and talk to us. These ones are more unusual, and these ones are potentials, we would not 
expect you to get that. If you do, you need to call us” And just ensure during the check-ups 
that those are…. pick[ed] up” (P7, M, Y, G3, N). It could be that pre-treatment information 
displayed in a colour-coded format may help patients be better aware of and prepared for 
the severity and progression of potential side-effects of treatment, including hearing 
deterioration and tinnitus.  
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All the participants were in favour of monitoring by hearing testing. Most found it convenient 
to have the three tests in the study at time points prior to treatment, at the end of treatment 
and three months after treatment, as these were arranged to coincide with other hospital 
appointments: “They were fine, because luckily they fitted in with appointments I already 
had, so it didn't put me out in any way, it was just like visiting this part of the hospital from 
another part, so it fitted in completely” (P42, F, O, G1, HL). However, one participant 
expressed his reservation at the timing of a test at the end of treatment: “I think [with] the 
middle one [the end of treatment test] I didn't really know much about, because I was 
so, with so many different drugs and everything, I wasn't quite on this planet, so I don't really 
remember much about the middle one, but yes the other two were fine, yes, OK” (P17, M, Y, 
G3, N). These responses suggested that, in addition to the baseline test, there is a need to 
arrange at least two tests after treatment to assess hearing deterioration, so that if patients 
are not well enough to attend the end of treatment test, they can still be investigated at the 
3-month follow-up. 
 
Some participants suggested that an additional test to monitor hearing be included during 
treatment: “Maybe if there had been one mid-way they could have seen if there had been a 
slight deterioration” (P30, M, O, G1, HL), and “I did wonder, because the business I'm in 
where I make people test software for example, the way they do it, maybe having one 
before, one during, one just at the end and then one x-months later, so just having an extra 
one so you have four different viewpoints over the timeline” (P7, M, Y, G3, N). There was 
additional merit in performing testing mid-treatment to help identify those who had a 
deterioration during treatment as, already mentioned, experiencing aural symptoms led to a 
change in treatment for some of the participants in this study. Therefore, there was evidence 
to support monitoring of hearing deterioration at four time points: pre-treatment, mid-
treatment, at the end of treatment, and at three months follow-up.  
 
For some participants, the study interview, a year after treatment, was the first time that they 
had an opportunity to discuss their aural concerns in depth. At interview, these participants 
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shared different ways in which there could be improvement in support, particularly in regard 
to tinnitus: "I think just whether or not hearing aids are advisable or appropriate in the 
circumstances…can they restore hearing or indeed get rid of tinnitus?" (P12, M, O, G1, HL). 
This participant (subsequently fitted with hearing aids soon after the study interview) may 
have had further delay in receiving hearing aid support, if discussion of his hearing 
difficulties had not taken place at the study interview: “I do not know whether I would have 
initiated [hearing aid fitting], or others would have initiated it for me!" (P12, M, O, G1, HL). 
Another participant was unclear what help could be given to overcome her tinnitus: “I would 
be grateful if there were any exercises that I could do, or if I could do anything to help myself 
to help [reduce] the tinnitus” (P6, F, Y, G3, HL). In addition to those who only discussed their 
aural concerns at interview, there was one participant who only became aware of their 
(unilateral) hearing deterioration as a consequence of being in the study: “I had a hearing 
test the day I finished radiotherapy and it had gone down a bit, but I had a hearing test then, 
about six weeks later, and that was when you noticed that it was down” (P29, F, O, G3, HL). 
When it was suggested to participant 29 that she might need a hearing aid, she said: “I didn't 
realize I needed one”, but aiding has been of benefit for her.  
 
Therefore, hearing monitoring conducted for this study enabled participants to benefit from 
hearing aids within the early post-treatment period; likewise, participants were able to avail 
themselves of appropriate advice when they were interviewed one year after treatment. 
However, these interventions and advice could have been offered as soon as tinnitus and 
hearing loss were identified had protocols been in place to give clear guidance that such 
information was available from audiology services. There appeared to be no difference in the 
pattern of support or information given based on different characteristics used in selecting 
participants for interview.  
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6.4 Summary  
 
Information on patient experience about hearing deterioration following HNC treatment 
revealed that there appeared to be little difference in experience between male and female 
participants, or those who had normal hearing prior to treatment compared with those who 
had a hearing loss before they started their treatment. There was no pattern on how hearing 
or tinnitus problems progressed, however participants with major hearing deterioration had 
more widespread problems with their change in hearing compared with those who had minor 
deterioration, and in some instances, younger participants experienced hearing deterioration 
differently to older ones. 
 
The majority of participants interviewed experienced a hearing change together with tinnitus, 
although these two symptoms did not necessarily occur concurrently. Of particular interest 
was the incidence of tinnitus in the majority of participants, and in some instances it was 
more bothersome than hearing deterioration. In addition, one participant experienced 
hyperacusis. All participants with major hearing deterioration found that their hearing change 
impacted negatively on their communication and their enjoyment of leisure pastimes. For 
one participant, the ability to listen was particularly affected by tiredness following the effects 
of cancer treatment. Participants had fewer strategies available in coping with tinnitus in 
contrast to the way that they had dealt with their hearing deterioration, however hearing aids 
were useful in dealing with both symptoms. Additional devices used in this study were an 
auto-inflation balloon to deal with middle ear dysfunction, and a doorbell with a lower pitch to 
manage hyperacusis aggravated by high-pitched sounds. More strategies were used by 
younger participants in overcoming hearing difficulties, which reflected their overall 
acknowlegment of hearing deterioration.  
 
The downplaying of symptoms was evident in some participants who showed a range of 
emotions that expressed their anxiety, annoyance, guilt and distress at experiencing tinnitus 
or hearing deterioration. Older participants indicated that they were less ready to admit to 
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their hearing deterioration, as this change highlighted loss of identity, self-worth, and self-
confidence by the association of hearing loss with the ageing process. Social isolation was 
noted in some of the younger participants.  
 
It appeared that the shock of receiving a cancer diagnosis distracted some participants from 
taking on board the information, where given, on the possibility of hearing deterioration as a 
result of treatment. Participants had to volunteer information of their aural concerns, as 
clinician checklists did not have hearing deterioration or tinnitus down as possible side-
effects. It was evident that communication between oncology and audiology services 
required improvement, as it was not clear which of these services was to share hearing test 
results with patients. It was also determined that there was no consistency when support for 
hearing loss or tinnitus was provided, as some patients waited up to a year before 
discussing their aural changes, whereas others received advice and management soon after 
completion of their treatment. In general, participants found that hearing monitoring was 
helpful, but, they suggested that better pre-treatment information would help alleviate anxiety 
and shock. 
 
The next chapter discusses the findings from quantitative data and qualitative data from this 
study together with the wider literature.  
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Chapter 7 Discussion 
 
7.1 Introduction   
 
This chapter will begin with a reminder of the research aims in this study, and by 
summarising the quantitative and qualitative results that were obtained. It will then discuss 
these findings with reference to wider literature, policy and practice on related topics. The 
chapter will continue by summarising what new knowledge was found and will then conclude 
by drawing out the significance of these findings for the clinical practice of caring for and 
supporting HNC patients. 
 
7.2 Summary of research findings 
 
7.2.1 Primary aims 
 
In addressing the first primary aim: to assess the incidence and severity of hearing 
deterioration after treatment for HNC, it was found, drawing on the quantitative data, that the 
incidence of hearing deterioration in patients undergoing treatment for HNC was 57% at the 
end of treatment, and 50% at 3-month follow-up after treatment. This result is based on 
CTCAE criteria for hearing deterioration and indicates the potential scale of the problem of 
hearing deterioration of HNC patients following treatment from one tertiary UK hospital. 
Albeit with a small sample size, this study showed that there was a 24% rate of Grade 1-2 
(minor) severity change in hearing, and a 26% rate in Grade ≥ 3 (major) severity change at 
3-month follow-up.  
 
In addressing the second primary aim: to explore the lived experience of participants with 
hearing deterioration after treatment for HNC, information was obtained from both qualitative 
and quantitative data. Drawing on the responses made in the qualitative interview data, the 
study found that participants had variable hearing-related treatment experiences prior to, 
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during, and after their treatment. In these responses, patterns of patient characteristics (age 
and severity of deterioration) became apparent. Such characteristics were used for selecting 
participants from the quantitative data for the qualitative interviews; other patient 
characteristics (gender and pre-treatment hearing) appeared not to be relevant in patient 
experience. All those who suffered major measured deterioration experienced a reduction in 
their ability to hear, whereas only some of those with minor deterioration perceived an aural 
change. The impact of hearing deterioration had more wide-reaching consequences for 
participants with major deterioration compared to those with minor deterioration, and there 
were instances when difference in age had a bearing on patient experience.  
In summary: 
• Experience of hearing change – some participants were not aware of any change, 
but the majority did perceive either a sudden or gradual change. Those who had 
either minor or major grades of hearing deterioration experienced negative impact. 
There appeared to be no pattern in the progression of symptoms;  
• Tinnitus – this was experienced and problematic for the majority of participants, 
particularly for those with more severe hearing deterioration; 
• Middle ear dysfunction – this caused irritation for some participants who had Grade 3 
deterioration;  
• Functional changes – all participants who sensed a loss in hearing, including those 
who acquired unilateral hearing loss, had altered ability in performing every-day 
tasks. Those with Grade 3 deterioration had many more difficulties with general 
communication, and also with leisure or environmental noise, compared with those 
who had Grade 1 change;  
• Coping mechanisms – General strategies, including the need to lip-read, were used, 
although younger participants made more effort to improve communication than older 
patients, who appeared to cope by putting less emphasis on their hearing loss. 
Those with Grade 3 deterioration found more solutions compared with those who had 
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Grade 1 change. Participants acquired hearing aids through audiology service 
provision, whereas others adapted to their loss using their own means to enhance 
both communication and enjoyment of pastimes;  
• Emotional responses – Younger participants overall were ready to recognise the 
change to their hearing, and felt that they were not adversely affected by their 
hearing loss, whereas older participants appeared less ready to acknowledge their 
hearing deterioration. Some younger participants with Grade 3 deterioration 
experienced isolation, although this may be linked more to lifestyle changes rather 
than to their age. It was evident that older participants felt a more general sense of 
loss. Downplaying of symptoms was displayed in some participants who asserted 
that their aural change did not have a negative impact on them or their lives, yet at 
the same time these people expressed feelings of anxiety, frustration or guilt. 
• Information and support – there was inconsistency in when test results were shared 
with patients, and in how patients received support if they had a hearing 
deterioration.   
 
These findings demonstrated that the experience of hearing deterioration was 
heterogeneous amongst the participants who were interviewed. Participants not only differed 
in how they sensed their deterioration, but also differed in how their daily living was affected, 
and in how they responded to change, both practically and emotionally. Patient experience 
was also varied in how and when participants received explanation of test results and were 
given advice to manage their aural change.  
 
7.2.2 Secondary aims 
 
These drew on the quantitative data.  
 
In addressing the first secondary aim: to describe overall hearing levels, the study found that 
there was an increase in the proportion of participants who had bilateral mild or moderate 
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hearing loss, from pre-treatment to 3-month follow-up hearing, with one participant 
developing severe hearing loss in one of her ears. However, hearing deterioration for some 
participants was transient as six participants tested at 3-month follow-up had improved 
overall hearing compared with levels obtained at the end of treatment. 
 
In addressing the second secondary aim: to determine types of hearing loss, it was found 
that there was a reduction in the number of participants with normal hearing at 3-month 
follow-up compared to pre-treatment hearing (from seven to two), and all of the 21 
participants developed sensorineural damage to one or both ears. Of these 21 participants, 
six also developed a mixed hearing loss (both sensorineural and conductive loss) in at least 
one ear, whereas the remaining 15 developed permanent SNHL only in one or both ears. 
Amongst seven of the 42 participants, there were eight ears that had a conductive 
component to the hearing loss, with middle ear dysfunction confirmed by abnormal 
tympanometry results.  
 
In addressing the third secondary aim: to examine the incidence and severity of hearing 
deterioration in relation to patient demographics and types of treatment, this study 
highlighted that older age (mean=68.7 years) was associated with a statistically significant 
(p=0.03) risk of developing hearing deterioration compared with participants who suffered no 
deterioration in hearing (mean=58.8 years). If hearing deterioration took place, younger age 
(mean=56.3 years) was associated with a greater severity of change compared with older 
age (p=0.02). The study also found that the use of chemotherapy in addition to RT 
administration was associated with a greater risk of developing hearing deterioration, than 
the use of RT alone (p=0.01). 
 
 
 
 
		 186 
7.3 Discussion of findings 
 
Findings from the quantitative data and qualitative data are brought together where relevant 
in this chapter and are discussed with reference to articles and policy statements principally 
related to HNC care. 
 
7.3.1 Incidence of hearing deterioration 
 
This study provided information on incidence rates of hearing deterioration from patients 
following curative RT or CRT treatment at a UK hospital. The potential influencing factors of 
aspects of recruitment, type of HNC studied, and study location, will be discussed in the 
following section.   
 
The method for recruitment used in this study was consecutive convenience sampling. All 
patients newly diagnosed with HNC who were eligible for RT or CRT treatment were invited 
to participate. It had been arranged with the oncology department in the study hospital for all 
newly diagnosed patients with HNC, due to have curative RT or CRT, to contact the 
audiology department and discuss participation in the study. Consequently, there was a high 
probability that all patients who were eligible for selection were invited to take part in the 
study. This methodology may have contrasted with other studies that also assessed a range 
of subtypes of HNC; in these latter studies, the method of recruitment was not clearly stated 
(Cheraghi et al., 2015; Niemensivu et al., 2015; Pan et al., 2005; Shorter et al., 2017; 
Theunissen et al., 2014b), and so the effect of selection bias is not known. As the 
methodology employed for recruitment in the current study was clearly stated, it is easier to 
understand and take account of the shortcomings of the recruitment process. Consecutive 
sampling imposed a limitation as there may have been seasonal variation in hearing 
deterioration within the 6-month period of recruitment. Hearing testing results, during the 
winter months, may have been affected by upper respiratory tract infection that is known to 
cause otological change (Doyle et al., 1999), and impair concentration (Smith, 2013); both 
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damage to the ear and poor concentration can affect behavioural hearing thresholds 
(Pichora-Fuller et al., 2016). Therefore, it is necessary that further studies are conducted 
with consecutive recruitment over at least a year period in order to mitigate any seasonal 
variation in hearing due to the common cold.  
 
This study contributes to the field of HNC literature by determining incidence rates of hearing 
deterioration across a broad range of HNC within the one study. The incidence rates of this 
study (reported above in section 7.2) in the early post treatment phase (within the first few 
weeks of treatment – Bentzen and Trotti, 2007) were within the wide range reported in the 
literature for people receiving HNC treatment, that vary from 0% (Niemensivu et al., 2015) to 
100% (Pan et al., 2005). However, it is difficult to make direct comparison with these 
previous studies because of different subtypes of HNC studied. The seven subtypes of HNC 
are cancers of the oral cavity, oropharynx, nasopharynx, hypopharynx, paranasal sinuses 
and nasal cavity, larynx, or salivary glands (Palaniappan, Owadally and Evans, 2015). This 
study incorporated similar proportions of patients with the three most common subtypes of 
HNC diagnosed in the UK: oral cavity, oropharyngeal and laryngeal cancer (accounting for 
82% of all HNCs in the UK), having treatment (accounting for 80% of study participants). As 
reported in the chapter on quantitative results (Chapter 5), hearing deterioration occurred 
across all seven subtypes of HNC. The inclusion of all seven subtypes in this study differed 
from other studies, examined in the literature review (Chapter 2), on adult patients that 
reported hearing deterioration from a limited range of subtypes of HNC (Theunissen et al., 
2014b; Pan et al., 2005; Niemensivu et al., 2015; Cheraghi et al., 2015). Theunissen et al. 
(2014b) reported 78% incidence of hearing deterioration, but only in patients (n=36) who had 
oral cavity, oropharyngeal, or hypopharyngeal cancer. Pan et al. (2005) found 100% 
incidence of deterioration, but their study did not include assessment of patients (n=35) who 
had laryngeal or hypopharyngeal cancer. Niemensivu et al. (2015) reported an 0% incidence 
rate of deterioration, but none of the patients they studied (n=22) had salivary gland cancer. 
Cheraghi et al. (2015) determined a hearing deterioration incidence rate of 51% from 29 
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patients in their study; however, the authors did not clarify the subtype of cancer in seven of 
these patients. Incidence rates reported in these other studies may have varied in part due 
to the different types of subtypes of HNC included, so this study helped to clarify that hearing 
deterioration may occur across all the different subtypes. However, a limitation to the current 
study, and in all these other studies (Theunissen et al., 2014b; Pan et al., 2005; Niemensivu 
et al., 2015; Cheraghi et al., 2015), was that subtype analysis was not performed. It was not 
possible to perform subtype analysis in this study due to the small sample size, and 
therefore, it was not ascertained if there was greater risk of hearing deterioration associated 
with particular subtypes than others, and treatment for each of these. Chapter 2 provided 
much evidence to show that hearing deterioration follows treatment for NPC, in the eight 
articles that focussed on this HNC subtype. However, there is less evidence of hearing 
deterioration in other HNC subtypes using current treatment techniques. Gudelj et al. (2014), 
investigating treatment of laryngeal and hypopharyngeal cancer, reported 26% incidence of 
hearing deterioration of sensorineural type at 6 months following the completion of 
radiotherapy (n= 23), but these authors commented only on laryngeal cancer in their 
findings, and the treatment used is now dated (2D RT). Other studies on parotid cancer (van 
der Putten et al., 2006; Chen et al., 1999; Schot et al., 1992) reported incidence of hearing 
deterioration between 20 and 57% following radiotherapy treatment, however all 3 of these 
studies used the ear contralateral to radiotherapy as the comparator rather than using 
baseline hearing tests, so it was not clear if hearing deterioration occurred in the ear 
exposed to RT. Further research is required to determine hearing deterioration either 
specifically in a particular subtype, or on a larger sample of general HNC with subtype 
analysis, to better inform patients of the risk of hearing deterioration based on their type of 
cancer and current treatment regimens. It is also important for these studies to use baseline 
hearing tests to ensure an accurate assessment and interpretation of hearing deterioration.  
 
From evidence currently available, this study appears to be the first to assess incidence 
rates of hearing deterioration following treatment of HNC in a UK hospital using current 
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techniques (of chemotherapy – cisplatin or carboplatin; and of IMRT). The incidence rates 
obtained in this study could be useful to inform the planning of clinical services as 50% of 
patients who receive HNC cancer treatment may require audiological support as a result of 
hearing deterioration at 3-month follow-up. However, it is noted that much caution is needed 
not to overstate the findings from this study, as it had a limited time for recruitment of a small 
number of patients (already discussed above), and it was based at one tertiary audiology 
department in the UK. McCarthy et al. (2015) reported regional difference not only in overall 
incidence of HNC cancer in the UK, but also in incidence rates for different subtypes of 
cancer: for example, they found a greater decrease in incidence rate of laryngeal cancer in 
the north-east of England compared with the south of England between 2002 and 2011, due 
to a change in the industrial landscape in this period. Therefore, there is need to build on the 
results from this study by performing further studies at different UK centres to account for 
regional differences in HNC cancer subtypes, to obtain an overall picture of hearing 
deterioration following HNC cancer treatment in the UK. 
 
Although this study focussed on hearing deterioration, it is important to note that transient 
hearing loss was also detected in the early post-treatment period. Some participants who 
had an initial deterioration in hearing, evident when comparing end of treatment test results 
to baseline test results, had improved hearing at the 3-month follow-up test. For these 
patients, the improvement in hearing was due to resolution of OME, with the restoration of 
normal middle ear function, as reported by Chan et al. (2009). In view of the possible 
improvement in hearing, some authors chose not to test hearing in the early post treatment 
phase (Schultz et al., 2010; Bhandare et al., 2007). Improvement in hearing is known to 
occur in the early stages after HNC treatment, not only due to resolution of OME, but also 
due to reversal of change to the inner ear (Zuur et al., 2006), although the mechanism for 
this reversal is unclear. Further research is required to confirm whether or not transient 
hearing loss occurs following initial damage to the inner ear with treatment for HNC.  
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7.3.2 Severity of hearing deterioration  
 
This section will first discuss patient experience in relation to varying severity of hearing 
deterioration, including functional difficulties and the effect of fatigue on hearing.  
 
This study provided information on severity of hearing deterioration for a consecutively 
diagnosed cohort of adult patients who received treatment for HNC. There were similar 
incidence rates of hearing deterioration of minor severity (Grade 1-2: 24%) and major 
severity (Grade ≥3: 26%) at 3-month follow-up. Two other studies (Cheraghi et al., 2015 and 
Theunissen et al., 2014b), also used the CTCAE criteria for assessing incidence rates for 
different degrees of severity that were employed in this study. However, Cheraghi et al. 
(2015) did not state clearly what these different degrees of severity were, and similarly, it is 
difficult to derive incidence rates of severity from the figures and tables included in their 
study. In contrast to Cheraghi et al. (2015), Theunissen et al. (2014b), in keeping with the 
current study, did provide clear information on incidence rates of hearing deterioration with 
different degrees of severity, and reported Grade 1 incidence of hearing deterioration at 
25%, Grade 2 incidence at 44%, and Grade 3 incidence at only 8%, across the 36 patients 
who had treatment for HNC in their study. It is clear that these rates differed in proportion to 
those obtained in the current study. This difference may be due to the different subtypes of 
cancer assessed between the studies, as Theunissen et al. (2014b) assessed only patients 
who had cancer of the oral cavity, oropharynx or hypopharynx, whereas this study included 
treatment of patients from all seven subtypes of HNC. Whereas the finding from Theunissen 
et al. (2014b) on severity of hearing deterioration is limited to a small subtype of HNC, the 
findings from the current study applied to all seven subtypes. Therefore, it appeared that if 
patients who are newly diagnosed with HNC have hearing deterioration following treatment 
at this UK centre, they had an almost equal chance of acquiring a minor or major degree of 
severity in deterioration that was determined by hearing testing at 3-month follow-up after 
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treatment. Further studies would be necessary to inform national policy as this study’s 
results represented only one centre in England and may not reflect findings in other regions.  
 
7.3.2.1 Major and minor hearing deterioration 
 
Whereas Chapter 5 of this thesis provided data on the proportion of patients who had 
deterioration of hearing following HNC treatment, Chapter 6 presented the findings from 
interview of 13 patients (selected from 21) who had a measured deterioration. Participants 
who had a major (Grade ≥3) deterioration in at least one ear perceived hearing deterioration, 
had more widespread problems in communication, socialising, and in their leisure pursuits, 
compared with those who had minor deterioration. This finding is intuitive – the greater the 
impairment, the greater the range of problems, and these contrasting findings between 
different grades of deterioration will be discussed throughout this chapter.  
 
The main contrast between participants with different grades of deterioration was that 
whereas all eight participants with major deterioration experienced aural change, only two 
out of five of those who had a minor Grade (1-2) deterioration perceived a deterioration. This 
lack in awareness of hearing deterioration for some participants with a minor deterioration is 
common with people who have age related change to their hearing; as there are small 
changes in hearing over a period of time, people with age-related hearing change naturally 
adapt without discerning a difference, and it is typically about ten years before people seek 
help with their hearing problems (Davis et al., 2007). However, both patients with minor 
hearing deterioration who perceived a change in hearing shared their difficulty in hearing the 
television at the usual volume prior to treatment, and one had problems that included 
understanding speech in restaurants, and difficulty in hearing alerting sounds such as the 
doorbell. This participant ultimately required hearing aids; two other participants with Grade 
1 deterioration (not interviewed) were provided with hearing aids within six months of 
completing their treatment. Correlating the findings of both quantitative and qualitative data 
		 192 
from this study therefore demonstrated that even a minor (but none-the-less significant for 
the patient) deterioration in hearing had an adverse effect on well-being. 
 
Hearing ability was measured using PTA, and a deterioration in hearing was determined 
using CTCAE criteria. Although Cheraghi et al. (2015) and Theunissen et al. (2014b) 
employed the same criteria, neither of these studies clearly indicated the effect of different 
severity grades of deterioration on patient experience. Most other studies do not use a 
measured deterioration in hearing, but rather a subjective deterioration that is rated by 
clinicians, and these studies reported only on higher grades of hearing deterioration (for 
example, Al-Mamgani et al., 2012; Wu et al., 2013; Huang et al., 2015; Bentzen and Trotti, 
2007; Du et al., 2015). As this was the first study to explore lived experience of hearing 
deterioration after cancer treatment, let alone HNC treatment specifically, it is difficult to find 
literature to make comparison with the study findings on perception of hearing loss with 
different grades of deterioration. The study by Nund et al. (2015) on patient experience 
selected participants who had communication difficulties after treatment, but it was not clear 
in their study how many of the participants had hearing difficulties following treatment, and 
the study did not assess the effect of severity in hearing deterioration. Therefore, in contrast 
to other studies, the current study provides clear evidence of the value in measuring even 
minor grades of hearing deterioration as this can identify patients in need of audiological 
support, and it is suggested that audiological support should be offered to all patients who 
suffer a deterioration in their hearing following HNC treatment. 
 
7.3.2.2 Lower speech frequency hearing deterioration 
 
The method used in this study for detecting hearing deterioration focussed on change in the 
higher speech frequencies, however, it is also important to consider the impact made on 
those with only lower speech frequency hearing deterioration with treatment. A limitation of 
the measured CTCAE criteria is that it covers hearing deterioration from 1kHz and above, 
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and does not account for lower speech frequency hearing deterioration, which was detected 
in one participant in the current study. This participant only had deterioration at 0.25kHz and 
0.5kHz, but required hearing aiding as she experienced difficulty in understanding 
conversation even in quiet conditions following her treatment. Her hearing difficulty was 
identified at her 3-month follow-up hearing test as part of the study, through conversation 
with the researcher. It is therefore important to ask patients if they have noticed a change in 
their hearing, even if hearing monitoring may not indicate that a deterioration has taken 
place. It was noted that this patient was recorded as having no problems with her hearing 
during the routine 3-month follow-up by an oncology specialist. It is known that clinician-
rated scoring underestimates the effect of communication difficulties encountered by 
patients (Lazarus et al., 2014; van der Molen et al., 2012). There is also an under-reporting 
of less severe subjective hearing deterioration in the cancer literature (Bentzen and Trotti, 
2007). These findings suggest that hearing deterioration may not be a priority consideration 
at routine oncology follow-up as there are so many other topics to cover on patient well-
being following treatment. It is therefore suggested that both an assessment of subjective 
and measured hearing is performed within the context of a hearing test appointment by 
audiology clinicians who focus on hearing. However, to avoid variability with subjective 
assessment even by audiologists, it is preferable to measure lower frequency hearing 
deterioration either by extending the CTCAE criteria to apply also to lower frequencies, or by 
assessing lower frequency hearing within the overall descriptor of hearing levels following 
treatment, which will be discussed later in this chapter. 
 
7.3.2.3 Functional changes 
 
Although participants with Grade 3 deterioration had more wide-reaching problems with 
communication and their leisure pursuits compared with those with Grade 1 deterioration, 
each participant identified different difficulties in communicating. Although some participants 
were clear in describing what parts of speech they could not hear, such as high frequency 
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sounds which corresponded to damage in the speech-hearing range that commonly occurs 
with treatment (Chan et al., 2009; Shorter et al., 2017), others had non-specific deafness. 
This finding was consistent with those in a review by Vestergaard Knudsen et al. (2010) on 
help-seeking behaviour in hearing impaired adults, which also concluded that self-reported 
auditory difficulty was possibly a more important factor in aural rehabilitation than objective 
hearing sensitivity. It is therefore important to have individual assessment to identify which 
particular aspects of speech are most difficult to comprehend, and what environments cause 
most difficulty, as each participant was affected by their hearing deterioration differently, a 
common feature of having hearing loss (Thomas, 1988; Meddis et al., 2010; Harrison, 2016). 
Patients can then be given different advice and rehabilitation options (for example, the 
provision of an additional program if hearing aids are suitable) depending on their particular 
hearing difficulty. 
 
7.3.2.4 Fatigue and hearing  
 
The effect of fatigue was noted by one of the participants (with a major deterioration in 
hearing), who expressed that he was “absolutely shattered still” some evenings a year after 
treatment, and the effect of the tiredness meant that he had to ask his daughter to slow 
down speaking for him to understand her speech. Depletion of energy levels following 
cancer treatment cannot be underestimated, and fatigue remains highly prevalent in this 
patient population at least up to a year after treatment (Schaller et al., 2015; Molassiotis and 
Rogers, 2012). As listening effort causes tiredness due to hearing loss (Alhanbali et al., 
2017), and poor concentration is known to adversely affect listening ability (Chermak and 
Somers, 1988; Pichora-Fuller et al., 2016), the combination of hearing deterioration and 
tiredness may make listening more difficult for this patient population. As fatigue following 
cancer treatment is a common and prolonged problem, it is important that patients are made 
aware that fatigue may exacerbate communication difficulties due to aural change following 
treatment. Fatigue also exacerbated the perception of tinnitus for this participant. 
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7.3.2.5 Tinnitus 
 
An emerging finding in this study was the impact of tinnitus on HNC patients following 
treatment, particularly as this is absent from other studies. Seven out of the eight patients 
who had major hearing deterioration perceived both a change in hearing and experienced 
tinnitus, whereas one out of the two patients with minor hearing deterioration experienced 
both these symptoms. An exploration of tinnitus was not a direct aim of this study, but 
tinnitus was discussed during the participant interviews as part of patient experience of 
hearing deterioration, with eight out of the 13 participants suffering from the sensation of 
tinnitus following treatment. Four of these participants found that their tinnitus was annoying 
or distressing.  
 
It is significant that tinnitus was experienced by the majority of participants at interview one 
year after treatment, whether they had either minor or major hearing deterioration. In 
addition, some of these participants were adversely affected by their tinnitus when 
interviewed. Some required advice regarding tinnitus only, while others required hearing 
aiding to help deal with their tinnitus, and reported benefit. Although tinnitus is a separate 
entity to hearing deterioration and can be experienced in the absence of hearing loss 
(Baguley, Cope and McFerran, 2016), in this study tinnitus was experienced with hearing 
deterioration, and the tinnitus was often more distressing to patients compared with their 
hearing loss. Although the majority of patients interviewed in this study experienced tinnitus, 
tinnitus is mentioned less often than hearing problems in the wider literature. 
 
There are approximately ten times more articles in PubMed on ‘hearing’ compared with 
‘tinnitus’, yet arguably in this study, tinnitus had more of a negative impact on patient 
experience than hearing change, and it has been reported that tinnitus severely affects the 
quality of life of people in 15-20% of chronic tinnitus sufferers (Durai, O’Keefe and 
Searchfield, 2017). Other studies on HNC treatment have measured the impact of tinnitus 
from a quantitative aspect only. Niemensivu et al. (2015) used the Tinnitus Handicap 
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Inventory (Newman, Jacobson and Spitzer, 1996) and reported that seven out of 31 patients 
had moderate to severe tinnitus, but they did not indicate how the tinnitus affected them, nor 
did the authors mention how patients were supported if they experienced these symptoms. 
Zuur et al. (2006) reported that 28 out of 146 patients experienced tinnitus during treatment, 
but they did not clarify how data was collected. In both of these studies it was not made clear 
how to manage tinnitus symptoms, nor what the impact of tinnitus was on patients. One 
participant interviewed in the current study experienced hyperacusis (causing pain and 
distress) with his tinnitus. Although there is not much known about hyperacusis, there is 
growing awareness of the negative impact that it has on quality of life (Baguley and Hoare, 
2018), and it seems that the finding of hyperacusis accompanying tinnitus following cancer 
treatment is also a novel finding from this study. It therefore appears that this study is the 
first to report the impact of tinnitus (and hyperacusis) by qualitative analysis in HNC 
treatment literature, and it would be useful for further research to be conducted in this area 
to verify the findings of this study.   
 
The lack of focus on tinnitus may be due in part to the knowledge that there is currently no 
cure for tinnitus (Hilton, Zimmermann and Hunt, 2013; Miroddi et al., 2015). However, there 
are strategies to help deal with tinnitus, including tinnitus retraining therapy, cognitive 
behavioural therapy (Baguley, Cope and McFerran, 2016), or use of hearing aids (NHS, 
2017a). There is research into newer techniques such as the use of internet guided cognitive 
behavioural therapy (Beukes et al., 2017). Help for dealing with tinnitus is available from 
hearing therapists, audiologists and medical practitioners, so it is important to encourage 
patients to seek help from professionals when they experience tinnitus (British Tinnitus 
Association, 2017). A tinnitus specialist is usually associated with adult audiology services, 
as in the study hospital, although it is not clear who these specialists are in NHS guidance 
on tinnitus (NHS, 2017a). It is necessary to undertake more research specifically on the 
incidence of tinnitus in post-treatment HNC patients to understand accurately the scale of 
the problem, and how best to address it. In view of the current lack of adequate referral 
		 197 
systems, if findings from further research are consistent with this study, referral systems for 
tinnitus support should be set up at local and national levels, with such support being 
integrated into hearing services for a sustainable model provision.  
 
7.3.3 Hearing status 
 
There was no association found between risk of hearing deterioration and participant 
hearing level prior to treatment (Chapter 5). This finding concurred with that of Shorter et al. 
(2017) and Grau et al. (1991) in their assessments of hearing deterioration following HNC 
treatment. Although Zuur et al. (2007) reported that patients with better pre-treatment 
hearing levels suffered more severe hearing loss than those who had poorer hearing to start 
with, this finding was not up-held in the current study. There was also no difference found, in 
Chapter 6, of patient experience based on pre-treatment hearing level, as patients who had 
either normal pre-treatment hearing, or (mild) hearing loss (according to BSA descriptors – 
BSA, 2011) prior to treatment experienced similar hearing difficulty following treatment. 
Therefore, it appears that there is no need to alter treatment regimen to patients who have 
mild hearing loss or normal hearing prior to treatment based on the finding that there is a 
similar risk of hearing deterioration following treatment. In addition, similar support should be 
given to patients to deal with a deterioration in hearing regardless of their pre-treatment 
hearing status.  
 
Although there was no difference found in the incidence of hearing deterioration based on 
pre-treatment hearing status (i.e. whether a participant had normal hearing or a hearing 
loss), quality of life was affected for some study participants following treatment with a 
change in their overall hearing level. The importance of measuring overall hearing was 
observed with one participant during their 3-month follow-up test appointment and was 
recognised with other participants following their interview one year after treatment. The 
significance of measuring different types of hearing loss became evident, not only because 
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each type impacted patients in different ways, but also because each type of loss required 
different specialist intervention. 
 
7.3.3.1 Descriptors of hearing level 
 
Using the 5-frequency octave average of 0.25, 0.5,1, 2 and 4kHz of the BSA criteria (2011), 
it was found in this study that there was an increased severity in the level of hearing loss for 
participants in the speech frequencies, when comparing hearing at 3-month follow-up after 
treatment with baseline levels. The study found that there was an increase in bilateral mild 
hearing loss from 31.0% to 42.9%, an increase in bilateral moderate hearing loss from 4.8% 
to 9.5%, and an increase in the proportion of patients with bilateral hearing loss from 38.2% 
before treatment to 57.2% after treatment (Chapter 5, Table 5.5). These findings suggest 
that there was a significant rise in the proportion of patients who may benefit from aural 
rehabilitation because of the deterioration in their overall hearing within the speech hearing 
range.  
 
It was important to measure overall hearing levels within the speech frequency range of 
0.25-4kHz using the BSA criteria, as hearing deterioration used by CTCAE criteria may have 
captured deterioration in the higher 6-8kHz region only. One participant, who had coped with 
bilateral moderate hearing loss prior to treatment, developed severe loss in one ear, and at 
her 3-month follow-up hearing test decided to acquire a hearing aid. Interestingly, Zuur et al. 
(2007) mentioned that in the Netherlands, patients who had overall hearing greater than 
35dBHL between 1-4kHz were entitled to a reimbursement for hearing aids. Normal hearing 
occurs when air conduction hearing thresholds are ≤ 20dBHL (Luxon, 2014). Thresholds 
greater than 35dBHL indicate moderate hearing loss, and if the criteria used by Zuur et al. 
(2007) were applied to the current study, the number of ears amongst the participants that 
were suitable for aiding would double from 9.6% (before treatment) to 19.1% (at 3-month 
follow-up). Although 1-4kHz covers most of the speech hearing range, important information 
on speech is also conveyed in the 0.25-1kHz range (Pavlovic, 1987), which is assessed in 
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the BSA criteria on overall hearing (BSA, 2011). Consequently, it is suggested that the BSA 
criteria are suitable for reporting the description of overall hearing level, as these criteria 
assess an extensive part of the speech range, and help to identify which patients may 
benefit from hearing aiding due to a development in the severity of hearing loss following 
treatment.  
 
7.3.3.2 Lip-reading and sudden-onset hearing loss 
 
Although the need to lip-read was adopted by some of the interview participants as a 
general strategy to improve their communication, it was noted that three participants, who 
had normal hearing [according to BSA (2011) guidelines] prior to treatment, gave comments 
that showed the importance for them to lip-read after their treatment. Each participant was 
aged less than the average age for participants interviewed in this study (<60 years old), and 
after treatment, they had normal low frequency (<2kHz) hearing but bilateral mild-moderate, 
or moderate severity, mid-high frequency hearing loss, and Grade 3 hearing deterioration. 
Nund et al. (2015) mentioned that some participants in their study had learned to lip-read, 
but the authors did not make clear what was the severity of hearing loss of participants 
following treatment. Therefore, the need for lip-reading with sudden onset hearing loss to 
address mild-moderate or moderate severity hearing loss due to HNC treatment appears as 
a novel finding in the literature.  
 
Lip-reading is a common strategy used by people to assist with their communication, 
particularly with the gradual development of mild-moderate high frequency hearing loss that 
is associated with ageing, where lip-reading helps to ‘to fill in the gaps’ of speech (Action on 
Hearing loss, 2017). Some study participants with bilateral major hearing deterioration did 
not focus on the need to lip-read, possibly because they had mild hearing loss prior to 
treatment, and had already started the process of relying more on lip-reading. However, the 
three participants who needed to lip-read had normal hearing before treatment, and the 
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acute change in their overall hearing status from normal to impaired appeared to make them 
need to lip-read, whereas before they did not have to rely on this.  
 
Each of the three study participants who needed to lip-read had a >30dB loss in hearing for 
each ear, constituting a sudden-onset hearing loss (Ira, Teh and Friedland, 2014). Although 
it was not clear exactly when the hearing loss took place, it was classed as sudden, as, 
according to criteria provided by The British Academy of Audiology (2009), it was detected 
within a week of completing CRT treatment. Sudden-onset hearing loss was the focus of the 
study by Cho et al. (2016) in their investigation of HNC patients. However, direct comparison 
with the current study is difficult, as Cho et al. (2016) assessed sudden loss at a much later 
time after treatment (median time of ten years), and the authors did not mention what, if any, 
aural rehabilitation of patients (including lip-reading) was offered. Other studies in the wider 
literature on sudden-onset loss provide little evidence of lip-reading support following the 
loss, and those that do, report on profound hearing loss (Galicia-Lopez et al., 2016). Other 
articles on sudden hearing loss focus more on quality of life measures rather than measuring 
hearing loss, and do not include lip-reading as a rehabilitation tool (Chen et al., 2013; 
Härkönen et al., 2017). So, although there are articles on sudden hearing loss, few provide 
advice on the benefits of lip-reading support. Therefore, it is important to acknowledge that 
mild-moderate sudden-onset hearing loss, occurring in the early post-treatment phase after 
HNC treatment, may have a negative impact on patients such that they require lip-reading to 
assist with their communication. Again, the findings of this study need to be verified by 
conducting further studies on larger sample sizes to establish the scale of the problem, 
which may then suggest amendments in policy to support patients who suffer hearing 
deterioration with treatment. Such policy should include information being provided to 
patients prior to treatment to inform them that they may require lip-reading after treatment, 
and to have protocols to direct patients on where to receive advice and training on  
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lip-reading, which is usually provided within audiology or hearing therapy services. It will also 
be necessary to conduct further study to ascertain the benefit provided by lip-reading 
support. 
 
7.3.3.3 Types of hearing loss 
 
Sensorineural loss 
 
All the 21 participants who suffered hearing deterioration had sensorineural damage to one 
or both ears following treatment, with the majority of participants developing only SNHL as 
determined by PTA at 3-month follow-up hearing testing. In defining types of loss, normal 
hearing occurs when PTA testing produces air conduction hearing thresholds between 0.25 
and 8kHz are ≤ 20dBHL, so that all sounds of human speech can be heard at normal 
conversational level (Pavlovic, 1987). Using this definition, unsurprisingly, the majority of 
patients prior to testing had mild high frequency SNHL, as the average age of patients in the 
study was 60 years, and high frequency hearing deteriorates with ageing (Davis et al., 
2007). The increase in proportion of SNHL following treatment may be linked to ototoxicity 
by chemotherapy and by RT (Theunissen et al., 2015). All of the thirteen participants who 
were interviewed had a sensorineural element to their hearing loss at their 3-month follow-
up. Ten of these had solely SNHL, and the majority (seven) experienced adverse effects on 
their quality of life, based on findings in each theme reported in Chapter 6. As SNHL is 
usually permanent, there is already much evidence on incidence of this loss following HNC 
treatment (see Chapter 2, sections 2.5.5.1 and 2.5.5.2), however, it appears that the current 
study is the first to clarify that SNHL has an impact on patient experience. 
 
Mixed hearing loss 
 
Using PTA and tympanometry tests, it was found that there was an increase in the number 
of participants with mixed hearing loss following treatment at their 3-month follow-up, 
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probably due to radiation treatment affecting structures in the middle ear (Bhandare et al., 
2007; Jereckzek-Fossa et al., 2003). Participants in the current study at their interview 
expressed annoyance in obtaining the sensation of aural fullness (a feeling of fullness in the 
ear, or of fluid in the ear) that is associated with OME following RT (Jereczek-Fossa et al., 
2003), during this early post treatment phase. Therefore, the findings from this study suggest 
that it is important to test hearing soon after treatment to detect middle ear dysfunction, and 
to let patients know before treatment that they may experience aural fullness as a result of 
their treatment. 
 
Three of the thirteen participants interviewed had mixed hearing loss at 3-month follow-up 
hearing testing, although others gave responses that indicated they had experienced OME 
at some stage during or after treatment. For some participants, the sensation of aural 
fullness went away soon after RT treatment was completed, indicating that middle ear 
dysfunction due to OME had resolved itself. However, for others, the sensation of fullness 
either returned or persisted up to the time of their interview, one year after treatment 
completion, indicating permanence in middle ear dysfunction that required intervention.  
 
Mills and Hathorn (2016) advocated treatment of OME by tympanoplasty and insertion of 
grommets (ventilation tubes that straddle the eardrum to deal with middle ear effusion).   
However, it is not advised to insert grommets following RT as this treatment may cause 
permanent tympanic membrane perforation or ear-infection (Liang et al., 2011; Chen et al., 
2001). Therefore, an alternative method of treatment is required. One study participant 
acquired an auto-inflation balloon to ventilate his ears (following advice from a specialist 
nurse in aural care) and used a nasal decongestant (prescribed by an oncologist) to alleviate 
the discomfort he experienced. Two months after using this combined treatment, the ear 
discomfort subsided. However, there is little evidence of wider use of the auto-inflation 
balloon device in the care of HNC patients, although the device has been effective in adults 
who did not have malignancy in proximity to the middle ear (Wanscher and Svane-Knudsen, 
2014). More research into the effectiveness of using of the auto-inflation balloon would be 
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helpful for patients who have permanent middle ear dysfunction due to OME after head and 
neck treatment.  
 
The current study provided evidence on both the proportion of patients developing mixed 
hearing loss, and the negative impact of middle ear dysfunction on patient experience, but 
there is little recognition of this impact in the wider literature, which raises concern that 
patients may not receive appropriate support for dealing with middle ear dysfunction in an 
efficient manner. In Chapter 5 of this thesis, Figure 5.2 shows that of 21 patients who had a 
hearing deterioration, approximately two-thirds developed SNHL and one-third developed 
mixed hearing loss at 3-month follow-up (or 14% of n=42 participants who completed 3-
month follow-up testing). This information may be useful for planning services, as each type 
of hearing loss after treatment completion can be managed differently: hearing deterioration 
of SNHL type can be managed by audiology, but deterioration that causes a conductive or 
mixed hearing loss needs first to be managed by ENT services. 
 
Current UK HNC patient management guidelines do not mention hearing loss, let alone 
middle ear dysfunction (Palaniappan, Owadally and Evans, 2015). Although the most recent 
US guidelines do mention that hearing loss can be a side effect of treatment, these 
guidelines refer patients directly to audiology services rather than to otology specialists 
(Cohen et al., 2016), which means that middle ear problems may not be managed by ENT 
doctors to provide the necessary intervention. This lack of recognition in policy in general is 
also reflected in web-based sources that do not state that clinicians involved in HNC 
treatment can be specialists in ear-related problems (Macmillan Cancer Support, 2017). 
Although some primary articles use the involvement of otologists in confirming middle ear 
dysfunction (Wang et al., 2004), others do not (Wang et al., 2015; Kwong et al., 1996), which 
indicates a lack of consistency with the involvement of otologists in managing middle ear 
problems. Therefore, there is a clear need to develop policy for efficient communication 
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between oncology, audiology, and otology services, to ensure that otology support is readily 
available for those patients found to have middle ear dysfunction following HNC treatment. 
 
Mixed loss due to middle ear dysfunction can become permanent (Bhandare et al., 2010; Oh 
et al., 2004; Wang et al., 2015), or may transform into SNHL with time, due to the effect of 
toxic materials from chronic inflammation affecting the auditory nervous system (Wang et al., 
2003). The researcher advises that hearing testing (using PTA and tympanometry) is 
performed systematically to identify both mixed hearing loss and SNHL following treatment 
of HNC, as both types of loss may follow CRT or RT, and may have a negative impact on 
quality of life. 
 
The previous sections in this chapter have discussed the incidence and experience of 
hearing deterioration based on severity of deterioration, and different aspects of hearing 
status. The following sections discuss the significance of gender, age, and treatment 
modalities on hearing deterioration after HNC treatment. 
 
7.3.4 Gender 
 
The results from Chapter 5 showed that there was no statistical association of hearing 
deterioration by gender. These results were similar to those found in other studies on 
hearing deterioration following HNC treatment (Chan et al., 2009; Oh et al., 2004; Shorter et 
al., 2017; Wang et al., 2015). In Chapter 6, it was also noted that there was no evident 
difference in patient experience of hearing deterioration between men and women, but this 
finding may have been due to the small sample size for this study. Saunders et al. (2005), in 
a survey study of attitudes to hearing loss among 325 participants with hearing loss, found 
that although there was no difference in negative associations with hearing loss between the 
sexes, men had poorer coping strategies than women for dealing with their hearing loss. 
Such poor strategies were withdrawal and pretending to hear. A suggestion from Saunders 
et al. (2005) to offer all patients coping strategies for dealing with hearing loss regardless of 
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gender is recommended by the researcher, and although no patterns in coping with hearing 
loss based on gender were found in the current study, there were patterns based on age, 
and these are discussed within the next section. 
 
7.3.5 Age 
 
In the current study, it was discovered that there were patterns of hearing deterioration 
associated with age, in both the quantitative and qualitative data. There was a statistically 
significant difference in the age of patients who suffered hearing deterioration compared with 
those who did not, with older patients more at risk of deterioration. However, younger 
patients were more at risk of developing more severe deterioration if this took place. There is 
no consensus in the literature regarding whether increasing age is associated with incidence 
of hearing deterioration. The study findings were consistent with those of Chan et al. (2009) 
and Wang et al. (2015) in that older patients were more at risk of hearing deterioration 
following treatment for HNC, but these findings contrasted with those of other studies on age 
and hearing deterioration (Oh et al., 2004, Petsuksiri et al., 2011, and Shorter et al., 2017). It 
is not clear why there is a lack of consistency in these findings, therefore more research is 
necessary to determine if age is a factor in predicting hearing deterioration, which could lead 
to either targeting support for patients, or potentially to offer alternative treatment to minimise 
hearing deterioration which is sometimes considered for paediatric oncology patients (Brock 
et al., 2012). 
 
There is also little information available whether a patient’s age determines the severity of 
hearing deterioration, if deterioration takes place. The current study found that major 
deterioration (Grade 3 or 4 change according to the CTCAE criteria for hearing) was 
associated with patients who had a mean age of 56.3 years, whereas minor deterioration 
(CTCAE Grades 1 or 2) was associated with older patients with a mean age of 68.7 years. 
This difference in age was statistically significant (see section 7.2). This finding was in 
agreement with Zuur et al. (2007) in their study of patients treated for either oropharyngeal, 
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oral cavity or hypopharyngeal cancer, but the finding from Zuur et al. (2007) was limited to a 
small range of HNC patients in contrast to the finding from this study. However, other studies 
that assessed severity of hearing deterioration using baseline hearing comparison have not 
focussed on the association with age (Chan et al., 2009; Li et al., 2010). Therefore, from the 
findings of the current study, it is suggested that HNC patients aged 56 years or younger 
who are due to receive treatment should be warned that if they do get hearing deterioration 
from treatment, it could be severe. It will be necessary to conduct further studies to verify 
these findings concerning the risk of age on the severity of hearing deterioration, and to 
consider what age is a significant cut-off.  
 
At interview, there were differences in the experiences of younger and older participants 
following treatment for HNC, including social isolation, a sense of loss and coping 
mechanisms. These experiences, as well as the downplaying of symptoms and the use of 
assistive devices, are discussed in the following section. 
 
7.3.5.1 Social isolation 
 
Social isolation was experienced, particularly by two of the younger participants in this study 
(aged 41 and 59). The husband of one participant withdrew from one to one conversation 
because of frustration at not being heard properly and the need to repeat words. Another 
participant reduced conversation with his family members as he could no longer hear them 
clearly in telephone conversations. The finding of isolation has been reported in other 
studies within acquired deafness literature, but not in studies on cancer and hearing loss. 
Aquino-Russell (2006) used descriptive phenomenology to explore the experience of 
acquired deafness and similarly found that seven participants sensed isolation due to their 
hearing loss. However, studies that have reported hearing deterioration in other cancers 
have not explored patient experience (BrydØy et al., 2009; Needles et al., 1982; 
Rademaker-Lakhai et al., 2006). Even the study by Nund et al. (2015) on the experience of 
communication difficulties following HNC treatment did not mention feelings of isolation. 
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Although increased isolation due to difficulty in speech articulation has been reported in 
HNC survivors (Swore Fletcher et al., 2012), it appears that the current study is first to 
identify the sense of isolation due to hearing deterioration following HNC. Isolation was 
evident among these two younger participants, but the isolation may be more due to 
changes within their busy social lifestyle rather than due to their age. 
 
7.3.5.2 Sense of loss 
 
The sense of loss with hearing deterioration seemed to be associated with older participants   
in this study. There was embarrassment with having loss, or disappointment in being 
provided with a hearing aid, as this highlighted for one participant that she once had perfect 
hearing and wearing a hearing aid made her feel old. This feeling of an increase in ageing 
has been reported in a questionnaire study on hearing aid use, in which 18% of respondents 
(n=97) indicated that they felt older when wearing hearing aids (Brooks, 1994). The study by 
Brooks (1994) also reported that one third of 95 respondents felt that others associated the 
use of hearing aids with senility. A recent qualitative study on age-related hearing loss 
reported that older adults associated shame with hearing loss, and that having a hearing 
loss made them feel older and stupid (David, Zoizner and Werner, 2018). The sense of loss 
due to disfigurement has been documented in HNC literature, most recently in a systematic 
review (Lang et al., 2013), but hearing loss is not mentioned. There is little other information 
on hearing loss and dismay, or even grief, in the wider literature. Kurtzer-White and 
Luterman (2003) explored parental grief among those who had children with hearing loss, 
and concluded that more support is required for those who have chronic grief. Therefore, 
hearing deterioration (or even aiding to address hearing loss) may cause feelings of a loss in 
mental capacity, as well as feeling older, and may compound other feelings of grief 
associated with HNC.  
 
Patients could benefit in talking through feelings of isolation or loss if these are affecting 
well-being; older patients, in particular, could also be helped by discussing their attitude to 
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hearing loss. Advice and support could be provided by clinical nurse specialists in HNC who 
deal closely with patients, and have been identified as the preferred clinical profession to 
discuss feelings of anxiety or depression in cancer patients (Baker-Glenn et al., 2011). 
Further studies need to be conducted to verify the range of feelings reported from this study, 
and feasibility studies would be needed to see if intervention from clinical nurse specialists 
concerning negative feelings related to hearing loss is appropriate and provides benefit for 
patients.  
 
7.3.5.3 Downplaying of symptoms 
 
In general, participants in this study attested that their hearing difficulties did not affect them. 
At interview, the majority of participants who were aware of their hearing or tinnitus problems 
did not feel that these symptoms were major factors for them, but elements of discomfort 
and frustration at their situation were evident. Some expressed guilt in asking for things to be 
repeated, and were embarrassed at the inconvenience that this caused others. Some 
required hearing aids, and although they stated that they did not feel their hearing 
deterioration or tinnitus was a problem, responses they made and help they required 
indicated that they downplayed the significance of their symptoms.  
 
This downplaying of the symptoms of hearing deterioration and tinnitus following HNC 
treatment appears to be an emerging finding from this study, although the downplaying of 
other problems following HNC has also been reported. Ganzer et al. (2015) investigated 
difficulties in eating of ten long-term survivors of HNC using a quality of life tool that 
assessed patients’ perception of problems, as well as the severity of their symptoms. The 
tool was used together with semi-structured interview, and findings were synthesised by 
content analysis. Downplaying of symptoms was evident because, although at interview 
patients gave a favourable response about being able to eat, the severity scale and the 
other interview findings suggested that patients had difficulty in eating due to problems 
encountered with swallowing and in salivary production. Therefore, practitioners need to be 
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aware of the potential support that patients may require if they display signs of the 
downplaying of symptoms following HNC treatment. It is important to help patients realise 
the actual impact of their hearing deterioration, and advise them that support can be given to 
improve their well-being. A method for helping patients gauge the effect of their change in 
aural symptoms is by using a patient related outcome measure (PROM), and this will be 
discussed further in the section below on information and support.  
 
7.3.5.4 General coping mechanisms 
 
There were differences with how older and younger participants coped with their aural 
change. This study found that in most cases younger participants and their families and 
friends found ways of adjusting to hearing change. They adapted in many instances by their 
own efforts and initiative rather than by receiving advice provided by health professionals. 
Some of these strategies were for the patient with hearing deterioration to inform others of 
their hearing problem, and for friends and family to gain the attention of the patient with the 
hearing deterioration before beginning a conversation with them. Some of the strategies 
reported in the study are commonly used for improving communication with people who 
have hearing difficulties (Dillon, 2001), and were mentioned in Nund et al. (2015) but within 
the context of communication difficulties as a whole in that study. The survey commissioned 
by Macmillan Cancer Support (2015) on attitudes and behaviours of older patients to cancer 
suggested that older patients are not necessarily aware of services to support them, and are 
likely to be passive by allowing health clinicians to be responsible for decisions about care. 
Therefore, it is important that patients who have hearing deterioration following treatment 
have an appointment with audiology services to discuss strategies for coping with their loss, 
particularly older patients who may place more responsibility on clinicians to inform patients 
of these strategies.  
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Although both younger and older participants interviewed suffered similar functional 
difficulties with their hearing change, and even though all the younger participants had 
greater severity deterioration, they readily acknowledged their loss and actively found ways 
to overcome their difficulty, even adopting a ‘fighting’ spirit. In contrast, older participants 
were less inclined to make changes to improve their hearing ability, whether they 
experienced minor or major deterioration. In a survey comparing the attitudes of older and 
younger patients with a range of different cancers (Macmillan Cancer Support, 2015), the 
majority of older patients surveyed felt they had achieved as much as they wanted in life 
compared with less than a quarter of those of working age, suggesting that younger patients 
had more to gain with a return to healthy living. This suggestion supported the finding in the 
current study that younger participants were active in dealing with their hearing loss. 
However, Hughes, Closs and Clark (2009) performed a qualitative systematic review on the 
experiences of older patients (age range 51 to 99 years) and reported that these patients 
adapted constructively to side effects of cancer treatment. As the majority of the patients in 
their review did not have HNC, it is probable that hearing deterioration was not considered 
as a side effect requiring adaption. Furthermore, Armero (2001) discussed that denial of a 
hearing loss can often create conflict between older patients and their significant others. 
Although conflict was not reported in the current study, older participants were aware of the 
impact that their hearing deterioration had on others. Therefore, it is important for 
audiologists to meet with both younger and older patients who have measured hearing 
deterioration following HNC treatment, not only to address difficulties that are perceived by 
patients, but also to discuss with them the impact that hearing deterioration has on others, 
whether the patient recognises this or not. 
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7.3.5.5 Assistive devices 
 
Although there was no apparent difference in this study between different age groups in the 
use of devices to help deal with hearing loss following treatment, there may be different 
access to technological support, according to age.  
 
In this study, hearing aids were the most common device used to help overcome hearing 
difficulty. Three out of the 13 patients at the time of their interview had hearing aiding 
following treatment, and two more went on to be fitted with these aids. Of the 42 participants 
who completed the 3-month follow-up hearing test, nine (21%) went onto be fitted with 
hearing aids within 18 months of treatment completion. Participants who required the use of 
hearing aids had oropharyngeal, oral cavity or laryngeal cancer. For these participants, 
aiding has proved to be of use with various situations including: one to one conversations; 
group situations; and tinnitus management. Hearing aiding has also been mentioned in Zuur 
et al. (2007) who stated that 25% of participants in their study of patients with oral cancer, 
hypopharyngeal cancer or oropharyngeal cancer, received hearing aiding, although the 
authors did not state when patients received these. The results from this study indicate that 
patients with oropharyngeal, oral cavity or laryngeal cancer, within a cohort who receive 
treatment for their HNC, also may require the use of hearing aids. However, it is apparent 
that the lack of literature on hearing aiding following HNC treatment indicates that most 
literature is focussed on treatment delivery and survival, rather than on the side effect of 
hearing loss. Further studies specifically analysing HNC subtypes will help to determine 
whether certain subtypes are more at risk of hearing deterioration, and thereafter reinforce 
targeted support to be given to these groups.  
 
The attitude to possessing a hearing aid was not always positive. Some study participants 
said it was vanity that made them not want to wear their aid. In their review, Hosford-Dunn 
and Huch (2000) suggested that violation of acceptable cosmetic appearance often leads to 
the rejection of hearing aid use. In this study, there appeared to be no pattern in attitude to 
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hearing aiding with age or gender. These findings were similar to those reported in the 
literature (Brooks and Hallam, 1998). However, there may be a difference in the overall 
attitude toward the acceptance of hearing aids of those who have a sudden-onset hearing 
deterioration (such as participants in this study), compared with those with age related 
hearing loss, though further research is needed to assess the acceptability of hearing aid 
use in patients who have hearing deterioration following HNC treatment.  
 
In addition to helping overcome hearing difficulty, the use of hearing aids was useful in 
dealing with tinnitus for participants in this study. Although not offered in this study, sound 
generators could be used, but a COCHRANE review found no evidence of additional benefit 
in using sound generators over that of hearing aids for dealing with tinnitus in a randomised 
trial (Hoare et al., 2014). Although it is known that hearing aids can help to deal with tinnitus 
in general (Cabral et al., 2016; Hodgson et al., 2017), it appears that the use of hearing aids 
specifically for tinnitus management following HNC treatment is an emerging finding from 
this study. Further studies would be needed to assess the benefit of hearing aiding in 
dealing with tinnitus as a result of treatment for HNC.  
 
There were other assistive devices used by study participants to improve their hearing, 
including amplifiers or earphones for use with the television (also reported by Nund et al., 
2015), or their listening comfort such as using a doorbell that had a lower pitch sound to 
reduce hyperacusis, or to hear the doorbell, as patients had high frequency hearing loss 
after treatment. Study participants and their carers showed resourcefulness in adapting to 
hearing deterioration and tinnitus by finding these assistive devices themselves, but they 
may have obtained the devices more quickly, and received additional support for their 
hearing needs, if referral to audiology services had been systematically in place. A recent 
study showed that HNC patients used internet access the least out of all those patients 
attending otology clinics, and older patients were less likely to obtain help information than 
younger patients (Pagedar et al., 2018). Therefore, it is suggested that for patients with 
tinnitus and hearing disorder, a policy be developed that includes clear referral pathways to 
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audiology services. Such a policy should also include appropriate advice on assistive 
devices and technology for improvement in listening to speech, and how to deal with 
environmental sounds more effectively. In addition, policy needs to ensure that older 
patients in particular receive this audiological support regarding technology as they may not 
have as ready access to internet sources as younger patients in order to investigate 
healthcare options. Furthermore, older people are less likely to seek advice as readily as 
younger patients. 
 
7.3.6 Treatment regimen 
 
Incidence of hearing deterioration with the administration of chemotherapy in conjunction 
with RT was in this study statistically significant (section 7.2); it was greater than with the 
administration of RT alone. It was not possible to perform a detailed assessment of the 
differences in patient experience of those who received RT or CRT, as RT treatment only 
was used in one participant interviewed who perceived a change in hearing. The following 
discussion focusses on comparing the incidence rates reported in this study with other 
studies based on treatment regimen. It will also discuss the impact of unilateral hearing 
deterioration, assumed to be related to RT treatment of patients in this study. 
 
Twenty-six percent of participants who had curative RT alone developed a deterioration in 
their hearing, compared with 70% or those who had curative treatment by concomitant CRT. 
These findings were similar to the majority of those reported in other studies on HNC. Some 
authors have also reported in their studies that CRT induced a greater hearing deterioration 
than RT which was statistically significant (Chan et al., 2009; Shorter et al., 2017; and Wang 
et al., 2015). This finding was reported by Du et al. (2015) in their systematic review on 
clinician-rated toxicity following treatment for NPC. However, other studies did not find a 
statistically significant association between treatment type and hearing deterioration [Oh et 
al. (2004) and Petsuksiri et al. (2011)], but these studies had evident factors that could 
account for their results. The findings from Oh et al. (2004) may relate to patients in their 
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study who were prescribed large doses of RT over-riding the effect of cisplatin 
chemotherapy. The conclusions from Petsuksiri et al. (2011) may pertain to hearing 
deterioration assessed by change in one frequency only, whereas it is known that 
measurement of changes in hearing is most reliable when determined by assessment of 
multiple frequencies (Simpson, Schwan and Rintelmann, 1992; Konrad-Martin et al., 2010). 
Therefore, the current study provides information on a cohort of patients who have a range 
of HNCs receiving UK standard treatment, and the findings add more evidence to support 
the majority finding in the literature that patients who receive CRT are more likely to suffer 
hearing deterioration following HNC treatment than those who have RT. It is therefore 
suggested that risk stratification should be used to target the monitoring of hearing in those 
patients who are due to receive CRT because of their greater risk of hearing deterioration 
with treatment.  
 
The one patient interviewed who had RT alone and perceived a change in her hearing 
suffered Grade 3 hearing deterioration in one ear only, and was only made aware of the 
deterioration during discussion of test results with an audiologist during the study. This 
participant was subsequently provided with a hearing aid, and found benefit not only with 
hearing in group situations, but also in quiet when talking with her husband. It was noted that 
two other participants interviewed also developed Grade 3 toxicity in only one ear although 
they received CRT (for hypopharyngeal and tonsillar cancer respectively); one of these 
participants also acquired a hearing aid to overcome his hearing difficulties. Each of these 
three participants had hearing loss of moderate severity in the high frequencies following 
treatment. A questionnaire study on unilateral, profound severity, sudden onset hearing loss 
reported that patients with this loss had hearing handicap similar to those who had bilateral, 
age-related, acquired hearing loss of moderate severity (Iwasak et al., 2013). Although there 
are approximately ten times fewer articles on unilateral hearing loss compared with bilateral 
hearing loss, recent National Clinical Institute of Clinical Excellence (NICE) guidelines have 
indicated that unilateral deafness in adults is important to address by including single-sided 
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deafness in the assessment and management of hearing loss (NICE, 2018). Unilateral 
deafness impacts on the ability to locate sounds (Kitterick, Lucas and Smith, 2015), and this 
impact may compromise patient safety. These findings suggest that patients who have 
unilateral hearing deterioration (change in one ear only) following treatment also require 
audiological advice and support, to make them aware of difficulties they may encounter by 
acquiring one-sided deafness following RT or CRT for HNC treatment, and of the possible 
benefit of hearing aid provision.  
 
7.3.6.1 Treatment toxicity 
 
In this study, Chapter 5 recorded that all 16 participants with chemotherapy-induced hearing 
loss had cisplatin as part of their treatment. Carboplatin was used at the start of treatment 
for two patients who had moderate hearing loss prior to treatment, and cetuximab for three 
others due to other factors. These five patients did not have hearing deterioration during 
their treatment, or in the early post treatment period to 3-month follow-up. These findings 
indicate that a change of treatment from cisplatin to carboplatin or cetuximab can minimise 
hearing loss, and the wider literature provides some evidence to support this.  
 
Carboplatin has been shown to induce either transient (Steinbach et al., 2012; Williamson et 
al., 2005) or permanent ototoxicity (Ozguroglu et al., 2006; Salvinelli et al., 2003), in ovarian 
or lung cancers, but has been shown to be less ototoxic than cisplatin in a COCHRANE 
systematic review of paediatric oncology patients (van As et al., 2016), and in a general 
review article (Landier, 2016). In addition, when the targeted molecular agent cetuximab is 
used with RT for HNC, there has been no reported loss in hearing (Ye et al., 2013; Pryor et 
al., 2009). Landier (2016) further reported that the efficacy of carboplatin in treating cancer 
was equivalent to that of cisplatin, suggesting that carboplatin could be a viable alternative to 
cisplatin. However, as there is little other literature available at present to support the more 
widespread use of alternative agents, cisplatin is the main drug used in treatment of head 
neck cancer in the UK, with carboplatin only used as a substitute if there is compromised 
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renal function, or impaired hearing, and cetuximab (a monoclonal antibody) used when there 
is over-expression of the epidermal-growth factor receptor (Palaniappan, Owadally and 
Evans, 2015). Therefore, more research is required to determine the value of greater use of 
these alternative agents, and also, although not explored in this study, the possible use of 
potential otoprotective agents such as sodium thiosulphate (Zuur et al., 2007), or aspirin 
(Crabb et al., 2017). 
 
 
7.3.7 Information and support 
 
 
There was no evident difference in the way participants received information or support, 
based on characteristics of age, pre-treatment hearing level, gender, or severity of hearing 
deterioration. This following section discusses how patients received information and 
support and their experience of unexpected symptoms; it then goes on to address the 
adequacy of service provision and to suggest improvements to clinical practice. 
 
7.3.7.1 Pre-treatment information 
 
Prior to treatment, study participants were given either verbal or written information that their 
hearing may deteriorate with treatment, which would suggest that patients were adequately 
prepared for any hearing deterioration that took place. However, it appeared that participants 
were not sufficiently prepared, as some expressed surprise at the severity of the change in 
hearing that took place, others had uncertainty in the progression of their hearing change, 
and others were not sure that the noise that they were hearing was tinnitus. The lack in 
sufficient preparedness of participants acquiring a loss in hearing was possibly due to the 
shock of being diagnosed with cancer, or because the focus at diagnosis was on the 
recovery of basic life functions. Shock at diagnosis is a common feature following diagnosis, 
as will be discussed below. 
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At the time of her diagnosis, one study participant said, “All you hear is the word cancer, and 
then that is it”, meaning that the shock of being diagnosed made it difficult for her to process 
other information. Humphris and Ozakinci (2006) reported that patients with HNC are prone 
to psychological distress immediately following diagnosis and during treatment. These 
authors stated that patients felt well informed about the treatment they received, but felt less 
prepared for lifestyle changes in the early post treatment period, presumably due to the 
effect of shock. In another study, shock at being diagnosed with cancer was expressed by 
12 patients who were due to receive surgery for their HNC, with the shock causing them to 
remember only half of what they were told (Parker et al., 2014). The experience of shock is 
common in other cancer patients, and Baker et al. (2013) reported that patients who had 
received a diagnosis of breast cancer were too emotionally distressed to engage with 
professionals prior to receiving treatment. The DH document ‘Improving Outcomes: A 
strategy for cancer’ (DH, 2011, p. 9), states that ‘patients and their carers are likely to want 
to have access to reliable and balanced information about their condition, possible 
treatments and side effects’. However, shock may affect how much information patients can 
absorb when receiving a diagnosis of cancer, including that their hearing may deteriorate 
with treatment.  
 
Although participants in the study received information before treatment about hearing 
problems being a possible side-effect of treatment, many appeared not to process this 
information, not only it seemed from the shock of diagnosis, but also because other 
information appeared to take priority. One finding in this study was that participants felt that 
clinicians were concerned to get patients through treatment, and that the clinicians’ attention 
was understandably focused on necessary functions, such as swallowing and speech (Fritz, 
2001). Another finding was that participants were more worried about eating rather than 
hearing problems. As patients are required to start treatment within 31 days of diagnosis 
(NHS, 2017b), there is not much time to absorb the combined news of receiving the 
diagnosis, starting treatment, and developing side effects of treatment. It is not surprising, 
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therefore that the focus at diagnosis is on preparing patients for treatment and on dealing 
with the immediate side-effects on basic functioning.  
 
It is important that patients receive adequate written information prior to treatment for them 
to refer to about the possibility of experiencing hearing deterioration, and the progression of 
aural change if perceived, particularly if this happens during treatment. One participant 
mentioned that he was aware at diagnosis that hearing difficulties may occur with treatment, 
but indicated that he was not prepared for his hearing to be so bad. Another experienced 
temporary hearing deterioration during treatment, and expressed anxiety at the prospect of 
the hearing deterioration returning. A third, who suffered hyperacusis, expressed distress at 
the prospect of his symptoms persisting. It is known that patients who receive RT for HNC 
experience uncertainly because of the unpredictability of side effects (Wells, 1998), and 
patients with other cancers, such as lung cancer, have high levels of distress when 
experiencing unexpected symptoms (Lowe and Molassiotis, 2011). Conversely, adequate 
information received by HNC patients at the point of diagnosis contributes to positive 
recovery two to six years after the completion of treatment (de Boer et al., 1999). It is 
therefore important that written, pre-treatment documentation contains information on all 
aural symptoms that may occur during treatment. 
 
It is also important that pre-treatment documentation contains information on the different 
ways that aural changes occur, not only during, but after treatment. Study participants 
experienced aural change in different ways: for some, hearing deterioration was noticed first; 
for others, tinnitus was the initial problem; for the remainder, they experienced both tinnitus 
and hearing deterioration simultaneously. Some experienced their symptoms suddenly, 
whereas others noticed their symptoms more gradually. Some who experienced 
deterioration at the end of treatment had a restoration of their hearing during the early post-
treatment phase. Others who experienced hearing loss during or after treatment, had a 
maintained loss when they were interviewed a year later. Some participants had a reduction 
in the severity of treatment-induced tinnitus a year after treatment. From discussion with 
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patients, it became clear that anxiety, uncertainty and distress could be significantly reduced 
if written information was developed to highlight aural problems that may be experienced 
during or after treatment. One participant suggested that it would be helpful if patients 
received information in a chart format as a colour-coded grid, not only for indicating possible 
hearing changes but also other potential side-effects. In such a chart, the side effects 
following treatment could be listed in rows, and that the columns of the chart would include 
information on how severe the symptoms might be and how often they occur, and whether 
they come early or late after treatment. Although lists of side-effects are available for HNC 
(ACS, 2017), these lists do not include hearing loss, and it is not clear if there are charts that 
graphically or visually show the side-effects of HNC treatment. Such a chart could be 
adapted from one in use for breast cancer which does show the side effects of treatment 
(Breastcancer.org, 2013), although there is no indication of severity or frequency of side-
effects in that chart. Not only could such a chart be readily available to patients prior to 
treatment, but it could be available during and following treatment. In addition, it is 
suggested that consent forms include information on side-effects such as hearing 
deterioration, to ensure that clinicians discuss at this early stage the possibility of a change 
in hearing.  
 
7.3.7.2 Information during treatment 
 
It is important that hearing deterioration is detected in a methodical way during treatment, as 
currently there appears to be a lack in structure of reporting such a change. At the 
researcher’s hospital, during treatment patients meet with a radiographer or an oncologist to 
discuss a list of possible side effects that may occur during treatment. Although the list is 
comprehensive and includes questions on basic functioning such as eating and swallowing, 
aural changes are not currently listed; therefore, it was necessary for study participants to 
alert their clinician that they were experiencing aural symptoms. To ensure that the 
emphasis of reporting does not fall on patients volunteering information of hearing loss 
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during treatment, it is suggested that an item on hearing issues be included in the clinician’s 
list of side-effects during treatment.  
 
An alternative to updating or amending a clinician checklist to capture hearing deterioration 
during treatment could be the adapting of an existing clinician-rated patient outcome 
measures scale. The Vanderbilt head and neck symptom survey v 2.0 (Murphy et al., 2010) 
is one such scale, and does have an item on hearing. However, in its existing form, the 
Vanderbilt scale is limited as it is difficult to correlate hearing difficulty with each point on the 
0-10 scale. In addition, there is caution in using clinician-rated tools, as these may not fully 
reflect patient experience (Maguire et al., 2013; Falchook et al., 2016; Basch, 2010). 
Following a systematic review of the literature, Maguire et al. (2013) concluded that existing 
supportive care need (SCN) tools in breast cancer did not address patients’ symptoms 
adequately, and that collaborative work between patients with lung cancer, health 
professionals, and tool developers was required for a SCN tool to address adequately the 
needs of patients. Falchook et al. (2016) compared practitioner and patient-reported toxic 
effects on voice and speech production following CRT for HNC treatment, and found that 
there was an under-reporting of patients’ concerns by practitioners; as a consequence, the 
advice and support for patients was inadequate. Therefore, there is evidence to favour the 
addition of an item on hearing deterioration in a clinician’s checklist of side-effects during a 
mid-treatment appointment, rather than relying on a clinician-rated outcomes measure.  
 
In addition to a clinician’s checklist, it is suggested that patients should provide information 
on what side-effects they experience during treatment in a structured way. In this study, 
some patients were proactive in relating their hearing problems during treatment, although 
they had no questionnaire to prompt them to do so. Therefore, it is recommended that 
PROMs be used. A PROM is developed with the involvement of patients to reflect more fully 
their experiences and help to identify their needs, as devised for patients with 
gastrointestinal problems (Whiteing and Cox, 2010). One that has been developed for 
cancer care was sent by the DH in 2012 as a survey to approximately 5000 cancer sufferers 
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in England to assess quality of life (DH, 2012). However, this PROM does not include 
hearing problems and it was not made clear in the DH document what involvement patients 
had in creating the questions being asked. The lack of a PROM regarding hearing loss 
following cancer treatment is a concern, and, in view of the findings in the literature and from 
this study of the effects of hearing deterioration, there is a great need to develop an 
appropriate tool. The use of an appropriate PROM with hearing-related questions may help 
to identify patients earlier so that they can receive suitable audiological support. It is noted, 
however, that there is a recent ‘patients concerns inventory’ (PCI) that has been developed 
by Aintree University Hospital (2017) for HNC that includes hearing problems on the 
checklist. It is welcomed that a local service has recognised the need to include hearing 
difficulties as an item of concern in its PCI and it is suggested that there is more widespread 
use of such forms to enable patients to communicate their need for audiological support in a 
more structured way, than merely vocalising their concerns.  
 
7.3.7.3 Support after treatment 
 
Study participants had different experiences of when they had the opportunity to discuss 
their hearing deterioration. At the time of testing, some participants were informed that their 
hearing had deteriorated by the audiologist, whereas others did not have such a discussion, 
possibly because the audiologists who tested them thought the oncologist with overall 
clinical care would do so. However, it transpired that for some participants, the study 
interview one year after treatment was the first time that they had had a discussion in depth 
about their hearing problems. It is noted that poor communication has been a problem in the 
NHS, including liaison between services (Pincock, 2004) and even within MDTs. Fleissig et 
al. (2006, p. 951) stated that, ‘multidisciplinary teams [involved with cancer care] should 
improve coordination, communication, and decision making between health-care team 
members and patients, and hopefully produce more positive outcomes. The 
recommendation by Fleissig et al. (2006) is applicable to communication between services 
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and within MDTs for cancer care (if audiology, in the future, is considered part of MDTs) for 
supporting patients with aural concerns following HNC treatment. It is therefore important to 
establish between the disciplines of audiology and oncology which clinical service provides 
information on hearing deterioration, and when to provide this information, so that patients 
receive information (including what speech they may be missing as a result of developing a 
deterioration in their hearing) in a timely and systematic way. 
 
Setting up of protocols between oncology, audiology, otology (to manage middle ear 
dysfunction) and hearing therapy services (to manage tinnitus) is important for cancer 
survivors to receive timely support to address their hearing deterioration and tinnitus 
concerns, and to live well in survivorship. It is now recognised that patients need to live well 
following cancer treatment, and Simcock and Simo (2016) recommended that HNC patients 
be referred to different services, including audiology for hearing support. This approach 
embraces NHS England’s vision mentioned in the 2016 document ‘Commissioning Person 
Centred Care for People Affected by Cancer’, that aims to support people ‘not only to live 
following cancer, but to live well’ (NHS, 2016, p 3). However, this document, which is an 
advance on the NHS cancer document of 2011 (DH, 2011) still does not mention hearing 
deterioration as one of the possible side effects of cancer treatment, indicating that there has 
been no advanced thinking in UK cancer policy over five years regarding the effects of 
hearing deterioration on cancer survivors. Whilst the ACS has guidelines recommending that 
patients be referred to audiological or other appropriate services for assessment and 
treatment of hearing loss (Cohen et al., 2016), it is disappointing that these guidelines do not 
mention tinnitus problems, which shows the lack of awareness of the negative impact of 
tinnitus. The guidelines also do not suggest involvement of otologists, which again shows 
that patient experience of middle ear dysfunction, which caused irritation and annoyance for 
patients interviewed in the current study, is not fully recognised as a feature of HNC 
treatment. Therefore, there is need to develop policy documents that involve 
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multidisciplinary input to ensure that patients receive the necessary support and 
management of their aural concerns.  
 
7.4 The need for hearing monitoring 
 
This study has shown the extent to which hearing deterioration occurs after treatment of a 
UK HNC patient group in the early post-treatment phase, and the impact this deterioration 
has on the well-being of cancer survivors. In view of these findings, it is recommended that 
hearing monitoring is implemented as part of care management for this patient group, as 
currently there are no national UK guidelines published or advocated by UK audiology 
professional bodies. Hearing monitoring schemes have been advocated over many years 
(Campbell, 2006), and recently the US have provided a framework (Cohen et al., 2016) that 
could be adapted for implementation in the UK. Although this framework provides good 
advice on monitoring, it needs to be adapted for use in the UK, based on findings from this 
study. This section will continue with a discussion on when and how to monitor, who should 
be involved and what tests should be used with the monitoring process.  
 
7.4.1 When to monitor 
 
The ACS provides advice on HNC survivorship by advocating baseline hearing testing and 
monitoring of hearing for early recognition and on-treatment management of hearing 
deterioration (Cohen et al., 2016). This implies that hearing testing during treatment is 
recommended, but the Society does not state how patients are managed if a hearing change 
is found, nor does it recommend when to perform hearing testing after treatment has been 
completed.  
 
In this study it was found that, in addition to baseline hearing testing, it was appropriate to 
perform end of treatment testing and 3-month follow-up testing. Testing at these time points 
enabled clinicians to identify patients who had a sustained hearing loss after treatment, and 
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such patients could then be referred to audiology for advice regarding hearing aiding and/ or 
tinnitus support. In addition, patients who had sustained middle ear dysfunction could be 
referred to otology services to monitor this condition and provide appropriate management 
and support. It was convenient for patients to arrange tests at these time-points, as the 
patients were already in hospital for the end of treatment test, and it was possible to arrange 
the 3-month follow-up test to fit in with the patient’s scheduled review with the oncologists. 
Two study participants commented on the convenience in attending these test 
appointments, as the participants did not have to arrange another day out at hospital to 
attend them.  
 
In addition to performing hearing testing before treatment, at the end of treatment, and at 3-
month follow-up after treatment, it is suggested that testing mid-treatment may be beneficial 
for patients. Some participants mentioned that hearing testing mid-treatment might help to 
capture hearing deterioration within this period. If this were possible, it might lead to a 
change in treatment which occurred with some study participants, although participants in 
the study by Zuur et al. (2007) appeared to continue with the same regime even though 
hearing deterioration was documented during treatment. The ACS also recommended on-
treatment monitoring of hearing deterioration (Cohen et al., 2016), for early recognition and 
management of hearing deterioration. Therefore, there is merit in performing a mid-
treatment test, not only for considering a change in treatment if this were possible, but also 
for identifying patients who may require audiological support following it, even if treatment is 
prematurely stopped due to ototoxicity (Shorter et al., 2017). Again, further study is required, 
to assess the feasibility and usefulness of testing mid-treatment.  
 
It is also suggested by the researcher that a hearing test be performed after the early post 
treatment period. During interview, one year after treatment completion, some participants 
mentioned that they felt ready to discuss their hearing concerns at that time, whereas they 
did not feel ready to do so earlier while still recovering from the effects of treatment. Hearing 
loss can also develop and progress after treatment (Yilmaz et al., 2008; Li et al., 2010) and 
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loss can be maintained as a long-term side effect of treatment (Kwong et al., 1996) reported 
in studies assessing hearing deterioration up to five years post treatment. Cho et al. (2016), 
in their study of sudden-onset post treatment deafness identified much later manifestation of 
hearing loss up to ten years after treatment, although caution is required in attributing the 
cause of hearing loss so long after treatment. Some other studies (Wang et al., 2004; Ho et 
al., 1999) have advocated follow-up of hearing up to at least five years following HNC 
treatment, but it is not clear whether resources of finance, manpower and capacity should be 
allocated to this as it is not clear if clinically significant deterioration takes place in the longer 
term (Theunissen et al., 2014b). Therefore, it is suggested that an audiology appointment is 
made one year after treatment completion to enable those identified earlier with hearing 
deterioration to have the opportunity to discuss their hearing concerns, if they have not felt 
ready beforehand. It is also an opportunity to repeat hearing testing to assess if there has 
been any deterioration in hearing after the early post treatment phase.  
 
7.4.2 Who to be involved in monitoring 
 
From the findings in this study, it is suggested that audiologists need to be involved in 
monitoring hearing deterioration by performing regular hearing tests. In addition, oncologists 
and radiographers need to be aware of any hearing or tinnitus concerns when consulting 
patients in clinic appointments during or after treatment. These clinicians will be assisted to 
ask about aural symptoms by possessing a clinical check list of side-effects of treatment that 
includes hearing loss and tinnitus, and for patients to have a PROM that includes both these 
symptoms.   
 
7.4.3 How to monitor 
 
This section discusses which classification system is best to detect hearing deterioration, 
and what tests are best used based on current knowledge of hearing deterioration following 
HNC treatment. It is suggested that the CTCAE criteria (NCI, 2010) are suitable for detecting 
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hearing deterioration in the higher speech frequencies, and in addition it is suggested that 
the BSA criteria (BSA, 2011) for describing overall hearing status is used to assess the 
impact of hearing deterioration in the lower speech frequency range. 
 
There is an on-going debate as to what criteria are best for determining significant 
deterioration in hearing following treatment. In the literature review of this thesis (Chapter 2), 
it was mentioned that some studies used their own classification system to monitor changes 
in individual frequencies (for example Hsin et al., 2010, and Oh et al., 2004), but these lack 
evidence to substantiate their use. Waissbluth, Peleva and Daniel (2016) compared the 
strengths and limitations of 13 established classification systems, including those of Brock et 
al. (1991) and ASHA (1994) and concluded that each of these classifications had strengths, 
but the main weaknesses were that all were poor in detecting small adverse changes, and in 
indicating what changes would be clinically significant for communication and quality of life. 
Crundwell, Gomersall and Baguley (2016), further advocated that research is needed to 
establish the links between self-reported hearing function impairment and ototoxic 
classification systems. Whilst the current study did not use PROMs, it did provide 
information on patient experience in relation to the CTCAE classification system (NCI, 2010), 
by a measured hearing deterioration using PTA. Those who suffered a Grade 1 or greater 
severity hearing deterioration, suffered adverse hearing in the mid-high speech frequency 
range to the extent that eight participants obtained hearing aids (within 18 months of the 
completion of their treatment), indicating that the CTCAE criteria were useful in detecting 
clinically significant hearing deterioration that affected patient quality of life. Furthermore, the 
criteria are used by oncologists to assess damage to other body systems following CRT or 
RT, so that changes in hearing are readily understood by those who are overseeing cancer 
care. 
 
In addition to monitoring high frequency hearing deterioration, it is also important to monitor 
overall hearing levels following HNC treatment. One patient in this study did not suffer 
hearing deterioration as per CTCAE criteria but they required hearing aiding. Following RT, 
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their overall hearing loss developed from a bilateral moderate loss to a severe loss in one 
ear after treatment according to the BSA guidelines (BSA, 2011) on describing hearing 
levels. This patient had a change in their low frequency hearing (less than 1kHz), which was 
not measured in CTCAE change, but the change was detected in the BSA (2011) descriptor 
guidelines. It is known that patients with low-frequency hearing loss benefit from aural 
support in addressing hearing difficulties (Halpin and Thornton, 1994). It is therefore 
suggested that overall hearing be recorded, using the BSA (2011) descriptors of hearing 
levels, that enable low-frequency hearing status to be monitored with HNC treatment.  
 
7.4.4 What tests to use 
 
This section will suggest that PTA and tympanometry be used in monitoring hearing 
deterioration in HNC treatment. Hearing monitoring requires the use of PTA prior to 
treatment, and at some time after treatment, to determine a measurable change in hearing. 
Testing needs to adhere to known protocols, such as the recommendation of the BSA (BSA, 
2011). This recommendation advises on how to perform hearing testing, and advocates 
testing of the standard octave speech frequencies between 0.25 to 8kHz for air conduction, 
and 0.5 to 4kHz for bone conduction. In view of the need to test higher frequencies to detect 
ototoxicity, it is suggested by the researcher that testing of 3 and 6kHz takes place routinely 
in monitoring protocols, in addition to the usual octave frequencies tested in PTA (Konrad-
Martin et al., 2010). The use of tympanometry in this study helped to confirm middle ear 
dysfunction, and this test is advocated by other authors (Waissbluth, Peleva and Daniel, 
2016; Hsin et al., 2010; Li et al., 2010; Pan et al., 2005). Therefore, there is evidence to 
suggest that tympanometry should be used together with standard PTA (0.25-8kHz) for 
monitoring hearing in HNC treatment. 
 
This study has provided evidence to support the implementation of hearing monitoring with 
HNC treatment to identify those with a hearing deterioration. However, as there is little 
evidence currently available that recommends a change in treatment for this patient 
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population if a hearing deterioration is detected, it is suggested that hearing monitoring 
should focus on the speech frequency range (up to 8kHz). Therefore, high frequency 
audiometry, although used to demonstrate hearing deterioration in frequencies >8kHz 
following head and neck treatment (Sakamoto et al., 2000; Zuur et al., 2008; Zuur et al., 
2009), may not yet be of much clinical use for HNC patients if it does not affect treatment or 
management. In addition, there are no standard protocols for assessing high frequency 
hearing (Rieke et al., 2017), so these will need to be set-up before establishing its use. A 
similar argument is made for not yet using OAE testing (an objective test that is more 
sensitive to ototoxic change than PTA – Konrad-Martin et al., 2005) in this patient group. 
However more research is required to assess the impact of higher frequency loss (>8kHz) 
more fully, as this has not been explored in the literature. In addition, future research into the 
use of higher frequency audiometry and OAE testing is merited if alternative (less ototoxic) 
treatments become more readily available in HNC treatment. 
 
7.5 Strengths and limitations of the study 
 
The main strengths of this study were that: 
• this was the first study to utilise a mixed-methods design to obtain information on 
hearing deterioration following HNC treatment, and to provide a unique 
understanding of this phenomenon by bringing together data from the qualitative and 
quantitative phases; 
• the methodology was appropriate to answer the research aims, with new findings 
being obtained separately through qualitative and quantitative data, and by 
integrating the data, where appropriate, in this discussion;  
• it was of good methodological quality: the study met all requirements to minimise 
potential threats to the validity of the findings self-assessed against the CASP cohort 
checklist (CASP, 2017b) for the quantitative phase of the study (section 4.2.7); and 
Maxell’s 1992 criteria for the qualitative phase (see section 4.3.6); 
		 229 
• it provided findings that can be used as the basis for further research, and that has 
implications for improving service delivery for the local population. 
 
The limitations in this study were that:  
• it assessed a short phase following treatment completion: the side-effects of hearing 
deterioration only in the early phase were measured, and it could have been useful to 
assess hearing at later time-points. However, it was important to establish hearing 
deterioration in the early phase for general HNC, to capture both SNHL and mixed 
hearing loss, as most articles have focussed on later stage changes (Schultz et al., 
2010; Tsang et al., 2012), or on SNHL (Li et al., 2010; Hitchcock et al., 2009). 
Assessment of longer term hearing deterioration after treatment could be the focus of 
another study;  
• there was no HNC subtype analysis made, due to the small sample size, so it was 
not possible to identify if subtypes of this cancer were more at risk to hearing 
deterioration than others; 
• there was no use of complementary findings: it could have been possible to ask 
participants to complete patient reported outcome measures on quality of life to 
complement the findings from qualitative interviewing. However, existing head and 
neck quality of life scales either omit hearing problems [for example, the European 
Organisation for Research and Treatment of Cancer (EORTC) Quality of Life 
Questionnaire QLQ-H&N35 (Bjordal et al., 2000)], or do not adequately address 
hearing difficulties. For example, the Vanderbilt head and neck symptom survey v 2.0 
(Murphy et al., 2010), has been shown to indicate an increase in hearing problems 
from the early recovery (≤6 month) period to a year following treatment (Cooperstein 
et al., 2012), but it is difficult to correlate hearing difficulty with each point on the 0-10 
scale. However, the development of quality of life tools could be another aspect for 
future research. 
		 230 
• it recruited over a 6-month period, and data was gathered at only one tertiary centre. 
It will be necessary to verify the findings from this study by conducting future 
research at other UK centres to provide a national profile on hearing deterioration 
after HNC treatment, and to recruit over a year period to allow for any season 
variations in diagnosing the disease.  
 
7.6 Summary 
 
In conclusion, this study set out to determine the incidence and severity of hearing 
deterioration in a cohort of patients in a UK hospital with HNC following treatment. It also 
explored patient experience of hearing deterioration for this patient group. The results from 
this study were discussed with reference to the wider literature, and the synthesised findings 
are summarised below. 
 
The study found that a substantial number of participants were affected by hearing loss 
following treatment of different subtypes of HNC. It was the first study in the UK to report 
incidence and severity figures for hearing deterioration, using current treatment regimen. 
The study determined that hearing deterioration after treatment occurred in patients across a 
broad range of HNC, with 57% deterioration at the end of treatment, and 50% deterioration 
at 3-month follow-up after treatment. It is difficult to make a direct comparison of the study 
findings of incidence of hearing deterioration with the wider literature due to different 
demographics of participants and treatments used, and to different classification systems 
employed to determine deterioration in hearing. However, the current study’s findings of 
hearing deterioration after treatment supported the majority findings of studies conducted 
previously and discussed in the literature reviewed.  
 
As a result of this study, it is suggested that monitoring of hearing across all the subtypes of 
HNC be conducted, as hearing deterioration occurred in all the seven subtypes of HNC, and 
as a substantial number of participants had hearing deterioration following treatment. Further 
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research in other UK cancer centres over a longer period would build a broader national 
picture of the impact of treatment on HNC patients.    
 
In addition, this study provided information on what factors may influence hearing 
deterioration. In common with the majority findings in other HNC literature, participants in 
this study who had CRT had greater risk of hearing deterioration than with RT alone, and 
that gender did not affect hearing deterioration. This study supported other findings which 
showed that younger age was associated with greater severity of hearing deterioration and 
that older age with greater risk of experiencing hearing deterioration, although there is no 
firm evidence to support that age influences hearing deterioration with HNC treatment. Pre-
treatment hearing level did not appear to affect the incidence of hearing deterioration, but 
there were not many other studies to compare this finding with. It was noted that participants 
who had carboplatin in this study had no further deterioration in their hearing, and 
carboplatin has been found to be less ototoxic than cisplatin in the wider literature.  
 
This study also provided novel insights into the experience of hearing deterioration in 
patients with HNC following treatment, and appears to be the first to use a mixed methods 
study design. These insights emerged as this study specifically assessed patient experience 
of hearing deterioration using qualitative methods in this patient group, with patterns of 
different experience discerned drawing on characteristics obtained from quantitative data 
that determined that hearing deterioration following HNC is a heterogeneous experience. 
Further fresh insights were gained by bringing together qualitative and quantitative data 
within this chapter. This chapter discussed the following points -  
• Some participants in this study were aware of aural changes during and after 
treatment. It appears that this study is the first to document this awareness in HNC 
literature; 
• Study participants were shown to have different experiences in the progression of 
their aural symptoms when interviewed at one year follow-up; some participants had 
		 232 
improvement, yet others had further deterioration in their hearing. These mixed 
findings concur with that in the wider literature on HNC treatment with variability in 
progression determined by quantitative methods;  
• Participants with major (Grade ≥3) hearing deterioration (as per CTCAE 
classification) had more wide-reaching problems with communication and their 
pastimes compared with those who had minor deterioration. However, some of those 
with minor deterioration in their hearing required hearing aiding as their change in 
hearing had a negative impact on their communication, providing new evidence in 
the importance to offer support to patients with any measured amount of hearing 
deterioration; 
• Fatigue experienced by study participants, is common in cancer literature, and is 
known to affect hearing ability; patients with hearing loss following treatment may 
have greater difficulty with their hearing due to fatigue;  
• A novel feature of this study was to report on tinnitus sensation from a qualitative 
aspect in HNC literature. It was noted that there was a large proportion of 
participants who experienced troublesome tinnitus alongside their hearing 
deterioration, with one participant suffering hyperacusis. However, there is less 
reporting of tinnitus in the wider literature than hearing deterioration, and a lack of 
recognition of tinnitus being a side effect in national guidelines. Referral protocols to 
health services are vague for tinnitus provision, and there appears to be no standard 
procedure for patients to access help for tinnitus following HNC care; 
• This study clarified that patients with SNHL following treatment had a poorer quality 
of life, as other studies appear not to have identified patient experience with SNHL. 
In addition, middle ear dysfunction suffered within the early post treatment phase 
created negative patient experience, another novel finding from this study. However, 
it was not clear in the literature if there are standard procedures to monitor middle 
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ear problems in the early post treatment phase or those that may continue into the 
longer term; 
• Although there was no greater risk in hearing deterioration based on pre-treatment 
hearing status, it was noted that patients who had normal hearing pre-treatment put 
emphasis on the need to lip-read after treatment. These participants acquired 
bilateral mild-moderate or moderate mid-high frequency sudden-onset hearing loss, 
and as current literature has focussed on congenital severe or profound or unilateral 
loss, the study results appear a novel finding. There are no national guidelines for 
accessing lip-reading services; consequently, patients are not made aware that they 
may need to lip-read in the early post treatment phase, and there are no clear 
pathways on how patients can receive support to improve lip-reading skills;  
• There was no pattern to hearing deterioration, either due to measured change or in 
patient experience, based on gender; 
• Although younger participants suffered greater measured severity in hearing 
deterioration, they appeared to acknowledge their loss more readily and found 
solutions to deal with it.  However, older participants, more at risk of developing a 
measured deterioration, appeared less ready to acknowledge their loss. The wider 
literature shows that this reluctance can have a negative impact on the ‘significant 
other’.  
• Some participants in this study had a sense of loss and isolation. Such emotions are 
common in the experience of people who have hearing loss, or who have HNC. 
Feelings of isolation appeared to be associated with younger participants, however 
this may be an incidental finding, whereas feelings of loss were more common 
among older participants, and this is supported by findings in the wider literature;  
• Some patients received hearing aids from audiology services, but others sourced 
other assistive devices themselves rather than from health professionals. Concern 
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was raised to ensure all patients, especially older ones, access advice and support 
from audiological services; 
• Participants who had unilateral hearing deterioration following RT or chemotherapy 
also had hearing difficulties that required addressing, a finding supported by recent 
NICE guidelines; 
• There was evidence that participants played down their aural symptoms, yet these 
symptoms had a negative impact on their quality of life. It was noted that there is not 
an adequate PROM available regarding hearing deterioration for cancer in general, 
let alone for HNC, although there is a local PCI available that does include hearing 
problems;  
• Study participants had varied experience in being prepared for the possibility of 
suffering a change in their hearing. It was recognised that the shock in receiving a 
diagnosis, reported in other cancer literature, meant that some patients were not able 
to absorb all information at diagnosis, so that written information on hearing 
deterioration should be in a format that is readily understood; 
• There was varied experience among participants receiving information on their 
hearing test results, and on the process of receiving support for their hearing and 
tinnitus concerns. It was noted that poor communication within the NHS can occur 
between services in relaying information for continuing care, so there is need for 
improved communication between professionals on how hearing deterioration results 
are shared, and how help for patients can be obtained; 
• During treatment, it was realised that both hearing and tinnitus concerns were not 
part of checklists that clinicians use for identifying side effects; this meant that it fell 
to patients to let clinicians know that they were experiencing either (or both) of these 
side-effects. 
 
In view of the scale and impact of hearing deterioration encountered in this study, it is 
suggested that hearing monitoring for HNC patients is required, and for a baseline 
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assessment to be performed and be measured against testing performed at the end of 
treatment and at 3-month follow-up after treatment. Some patients were ready to receive 
hearing aid support at their 3-month follow-up, and testing appointments at these three time 
points coincided with other hospital appointments to reduce the burden on patients making 
multiple visits to attend hospital. In addition, it is suggested that a mid-treatment hearing test 
should take place, to alert clinicians to change treatment if possible and identify those 
patients who may need aural support after treatment. Also, it is advised that a 1-year post 
treatment hearing test takes place for those patients requiring more time to recover from the 
effects of treatment, and to identify those who may have further deterioration in their hearing. 
 
There are many different classification systems used to measure and grade hearing 
deterioration in people with HNC, which made meaningful comparison of incidence and 
severity rates difficult. It is suggested that the CTCAE criteria be used for identifying hearing 
deterioration, for both research and clinical practice, based on the number of studies 
(including the current study) using these specific criteria, and others that support ≥15dB 
change in hearing across multiple frequencies as clinically significant, together with BSA 
descriptors to assess overall hearing levels, based on these criteria providing 
complementary clinically useful information presented in this study.  
 
This chapter discussed the findings of this study in relation to the wider literature, and 
highlighted that tinnitus and hearing deterioration are neglected in the survivorship agenda, 
although both symptoms had a negative impact on patient experience, and were 
experienced amongst a substantial number of patients following HNC treatment. The 
following chapter will take forward these findings to suggest recommendations for research, 
for education, and for policy and for practice, in order to provide improved support and 
service for this patient group.
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Chapter 8 Conclusion 
 
 
 
8.1 Introduction 
 
 
This thesis: “A study of hearing deterioration following treatment for head and neck cancer in 
a UK hospital”, employed a mixed method approach to explore hearing deterioration 
following treatment of HNC in the UK. There were two main aims: first to assess the 
incidence and severity of hearing deterioration, and secondly to explore patient experience 
of hearing deterioration. Following recommendations for future research to create a robust 
examination of the findings in this limited study, this chapter, with reference to the wider 
literature, will show the contribution made by this study to clinical practice and potential 
policy changes to create better patient care for HNC survivors in the UK.  
 
8.2 Recommendations for future research 
 
 
8.2.1 Building on the incidence findings from this study 
 
The incidence rates of hearing deterioration after treatment of HNC found in this study were 
based on a small sample size in one UK hospital, and focussed on hearing testing up to 
three months in the early post treatment period. As it is not possible to make generalisations 
from the study findings, from a sample of this size, and make alterations in service provision 
in the longer term, it will be necessary to conduct further studies with a larger patient group 
to consider how best to manage hearing deterioration by gaining greater understanding in 
the following areas: 
• The scale of hearing deterioration in the UK: To better understand the full scale 
nationally, research needs to be carried out with a larger sample size, in other UK 
centres, and with consecutive recruitment for at least a year, to account for any 
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regional variations in the proportions of the subtypes of HNC, and for any seasonal 
variation in hearing loss due to upper respiratory tract infections; 
• Performing subtype analysis: Future studies should either provide subtype 
analysis, or focus on particular types of HNC to determine if patients with particular 
subtypes of HNC are more at risk of hearing deterioration than others; 
• The progression of hearing deterioration in the longer term: From previous 
studies in published literature, it is not clear whether hearing deterioration following 
treatment further deteriorates over time to a clinically significant amount. More 
longitudinal studies should be conducted to measure the long-term effects of hearing 
deterioration on people with HNC (one and two years after treatment);  
• Identification of risk factors: The study found that older patients and those who 
received combined chemotherapy and RT, were more at risk of hearing deterioration 
than younger patients and those who had RT only treatment respectively. However, 
where hearing deterioration did occur, younger patients were more severely affected. 
To better at facilitate the delivery of targeted supportive care, future research should 
focus on confirming the risk factors identified in this study. 
 
 
8.2.2 Verifying novel findings from this study 
 
Novel findings emerging from this study were the impact of tinnitus (including hyperacusis) 
on patients, and the impact of hearing deterioration on patients who found themselves 
suddenly depending on lip-reading even though they only had mild-moderate, mid-high 
speech frequency hearing loss. It was also found that isolation and loss were associated 
with hearing deterioration following cancer treatment. There is need to verify and expand 
upon these findings (on larger sample sizes) in the following ways: 
• Determining the impact of tinnitus: More research should be conducted to 
determine the incidence of tinnitus and hyperacusis following HNC treatment, and 
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explore patient experience to understand more fully the extent and impact of tinnitus 
and hyperacusis on this population;   
• Determining the need to lip-read: Further study is needed to determine what 
proportion of patients require lip-reading soon after they have received treatment. In 
addition, an investigation into the acceptability and use of lip-reading training for 
patients might also be valuable;  
• Further exploration of patient experience: Drawing on the experience of the 
participants in the study, feelings of loss and isolation were identified. These findings 
need to be verified with a larger sample size, to find out if the patterns of isolation 
and loss associated with younger and older patients respectively are replicated. 
Where this occurs, it may be possible to provide targeted advice and support to 
patients, before and after treatment. In addition, it is recommended that a feasibility 
study is performed on the effectiveness of clinical nurse specialists in providing 
advice and support to patients who experience isolation or loss.  
 
 
8.2.3 Assessing alternative treatments and tests 
 
In Chapter 5 it was reported that all 16 participants with chemotherapy-induced hearing 
loss had cisplatin as part of their treatment regime, but that none who had carboplatin 
only chemotherapy incurred hearing deterioration. In Chapter 7 it was suggested that 
hearing deterioration could be minimised if alternative treatment was used, and that 
patients could be identified earlier with hearing problems if they were given self-report 
forms or were tested by instruments more sensitive in detecting hearing deterioration 
than standard pure-tone audiometry. There is the potential to improve patient well-being 
in minimising hearing deterioration, or if deterioration takes place, for it to be detected 
earlier, in the following ways: 
• Using alternative treatment: In Chapter 7, it was proposed that carboplatin was a 
viable substitute for cisplatin due to it being less ototoxic than cisplatin. However, 
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there is need for more research into both the effectiveness of carboplatin in treating 
cancer, and the ototoxic effect of carboplatin, before advocating the regular use of 
carboplatin over cisplatin; 
• Using a standard PROM: PROMS are instruments used by patients to document 
different aspects of side-effects from treatment. As there currently is no PROM 
available that assesses hearing related problems following treatment, it is 
recommended that future research should focus on developing a PROM that 
includes hearing deterioration and tinnitus following HNC treatment; 
• Using an auto-inflation balloon device: The use of this device provided relief for a 
participant who had middle ear dysfunction following treatment. It is recommended 
that further studies are conducted to assess the effectiveness of this device on a 
larger number of participants;  
• Using additional tests: Once the need to monitor hearing deterioration following 
HNC treatment has been recognised (using standard PTA and tympanometry), it is 
recommended that research is conducted on the usefulness of additional tests, such 
as distortion product OAE and higher-frequency audiometry testing, for earlier 
detection of hearing deterioration; 
• Using hearing aids: Hearing aids provided relief for patients who suffered hearing 
deterioration and tinnitus following treatment. Further study on whether hearing aids 
are of benefit to or acceptable to patients would identify if there is greater uptake on 
these devices from those who have sudden-onset loss due to treatment related 
deterioration, compared with those who have age-related hearing loss.  
 
8.3 Recommendations for clinical policy and practice 
 
This study identified two main areas that required improvement in policy, practice and 
education to offer better support for patients who experience hearing deterioration (and/ or 
tinnitus) following their HNC treatment: monitoring of aural change, and information about 
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aural changes. In addition, it is recommended that targeted management should be offered 
to patients more at risk of hearing deterioration, or for those who display downplaying of 
symptoms. These areas of concern should be discussed in MDT meetings to obtain 
consensus in how to implement change, and how to create or adapt policy and protocols. 
The team should involve oncologists, ENT doctors, clinical nurse specialists in HNC, 
radiologists, and audiologists. Each speciality should understand their role in information 
sharing, monitoring and support, and offering targeted care to HNC patients who are due to 
receive treatment, and as a consequence may suffer aural change.  
 
 
8.3.1 Monitoring aural change 
 
• When to monitor: It is recommended that hearing monitoring become a standard 
procedure for assessing hearing deterioration of patients who have HNC treatment 
(Crundwell, Gomersall and Baguley, 2016; Waissbluth, Peleva and Daniel, 2017). It 
is also suggested that there should be at least five time points for monitoring hearing: 
pre-treatment; during treatment; at the end of treatment; at three months following 
the completion of treatment, and one year after treatment completion;  
• What to monitor: This study reported that all the patients who had a hearing 
deterioration either suffered sensorineural damage, which caused difficulty in hearing 
and communication. In addition, some patients who also suffered middle ear 
dysfunction (Chapter 5, Figure 5.2) were adversely affected by owning feelings of 
irritation at not being able to hear, even if this dysfunction resolved in the longer term. 
As previously discussed in this chapter, tinnitus was bothersome for the majority of 
patients who suffered hearing deterioration following their HNC treatment. Therefore, 
it is recommended that SNHL, middle ear dysfunction and tinnitus are included in an 
aural change monitoring program; 
• How to monitor: Hearing tests performed should include PTA to test speech hearing 
in the octave frequencies between 0.25 and 8kHz (for air conduction – including half 
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octave frequencies at 3 and 6kHz) and between 0.5 and 4kHz (for bone conduction) 
to identify SNHL and mixed hearing loss, and tympanometry to help identify the 
nature of middle ear disorder. In this study, it was difficult to compare incidence of 
hearing deterioration with other studies as different criteria were used for determining 
a clinically significant change. Based on the findings of this study, it is recommended 
that the CTCAE criteria are used for determining hearing deterioration, as these 
criteria involve the assessment of several frequencies (Simpson, Schwan and 
Rintelmann, 1992), and deterioration of at least 15dB was used in the majority of 
high quality articles reviewed in Chapter 2. In addition, it is recommended that overall 
hearing be recorded, using BSA (2011) descriptors of hearing levels with the 
calculation of PTA averages (including 250Hz), to enable low-frequency hearing to 
be measured and to gauge the overall level of hearing difficulty of a patient. Although 
low-frequency change may be temporary due to middle ear dysfunction, it is still 
important to be aware of this change, as patients with low-frequency hearing loss 
also benefit from aural support in addressing hearing difficulties (Halpin and 
Thornton, 1994). Tinnitus could be assessed using a self-report measure such as the 
Tinnitus Handicap Inventory;  
• Who to perform the monitoring: During treatment, oncologists and radiographers 
should ask patients if they have experienced hearing loss or tinnitus using checklists 
updated to inform of aural change, and to review PROMs provided by patients for 
confirmation. In addition, during and after treatment, audiologists can verify a change 
in hearing using hearing tests, and assess the development and impact of tinnitus, if 
experienced, by discussing the Tinnitus Handicap Inventory completed by patients. 
 
8.3.2 Information and support for patients 
 
• Pre-treatment information: From a participant interview, it was found that 
information given to patients prior to treatment could be considerably improved. It is 
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recommended that patients be alerted to the possibility of aural change, including the 
manifestation and severity of hearing loss and tinnitus, to minimise anxiety if these 
symptoms occur. For strong visual effect, this information could be presented within 
a colour-coded grid alongside other side-effects of treatment. Pre-treatment consent 
forms should also include information on possible hearing deterioration; 
• Information sharing during and after treatment: Participants during their study 
interview mentioned that they needed to proactively volunteer information of their 
hearing deterioration (or tinnitus) experienced during treatment. Therefore, it is 
recommended that the clinicians’ checklist of side effects that occur with treatment 
should be updated to include hearing deterioration and tinnitus. In addition, while 
patient self-reporting measures are available, they do not adequately cover aural 
changes with treatment. Therefore, it is recommended that a patient self-reporting 
measure is developed to include hearing deterioration and tinnitus;    
• Discussing test results: It was found that some patients received information on 
their hearing status at the time of testing with the audiologist who tested them, 
whereas others discussed their hearing concerns for the first time at interview a year 
after the completion of their treatment. Therefore, protocols need to be created or 
adapted to ensure that there is clarity and consistency on which clinical specialty 
shares test results with patients. It is recommended that audiologists should discuss 
test results with patients, and refer patients on to appropriate specialities to manage 
aural change; 
• Managing aural change: In Chapter 5 of this study, Figure 5.2 showed that 
participants experienced SNHL or middle ear dysfunction with their hearing 
deterioration; patients were also adversely affected by either minor or major hearing 
deterioration, including those who experienced deterioration in one ear only (see 
discussion in Chapter 7). Clear sign-posting is required as soon as possible to direct 
patients to receive the appropriate advice or support they require if they have a 
measured aural change on testing, or if they are found to be adversely affected by 
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their change in hearing by either clinician-rated or self-report questionnaires. It is 
recommended that those who have purely SNHL deterioration should be seen by an 
audiologist to discuss and manage the hearing loss. Audiologists can share 
strategies to improve communication, and make patients aware of the impact of 
hearing loss on patients’ families and friends, even if a measured change in hearing 
is not perceived by the patient. Audiologists can make patients aware of assistive 
devices including hearing aids and alarm systems, and also discuss with them how 
best to address their functional difficulties, as each individual patient experiences 
hearing deterioration differently (Thomas, 1988). It is therefore suggested that 
patients who have middle ear dysfunction be first seen by ENT to manage the 
dysfunction, and then by audiology to manage hearing loss caused by persistent 
dysfunction. Those patients who have tinnitus should be seen first by audiologists, if 
the tinnitus occurs with hearing deterioration that could be helped by fitting of a 
hearing aid, or if hearing aids are not suitable, patients should be referred to hearing 
therapy services for general advice on tinnitus. Patients who are struggling in their 
communication following sudden-onset hearing deterioration, with or without hearing 
aiding, may benefit from lip-reading. Therefore, patients should receive more 
information about the possible need to lip-read following treatment of their HNC. 
Appropriate support in helping patients to develop lip-reading skills should also be 
provided, by hearing therapy or an alternative service.  
 
 
8.3.3 Targeted support for patients 
 
• Using risk stratification: This study identified certain factors that were associated 
with hearing deterioration: older patients with a mean age of 68.7 years were most at 
risk of developing a hearing deterioration, although younger patents with a mean age 
of 56.3 years were at greater risk of experiencing more severe deterioration if they 
experienced a hearing change. Patients who were treated with CRT were more at 
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risk of developing hearing deterioration compared with those who had RT alone. 
Therefore, risk stratification could be used to target more frequent measurements 
and interventions to those at risk of developing severe deterioration. However, as 
discussed earlier, further research to verify at-risk groups should be conducted 
before any modifications to current practice are made; 
• For those who express symptoms of loss and isolation: Some patients 
experienced a sense of loss and social isolation following hearing deterioration after 
cancer treatment. If such feelings affect their well-being, patients could benefit by 
talking through these emotions with clinical nurse specialists in HNC. 
 
8.4 Recommendations for education of survivors and practitioners  
 
As a result of conducting this study, the researcher and colleagues in his audiology 
department have been invited to talk at local Well-being events for HNC survivors. At these 
events, audiologists have given presentations on how the ear works, and survivors or carers 
have asked questions related to hearing and tinnitus problems. Feedback from these talks 
has been positive and has shown the benefit of sharing information on the problems that 
hearing deterioration and tinnitus create. It is therefore recommended that aural symptoms 
should be part of HNC survivorship events. There is also a need to educate those involved 
in caring for HNC patients of aural changes with treatment: 
• At a multidisciplinary event: From the findings of this study, it is recommended that 
health care practitioners in the MDT, involved in the care of HNC patients, are 
educated about the incidence of hearing deterioration and tinnitus as side effects in 
the early post treatment phase of current UK treatment. All members of the team 
should also be alerted to the fact that each of these symptoms adversely affects 
patient experience. In addition, these clinicians should be made aware that different 
services (audiology, ENT and hearing therapy) ought to be involved in providing 
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patient advice and support. This education could be achieved during teaching within 
a HNC MDT research or audit meeting; 
• Through formal training: Given that cancer incidence and survivorship from 
treatment are on the increase, although ototoxicity is taught in audiology degree 
courses, it is surprising that the extent of treatment-induced hearing deterioration or 
tinnitus, and the impact of these symptoms, is not more adequately covered. 
Audiology courses should therefore give emphasis to treatment-related hearing 
deterioration and tinnitus, and to training on how best to manage these symptoms;  
• Emphasising the effect of tiredness: It is well known that patients recovering from 
cancer suffer fatigue, and that people who have hearing loss need to concentrate to 
hear effectively. Oncologists and audiologists need to be aware that tiredness 
following recovery from treatment can affect patients’ concentration, which can make 
it more difficult for patients who have hearing deterioration to hear well. Awareness 
training of oncologists and audiologists can be accomplished at scheduled team 
audit meetings. Patients who are struggling with their hearing, particularly due to 
tiredness, may benefit from sleep management support. 
 
8.5  Conclusions  
 
This study has provided new insights into the incidence and experience of hearing 
deterioration (and tinnitus) in a UK hospital, demonstrating the significance of this side-effect 
following treatment of HNC. Patients in this study reported that at the time of their cancer 
diagnosis, they had so much information to absorb, they were not fully aware that hearing 
change may occur with their treatment. They were also surprised at the severity of their 
hearing deterioration. Therefore, oncologists need to be aware that at diagnosis patients 
may not be fully alert to the possibility that they may develop hearing deterioration or tinnitus 
with treatment, and consequently oncologists should be ready at any point during the post-
treatment phase to sign-post patients to audiology services.  
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Although the NICE 2004 document ‘Improving Outcomes in head and neck cancer’ 
mentions, in the ‘After Care and Rehabilitation’ section, that hearing problems can occur 
after treatment, no detail is provided within the document of involvement with audiology 
services for addressing aural problems. The more recent NHS document on survivorship 
‘Improving Outcomes: A strategy for Cancer’ (DOH, 2011), does not even include hearing 
deterioration as a consequence of cancer treatment. This study shows that there is a 
significant gap in professional awareness of post-treatment experiences of patients which 
needs to be addressed if cancer survivorship policy is to effectively address the impact of 
hearing deterioration and tinnitus on quality of life; and the consequent need to involve 
audiology services for managing these side-effects from HNC treatment. Cancer clinicians 
should be made aware of the high incidence of hearing deterioration and tinnitus in this 
patient group. Oncologists should also actively involve audiology and otology specialists in 
creating care pathways to provide timely specialist assessment, management and support of 
patients who experience hearing deterioration or tinnitus in the early post-treatment phase.    
 
Importantly, this study has highlighted the fact that hearing deterioration and tinnitus are 
neglected side-effects following HNC treatment. Arguably, they have been overlooked for 
too long in relation to patient well-being if the absence of hearing deterioration from the NHS 
document ‘Improving Outcomes; A strategy for cancer’ can be taken as an indicator. 
 
While survivorship from head and neck cancer is improving, it is important to provide fuller 
and more effective post-treatment support to improve patients’ quality of life. This could be 
achieved by simple, cost-effective and timely interventions by audiological services in 
providing advice and support to address hearing deterioration and tinnitus. It is the 
contention of this study that all these measures would make a significant impact in improving 
these patients’ quality of life by extending and adjusting our current provisions and protocols 
to create a more holistic and patient-centred care programme that recognises and responds 
to the incidence of hearing deterioration in recovering head and neck cancer patients.
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Appendix 1.1 Staging of head and neck cancers  
 
 
 
Stage Example Description 
0 Tis, N0, M0 The cancer is only growing in the part of the head and neck 
where it started. No cancer cells are present in deeper layers of 
tissue, nearby structures, lymph nodes, or distant sites 
I T1, N0, M0 The primary cancer is 2 cm across or smaller, and no cancer 
cells are present in nearby structures, lymph nodes, or distant 
sites 
II T2, N0, M0 The cancer measures 2–4 cm across, and no cancer cells are 
present in nearby structures, lymph nodes, or distant sites 
III T3, N0, M0 
 
T1–3, N1, M0 
The cancer is larger than 4 cm across, and no cancer cells are 
present in nearby structures, lymph nodes, or distant sites or 
The cancer is any size but has not grown into nearby structures 
or distant sites. However, cancer cells are present in one lymph 
node, which is located on the same side of the head or neck as 
the primary cancer and is smaller than 3 cm across 
IVA T4a, N0/N1, 
M0 
 
 
 
 
T1–4a, N2, 
M0 
The cancer is any size and is growing into nearby structures. 
Cancer cells may not be present in the lymph nodes, or they may 
have spread to one lymph node, which is located on the same 
side of the head or neck as the primary cancer and is smaller 
than 3 cm across. Cancer has not spread to distant sites. Or  
The cancer is any size and may or may not have invaded nearby 
structures, it has not spread to distant sites, and one of the 
following is true: cancer cells are present in one lymph node, 
located on the same side of the head or neck as the primary 
cancer and measuring 3–6 cm across (N2a); cancer cells are 
present in one lymph node on the opposite side of the head or 
neck and measuring less than 6 cm across (N2b); cancer cells 
are present in 2 or more lymph nodes, all smaller than 6 cm 
across and located on either side of the head or neck (N2c) 
IVB T4b, any N, 
M0  
 
Any T, N3, 
M0 
The cancer has invaded deeper areas and/or tissues. It may or 
may not have spread to lymph nodes and has not spread to 
distant sites or 
The cancer is any size and may or may not have grown into other 
structures. It has spread to one or more lymph nodes larger than 
6 cm across, but has not spread to distant sites. 
IVC Any T, Any 
N, M1 
§ The head and neck cancer is any size and may or may not have 
spread to lymph nodes. Cancer cells have spread to distant sites 
		 248 
Appendix 2.1 Data extraction form – quantitative study 
 
 
 
Review aim: “How many adult patients who have treatment for their head and neck cancer 
have hearing loss and what is their experience?” 
 
(Quality assessment questions are italicised and underlined – CASP checklist/ qualitative 
assessment - Maxwell 1992 Qualitative checklist: Tong A, Sainsbury P, Craig J. 
Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for 
interviews and focus groups. Int J Qual Health Care 2007; 19:349–57. 
doi:10.1093/intqhc/mzm042) 
 
General information  
Date form completed: Feb 8 2018 
Name of person extracting data: Presanna Premachandra 
Title: Sensorineural hearing loss after treatment of nasopharyngeal carcinoma: a 
longitudinal analysis 
Authors: Chan, S.H., Ng, W.T., Kam, K.L., Lee, M.C.H., Choi, C.W., Yau, T.K., Lee, 
A.W.M. and Chow, S.K. 
Journal: International Journal of Radiation Oncology, Biology, Physics, 73(5), Pp. 1335–
1342. 
Date of publication: 2009 
Country of Study: Hong Kong 
 
Population and setting 
 (p) 
Definition of Head and Neck cancer: N/A  
Sub Type of cancer: NPC 1335 
Histology: Not given  
Stage of cancer: I-IV 1337 
Aetiology: Not given  
Inclusion criteria: newly diagnosed, non-metastatic NPC 1335 
Exclusion criteria: baseline threshold >55 dB was excluded, because accurate 
detection of bone conductive hearing loss at >70 dB was not feasible. 
1335-6 
Method/s of recruitment: Consecutive  1335 
Was recruitment done in an acceptable way? Recruitment period greater than a 
year. Accounting for seasonal variation. In a single hospital.  
1335 
Notes: May not reflect any regional differences/ susceptibility due to different 
aetiology/ histology 
 
 
Methods 
 (p) 
Aims of Study:  A longitudinal study was conducted to quantitatively analyse the 
effect of RT with or without chemotherapy in relation to the probability of SNHL 
development and to derive a cochlea tolerance dose in the setting of concurrent 
chemoradiotherapy. 
 1335 
Are aims clear? Yes. Identify how many are affected with SNHL following 
radiotherapy treatment, risk factors, and maximum radiation dose to the cochlea 
allowed before hearing loss occurs 
 
Design: Pre and post treatment design to assess the effect of the intervention on 
hearing 
1336 
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Methodology: Quantitative 1335 
Start date: September 2004 1335 
End date: December 2005 1335 
Duration of participation: Up to 2 ½ years 1337 
Was research design appropriate to answer research question? Yes  
Notes:   
 
Participants 
 (p) 
Total number of participants: 97 invited to participate. 87 recruited 1335 
(Or if no. of ears, can no. of participants be calculated? If so, what?): 170 ears 1337 
People per cluster: 15 Stage I and II (RT only); 72 Stage III and IV CRT 1336 
Were there baseline imbalances between groups? Yes – patients with different 
stages of cancer were given different treatments 
 
Withdrawals and exclusions: !0 patients excluded due to pre-treatment hearing 
threshold. 18 ears (equivalent 9 patients) completed testing at 2 ½ years 
1335 
Age: 23-78; Median 50 1137 
Sex: M- 112; F - 58 1137 
Co-morbidities: Not given  
Subgroups reported: N/A  
Notes: At least 4 patients had only one ear included in assessment. Difference in 
the effect of chemo could be related to the cancer stage, if a difference is noted 
between RT and CRT 
 
 
Quantitative method 
What Test was performed: 
PTA  
(p) 
1137 
Definition of hearing change: Hearing loss was divided into low- and high-
frequency types. The mean bone conductive hearing loss at 0.5, 1, and 2kHz 
was calculated, and this represented the low-frequency type. The high-frequency 
type comprised the hearing threshold at 4kHz alone. Clinically relevant, 
persistent SNHL was defined as an increase in the bone conduction threshold by 
>=15 dB (relative to the baseline reading) that persisted on at least two 
consecutive audiograms. Any two consecutive post-treatment hearing loss 
findings of >=30 dB was regarded as severe SNHL. The interval to the 
development of SNHL was defined as from the date of RT completion to the first 
consecutive reading of persistent SNHL. 
1336 
Is testing technique validated? No  
Is equipment validated/calibrated? Yes – every 6 months 1336 
Time points for testing:  
Baseline, 6, 12, 18, 24, 30 months post completion of RT 
 
Is a reason given for time points of testing? No  
Imputation of missing data: If yes – what method used. No  
Is statistical analysis used appropriate: The probability of persistent SNHL was 
estimated using the Kaplan-Meier method, and the difference was compared 
using log–rank statistics. Multivariate analysis was performed using the forward 
stepwise logistic regression model to identify the prognosticators for the 
development of persistent SNHL. The dose–response relationship was 
estimated with logistic regression analysis using the mean cochlear dose and 
concurrent cisplatin dose as covariates. Finally, the two-sided t test was used to 
compare the percentage of SNHL in the population at different cut-offs of the 
mean cochlea dose to explore the best dose-constraint value. Method for 
assessing covariables is appropriate 
1336 
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Have confounding factors   Yes – increasing age 
Been identified? 
1336 
Have confounding factors been accounted for? No - No adjustment of hearing 
loss with increasing age was made, assuming that the hearing deterioration with 
age was negligible in this relatively short study period. 
1336 
Notes: Some patients had chemotherapy after radiotherapy, so hearing loss for 
these patients (not identified) will be at different times to those who had RT 
alone. 
 
 
Risk of bias and validity 
 (p) 
Was patient assignment randomised? If so how?  No randomisation. Pt’s were 
allocated to different treatment as per protocol for the stage of cancer 
1336 
Was blinding of participants and personnel done? None mentioned  
Blinding of outcome assessment: Not mentioned  
Incomplete outcome data: No mention of attrition, of imputing missing data  
Selective outcome reporting? Not apparent  
Other bias: Not apparent  
Notes: Data given with increase in time post treatment and mean hearing 
thresholds do not account for those who dropped out who may have 
characteristics that influence hearing change (egg stage of cancer) 
 
 
Treatment Group 1  
Stage I or II cancer (p) 
Type of treatment: RT only 1136 
No. randomised to group: not randomised - 15 1136 
Description of intervention Patients with StageT1 or T2 disease received 
conventional [timing of] RT (2 Gy/daily fraction, five 
fractions weekly) 
1136 
Duration of treatment period: Not clear  
Timing: As above  
Notes: Either 3D-CRT or IMRT given. Although the numbers who received 3D-
CRT or IMRT are given, there is no breakdown of either of these treatments in 
relation to hearing test data 
 
 
Treatment Group 2 
Stage III or IV cancer (p) 
Type of treatment: Induction chemo with CRT, or RT with CRT and adjuvant 
chemo 
1136 
No. randomised to group: not randomised - 72 1136 
Description of intervention: Stage T3 or T4 disease received accelerated RT (2 
Gy/daily fraction, six fractions weekly. Stage III and IV patients were treated with 
induction chemotherapy followed by concurrent chemoradiotherapy until late 
2005. The induction chemotherapy regimen included cisplatin 100 mg/ m2 on 
Day 1 and 5-fluorouracil 
1,000 mg/m2 on Days 1–5 every 3 weeks for three cycles, followed 
by concurrent cisplatin 100 mg/ m2 with RT for two to three cycles. 
Cisplatin was replaced by carboplatin (area under the curve, for 
patients with suboptimal renal function. 
1136 
Duration of treatment period: Between 5 and 7 weeks – not clear  
Timing: As above  
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Notes: The treatment groups were brought together for calculating hearing loss 
Cochlea dose (Gy) 
Maximal dose range 36.6–73.8; Median 57.4; Mean dose range 33–71.7; 
Median 48.9 
Treatment regimen (ears): RT alone 30; Chemoradiotherapy 140 
Chemotherapy 
Concurrent cisplatin dose (mg/ m2); Median 160; Range 0–300 
No concurrent cisplatin dose (mg/m2); Median 240; Range 0–300 
 
 
Results 1 Hearing deterioration incidence/prevalence: SNHL >=15dB deterioration 
 (p) 
What were the No. of 
missing participants 
and reasons: 
Treatment Group 1 
Grouped data 
Low frequency (0.5, 1, 2kHz 
average) 
Treatment Group 2 
Grouped data 
4kHz 
1137 
Subgroup: N/A   
Time point: 6 months 16 out of 170 ears 83 out of 170 ears  
12 months 23 / 168 ears 92/ 168 ears  
18 months 17/ 152  78/ 152  
24 months 12/ 98 42/ 98  
30 months 4/ 18 9/ 18  
Results:     
Notes:  
 
Results 2 Hearing deterioration severity/grade: SNHL>=30dB deterioration  
 (p) 
What were the No. of 
missing participants 
and reasons: 
Treatment Group 1 
Grouped data 
Low frequency (0.5, 1, 2kHz 
average) 
Treatment Group 2 
Grouped data 
4kHz 
1137 
Subgroup: N/A   
Time point: 6 months 3 out of 170 ears 34 out of 170 ears  
12 months 2 / 168 ears 39/ 168 ears  
18 months 2/ 152  36/ 152  
24 months 3/ 98 17/ 98  
30 months 1/ 18 2/ 18  
Results:     
Notes:  
 
Results and risk factors 
Risk factors: 
Gender, *age, pre-treatment hearing, *treatment dose and treatment regime 
(* significant) 
The log–rank test showed that the concurrent chemoradiotherapy group had a significantly 
greater incidence of SNHL at a high frequency (55% vs. 33.3%, p = 0.02) compared with 
the RT-alone group but not at a low frequency (7.9% vs. 16.7%, p = 0.17). The median 
interval to the development of persistent SNHL (either high or low) was 12 months. 
Univariate analysis was performed to identify the potential prognosticators determining the 
development of SNHL. Gender, maximal cochlea dose, mean cochlea dose, concurrent 
cisplatin dosage, non-concurrent cisplatin dosage, and baseline 
hearing threshold were tested. The results are listed in Table 3. A correlation analysis was 
performed, and age correlated significantly with the baseline hearing threshold at 
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both high and low frequencies (correlation coefficient, 0.536 and 0.499, respectively; p < 
0.001 for both). Hence, only age was entered into the multivariate analysis. The 
concurrent cisplatin dosage (p < 0.01) and mean cochlea dose (p = 0.013) were important 
determinants of high-frequency SNHL, and age (p = 0.03) was significant in governing 
low-frequency SNHL. These factors remained statistically significant on multivariate 
analysis. Because no consensus has been reached regarding the percentage 
of hearing loss considered justifiable, we arbitrarily defined the percentage as <15% for 
severe persistent SNHL, resulting in a dose constraint of 47 Gy for patients receiving 
concurrent chemoradiotherapy. Odds ratio data is reported with confidence values given, 
but no explanation is given of what the odds ratio is comparing. 
 
Quality assessment of results 
 
RCTs and Cohort studies 
How precise are the results? Percentages are given for incidence – ok. The log–rank test 
showed that the concurrent chemoradiotherapy group had a significantly greater 
incidence of SNHL at a high frequency (55% vs. 33.3%, p = 0.02) compared with the RT-
alone group but not at a low frequency (7.9% vs. 16.7%, p = 0.17). The median 
interval to the development of persistent SNHL (either high or low) was 12 months. 
Univariate analysis was performed to identify the potential prognosticators determining the 
development of SNHL. Gender, maximal cochlea dose, mean cochlea dose, concurrent 
cisplatin dosage, non-concurrent cisplatin dosage, and baseline 
hearing threshold were tested. The results are listed in Table 3. A correlation analysis was 
performed, and age correlated significantly with the baseline hearing threshold at both 
high and low frequencies (correlation coefficient, 0.536 and 0.499, respectively; p < 0.001 
for both). Hence, only age was entered into the multivariate analysis. The concurrent 
cisplatin dosage (p < 0.01) and mean cochlea dose (p = 0.013) were important 
determinants of high-frequency SNHL, and age (p = 0.03) was significant in governing 
low-frequency SNHL. These factors remained statistically significant on multivariate 
analysis. Because no consensus has been reached regarding the percentage 
of hearing loss considered justifiable, we arbitrarily defined the percentage as <15% for 
severe persistent SNHL, resulting in a dose constraint of 47 Gy for patients receiving 
concurrent chemoradiotherapy. Odds ratio data is reported with confidence values given, 
but no explanation is given of what the odds ratio is comparing. 
Do you believe the results?  Some mis-reporting here. Table 2 mentions 83 ears out of 
170 at 6 months post RT with hearing loss (<50%), yet the text states 87 ears (>50%). 
Also, graphs shown in figure 2 show probability of SNHL loss development beyond 30 
months, yet time of testing hearing after treatment was only up to 30 months, and there is 
no explanation of why these extended times are given in the text. The reporting of some 
data is not complete, e.g. the odds ratio data for concurrent chemoradiation is not given a 
comparator.  
Can the results be applied to the local population? The % incidence values can be applied 
to a group of NPC patients who receive 3D-CRT or IMRT in a similar ratio, but as the 2 
radiotherapy techniques differ in their actual dosing of the ear, the results cannot be 
applied to one or other of these groups. The results are compelling regarding the additive 
effect of chemotherapy to radiotherapy in creating hearing loss, but stage of cancer too 
needs consideration. However, RT only for Stage I/II NPC cancer persists as the 
treatment of choice as does CRT for Stage III/IV cancer. No accounting was made of the 
effect of carboplatin for those patients who had this instead of cisplatin.  
Do the results of this study fit with other evidence? Yes, re HF loss with chemotherapy 
and radiotherapy. No accounting of increasing age, with increase in LF loss was given., 
but age was equated to (substituting) to baseline hearing level...perhaps raised LF pre-
treatment levels indeed show hearing loss that is more susceptible to change than normal 
hearing before treatment. It was stated that most hearing loss occurred after 12 months, 
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but testing was done at 6-month time periods, with persistent loss deemed to be at 2 
consecutive test periods. Earlier testing post treatment may show higher incidence of 
hearing loss, and even if this has a conductive element, reduced overall hearing will have 
an impact on patient experience. Also, some OME can persist and even preclude SNHL 
or permanent mixed HL. 
What are the implications of this study for practice? 
Notes: Results indicate that chemoradiotherapy produced statistically greater incidence 
and severity of hearing loss compared to RT alone.  A dose constraint of 47Gy was 
suggested, but this was for combined 3D-CRT/ IMRT – perhaps this dosage would be 
different for IMRT alone. 
 
Other information  
Have important 
populations been excluded 
from the study? 
Yes/No/Unclear 
No. All patients who should have been included, were.  
Does the study directly 
address the review 
question? 
Yes/No/Unclear 
Yes. It provided information on the % of patients who had 
SNHL development with RT with or without chemotherapy, 
what factors may contribute to SNHL, and a recommended 
maximum radiation dose to the cochlea 
Key conclusions of study 
authors 
Persistent high-frequency SNHL after chemoradiotherapy is 
common. The incidence and severity of high-frequency 
SNHL are significantly related to the mean cochlea radiation 
dose and the dose of concurrent cisplatin (synergistic effect). 
With the current treatment protocol, they recommend a 
mean cochlea radiation dose of <47 Gy to control the 
ototoxicity of chemoradiotherapy for NPC patients. 
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Appendix 2.2 Data extraction form – qualitative study 
 
 
 
Review aim: “How many adult patients who have treatment for their head and neck cancer 
have hearing loss and what is their experience?” 
 
(Quality assessment questions are italicised and underlined – CASP checklist/ qualitative 
assessment - Maxwell 1992; Qualitative checklist: Tong A, Sainsbury P, Craig J. 
Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for 
interviews and focus groups. Int J Qual Health Care 2007; 19:349–57. 
doi:10.1093/intqhc/mzm042) 
 
General information  
Date form completed: 1st Feb 2018 
Name of person extracting data: Presanna Premachandra 
Title: Communication Changes following non-glottic head and neck cancer management: 
The perspectives of survivors and carers 
Authors: Nund, R.L., Rumbach, A.F., Debattista, B.C., Goodrow, M.N.T., Johnson, K.A., 
Tupling, L.N., Scarinci, N.A., Cartmill, B., Ward, E.C. and Porceddu, S.V. 
Journal: International Journal of Speech-Language Pathology, 17(3), pp. 263–272. 
Date of publication: 2015 
Country of Study: Australia 
 
Population and setting 
  (P) 
Definition of Head and Neck cancer: Not stated  
Sub Type of cancer: oral cavity (4), nasopharyngeal (2), oropharyngeal (7) and 
hypopharyngeal (1) primaries  
265 
Histology: Not stated  
Stage of cancer:  
T1-2: 9 
T3-4: 5 
266 
Aetiology: HPV/smoking/alcohol intake 266 
Inclusion criteria: 
Group 1: Head and neck cancer survivors - Not clearly stated  
Group 2: Carers – Not clearly stated 
 
Exclusion criteria: 
Group 1: Head and neck cancer survivors (non-glottic) 
Participants were excluded from the study if they: (a) had received primary 
surgical management; (b) had pre-existing conditions associated with 
communication impairments (e.g. neurological conditions, moderate–severe 
cognitive impairments, degenerative conditions, hearing impairment); (c) were 
considered palliative; and/or (d) were not proficient in English.  
Group 2: Carers 
Carer participants were excluded if: (a) they had previously or were currently 
undergoing treatment for HNC; (b) had pre-existing conditions associated with 
communication impairments (e.g. neurological conditions, moderate–severe 
cognitive impairments, degenerative conditions, hearing impairment); (c) were not 
proficient in English; and/or (d) if their partner with communication changes had 
265-
266 
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been excluded for the aforementioned reasons. 
 
Method/s of recruitment: Maximum variation sampling (purposive) 265 
Was recruitment done in an acceptable way? Not clear how recruitment was done  
Notes: Not clear how participants were recruited, if all those eligible to be 
recruited were approached (and reasons for non-inclusion were not given). 
Inclusion criteria not clearly stated.  
 
 
Methods 
 (P) 
Aims of Study:  
1. to explore the views and experiences of communication changes following 
curative chemoradiotherapy for non-glottic HNC from the perspective of 
both the HNC survivor and their carer.  
2. to understand the challenges faced by both HNC survivors and carers in 
regard to communication changes and elucidate the skills needed and 
support required, to adjust to these communication changes following 
treatment  
265 
Are aims clear? Yes 265 
Design: Interview 265 
Methodology: Qualitative - phenomenology 265 
Start date: Not stated  
End date: Not stated  
Duration of participation: 20 minutes – 2 hours 266 
Was research design appropriate to answer research question? Yes  
Notes: Sampling method appears to be appropriate  
 
Participants 
 (P) 
Total number of participants: 23  265 
(Or if no. of ears, can no. of participants be calculated? If so, what?):  
People per cluster: 14 patients (Group 1) and 9 carers (Group 2) 265 
Were there baseline imbalances between groups? N/A  
Withdrawals and exclusions: Withdrawals not provided. No further exclusions 
stated from original criteria 
 
Age: 
Group 1 (patients): 43-67 years (mean 56.1; SD 7.8) 
Group 2 (carers): 45-60 years (mean 52.4; SD 5.05) 
265 
Sex: 
Group 1 (patients): 12 males; 2 females 
Group 2 (carers): 8 females; 1 male 
265 
Co-morbidities: Not stated  
Subgroups reported: Not provided  
Notes: Male dominated patient group and female dominated carer group. All 
working age or near retirement age. 
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Qualitative method checklist 
 
Interviewer/facilitator: Which author/s conducted the interview or focus 
group? Principal investigator 
266 
Credentials: What were the researcher's credentials? E.g. PhD, MD. PhD 263 
Occupation: What was their occupation at the time of the study? Not clear  
Gender Was the researcher male or female? Assumed female 263 
Experience and training What experience or training did the researcher have? Not 
clear 
 
Relationship established Was a relationship established prior to study 
commencement? Not clear 
 
Participant knowledge of the interviewer What did the participants know about the 
researcher? e.g. personal goals, reasons for doing the research Not clear 
 
Interviewer characteristics What characteristics were reported about the 
interviewer/facilitator? e.g. Bias, assumptions, reasons and interests in the 
research topic Not clear 
 
Methodological orientation and Theory What methodological orientation was 
stated to underpin the study? e.g. grounded theory, discourse analysis, 
ethnography, phenomenology, content analysis  
Phenomenology  
265 
Sampling How were participants Selected? e.g. purposive, convenience, 
consecutive, snowball Purposive (Maximum variation) 
265 
Method of approach How were participants approached? e.g. face-to-face, 
telephone, mail, email Not clear 
 
Sample size How many participants were in the study? 23 (14 patients and 9 care 
givers) 
265 
Non-participation How many people refused to participate or dropped out? 
Reasons? Not stated 
 
Setting of data collection Where was the data collected? e.g. home, clinic, 
workplace Not stated 
 
Presence of non-participants Was anyone else present besides the participants 
and researchers? Not clear 
 
Description of sample What are the important characteristics of the sample? e.g. 
demographic data, date  
Group 1: Head and neck cancer survivors (non-glottic) – April 2007 – April 2012 
All participants had self-reported changes to their communication during and/or 
following treatment.  
• curative treatment (chemoradiation) 
• gender 
• age 
• geographical residence (major city/remote) 
• months since treatment (<3 months/>3 months) 
Participants were excluded from the study if they: (a) had received primary surgical 
management; (b) had pre-existing conditions associated with communication 
impairments (e.g. neurological conditions, moderate–severe cognitive 
impairments, degenerative conditions, hearing impairment); (c) were considered 
palliative; and/or (d) were not proficient in English.  
Group 2: Carers 
265- 
266 
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Carer participants were either in a de-facto relationship or were married to an 
individual with non-glottic HNC. Carer participants were also excluded if: (a) they 
had previously or were currently undergoing treatment for HNC; (b) had pre-
existing conditions associated with communication impairments (e.g. neurological 
conditions, moderate–severe cognitive impairments, degenerative conditions, 
hearing impairment); (c) were not proficient in English; and/or (d) if their partner 
with communication changes had been excluded for the aforementioned reasons.  
Interview guide Were questions, prompts, guides provided by the authors? Was it 
pilot tested? Yes, guides were given, but not stated if pilot tested 
266 
Repeat interviews Were repeat interviews carried out? If yes, how many? Not 
stated 
 
Audio/visual recording Did the research use audio or visual recording to collect the 
data? Audio recording 
266 
Field notes Were field notes made during and/or after the interview or focus 
group? Not stated 
 
Duration What was the duration of the interviews or focus group? 20 minutes to 2 
hours 
266 
Data saturation Was data saturation discussed? No  
Transcripts returned Were transcripts returned to participants for comment and/or 
correction? Not stated 
 
Number of data coders How many data coders coded the data? More than 1 – not 
clear - perhaps all 10 co-investigators? 
266-
267 
Description of the coding tree Did authors provide a description of the coding 
tree? Yes:  
1. Open codes from participant statements were 
2. Grouped into categories 
3. Categories refined until consensus reached to created revised list 
4. Transcripts recoded using revised list of categories 
5. Themes were developed by considering relationship between categories  
266-
267 
Derivation of themes Were themes identified in advance or derived from the 
data? Derived from data 
267 
Software What software, if applicable, was used to manage the data? NVivo10 266 
Participant checking Did participants provide feedback on the findings Not stated  
Quotations presented Were participant quotations presented to illustrate the 
themes / findings? Was each quotation identified? e.g. participant number Yes and 
yes egg: 
“The biggest challenge is getting other people to adapt to your hearing. You get a 
bit offended from time to time when they won’t bother to talk to you because they 
think you can’t hear” [P012]  
267 
Data and findings consistent Was there consistency between the data presented 
and the findings? Yes, as the quotations are used within the themes in the results 
267-
270 
Clarity of major themes Were major themes clearly presented in the findings? Yes 
– 4 themes  
267-
270 
Clarity of minor themes Is there a description of diverse cases or discussion of 
minor themes? No 
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Results 4 Hearing deterioration – patient experience 
 (P) 
No. of missing 
participants and 
reasons: 
Treatment Group 1 
Not stated 
Treatment Group 2 
Not stated 
 
Theme 1: 
Impairments in 
communication 
sub-systems  
 
HNC survivors spoke often of the physical changes resulting 
from treatment which had an impact on their communicative 
abilities (Table II). Many described experiencing changes to 
their voice for months and years following treatment. In 
particular, functional loss was noted in conversational 
exchanges: “[I need] to use so much more energy to be able to 
get the voice out” [P009]. Sometimes this led to the 
communicative intent being misinterpreted as aggression: “The 
response will come back ‘stop yelling’. I’ll say, ‘I’m not yelling, I 
have to use this voice so that you can hear me’” [P009]. 
Additionally, some participants reported pitch changes, 
hoarseness, vocal fatigue, a feeling of something in the throat 
and that their voice was often worse first thing in the morning. 
For half the participants, xerostomia (dry-mouth) had a 
substantial impact on everyday communication: “The dry mouth. 
It affects every- thing. It affects your throat, it affects your 
mouth, eating, swallowing, talking ... everything, it affects 
everything” [P009]. A few participants also spoke about the 
negative impacts of chemoradiotherapy- induced hearing 
impairment following treatment: “I’ve gone partly deaf and that is 
what makes it hard. I can’t hear what’s going on. I don’t know 
what’s going on” [P016]. 
267 
Theme 2: The 
challenges of 
communicating 
in everyday life  
 
Both HNC survivors and carer participants discussed a number 
of challenges they faced regarding communicating in everyday 
life (Table III). This theme was particularly relevant for the HNC 
survivors who had experienced hearing impairment as a result 
of their treatment. The most frequently reported challenge was 
the lack of understanding from others about their 
communication changes: “The biggest challenge is getting other 
people to adapt to your hearing. You get a bit offended from 
time to time when they won’t bother to talk to you because they 
think you can’t hear” [P012]. As a result of this lack of 
understanding, this participant noted that “you feel as if you’re 
left out quite often because people get frustrated and rather 
than say something to you they don’t bother” [P012].  
Another frequent challenge, particularly for the HNC survivors 
with hearing impairment, was “the background noise, when 
that’s happening it is a lot harder for me” [P019]. Finally, both 
HNC survivors and carers faced challenges regarding support 
for communication during treatment from health professionals 
267 
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such as speech-language pathologists: “they were very good, 
but it [the sessions] was really not to do with communication, it 
was really to do with being able to swallow and what sorts of 
food I could eat. That was frustrating for me” [P009]. One of the 
carer participants summed up her experience  
 
Theme 3: Broad 
ranging effects 
of 
communication 
changes  
 
The physical changes to the communication sub- systems as a 
result of treatment, coupled with the challenges of 
communication in everyday life, resulted in broad ranging 
effects on communication interactions for both the HNC 
survivors and their carers (Table IV). The most dominant 
category was the impact of the communication changes on 
family life, particularly in regard to family relationships and roles 
and responsibilities within the family unit. One HNC survivor 
noted that: “My children tend to talk to my wife more now. I miss 
out on bits of information” [P012]. Conversely, one of the carer 
participants commented that: “He doesn’t like to read with [our 
daughter] anymore because he lisps a lot if he hasn’t got his 
teeth in properly” [C002]. These impacts were not confined to 
the family unit alone and both groups of participants commented 
on the impact of the communication changes on their social 
lives, as noted by this HNC survivor: “You might not go out as 
often as you should. It’s just much easier not to have to 
communicate” [P012]. Similarly, one of the carer participants 
stated that during treatment and in the acute recovery period 
that “it was a bit like life was on hold, we didn’t go out, we didn’t 
visit people and he preferred they didn’t visit us” [C005]. For the 
HNC survivors, the impact also extended into their work life: “I 
load trucks and I sent 20 tonnes of the wrong steel to Sydney 
because I couldn’t hear well. They [work] weren’t impressed” 
[P016].  
As a result of these impacts, both the HNC survivors and the 
carers spoke about their emotional response to the 
communication changes including frustration and 
embarrassment for HNC survivors: “With communication it’s 
mainly [the] embarrassment. I’ve been [involved] in this 
[community organisation]. I’m seriously thinking of quitting 
because of [my communication changes]” [P011] and 
frustration, concern and sadness for carers. Despite these 
broad ranging effects, some HNC survivors and carers spoke 
about how they had not let the communication changes become 
a barrier: “it doesn’t stop you from talking, it might just slow me 
down for a couple of minutes” [P008].  
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Theme 4: 
Adaptations as 
a result of 
communication 
changes  
 
The fourth theme to emerge from the interviews related to the 
comments made by both HNC survivors and carers regarding 
the necessary adaptations required to adjust and cope with the 
communication changes (Table V). To facilitate successful 
communication interactions and adapt to changes in their 
communication, the HNC survivors used a number of p such as 
ensuring they always carried a bottle of water “to be able to talk 
to people” [P009]. A couple of HNC survivors also discussed the 
use of chewing gum, artificial saliva and oral sprays to increase 
moisture in the mouth.  
In order to adapt to the changes to hearing, HNC survivors 
discussed a number of strategies including moving closer to 
their communication partner, asking them to speak louder and 
confirming the message to ensure what they heard was correct. 
Survivors who experienced voice changes improved their 
communication by performing vocal hygiene strategies such as 
drinking hot water with honey, using steam and, in the case of a 
professional voice user, ensuring she completed a proper warm 
up before performing. They also discussed other strategies 
such as avoiding communication interactions if possible, using 
non-verbal communication such as lip reading and exploring the 
use of different technologies such as earphones for the 
television and hearing aids. Carer participants reported using 
similar strategies to the HNC survivors, such as encouraging 
their partner to drink water to relieve their dry mouth, answering 
the phone for their partner so that they didn’t have to talk, 
repeating themselves to ensure their partner had received the 
correct message, pursuing Auslan classes to learn sign 
language and conducting their own research into technology 
that could assist with communication changes. Some HNC 
survivors and carers reported participating in regular sessions 
with a speech-language pathologist and dietitian. However, 
these interactions when discussed by participants were focused 
on mealtime difficulties and not the management of their 
communication changes.  
Emotional adaptation was also paramount to adjusting to the 
changes to communication for both survivors and carers. A 
number noted that “it’s just an acceptance thing” [P019] and that 
the change “is what it is ... you just deal with it” [P019]. Others 
remained hopeful that their communicative function (or their 
partner’s communicative function) would one day return to 
normal. Finally, HNC survivors and carers both discussed the 
importance of support from their family and friends, as well as 
from other HNC survivors and carers as part of their adjustment 
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to communication changes.  
 
Quality assessment of results 
 
Qualitative studies 
 (P) 
Descriptive validity: How factually accurate is the account?  Accurate: Verbatim 
quotes were used following audio recording 
266 
Interpretive validity: How well do findings represent meanings from the 
participants’ perspective? It was not clear how many interviewees were 
represented in each theme  
 
Theoretical validity How do the findings of the study support underlying theory? 
The premise of a negative impact following communication change (p264) was 
upheld with not only the patient, but also the carer (p265) 
264 
 
265 
How generalisable are the results? Not very! Not clear how representative this is of 
the HNC patient population 
 
How reproducible are the results? Very - Method for creating themes from 
categories/ quotes clearly given 
 
Has the researcher minimised their bias? This was not addressed  
Have ethical issues been taken into consideration? Yes - Consent for participation 
was stated. Ethics committee clearance stated 
266 
 
Other information  
Have important 
populations been excluded 
from the study? 
Yes/No/Unclear 
Yes, patients who have pre-existing hearing loss; they may 
have a greater impact on their loss with treatment  
Paper did not include those who had radiotherapy only, or 
those with nasal or salivary gland HNC, or consider hearing 
perspective of patient with laryngeal cancer. 
Does the study directly 
address the review 
question/ aims? 
Yes/No/Unclear 
Yes 
Key conclusions of study 
authors 
Health professionals should consider the impact of 
communication changes on the everyday lives of HNC 
survivors and their carers and provide adequate and timely 
education and management to this population. Providing 
interventions which adopt a holistic and family-centred 
approach to communication management may be most 
beneficial to achieve positive long-term outcomes for a 
whole family unit living with the effects of HNC 
management. 
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Appendix 2.3 CASP quality rating form - quantitative studies 
 
 
 
             
 
1. Did the study address a clearly 
focused issue?  Y Y N N Y Y Y C Y Y Y Y Y Y 
2. Was the cohort recruited in an 
acceptable way?  Y C C Y C C C C C C C C C C 
3. Was the exposure accurately 
measured to minimise bias? Y C C Y C Y Y Y Y Y Y Y Y Y 
4. Was the outcome accurately 
measured to minimise bias? Y N C C C C Y Y C C C C C C 
5. (a) Have the authors identified all 
important confounding factors? *  Y Y C C Y N N N Y Y C Y Y Y 
(b)   Do/ does design and/or analysis 
account for confounding factors?  Y Y Y C Y N N N N Y Y Y Y Y 
6. (a) Was the follow up of subjects 
complete enough?  C Y C Y Y C Y C Y N Y Y Y C 
(b)   Was the follow up of subjects long 
enough?  Y Y Y C Y Y Y Y Y Y Y Y Y Y 
7. What are the results of this study?                
8. How precise are the results?                
9. Do you believe the results?  C N N Y Y Y C N Y C Y Y Y Y 
10. Can the results be applied to the 
local population?  Y C N Y Y Y Y N Y Y Y Y Y C 
11. Do the results of this study fit with 
other available evidence?  Y Y C Y Y C C Y Y Y Y Y Y Y 
12. What are the practical implications                
Overall quality rating H M L H H M M L H M H H H H 
Key: Y ––yes; N - no; C - Can’t tell; * see below; H – high quality; M – medium quality; L - low quality 
*Question 5 b * Important risk factors: radiotherapy type, radiotherapy dose, chemotherapy dose, treatment regime, age, time of testing (Yes: 5-6/6; Can’t tell: 3-4; No: <3) 
Other factors: Gender, stage of cancer, aetiology, pre-treatment hearing, pre-treatment middle ear status, post-treatment middle ear status, diabetes mellitus, hypertension 
Quantitative study quality assessment scoring: Each yes response = 1. High quality: scores >7; Medium quality: scores 5-7; Low quality: scores <5  
C
ho 2016 
H
sin 2010 
C
heraghi 2015 
C
han 2009 
Lastrucci 2017 
Li 2010 
Loim
u 2015 
N
iem
ensivu 2015 
O
h 2004 
Pan 2005 
Petsuksiri 2011 
Shorter 2017 
Theunissen 2014b 
W
ang 2015 
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Appendix 2.4 CASP quality rating form – qualitative study 
 
 
 
1. Was there a clear statement of the aims of the research? 
 Y 
2. Is a qualitative methodology appropriate? 
 Y 
3. Was the research design appropriate to address the aims of the research?  
 Y 
4. Was the recruitment strategy appropriate to the aims of the research? 
 Y 
5. Was the data collected in a way that addressed the research issue?  
 Y 
6. Has the relationship between researcher and participants been adequately considered? 
 C 
7. Have ethical issues been taken into consideration? 
 Y 
8. Was the data analysis sufficiently rigorous?   
 C 
9. Is there a clear statement of findings? 
 Y 
10. How valuable is the research? 
  
              Overall quality rating H 
Key: Y – yes; N - no; C - Can’t tell; * see below; H – high quality; M – medium quality; L - low quality 
Quantitative study quality assessment scoring: Each yes response = 1. High quality: scores >7; Medium quality: scores 5-7; Low quality: scores <5  
 
 
N
und 2015 
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Appendix 2.5 UK papers excluded from review 
 
 
 
1st Author (year) Focus Why rejected 
Baker (1981) Malignant tumors of the nasopharynx Presenting symptoms of disease 
Brennan (2006) Nasopharyngeal carcinoma Presenting symptoms of disease 
Bhide (2007) Otological toxicity after postoperative 
radiotherapy for parotid tumours 
Review 
Crabb (2017) COAST (Cisplatin ototoxicity 
attenuated by aspirin trial): A phase II 
double-blind, randomised controlled 
trial to establish if aspirin reduces 
cisplatin induced hearing-loss 
Multi-cancer trial with HNC results not 
separated in analysis 
Dias (1966) Effects on the hearing of patients 
treated by irradiation in the head and 
neck area  
Review 
Dunphy (2014)  Intensity modulated radiation therapy 
(IMRT) in head and neck cancer 
Poster presentation at conference 
Evans (1988) Assessment of permanent hearing 
impairment following radical 
megavoltage radiotherapy 
Hearing loss in the irradiated ear was 
compared with the non-irradiated ear of each 
patient, therefore not using same ear as a 
baseline reference. 
Gaze (1992) Routine nasopharyngeal biopsy in 
adult secretory otitis media 
Presenting symptoms 
Gibb (2000)  The role of radiation in delayed hearing 
loss in nasopharyngeal carcinoma  
Case study 
Glazer (1980) Audiologic management of head and 
neck carcinoma patients 
Hearing aids 
Glynn (2006) Routine nasopharyngeal biopsy in 
adults presenting with isolated serous 
otitis media: is it justified? 
Presenting symptoms of disease 
Harrison (2017) Active surveillance management of 
head and neck paragangliomas: case 
series and review of the literature 
Non HNC 
Hyde (2000) Hearing loss associated with 
maxillectomy  
Using obsolete treatment (radiotherapy prior to 
2004); includes children  
Jolly (2017) A case of pulsatile tinnitus Case study 
Jones (2006) Auditory toxicity after parotid irradiation Comment on an article 
Masterson (2014) De-escalation treatment protocols for 
human papillomavirus-associated 
oropharyngeal squamous cell 
carcinoma 
Review  
Matz (1968) Nasopharyngeal cancer Presenting symptoms or disease 
McNeill (2004) Conventional behind-the-ear hearing 
aids after subtotal petrosectomy with 
blind sac closure. 
Hearing aids 
Pratt (1981) Nasopharyngeal irradiation treatment 
of hyperplastic adenoids 
Children 
Rackley (2017) Unilateral radiotherapy for surgically 
resected lateralized squamous cell 
carcinoma of the tonsil 
Pre-treatment hearing check not done  
Ross (2009) 
 
Epirubicin, Cisplatin and Protracted 
Venous Infusion 5-Fluorouracil 
Chemotherapy for Advanced Salivary 
Adenoid Cystic Carcinoma  
Survival – not addressing hearing loss. 
Sanders (2014) Sequential TPF chemotherapy 
followed by concurrent 
chemoradiotherapy in locally advanced 
head and neck cancer - a retrospective 
analysis of toxicity and outcomes 
Survival – not addressing hearing loss. 
Singh (1991) Late audiovestibular consequences of 
radical radiotherapy to the parotid 
Pre-treatment hearing tests not done 
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Symonds (1992) Late audio-vestibular consequences of 
radical radiotherapy to the parotid  
Comment on an article 
 
Thomson (2016) Indications for Salivary Gland 
Radiotherapy 
Review  
Watson (2016) Diagnosis and management of a 
tympanic membrane hemangioma 
Non HNC 
Yardley (1998)  Use of transient evoked otoacoustic 
emissions to detect and monitor 
cochlear damage caused by platinum-
containing drugs  
Patient disease type not reported 
Key: HNC – head and neck cancer 
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Appendix 4.1 Pilot study 
 
 
 
The author had conducted a pilot study to assess hearing deterioration of patients having 
head and neck cancer treatment.  A retrospective assessment was conducted of hearing 
thresholds conducted at the author’s audiology department between May and October 2013. 
A comparison was made of pre-treatment testing to post-treatment testing of head and neck 
patients. Intra-patient comparison was not performed as not all of the patients assessed had 
the pre and post treatment hearing tests. Consequently, a comparison was made of the 
hearing of grouped ear thresholds. 
Post-treatment hearing testing was performed on patients between the ranges of 2 months 
and 5 years after treatment, with the results shown below:  
 
N
um
be
r 
of
 e
ar
s 
M
ea
n 
ag
e  Frequency (kHz) 
0.25 0.5 1 2 3 4 6 8 
Pr
e-
tr
ea
tm
en
t 
86 60 M
ea
n 19.07 18.90 20.47 23.60 38.24 37.21 50.85 51.80 
SD
 17.06 17.83 17.87 19.91 23.74 24.08 28.95 28.43 
Po
st
-tr
ea
tm
en
t 
48 58 M
ea
n 21.77 20.52 21.98 27.71 45.13 50.21 65.57 65.00 
SD
 13.13 13.24 14.89 15.88 18.90 19.29 21.96 21.11 
 
It can be seen that hearing thresholds at 6 and 8kHz are most affected by this pooled ear 
comparison. The average deterioration for each of these frequencies is approximately 15dB 
and this is classed as a clinically significant difference as Grade 1 change according to 
CTCAE criteria. This data was used to determine the study sample size, for intra-patient and 
intra-group comparison.   
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Appendix 4.2 Common Terminology Criteria for Adverse Events  
    (CTCAE) v 4.03 (2010) – hearing 
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Appendix 4.3 Interview questions 
 
 
 
1: Can you tell me about your experience of hearing loss (can include deterioration) since 
being diagnosed with head and neck cancer? 
Before, during and after treatment? 
Impact on life? 
2:  What information or support did you receive to help you understand and manage your 
hearing deterioration? 
3: How do you think we can support people with hearing deterioration having had cancer 
treatment? 
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Appendix 4.4 Study approval documents 
 
Approval for the original study (Phase 1) was obtained from: 
• NRES Committee London Westminster: 08 January 2015 (Reference 14/LO/2249); 
• Faculty of Health and Medical Science Ethics Committee: University of Surrey 23 
January 2015 (Reference EC 2015 05); 
• Research and Development Department Guys and St Thomas’ NHS Foundation 
Trust: 21January 2015 (Reference RJ115/N025). 
 
Approval was based upon the following documents: 
• Evidence of Sponsor insurance or indemnity (non-NHS Sponsors only); 
• GP/consultant information sheets or letters: v1 (15 December 2014); 
• IRAS Checklist XML: [Checklist_01122014]; 
• IRAS Checklist XML: [Checklist_06012015]; 
• Supervisor CV_Roma Maguire;  
• Participant demographics: v1 (28 November 2014); 
• Checklist: v2 (06 January 2015); 
• Reply to REC: (06 January 2015); 
• Participant consent form: v1 (28 November 2014); 
• Participant consent form: v2 (18 December 2014); 
• Participant information sheet: (PIS) v1 (28 November 2014); 
• Participant information sheet: (PIS) v2 (18 December 2014); 
• REC Application Form [REC_Form_01122014]; 
• Research project protocol proposal: v1 (28 November 2014); 
• Summary CV for Chief Investigator (CI) [CV_Presanna] - (28 November 2014); 
• Summary CV for supervisor (student research) [Professor Kearney]. 
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Approval for substantial amendment (Phase 2) was obtained from: 
• NRES Committee London-Westminster: 03 May 2016 (Reference 14/LO/2249); 
• Faculty of Health and Medical Science Ethics Committee: University of Surrey 04 
May 2016; 
• Research and Development Department Guys and St Thomas’ NHS Foundation 
Trust – 21 January 2015 (Reference RJ115/N025). 
 
Documents that were granted Ethics and Research approval for Phase 2 included: 
• Interview schedules or topic guides for participants: v1 (08 April 2016); 
• Notice of Substantial Amendment (non-CTIMP): v1 (08 April 2016); 
• Email clarification: 12 April 2016; 
 
• Participant consent form: v8 (08 April 2016); 
• Participant information sheet (PIS): v9 (28 April 2016); 
• Research protocol or project proposal: v8 (08 April 2016) 
• Summary CV for supervisor (student research) [Professor Emma Ream] 
 
The study project protocol proposal included a statement that the study had been conducted 
in compliance with the Research Governance Framework for Health and Social Care, and 
the guidelines produced by Good Clinical Practice (GCP).   
 
Compliance and non-Compliance 
 
The author ensured that the trial was conducted in compliance with the principles of the 
Declaration of Helsinki (1996), and in accordance with all applicable regulatory requirements 
including but not limited to the Research Governance Framework, the Guys and St 
Thomas’s Trust Research Office policies and procedures, and any subsequent 
amendments.   
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A noted systematic lack of adherence to standard operating protocols, the study protocol, or 
the GCP by either the author or the study staff, which could have led to prolonged collection, 
deviations, breaches or suspected fraud, would constitute non-compliance.  Such non-
compliances would be identified in a variety of different ways such as monitoring visits, 
CRFs, communications and updates.  
 
In the case of any non-compliance, the sponsor maintained a log of such non-compliances 
to ascertain if there were any trends developing which needed to be investigated. The 
sponsor would assess the non-compliances and specify a time frame in which they should 
be dealt with.  Each action would be given a different time-frame dependent upon the nature 
and severity of the non-compliance. If the non-compliances were not dealt with according to 
the specifications, the sponsor and the R&D Office would agree appropriate action, including 
an on-site audit.  If compliance with recommendations following the on-site audit were not 
adhered to, the study could be invalidated. 
 
Monitoring and Audit 
 
This study was subject to audit by any method listed below. By:  
• The risk assessment process; 
• An individual investigator or department requesting an audit; 
• Being identified via an allegation of research misconduct or fraud or a suspected breach 
of regulations; 
• Being selected at random. The DH states that Trusts should audit a minimum of 10% of 
all research projects; 
• Being randomly selected for audit by an external organisation; 
• Internal audits conducted by a sponsor’s representative. 
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Appendix 5.1 Participant characteristics – tested at 3-month follow-up  
               after treatment 
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Right Left Right Left 
2 1 3 F 52 Hypopharynx IVA None CRT N N 
4 1 0 F 81 Parotid II S  RT Mild N 
5 0 1 M 59 Tongue III S A RT N N 
6 3 3 F 56 Nasopharynx III V CRT N Mild 
7 3 3 M 46 Tongue IVA None CRT Mild N 
9 0 1 M 61 Tongue IVA S A CRT N N 
11 0 3 M 51 Tonsil IVA V CRT N N 
12 0 1 M 52 Tongue IVA S A CRT Mild Mild 
17 3 3 M 59 Tongue IV S A CRT N N 
18 0 1 M 61 Tongue IVA A CRT Mild Mild 
19 1 0 M 55 Tonsil IVA S A CRT N N 
21 3 3 M 65 Tongue IIIA S A V CRT Mild N 
29 0 3 F 67 Gingiva III None RT N N 
30 1 1 M 64 Tongue IVA A CRT Mild Mild 
35 1 1 F 86 Lip III None RT Mod Mod 
37 0 1 M 73 Tonsil IVA S A V CRT Mild Mild 
40 3 3 F 52 Gingiva/Mandible IVA None CRT Mild Mild 
42 1 1 F 72 Nasal cavity II S RT Mild Mild 
49 3 1 M 62 Vallecula IVA S A V CRT Mild Mild 
51 3 3 F 55 Tonsil IVB S  CRT N N 
53 3 3 M 65 Glottis III S  CRT N Mild 
Key: Aetiology (S-smoker or ex-smoker; A- alcohol drinker (> 14 units/week); V- virus confirmed); Pre-treatment 
hearing status (N-Normal; Mod-Moderate) BSA guidelines; RT – radiotherapy; CRT - chemoradiotherapy 
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Appendix 6.1 Transcript from Interview 1 
 
 
Initial categories 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Continuous Tinnitus 
Reduced pitch 
hearing 
Combination of aural 
symptoms 
Difficulty with hearing 
TV  
Benefit of hearing 
aids for hearing 
 
Pre-treatment 
hearing ok  
Awareness of aural 
change with 
treatment 
 
In vivo codes (INT – Interviewer; P – Participant 51) 
Date: 5th–June 2016  
INT - Thank you for agreeing to participate in this study that is part 
of a doctoral thesis.  I wish to seek your views of the extent of 
impact of hearing loss following treatment for head and neck 
cancer, which currently is not known.  The interview should take 
no longer than an hour. 
INT - So first of all please can you tell me about your experience 
of hearing loss or deterioration since being diagnosed with head 
and neck cancer? 
P51 - What as in now that I have the tinnitus since I have had the 
treatment which I have never had before and my only problem is I 
have not got general deafness problems it is purely a certain pitch 
level that I cannot hear. Other people are fine and there is no 
rhyme nor reason to it, it is not deep voices, high voices, male, 
female, television is my worst problem and I do struggle with 
TV.  Once I have got my hearing aids in, in general conversation I 
am fine in a room of people, absolutely fine  
INT - How was your hearing before you started–treatment? 
P51 - Perfect absolutely spot on in fact I had a left sphenoid 
wing meningioma back in February 2014 and my hearing after 
having that removed actually increased, it became I could hear a 
pin drop So all of a sudden to now have these hearing problems 
has taken me, you know, I have really found a difference.   
INT - How did it make you feel to have a change in your hearing 
after the treatment?  
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Not bothered with 
hearing aids, or by 
hearing change 
Difficulty with 
hearing: in social 
gatherings; hearing 
TV; in cinema; in 
social gatherings 
with background 
noise (music) 
Problems still with 
hearing aids  
Hearing in context of 
cancer 
 
 
 
 
 
Sudden hearing loss  
 
Fluid in ear 
Temporary hearing 
loss 
Sudden tinnitus 
High-pitched sound 
Reduced hearing 
clarity 
Hearing in context of 
cancer 
 
 
 
Acceptance of 
hearing loss 
Tell others of a 
communication 
problem 
 
P51 - I do not mind the fact that I have to wear hearing aids, I do 
not mind the fact that there are certain people I cannot hear, main 
thing is it is the social side of things, as well as TV, it is going to 
the cinema You cannot hear some things that happen at the 
cinema but if you put the hearing aids in, obviously when you 
have got the music and that, it is really loud. It is more of the 
social side of it.  I struggle in a crowded bar or a pub or anything 
like that that has also got music that I do struggle with because 
then I cannot wear my hearing aids because everything is just 
way too loud and then if I am with a table full of people I then do 
struggle with them. But generally, I am fine with it; fine with it 
compared to some of the other problems I have been left with 
 
 
INT - Please let me know a little bit more about when you first 
noticed a change in your hearing 
P51 - It was immediately after, I had day 1 and 29 of Cisplatin and 
it was immediately after day 29 When I had the first on day one 
chemo, day two I woke up and it was like I was under water. My 
hearing was very like I had got water in my ears and I sort of was 
not shouting at people but I could not hear myself talk. Well after 
about a week that improved, it went, and my hearing went back to 
normal until I did the day 29 Cisplatin and then after that, that is 
when I was suddenly getting the high-pitched tinnitus and I did 
notice I was struggling to hear people. Because I was quite ill with 
the treatment it was not until I had finished my radiotherapy that 
then I really, and I started to feel better in myself, that I really 
realised I had a problem with hearing  
I - How has the hearing change made you feel about yourself? 
P51 - I am fine with it, I am fine with the fact that I have got a 
hearing problem I think it helps that my parents wear hearing 
aids.  My father-in-law wears hearing aids, you know so I have no, 
whenever I talk to someone that I do not know or if I am in a room 
with people I tell people that I have got a hearing problem so you 
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Not bothered with 
hearing aids 
 
 
 
 
 
 
Others have to 
repeat themselves 
Frustration by partner 
 
 
Withdrawal by 
partner from 
communication 
 
 
 
 
 
Maintained hearing 
loss 
 
 
 
know so I might going excuse me, excuse me, pardon, you know 
sort of.  I am fine with it; it has not made me self-conscious or 
anything like that and I mean I have got long hair but I wear my 
hair up and when I have got my hearing aids in and I really do not 
mind if people see them or not 
INT - How have your friends and family taken to you wearing the 
aids? 
P51 - Again with my family there is not much change because 
they are used to like my mum and dad not being able to hear and 
having to like repeat everything they say. My husband gets a bit, 
every now and again, he goes oh you know he gets quite agitated 
by it at times because I cannot hear him because I do not wear 
my hearing aids all the time. But that I think is because my 
hearing was so good before the treatment he never had to repeat 
himself and that but he is realising that’s how it is or just does not 
talk to me. 
INT - And with the treatment, the second dose of chemo, you 
noticed that things were deteriorating and treatment 
finished.  What happened to your hearing after that? 
P51 - It did not get any worse.  It stayed how it was the minute I 
had had the second lot of treatment, within the couple of days 
after that is exactly how it is now It has not. I do not think, I mean 
it might have done with the tests you did, but I do not think it has 
deteriorated any more or changed, you know within the pitches or 
anything like that. 
INT - Okay so today is the 3rd of June and can you remember 
when you finished your treatment?  
P51 - 2nd of October. 
INT - That's about 8 months now. That is from the hearing side of 
things so just to clarify from the hearing perspective you are 
noticing difficulty in what circumstances specifically?  
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Difficulty hearing: TV;  
social gatherings with 
background noise –
music and people  
 
 
Difficulty hearing in 
social gatherings 
 
 
 
 
Others speak louder 
 
 
Others need to gain 
attention 
 
 
Withdrawal from 
going to cinema 
 
 
Difficulty hearing in 
the cinema 
 
Others annoyed by 
hearing change 
Increase in TV 
volume 
Others bothered by 
hearing change 
P51 - With the TV definitely, and it is loud noisy social events. If 
there was four of us out for a meal at a table that is fine but when 
you are in a pub or anywhere with a lot of music and there is a 
group of you, because the music is then so loud I do not put the 
hearing aids in but then I cannot necessarily hear people talk 
because there is a lot of noise around you from other people.  You 
know what is the lesser of two evils?  You are either really loud 
with the music and that or you cannot hear people.  They are the 
big ones, big social gathering events. 
INT - In those circumstances what do you do?  
P51 - I do not wear the hearing aids but I tell my friends that you 
know that I have not got them in so basically, they either have to 
shout at me or, they have all been good, because they know that I 
wear them they know I have got problems that if I ignore them 
they do not take offence by it they just nudge me and go ‘I was 
talking to you.’ You know.  
INT - Has there been much change to your life as a consequence 
to the hearing change?  
P51 - No, it is silly things like I used to go to the pictures, I do not 
go to the pictures anymore because the noise because obviously 
you do not get subtitles in the cinema, and the noise is so, you 
know there is no in between with the hearing, it is either really, 
really, loud because you have got your hearing aids in or again 
there are some voices you cannot hear even though a cinema is a 
loud place, you know there is still certain pitches I cannot, it is like 
they are mumbling and I cannot hear them. Other than that, no I 
still go out, I still socialise, I still you know, see people, do things, 
no it has not changed it. I think if anything it has changed my 
husband a bit more because he does get annoyed indoors when I 
have to have the telly louder because for him that is too much for 
him and he says, ‘turn it down, it is really, really, loud I cannot 
listen to it, it is too loud’.  So, if anything, I think it has affected him 
a bit  
INT - Right.so there's been an effect on your immediate circle? 
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Others not bothered 
by hearing change 
Others have to 
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Difficulty hearing in 
environmental 
noise 
 
 
 
 
 
 
 
Difficulty hearing in 
environmental 
noise 
 
Lip-reading 
 
Unaware on need to 
lip-read 
Others need to speak 
clearer 
 
 
 
 
 
 
P51 – Yes other than that no-one else minds because as I say 
mum and dad wear hearing aids so they do not mind coming 
around to a loud telly or anything.  And as I said [my husband] 
when he has to keep repeating himself sometimes he gets a bit, 
you know, flustered by it. 
INT - Right with the repetition? 
P51 - Yes. 
INT - With your husband.  In the one to one is it any specific 
circumstance with the one to one or if you are doing a particular 
activity? 
P51 - No - I mean it is silly things like I can be in the kitchen and if 
the washing machine on, the tumble dryer, the dishwasher or 
whatever then I cannot hear him if he is in the front room and talks 
to me where I used to be able to. 
INT - so please could you just continue with what circumstances 
in the one to one that you are finding particularly difficult. 
P51 - If I am in a different room to somebody and they talk to me, 
if I have got say, I do not know, the tumble dryer or washing 
machine, anything like that, I now cannot hear them whereas I 
used to be able to.  Sometimes my husband has a habit of sitting 
with his laptop on his lap and obviously the screen is right in front 
of him so sometimes I cannot hear him.  I know it sounds silly, it is 
as though it has been blocked by the screen but literally only on 
the other settee opposite the room from him, things like that.  He 
forgets sometimes that he has to talk a bit clearer to me.  That is 
another thing, it is weird, because sometimes his voice is perfectly 
clear and other times it is not but he does not change his pitch 
greatly in how he‘s talking. 
INT - I am wondering whether in those circumstances, is he facing 
you or is he turning aside maybe? 
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Others need to face 
listener to be heard  
 
Lip-reading 
 
 
 
 
 
Continuous tinnitus  
Whistle sound 
Not bothered by 
tinnitus 
Ignore tinnitus 
Benefit of hearing 
aids for tinnitus 
Not bothered by 
tinnitus 
 
 
Sudden tinnitus  
 
 
 
 
 
 
 
Acceptance of 
hearing loss 
P51 - No he is not facing me so he is either turning to side or as I 
say he is in a different room but before I used to be able to hear it, 
it was not a problem. But it is things like that with one to one but if 
I am actually sitting like this, across a table from him I am fine with 
it, absolutely fine. 
INT – Good.  Noises - tell us about noises  
P51 - It is like a very high-pitched whistle in my head constantly 
but it does not affect my sleeping and I have sort of learnt to sort 
of ignore it during the day. It is only if I am sitting and it is silent 
and then you can that you hear it but then every now and again if I 
put my hearing aids in it goes.  So, it is like nice to have some 
peace and quiet.  It does not affect anything I do; it does not affect 
the sleeping or anything like that 
INT–- That is good - and when did the high pitch come about? 
P51 - Literally as soon as I had the second lot of chemo–on day 
29  
INT - So you have had the change, and if I am correct in 
understanding you have been able to take that on board and you 
have noticed alterations to circumstances but in terms of how it 
has made you feel about yourself, from what I understand it has 
not really made that much of an impact?  
P51 - No - it has not made me self-conscious or I am not 
embarrassed by it or anything like that.  You know how many 
people have hearing problems in this day and age?  You know it 
does not upset me, it does not embarrass me, it does not worry 
me, no, I am fine with it.  
INT - That is good.  Moving on to another question what 
information or support did you receive to help you understand and 
manage your hearing deterioration? 
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explanation clear 
Hearing in context of 
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Hearing in context of 
cancer 
 
 
Hearing test 
explanation clear 
 
 
 
 
P51 - I knew from, it is a lot to take on board, when you are first 
told that you have got cancer and this is what is going to happen 
they do briefly explain that this is possible what could happen from 
having chemo-radiotherapy so they talk about your loss of taste 
buds, saliva, the mouth ulcers, loss of hearing, they talk about it 
but to be perfectly honest with you, you do not take it in. You hear 
is the word cancer and then that is it.   And then literally you are in 
the start of the tests you know week long of tests to make sure 
you are okay for the treatment and then you are starting so you do 
not really get time to think about it because my problem for the 
hearing did not click in until day 29 so I was like 4 or 5 weeks in by 
that time and by that time I have got the saliva problems, the 
phlegm problems, the taste buds, the ulcers and I was really ill. 
So, it was not until I think I came back to you at the end of my 
treatment and then you explained to me look that this is what has 
happened, it has not got any better, these are your options. So, 
you really did not get much to start with because they were more 
concerned with giving you how you were physically going to feel 
and cope with it for 6 weeks.  
INT - So a lot to take on board? 
P51 - Absolutely.  Because you are given hundreds and hundreds 
of leaflets and pamphlets and booklets, I came out with a wad like 
that, you know, but the thing they emphasise on when you are first 
told you have got cancer, this is your treatment plan, this is what 
is going to happen, the things they really concentrate on are what 
are actually going to physically affect you whilst you are having 
your treatment.  How you are going to get through it.  What is 
going to happen.  And obviously the hearing I do not think they 
see that as a physical problem at that time.  And as I say it was 
when I came to see you at the end of my treatment and you did 
the re-test and you said this is the situation and you went through 
it all and explained it and what my options were, you know, and 
everything like that.  
INT - Yes, it is a lot to take on board.  
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Acceptance of 
hearing loss 
P51 - Yes. 
INT - When do you think it would have been helpful for you to 
have received information about the hearing?  When do you think 
you would have been ready to receive that?  
P51 - I think it was right actually how I got it to be honest with you 
because I did have such a rough time getting through the 
treatment and there are so many other physical things that affect 
you a lot more and it is not as though you have lost your hearing, 
it is just that it has deteriorated.  It has changed a bit, you know, 
you have not lost it and there are a lot worse things could have 
happened coming out of it you know.  So, believe it or not I 
actually think I am quite lucky with how I have come out the end of 
it because I was really, really ill because I ended up in hospital for 
2 weeks at the end of my treatment.  I had serious eating 
difficulties and so the hearing side of it, you know what, it is what it 
is. 
INT - It is what it is. 
P51 - That is how I have unfortunately looked at it and I think I 
have still got my hearing, I am not deaf, you know I still have my 
hearing it has just changed a bit and people have got to realise 
that.  
INT - So that was in terms of information and support.  We were 
able to, at the end of your treatment re-test your hearing and 
explain that there has been a change.  In terms of any further 
action to help you with your hearing when do you think you would 
have liked that to have happened?  So, you had the explanation of 
your change in hearing at the end of treatment, in terms of when 
were you ready to actually receive help, when would that have 
been? 
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P51 - No, I think that was right as well because I would not have 
wanted any help from you while I was having the treatment 
because quite honestly getting through the treatment is bad 
enough, it is not until you have the re-test and you start to feel a 
bit better in yourself and all the other symptoms start calming 
down that you can deal with, I know hearing is not trivial, but in 
compared to whatever else you are going through then it is quite a 
trivial one. So, you know I think that was quite right. 
INT - Okay. 
P51 - Definitely would not want to suddenly be told ‘would you like 
hearing aids’ or whatever when you get to day 29 and have the 
problem, definitely would not want them doing that then.  
INT - So from what I understand certainly at the end of 
treatment?  Any time after that? 
P51 - I do not know.  I think that depends on the person.  
INT - As for you it was though at what time?  
P51 - It was right for me but it might not be for somebody else, like 
somebody a bit older because I think you have got to be able to 
cope.  I think it is the person as well, I mean there were certain 
things that they were trying to do me and I had to put my foot 
down and say I cannot do it because I was so ill with my 
stomach PEG and everything like that and I lost 4 stone in the 
space of like about 8 or 9 weeks and I was so ill that for me I got 
to the end of my treatment, I started feeling right, I thought now 
okay this is it I have got to get myself back, fighting fit, and so that 
is when I just wanted to get it done.  I did not want to wait.  If you 
had said to me get everything else done and come back to me in 
another 3 months and then we will talk about the hearing aids, 
then we will talk, no.  I am through the treatment, that is it; I have 
beat it now I have to get myself back as I was.  But not everybody 
is like that.  
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INT - Absolutely.  What further support do you think we could offer 
to people who have experienced hearing deterioration after 
cancer treatment?  
 
P51 - You see I am quite happy with it.  I feel that I was, I knew 
from the word go I was going to have some hearing problems. 
Admittedly it was when I had the second lot of chemo treatment, 
when I actually spoke to the oncology team and explained that I 
had the hearing problem, they were very much, oh that is 
standard, that is going to happen, but do not worry you are under 
audiology.  So, they did not go into it at all then. I did not know, I 
suppose really, I thought it was going to get better like it did on 
day one when I had the first lot of chemotherapy and within a 
week or so it got better but no I as quite happy with how it was 
explained and what happened and everything like that.  
 
INT - Thank you.  I just want to go back. You said that you knew 
that the hearing might change?  Earlier you said that you were 
given a whole lot of information.  When was it that you 
remembered that ‘I knew my hearing was going to change?’  Or 
what state did you think to remember? 
P51 - When they actually said to me when I went after the second 
lot of chemo and they said to me what problems are you 
experiencing, blah, blah, blah, and I said I have got this hearing 
thing, that is when they said yes but your hearing will change, that 
is how it is, and then all of a sudden you remember when you had 
your first lot of chemo, oh yes it did change but then you assume, 
or I assumed oh perhaps it will go back like it did before so I will 
be okay.  I did not realise it was going to be as definite as it 
was.  But it is not that bad, I know that is a bit of a contradiction in 
what I am saying really, the fact that I did not know it was going to 
be permanent but you know what, I am ok with it. 
INT - You have been quite accepting in other words? 
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P51 - Yes, you know I think you have to look at it, that it is cancer, 
it could have ended a lot differently.  So, to have a minor hearing 
problem to me is nothing in comparison to other situations. 
INT - Surely. Who was it that you spoke with when you noticed 
after day 29, which were the specialists?  Which were the 
specialities? 
P51 - You see on a Wednesday in outpatient oncology, you see 
one of the chief radiographers, I cannot remember her name but 
you actually see her and she is the one that prescribes your 
medicines and she is the one that goes through you know like 
what other problems you have got and she give you a list of 
medication and that is when I said to her about it.   
INT - So it was not actually with one of the oncologists it 
was actually with one of the paramedical staff.  
P51 - Yes, because every Wednesday you see them, you only 
see the oncologist every, I cannot remember, it is not very 
Wednesday you see the oncologist but you do see this, what as 
her name, I do not know she is one of the chief radiographers, 
and you see her every Wednesday and she goes through 
everything with you.  Like your eating, your symptoms, your 
illnesses, your sickness, everything like that.  
INT - And that list is a pretty comprehensive list? 
P51 - Yes. 
INT - Within that is there a specific one on hearing or …? 
P51 - No 
INT - There is not.  So just a comprehensive list and do you have 
anything else? 
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During treatment, no 
discussion of aural 
problems prompted 
by clinician 
 
P51 - Yes.  At no point throughout it do they ask you how your 
hearing is.  They just say to you any other things and I just 
happened to mention about the hearing.  But they never actually 
say have you noticed any hearing problems, difficulty, noises, 
tinnitus, anything like that.  Never do they mention that.  
INT - Okay.  Well here is an opportunity for us to try to perhaps 
change this.  Do you have any other questions about your hear–
ng at all? 
P51 - No, I mean I am, as I say now that you have tweaked to 
give me a second programme for telly and that I think I am going 
to go and try that and hopefully that is good but I did not realise 
that I could have a second programme put in, I thought that was 
how the hearing aids were.  I must admit.  I did not realise you 
could have like a second programme. 
INT - Right so just to clarify for the purposes of the interview.  We 
have provided hearing aids after your 3-month check, yes and 
how has that experience been for you? 
P51 - Fine, I mean the nice thing, the one thing I will say that was 
really nice was the fact that you have always accommodated me 
as in whenever I have had to come you have always said right let 
us know when you are in here already and we will fit you in on that 
day.  You know what, that is really helpful, really nice because 
when you feel so ill, so rough and you have to come up by train 
and that and you are the one department that does that which is 
really nice, I must say that.  
INT - Thank you.  In terms of the hearing aids, what problems had 
you after treatment that have been improved with the hearing aids 
and which situations are still a problem for you?  Shall I re-phrase 
that?  
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Problems still with 
hearing aids 
 
 
Benefit of hearing 
aids for hearing  
 
P51 -–Yes sorry.  
INT - You are having difficulties with some one-to-one 
circumstances, cinema, TV so which of the situations has been 
improved with hearing aiding and which situations are still a bit 
problematic for you? 
P51 - The ones that have improved are definitely one-to-one 
because even before I had the hearing aids there are some 
people that, you know, silent room one to one I still have trouble 
hearing them because of the pitch of the voice.  With the hearing 
aids, I do not have that problem at all now.  Concerns still are with 
the telly which hopefully the second programme will now rectify 
but it is when you are in a crowded, noisy environment and you 
have to take the hearing aids out and then you struggle with 
anybody that even if they are sitting opposite you, I struggle with 
that.  They are the ones I struggle with, but general day to day has 
improved greatly with the hearing aids. 
INT - That is very good to hear, very good to hear.  Okay I think 
we have finished now, thank you very much participating in the 
interview. 
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Appendix 6.2 Themes, subthemes and initial categories  
 
 
 
# - Interview number; P – Participant number 
 
 
 
Theme 1 – Sensation of impairment 
 
 
Subtheme –  Hearing Change 
 
Reduced pitch hearing #1/P51, #2/P11, #6/P53, #11/P7, #13/P7 
 
General deafness #5/P12, #13/P17 
 
Dull ear sensation #11/P7 
 
No change from pre-treatment hearing #3/P5, #4/P9, #10/P42 
 
Sensation of wax #3/P5 
 
Blocked ear #2/P11 
 
Pressure in ear #2/P11 
 
Fluid in ear #1/P51, #11/P7 
 
Aware of hearing problems before treatment #9/P2, #4/P9, #10/P42, #13/P17 
 
Pre-treatment hearing ok #1/51, #7/P6, #8/P29, #12/P30 
 
Sudden hearing loss #1/P51 
 
Awareness of aural change with treatment #1/P51, #5/P12, #8/P29,  
#6/P53, #7/P6, #11/P7, #12/P30 
 
Gradual hearing loss #5/P12, #7/P6, #13/P7 
 
 
Subtheme –  Tinnitus  
 
Combination of aural symptoms #1/P51, #5/P12, #7/P11, #7/P6,  
 
High hum sounds #2/P11 
 
Tinnitus hovers over ears #5/P12 
 
Tinnitus in ear #6/P53 
 
Ringing sensation #6/P53, #13/P17 
 
White noise #11/P7 
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Whistle sound #1/P51, #11/P7 
 
“shh” sound #11/P7 
 
Tinnitus in head #11/P7 
 
High pitch sound #1/P51, #7/P6 
 
Sea sound #8/P29 
 
Tinnitus continuous #7/P6 
 
Tinnitus in the background #5/P12, #2/P11 
 
Buzzing sound #13/P17 
 
Tinnitus and noise #11/P7 
 
Hyperacusis #11/P7 
 
Ear pain #11/P7 
 
No tinnitus #3/P5, #4/P9, #9/P2, #12/P30, #10/P42 
 
Sudden tinnitus #1/P51, #11/P7 
 
Gradual tinnitus #7/P6 
 
 
Subtheme –  Progression of aural change 
 
Deterioration in hearing #11/P7, #9/P2,  
 
Temporary hearing loss #1/P51, #11/P7 
 
Fluctuating hearing loss #2/P11, #6/P53, #7/P6, #3/P5 (wax), #5/P12  
 
Maintained hearing loss #1/P51, #2/P11, #12/P30 
 
Unsure if hearing change has altered #5/P12 
 
Improved hearing #6/P53, #7/P6 
 
Continuous tinnitus #1/P51, #5/P12 
 
Reduction in tinnitus #5/P12, #6/P53, #13/P17, #7/P6  
 
Fluctuating tinnitus #8/P29 
 
Change in tinnitus #11/P7, #5/P12 
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Theme 2 – Functional changes 
 
 
Subtheme –  Communication difficulties 
 
Reduced hearing clarity #5/P12, #6/P53 
 
Difficulty with hearing in shops #6/P53 
 
Difficulty with hearing in social gatherings #1/P51, #5/P12, #9/P2, #13/P17 
 
Difficulty with hearing in restaurants #5/P12 
 
General communication problems #6/P53, #7/P6, #9/P2, #13/P17 
 
Difficulty with hearing on the phone #6/P53, #7/P6, #13/P17 
 
Difficulty with hearing in background noise (people) #1/P51, #6/P53, #8/P29,  
 
Difficulty with hearing due to tiredness #11/P7 
 
Difficulty with fast talking #11/P7 
 
Difficulty with high pitched talkers #11/P7 
 
No hearing difficulties #3/P5, #4/P9 
 
1:1 ok #6/P53, #7/P6, #8/P29, #9/P2 
 
Tinnitus made worse with stress/tiredness #11/P7 
 
Unaware of need to lip-read #1/51 
 
 
Subtheme –  Problems with entertainment 
 
Difficulty with hearing music #2/11, #11/7 
 
Difficulty with hearing TV or radio #1/51, #6/53, #9/2, #11/7, #12/30, #7/6 
 
Difficulty hearing in the cinema #1/51, #11/7 
 
Difficulty hearing in social gatherings in background noise (music) #1/51, #2/P11, #13/P17 
 
 
Subtheme – Problems with environmental sounds 
 
Problems with the computer #5/12 
 
Missing doorbell sound #5/12, #11/7 
 
Difficulty hearing in environmental noise #1/51 
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Theme 3 – Coping mechanism 
 
 
Subtheme –  General strategies 
 
Asks speaker to repeat/ others have to repeat themselves #1/51, #13/17, #5/12, #9/2 
 
Asks speaker to speak louder/others speak louder #1/51, #7/6, #13/17 
 
Asks others to speak clearer/Others need to speak clearer #1/51, #11/7 
 
Lip-reading/ Others need to face listener to be heard #1/51, #11/7, #13/17, #7/6 
 
Unaware of need to lip-read: #1/51 
 
Tells others there is a hearing problem #1/51 
 
Others need to gain attention #1/51 
 
Others not aware of need to alter communication #12/30 
 
Need to concentrate more to listen #9/2, #13/17 
 
Reduction in background noise #13/17 
 
Change in listening to music #2/11, #11/7 
 
Increase in TV volume #1/51, #5/12, #9/2, #12/30, #11/7 
 
Reduction in TV volume #11/7 
 
Need to concentrate more to listen to TV #7/6, 
 
Use subtitles #11/7 
 
Tell others to slow down their speech #11/7 
 
Pretend to hear #5/12 
 
Make out that they are stupid #6/53 
 
Ignore tinnitus #7/6, #2/11, #1/51 
 
 
Subtheme – Use of assistive devices 
 
Use headphones/earphones #11/7, #5/12 
 
Benefit of hearing aids for hearing #1/51, #6/53, #8/29 
 
Benefit of hearing aids for tinnitus #1/51 
 
Cover ears #11/7 
 
Problems still with hearing aids #1/51 
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Change doorbell frequency #11/7 
 
Obtain auto-inflation balloon for OME #11/7 
 
 
 
Theme 4 – Emotional response to aural change 
 
 
Subtheme – Attitude to hearing deterioration 
 
Not bothered by hearing change #1/51, #5/12, #6/53, #7/6, #9/2, #13/17 
 
Acceptance of hearing loss #1/51, #2/11, #6/53, #5/12 
 
Not bothered with hearing aids #1/51 
 
Not bothered by tinnitus #1/51, #5/12, #2/11, #8/29, #13/17 
 
Acceptance of tinnitus #2/11, #5/12, #13/17 
 
Try to overcome difficulties #1/51, #7/6, #11/7 
 
Hearing in context of cancer treatment #1/51, #5/12, #13/17 
 
Possible denial of hearing loss #5/12 
 
 
Subtheme – Downplaying of symptoms 
 
Uncertainty with progression of aural symptoms #1/51, #11/7 
 
Disappointment at return of symptoms #1/51 
 
Frustration with hearing loss #7/6 
 
Irritation with hearing loss #11/7 
 
Annoyance in having a hearing loss #2/11 
 
Annoyance with tinnitus #7/6, #11/7, #5/12 
 
Irritation with tinnitus #11/7 
 
Distraction by having tinnitus #11/7 
 
Tinnitus a terrible sensation #6/53 
 
Guilt in causing inconvenience to others #7/6 
 
Others annoyed by hearing change #1/51, #7/6 
 
Others not bothered by hearing change #1/51, #6/53, #13/17, #3/5, #4/9, #5/12, 
 
		 291 
Others bothered by hearing change #1/51, #11/7, #5/12, #7/6 
 
 
Subtheme – Sense of loss 
 
Disappointment with having hearing aids #8/29 
 
Reduced confidence with having hearing aids #8/29 
 
Stigma with hearing loss #7/6 
 
 
Subtheme – Social isolation 
 
Other reduce amount that is said #11/7 
 
Withdrawal by partner from communication #1/51 
 
Withdrawal from phone use #13/17 
 
Withdrawal from going to cinema #1/51 
 
 
 
Theme 5 – Information and support 
 
 
Subtheme –  Pre-treatment information 
 
Pre-treatment, made aware that hearing may change #1/51, #4/9, #5/12, #6/53, #9/2, #11/7 
 
Shock of cancer diagnoses #1/51 
 
 
Subtheme – Discussion of aural changes 
 
During treatment, patient alerted clinician of aural problem #1/51, #11/7 
 
During treatment, no discussion of aural problems prompted by clinician #1/51 
 
Change in treatment #11/7 
 
Hearing test explanation clear #1/51, #2/11, #11/7, #7/6, 
 
No explanation of hearing #13/17, #5/12 
 
No explanation of tinnitus #5/12, #7/6 
 
Management options for aural care #2/11, #3/5, #13/17, #11/7 
 
Management options for a change in hearing #5/12, #8/29, #11/7, #13/17, #6/53, #10/42, 
#12/30 
 
Delay in seeking hearing support #5/12, #8/29 
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Hearing support to be by audiology #1/51 
 
 
Subtheme –  Further support 
 
Greater awareness of potential change in hearing #6/53 
 
Tinnitus explanation and management #7/6, #5/12 
 
Support depends on individual circumstances #1/51, #8/29, #11/7 
 
Hearing support timing #1/51 
 
Hearing test timing #2/11, #3/5, #4/9, #5/12, #8/29, #11/7, #9/2, #10/42, #13/17 
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Section B Research log  
 
 
 
A research log is used to document progress of a study project from its inception to 
completion. It serves to identify areas of development for the individual conducting the study. 
It also points up influences that may have altered the direction of the study. The following 
account will detail how the research question itself, and the nature of the research enquiry, 
developed during the five years of study (2012-2017) within the Doctorate of Clinical 
Practice (DClinPrac) programme undertaken by the author of this log.  
 
Background – identifying and clarifying the research question 
 
The researcher is an audiologist with experience in paediatric habilitation of hearing and 
adult hearing rehabilitation, as well as in the clinical assessment of balance disorder. The 
project being logged began in January 2012 as an evaluation of a novel balance system 
assessment tool that was being developed in his host department. However, a year and a 
half into the course, in June 2013, it was realised that the assessment tool was already 
being evaluated, and his supervisors advised that while further investigation may 
complement findings, it would not necessarily add to research knowledge, a critical 
determinant for doctoral research enquiry.  
 
In a previous post, the researcher had been involved in the systematic assessment and 
monitoring of hearing for children receiving cancer treatment.  However, in his current 
position, the monitoring of hearing was not standard procedure in the service provision for 
adults receiving cancer treatment, although patients who had received treatment for HNC 
were requesting support and advice when they discovered they had experienced hearing 
loss – sometimes as much as up to two years after treatment. 
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In order to address this situation, the researcher, in consultation with oncologists specialising 
in the treatment of patients suffering from HNC, set up a monitoring protocol to assess 
patients’ hearing before and after treatment.  At this point the researcher agreed with his 
supervisors to use the evaluation of this protocol as a new subject for his research study. It 
therefore seemed appropriate to make the evaluation of this hearing monitoring protocol the 
subject of one of the course assignments, on service development and leadership. 
Information from this assignment then became the basis of the proposal submitted to the 
necessary ethics committees.  
 
In July 2014, with the appointment of a new team of supervisors, who were both specialists 
in cancer care, it was decided to review the aims of the study. As the monitoring protocol 
was already in place, it was felt by the new supervisors that an evaluation of the protocol 
would be of limited value, and therefore there would be insufficient originality for a research 
project at doctoral level.  
 
It was then decided to shift the focus of the project, and conduct a quantitative assessment 
to determine how many people experienced psychoacoustic change following treatment for 
cancer in the UK. The researcher advised his supervisors that to his knowledge at the time, 
the incidence of hearing loss in relation to HNC treatment had not previously been measured 
in a UK population. 
 
Literature review 
 
The review of literature within the subject area of the project enables the student to evaluate 
current knowledge and experience within the field and to discover gaps in that knowledge 
which would warrant investigation suitable for doctoral research. Such a review also 
provides an insight into the appropriate methods and methodology for this particular area of 
enquiry. The first stage of the literature review entails the development of a search strategy 
to identify literature strictly relevant to the subject to be identified; the second stage involves 
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the critical appraisal of the material to enable the student to assess the quality of the studies 
being reviewed.  
 
In order to develop the skills required to conduct a comprehensive search of the literature 
available, throughout the course the researcher has taken advantage of a number of training 
sessions made available at both the University of Surrey and King’s College Hospital 
Library. It was also helpful to discuss the research process with a post-doctoral researcher 
who had experience in creating frameworks for systematic reviews.  The ‘advanced research 
methods’ module of the DClinPrac programme, while giving attention to the critical appraisal 
of papers identified in the search, also provided opportunities for a further stage in the 
literature review process, namely the application of the knowledge obtained to the student’s 
own particular study project. 
 
In consultation with his supervisors, the researcher revised his search strategy several 
times. Initially, the strategy was found to be too broad and the results included too many 
irrelevant articles. However, when the strategy was narrowed, it was found that important 
relevant studies failed to appear. This meant a third adjustment was necessary.  At this point 
the supervisors noted that in papers being identified there was considerable overlap with the 
subject area of the researcher’s project. It was therefore suggested that the project did not 
offer sufficient novelty for doctoral research. The matter was resolved by modifying the 
research question to include a qualitative element, to assess patient experience of the wider 
implications of hearing deterioration following HNC treatment. The search strategy was 
modified accordingly and this resulted in only one article being identified, a study that dealt 
with general communication difficulties following cancer treatment.  A way was therefore 
open for the researcher to pursue an in-depth study of issues particularly related to patient 
experience of hearing deterioration.  
 
Over a period of four years the scope of the literature review was changed at least four 
times.  This brought home to the researcher the importance of clearly identifying the 
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research question, and of selecting appropriate search terms for reviewing the literature – a 
process that may require revision a number of times.  
 
Study design 
 
Throughout this study project, the researcher has come to appreciate the relative value and 
appropriateness of both quantitative and qualitative methods of enquiry.  
 
From experience as an undergraduate in biochemistry, and as a post graduate student 
working on an MSc in audiology, his studies had tended to draw on deductive methodology 
with its emphasis on quantitative enquiry. It was perhaps natural therefore, that the 
researcher began the current study as a quantitative enquiry, using hearing tests pre and 
post treatment to determine the incidence and severity of hearing deterioration, although the 
qualitative element of patient experience was always present in his thinking.  
 
The ‘community of practice’ module of the course, and specifically the philosophy of science 
element within the module, was particularly valuable in helping the researcher to recognise 
how different scientific paradigms contribute to the understanding of phenomena. The 
‘advanced research’ module discussed how phenomena are explored using different 
methodologies and methods. Relating this understanding of scientific enquiry to his own 
study, the researcher adopted a critical realist stance, using mixed methods methodology, to 
view and explore the phenomenon of hearing deterioration in patients who had received 
treatment for HNC.  
 
This first phase of the research project (the quantitative enquiry) led to a second phase in 
which participants from phase one who had measurable hearing deterioration were 
interviewed to explore patient experience of hearing deterioration – thus introducing a 
qualitative element, and a mixed methods methodology into the study. 
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The course was therefore instrumental in enabling the researcher to see how both 
quantitative and qualitative enquiry was appropriate in his specific study to explore the 
phenomenon of hearing deterioration following treatment of patients with HNC. The final 
study design consequently made use of mixed methods methodology, with the phases 
arranged in a sequential explanatory pattern.  
 
Research governance 
 
At the outset of the study, the researcher undertook the ‘good clinical practice researcher 
training’ course, which is mandatory for undertaking NHS UK research. This course included 
an examination of the principles of the Declaration of Helsinki (2008), which sets out ethical 
principles relating to clinical trials on humans. The declaration obliges researchers to act in 
the best interest of study participants and to ensure that accessible information is made 
available to potential participants so that they can make informed decisions prior to and 
during the study. These requirements were met in the online IRAS application form which 
contains questions covering every aspect of the research project, and requires submission 
of copies of participant information sheets and consent forms.   
 
The IRAS form, necessary for NHS ethics approval, in order to ensure adequate governance 
of the project by all relevant supervisory bodies, required identification of the sponsor of the 
study (in this case the University) who was responsible for ensuring a proper framework was 
in place for the study to be conducted.  The sponsor is also responsible for the covering of 
indemnity and monitoring arrangements.   
 
As there was no change in the usual treatment provision of participants involved in the 
study, the application was submitted for ‘proportionate review’ by the London-Westminster 
NHS ethics committee. The application was given a provisional favourable opinion, subject 
to minor amendments being made. The amendments were made and the application was 
duly approved by the NHS committee in January 2015. This led to approval by the University 
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ethics committee and the Research and Development Department of the host hospital, 
enabling the study to start in February 2015. 
 
As the study progressed however, it became evident, as discussed in the literature review 
section above, that expansion of the project was required to fully capture the qualitative 
assessment of patient experience. The study was adapted to include the second phase, a 
qualitative element (exploring patient experience in interviews), and this necessitated a 
change from a purely quantitative enquiry to a mixed methods methodology. The host 
hospital’s Patients Experience Manager gave helpful advice on how to ask questions for the 
interviews now being included. Because of the change in the research methodology, a 
‘substantial amendment’, to the study protocol was submitted in April 2016 to the NHS ethics 
committee. This submission included updated consent and participant information sheets. 
The amended application was successful, and so the second phase of study commenced in 
June 2016.  
 
As part of the governance procedure, the host hospital’s Research and Development Team 
required notification when the collection of study data was completed. The collection of data 
for Phase 1 (the quantitative element – hearing testing) was completed in February 2016, 
and data for Phase 2 (the qualitative element – participant interviews) was completed in July 
2016, and notification given at each stage.  
 
Data collection 
 
Phase 1 of the project took one year to complete. Hearing test data was collected at three 
time points: before treatment, at the end of treatment and three months post treatment. 
Liaison with oncology and radiography colleagues was essential to co-ordinate testing, as 
participants often had altered hospital appointment dates that required alteration to the 
hearing testing schedule. As the researcher was working full-time at his hospital post, 
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involvement of team members within the audiology department was also essential for 
booking appointments and assisting with performing the tests. 
 
Phase 2 was completed over two months and was more manageable to arrange that Phase 
1. As with the hearing tests for Phase 1, the interviews were conducted on dates that 
participants were coming to hospital for other appointments, although this was not always 
possible, and some came voluntarily to attend for interview only.  
 
Results and writing up 
 
Support from the in-house statisticians at the host hospital was essential for formulating 
relevant statistical data analysis for the quantitative phase of the study. As the researcher 
lacked experience in qualitative research prior to the study commencement, he drew heavily 
on reading material around the subject and on 
the knowledge and support of his study supervisors in analysing the mass of material 
contained in the transcripts of interviews. 
 
Study chapters were regularly submitted in draft form for review by the course supervisors 
who constantly encouraged the researcher to adopt a more critical approach to his material 
and avoid the descriptive style that characterised much of his earlier writing. In order to 
address this issue, and to develop his written communication skills more generally, the 
researcher participated in two writing-group workshops, provided by the Researcher 
Development Programme at the host University.  
 
Communication  
 
The researcher gave presentations on the study to a PhD writing group at the host university 
and to hospital research groups (audiology and oncology).  Following the presentation to the 
oncology research group, the researcher was invited to give a presentation on audiology 
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support at a well-being event provided by the host hospital for survivors of HNC treatment 
and their carers and family members. Audiology support is now regularly featured in this 
survivorship programme. 
 
The researcher also participated in the ‘23 Things for Publication Programme’ web-based 
course that offered guidance in writing journal articles. Skills learned on this course assisted 
the researcher in writing a paper on Phase 1 results. This paper, intended for publication in 
an academic journal was submitted together with the study as required by the DClinPrac 
degree programme.  
 
Summary 
 
The researcher has benefited from all aspects of the research process and has learned 
much throughout this journey. He has a much greater understanding and appreciation of the 
rigour required to undertake academic research, and through the various amendments 
required by the applications for approval by the ethics committees, realises the necessity for 
regular evaluation and where necessary, for alteration to an original research design. This 
can even involve the redefining and rewording of the research question.  
 
The researcher now also understands that social science research requires good teamwork, 
communication, and cross-discipline co-operation to ensure that the process progresses 
smoothly.  
 
Having concluded this study, the researcher hopes that more will be learned about the inter-
relationship between treatment for cancer and hearing, that the medical disciplines involved 
will discover new opportunities for professional co-operation, and most importantly, that in 
future patients will receive the support and service provision they require for their more 
complete well-being. (Word count: 2283). 
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Section C Overview of the integration of knowledge,  
  research and practice 
 
 
Introduction 
 
The DClinPrac course offers an opportunity for researchers to develop an understanding of 
organisational and scientific knowledge, and of what shapes and influences health policy. It 
also provides an opportunity for involvement in translational research by the formulating of a 
project to enhance human health and well-being. The course was well suited for clinicians in 
managerial and clinical responsibility not only for their personal development, but also for the 
enhancement of their specific health discipline and others that relate to it. 
 
The researcher is an audiologist with twenty years of NHS experience. On commencing the 
course, the researcher was new to the role of clinician-manager with leadership 
responsibilities. Prior to the course, the researcher attended a leadership-management 
training seminar organised by an audiology department: ‘Steering a true course’ (South Tees 
Hospitals NHS Foundation Trust, 2015). This course focussed on the practicalities of 
influencing change within audiology teams, however, its remit did not include the application 
of research. The researcher is aware of the apparent paucity of translational research in 
audiology within the UK, and was therefore attracted to the DClinPrac course with its 
emphasis on developing researcher skills within the context of health policy and leadership. 
The taught elements of the course included the following modules: communities of practice; 
politics, policy and power; advanced research methods; and service development and 
leadership. Each of these modules will be discussed in turn. 
 
Communities of practice 
 
This module exposed the researcher to different types of knowledge, including 
organisational, embodied and scientific. Organisational knowledge is that which is known 
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and shared, such as from national standard frameworks and NICE. Lectures on the course 
suggested that NHS provision can be improved by drawing upon embodied knowledge, 
which is held by individuals within and without the organisation. Involvement of patient 
groups and external monitoring can help in the development of holistic health policy by 
applying relativist knowledge that recognises and accepts different perspectives on a 
situation.  
 
The philosophy of science lectures showed how in scientific knowledge phenomena are 
viewed in different ways. The researcher found it of value to be made aware of these 
different layers of knowledge within ‘communities of practice’ which are often self-selecting 
individuals and groups who wish to share knowledge, solve problems and implement change 
for service improvement. 
 
Policy, politics and power 
 
The importance of communities of practice was carried through the policy, politics and power 
module. Health policy is influenced by different ideologies, economic evaluations and ethics. 
The researcher considered all these aspects in the module assignment on the white paper, 
‘Any Qualified Provider’ (NHS, 2012a) particularly with its application to audiology (NHS, 
2012b).  In an attempt to address the request for patient choice in health provision, and to 
reduce the expenditure of public services, the Government initially rolled out the policy as 
‘Any Willing Provider’. However, this was conducted without consulting relevant health 
professionals and with limited public involvement. Following considerable public outcry, the 
policy was revised and re-named ‘Any Qualified Provider’ in order to ensure that appropriate 
clinical and operational standards were met. When these standards were applied to 
audiology, it meant that private competitors were also accountable to the same levels of 
clinical expertise and moral code of conduct as usual NHS health providers. The module 
was valuable in that it highlighted the different perspectives on commissioning of services, 
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and it also underlined the importance of involving all relevant stakeholders at the outset, in 
the hope that transparent operation would result in effective policy acceptable to all parties 
concerned.  
 
Advanced research methods 
 
Different methodologies and methods were discussed within this module. The assignments 
for this module included doing a critique of existing evidence for formulating a research 
question; they also required students to create a structure of research design, which drew 
upon both qualitative and quantitative methodologies. These exercises were useful for the 
researcher’s own study project which had itself employed both quantitative and qualitative 
data collection phases.  
 
Service evaluation and leadership 
 
The principle of conceptual frameworks underpinning research was introduced in this service 
evaluation and leadership module to enable the evaluation of policies and procedures. One 
such framework was the Medical Research Council (MRC) model for evaluating complex 
health interventions. The researcher employed this particular model in his module 
assignment: ‘Audiology assessment of patients undergoing chemo-radiotherapy for 
treatment of head and neck cancer’. He used this assignment in preparing the proposal on 
the evaluation of a monitoring protocol for hearing to be submitted to the various ethics 
committees. 
 
The leadership aspect of the course discussed different models of leadership, and offered a 
critique of various models, from individual (‘Great Man’) leadership to group (distributed) 
leadership. These lectures described the evolution of these different styles, from leadership 
focussed in one individual to an understanding of leadership as the activity of a team. Good 
leadership requires good communication and transparency. Distributed leadership was 
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chosen as most applicable for the leadership assignment, as involvement of different 
stakeholders was required for the monitoring programme to be adopted and implemented.  
 
Research project 
 
The researcher used elements from each of these course modules in shaping his ideas for 
the research study of the DClinPrac programme. The communities of practice module 
highlighted the advantages of sharing knowledge from different perspectives in order to 
ensure holistic care. Drawing on principles learned from this module, the researcher 
attended multidisciplinary team meetings where ENT surgeons, oncologists, speech 
therapists, dentists, dieticians, physiotherapists, clinical nurse specialists and radiographers 
discussed treatment plans for patients with HNC. It was valuable to see the different 
approaches made by each specialty on patient care, but there was no discussion of 
audiological issues. 
 
The researcher was aware that a recent UK health policy document on cancer care (DH, 
2011) stressed the importance of advocating the most suitable treatment regimen and the 
need to provide appropriate support to enhance survivorship, but this document did not 
mention support for patients with hearing loss following treatment. However, the researcher 
was aware of patients who were attending his audiology clinic two or more years following 
the end of cancer treatment.  
 
Subsequently, the researcher met with oncologists who specialised in HNC care to discuss a 
process for monitoring hearing loss in patients receiving treatment. This discussion brought 
forth a positive response from the oncologists and the suggestion that co-operation between 
oncologists and audiologists would be beneficial for more comprehensive patient care. 
Consequently, the research enquiry for this study began with an evaluation of the monitoring 
programme, drawing on the responses obtained from interviews with different stakeholders: 
patients, oncologists and staff of the audiology department, in order to gain different 
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perspectives. A cost-benefit analysis was also to be included as part of the study, in order to 
determine if there was a difference in overall costs if audiological intervention were to be 
made soon after treatment completion rather than the current practice of intervention at two 
years or more from the end of treatment. 
 
As mentioned above in the discussion of the service evaluation and leadership module of 
this course, the MRC model for evaluating complex health interventions was to be used as 
the conceptual framework for the study. However, the focus of the researcher’s project was 
then changed when new study supervisors suggested that as a monitoring protocol was 
already in place, an evaluation of the protocol would be of limited value and of insufficient 
originality for a research project at doctoral level. This shift of focus involved research into 
determining how many people experienced hearing change following treatment for cancer in 
the UK. This required developing different research methods and methodologies discussed 
in the advanced research methods module. The change of perspective enabled the 
researcher to appreciate how a phenomenon (in this case, the study of hearing 
deterioration) can be approached in different ways depending upon the knowledge, training, 
expertise and conceptual or theoretical perspective of the researcher and/or supervisors.  
 
In summary, the change in the direction of the study meant drawing upon different types of 
knowledge in the investigation.  Viewing human health from an economic perspective (the 
cost-benefit analysis) drew upon organisational knowledge; the change of focus to viewing 
patient experience from a clinical perspective has involved investigating scientific 
knowledge. Information acquired from each of the modules in the study programme has not 
only assisted the researcher throughout the entire project, it has also deepened and 
enriched his overall academic experience and personal development.  
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Personal development 
 
The researcher has greatly enjoyed his participation in this course. By having the opportunity 
to explore different scientific paradigms and to acquire new knowledge in the investigation of 
the subject area for the research project, he found himself changing his mind-set, and thus 
developing both personally and professionally. There were seminal moments for the 
researcher in each area. During the community of practice module, he found the introduction 
of qualitative enquiry confusing at first; it simply did not register as being relevant in a 
scientific study. The researcher still tends to favour quantitative methodology, but as a result 
of this course he is more open to the consideration of the validity of individual experience 
and the recognition of the importance of feelings. The inclusion of qualitative methods in this 
study has thus contributed to a deepening of his personal growth in his approach to scientific 
study.  
 
In the area of professional growth, the researcher was aware of feeling discomfort  
in the leadership module of the course, during a lecture on clinician-manager roles. 
The lecturer was drawing upon discussions in a series of seminars he had conducted with 
clinicians and managers on the subject of patient care. In general, clinicians tend to focus on 
individual benefit, having a more immediate responsibility for the care and well-being of 
patients, whereas managers tend to have a larger perspective, being responsible for the 
overall governance and day-to-day running of a particular department, and on the service as 
a whole. When these two groups are brought together within a work environment, tensions 
can arise if there is not a recognition that both views have their place and both need to 
understand how their roles inter-relate in service provision. The researcher realised that he 
was experiencing this tension within himself as a clinician-manager, a peculiar role, which he 
had not understood and certainly had not been prepared for when he took up the role. 
Consequently, the researcher believes that specialist training is needed to help clinicians 
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prepare for embarking on this dual role and responsibility.  A course such as the DClinPrac 
is well suited to meet this need.  
 
Summary 
 
The DClinPrac course is ideal for clinician-managers undertaking research that involves 
evaluation of processes and the formulation of policy within healthcare. It is particularly 
suitable for those wishing to develop an understanding of the influences on health care 
provision, and how services within the NHS are organised.  
 
Learning with students from other health disciplines enabled the researcher to obtain a 
broader perspective of health care generally and service delivery in particular. In addition, 
having supervisors from different disciplines of health care meant that when the study 
project changed from an exercise in monitoring service evaluation to a more clinical 
examination of patient experience, the different perspectives of the various teams of 
supervisors was advantageous in assisting the researcher in formulating the changes in the 
proposals.  
 
The University of Surrey no longer offers the DClinPrac, but has replaced it with the 
Integrated PhD course which, while still maintaining core modules on leadership and health 
policy, allows more time for students to undertake research. It is also open to nurses and 
allied health professionals to enable inter-disciplinary learning. In addition, within the 
Government’s Modernising Scientific Careers framework there is the Higher Specialist 
Scientific Training Scheme, which offers a Doctorate in Clinical Science (DClinSci) 
programme specifically for audiology clinicians (DH, 2015).  Of these two new courses, the 
Integrated PhD appears to be more suited to audiologists who wish to develop managerial 
skills and contribute to health policy. But for those audiologists who wish to have more in-
depth training in specialist audiology fields and to promote clinical research, it would seem 
that the DClinSci may be the more suitable option. (Word count: 2020). 
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